
<html lang="en"     class="pb-page"  data-request-id="3feee145-9abd-472e-8dcc-ef28ad0e8c7a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-13;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm401564r;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation" /></meta><meta name="dc.Creator" content="Magid  Abou-Gharbia" /></meta><meta name="dc.Creator" content="Wayne E.  Childers" /></meta><meta name="dc.Description" content="The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regula..." /></meta><meta name="Description" content="The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regula..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 7, 2014" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401564r" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401564r" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401564r" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401564r" /></link>
        
    
    

<title>Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401564r" /></meta><meta property="og:title" content="Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0018.jpeg" /></meta><meta property="og:description" content="The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regulatory hurdles, and the industry’s perceived tarnished image. Pharma has responded by embarking on a range of initiatives. Other sectors, including NIH, have also responded. Academic drug discovery groups have appeared to support the transition of innovative academic discoveries and ideas into attractive drug discovery opportunities. Part 1 of this two-part series discussed the criticisms that have been leveled at the pharmaceutical industry over the past 3 decades and summarized the supporting data for and against these criticisms. This second installment will focus on the current challenges facing the pharmaceutical industry and Pharma’s responses, focusing on the industry’s changing perspective and new business models for coping with the loss of talent and declining clinical pipelines as well as presenting some examples of recent drug discovery successes." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401564r"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401564r">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401564r&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401564r&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401564r&amp;href=/doi/10.1021/jm401564r" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5525-5553</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm4011687" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm500401x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Magid++Abou-Gharbia">Magid Abou-Gharbia</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wayne+E.++Childers">Wayne E. Childers</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 1-215-707-4949. E-mail: <a href="/cdn-cgi/l/email-protection#2e4f4c415b434f496e5a4b435e424b004b4a5b"><span class="__cf_email__" data-cfemail="85e4e7eaf0e8e4e2c5f1e0e8f5e9e0abe0e1f0">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401564r&amp;href=/doi/10.1021%2Fjm401564r" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5525–5553</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 15, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 October 2013</li><li><span class="item_label"><b>Published</b> online</span>7 February 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 July 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401564r" title="DOI URL">https://doi.org/10.1021/jm401564r</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5525%26pageCount%3D29%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMagid%2BAbou-Gharbia%252C%2BWayne%2BE.%2BChilders%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D13%26contentID%3Djm401564r%26title%3DDiscovery%2Bof%2BInnovative%2BTherapeutics%253A%2BToday%25E2%2580%2599s%2BRealities%2Band%2BTomorrow%25E2%2580%2599s%2BVision.%2B2.%2BPharma%25E2%2580%2599s%2BChallenges%2Band%2BTheir%2BCommitment%2Bto%2BInnovation%26numPages%3D29%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5553%26publicationDate%3DJuly%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401564r"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6413</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">31</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401564r" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Magid&quot;,&quot;last_name&quot;:&quot;Abou-Gharbia&quot;},{&quot;first_name&quot;:&quot;Wayne&quot;,&quot;last_name&quot;:&quot;E. Childers&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;5525-5553&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401564r&quot;},&quot;abstract&quot;:&quot;The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regulatory hurdles, and the industry’s perceived tarnished image. Pharma has responded by embarking on a range of initiatives. Other sectors, including NIH, have also responded. Academic drug discovery groups have appeared to support the transition of innovative academic discoveries and ideas into attractive drug discovery opportunities. Part 1 of this two-part series discussed the criticisms that have been leveled at the pharmaceutical industry over the past 3 decades and summarized the supporting data for and against these criticisms. This second installment will focus on the current challenges facing the pharmaceutical industry and Pharma’s responses, focusing on the industry’s changing perspective and new business models for coping with the loss of talent and declining clinical pipelines as well as presenting some exa&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401564r&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401564r" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401564r&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401564r" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401564r&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401564r" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401564r&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401564r&amp;href=/doi/10.1021/jm401564r" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401564r" /></input><a href="/doi/pdf/10.1021/jm401564r" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401564r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401564r%26sid%3Dliteratum%253Aachs%26pmid%3D24428137%26genre%3Darticle%26aulast%3DAbou-Gharbia%26date%3D2014%26atitle%3DDiscovery%2Bof%2BInnovative%2BTherapeutics%253A%2BToday%25E2%2580%2599s%2BRealities%2Band%2BTomorrow%25E2%2580%2599s%2BVision.%2B2.%2BPharma%25E2%2580%2599s%2BChallenges%2Band%2BTheir%2BCommitment%2Bto%2BInnovation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D13%26spage%3D5525%26epage%3D5553%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a>,</li><li><a href="/action/doSearch?ConceptID=292602" title="Biomarkers">Biomarkers</a>,</li><li><a href="/action/doSearch?ConceptID=292043" title="Pharmaceutics">Pharmaceutics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jmcmar.2014.57.issue-13/production/jmcmar.2014.57.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regulatory hurdles, and the industry’s perceived tarnished image. Pharma has responded by embarking on a range of initiatives. Other sectors, including NIH, have also responded. Academic drug discovery groups have appeared to support the transition of innovative academic discoveries and ideas into attractive drug discovery opportunities. Part 1 of this two-part series discussed the criticisms that have been leveled at the pharmaceutical industry over the past 3 decades and summarized the supporting data for and against these criticisms. This second installment will focus on the current challenges facing the pharmaceutical industry and Pharma’s responses, focusing on the industry’s changing perspective and new business models for coping with the loss of talent and declining clinical pipelines as well as presenting some examples of recent drug discovery successes.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60650" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60650" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><div class="quote"><p class="first last">“It was the best of times, it was the worst of times...”</p></div>This famous line opens Charles Dickens’ classic novel <i>A Tale of Two Cities</i> and speaks to the paradox of life and the fact that there are often both good and bad sides to things. The apropos statement was also used in a 2012 PricewaterhouseCoopers report to describe the situation that the pharmaceutical industry finds itself facing.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Dramatic changes to the scientific and business environments have made it impossible for pharmaceutical and biotech companies to continue operating as they have over the past 30 years. A perceived decline in innovation, fierce market competition from generics, increased regulatory hurdles, and key patent expirations on a number of blockbuster drugs (the so-called patent cliff) have all put significant pressure on branded pharmaceutical companies and threatened the future of the industry as a whole. Yet, it is this adversity and the absolute need for change that may be the industry’s salvation. Things cannot go on as they have; there must be change. The industry has finally admitted this truth and has embarked upon a journey to find its path forward. Initial responses to the changing environment, beginning in the late 1990s, were harsh. Many companies have downsized, cut the number of research projects, outsourced many functions, and underwent mergers and acquisitions in an effort to survive as they seek to identify and establish business models that will guide them through the economic uncertainty. A number of initiatives have been instituted to ensure survival so that the industry can maintain its quest to identify and develop innovative new drugs to treat unmet medical needs. This second installment of our two-part series<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> presents and discusses some of the major challenges facing the pharmaceutical industry and Pharma’s responses to these challenges. However, before that subject is breached, we present a short aside on the widespread impact that drug discovery has on the biomedical field as a whole and a brief review of the general drug discovery process that has been the standard over the past 30 years as background for the following discussion on challenges and changes.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Drug discovery process.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Broad Impact of Drug Discovery on Biomedical Research</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55428" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55428" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In its simplest definition, drug discovery is the process by which new medications are identified. Drug discovery draws upon an integrated set of disciplines that work together to support the myriad activities needed to identify and validate drug targets relevant to a disease, to design or discover probes that elicit a desired pharmacological response from that target, and to optimize those probes to provide druglike candidates that safely and effectively treat the disease in question.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Those goals are important in their own right; however, many other areas of biomedical research have also benefited from drug discovery. Molecules and biological agents that may not possess the druglike properties needed to advance in the discovery process often provide tool agents that can be used by basic researchers to ask fundamental questions, to characterize biological systems and pathways, and to discover new drug targets or to understand existing ones better. The medical devices industry has also benefited from drug discovery. A classic example of this synergy is the advent of drug-eluting stents.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Percutaneous coronary intervention (PCI) has spared countless patients the need for coronary bypass surgery, but the technique was originally plagued by restenosis, the renarrowing of dilated artery segments. The introduction of drug-eluting stents (also known as coated stents, stents that slowly release drugs that inhibit restenosis) has significantly reduced the number of patients requiring follow-up revascularization (clinical trial results have recently been summarized by Li et al.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a>). Drug discovery activities also provide support to clinical research and drug development. For example, advances in formulation science have made it possible to evaluate clinically and launch drug candidates with poor physicochemical properties.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The antimitotic taxane analogue paclitaxel and the antifungal agent itraconazole are good examples of drugs whose development was originally threatened by poor solubility. Discovery medicinal chemists are routinely called upon to synthesize standard samples of major metabolites to support and facilitate clinical development of drug candidates. Enzymatic methods are now routinely used to obtain or scale up metabolites that are difficult to obtain through traditional organic synthesis. Chemistry platforms such as electrochemistry are now being applied to study metabolism.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Furthermore, the emerging field of metabolomics can assist in biomarker identification and can guide the selection of subjects for clinical trials by identifying patients more likely to respond or less likely to experience adverse effects.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In translational medicine, PET and SPECT imaging agents now play an integral role as biomarkers, measuring drug target engagement, guiding dose selection, diagnosing and characterizing disease states, and monitoring treatment effectiveness and progress.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> Imaging agents must be endowed with a specific and specialized collection of biological, physicochemical, and ADME properties, which is the inherent specialty practiced by the discovery medicinal chemist. As can be seen from just these few examples, the quest to discover new drugs has had a widespread impact on a number of biomedical research sectors.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Drug Discovery Process</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22352" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22352" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Business models vary between large pharmaceutical corporations, smaller biotech companies, government research groups, and academic drug discovery laboratories, but the general drug discovery process that they all follow is essentially the same (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> The first step is to identify a biological target whose pharmacological manipulation is expected to impact beneficially on a disease state. The target must be relevant to the disease and druggable. According to a 2006 summary by Overington et al.,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> there are approximately 1500 drugs that have been approved for use in humans (1204 small-molecule drugs and 166 biological agents). These drugs work through their actions on 324 unique biological targets. A seminal paper by Hopkins and Groom in 2002<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> introduced the concept of the druggable genome and suggested that 600–1500 of the approximately 30 000 human genes could be relevant, druggable targets. These results did not take into account the possibility of multiple targets from a single gene through complex formation, splice variation, post-translational modification, and the existence of multiple receptor states for receptors, ion channels, and others.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Thus, although the number of predicted druggable genes is significantly smaller than the total genome, the chances are good that novel, viable drug targets still await discovery and exploitation. Many tools and techniques have been used to identify potential drug targets.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Bioinformatics, database mining, genetic association, and phenotypic screening have all been applied successfully. Precedence from known drugs and probe molecules can also assist in new drug target identification. Nearly 25% of known drugs have no known primary target or, at best, lack a well-defined mechanism of action.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Drug repositioning has become a popular subject for the drug discovery sector and is one of the missions of the recently formed National Center for Advancing Translational Sciences.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Examples of successfully repurposed drugs include gabapentin, ropinirole, buprenorphine, thalidomide, minoxidil, and aspirin.</div><div class="NLM_p">Once a potential new drug target is identified, it must be validated and shown to be relevant to the disease state.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> It is of the utmost importance to gain a high degree of confidence that the target is a good one before launching into a costly drug discovery campaign. The sequencing of the human genome has had a significant impact in this area.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Not only have potential new drug targets been identified but also the complex interaction between biochemical systems is now better understood, allowing researchers to predict potential synergy or redundancy between various systems. Today, medicinal chemists speak of families of drug targets such as the kinome, transporterome, and proteasome. There are also genetic considerations in target validation such as whether or not the target is expressed in tissues that are involved in the disease and at an appropriate age for the patient. However, a target must also pass other criteria to be considered validated. It is important to show that manipulation of the target (either enhancement or inhibition of its action) produces a biological change that will impact positively on the disease with a minimum of deleterious side effects. This question can be answered in a number of ways. The target should be characterized at as many levels as possible, including biochemical, cellular, isolated tissue, and in vivo. Transgenic animal models where the target has been either knocked out or knocked in are widely used to associate the target with a disease-related phenotype. One recent development in the field of transgenics is the use of cost- and time-efficient zebrafish in place of murine transgenics, most notably in the areas of cardiovascular safety and regenerative medicine. When small-molecule or biological tool compounds are not available to study the pharmacology of the target, antibodies, antisense technology, and RNA interference (siRNAs) can often be used to inhibit the activity or expression of the target, although these approaches are not without disadvantages such as high cost, the need for careful controls to ensure proper interpretation of data, and the inherent difficulties of getting such large molecules to their intracellular targets, especially in an in vivo setting. Questions of specificity and uniqueness must be addressed. Are there alternate pathways that the disease can employ if a drug is given for a candidate target? Will manipulating the target primarily affect the disease or will there be deleterious side effect that may limit dose or use of drugs affecting the target? Another issue that goes hand-in-hand with reliability is druggability. Not all potential drug targets will suitably interact with small molecules or biological agents. When the 3D structure of a target is known but that of its potential binding sites is not, computational methods can be employed to suggest likely locations.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Virtual screening of focused small-molecule or fragment-based libraries can provide additional confidence in a target before a costly high-throughput screen is attempted. Detailed thought processes for validating potential drug targets have been proposed in the literature. Wisely, the value of the human insight of experienced structural biologists and medicinal chemists is still apparent in many of these druggability rubrics.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p last">A plethora of papers and reviews discuss the hit identification, hit-to-lead, and lead optimization activities associated with drug discovery. Some have represented that process as crafting a key to fit into a 3D lock (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). An important aspect that enhances the chances for success is the identification of druggable scaffolds,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> whether those scaffolds come from virtual screening, fragment-based design, high-throughput screening, or rational design based on known drugs or probes. To that end, Lipinski’s rule of five and its variations still play an important role in triaging and prioritizing potential chemical scaffolds for initiation of structure–activity relationship (SAR) campaigns.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> High-throughput chemistry and in vitro biology have made it possible for drug discovery teams to gather and analyze a tremendous amount of SAR information in their quest for potent, selective, and efficacious drug candidates.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The establishment of high-throughput in vitro physicochemical and ADME screens and in silico ADME have allowed medicinal chemists to prioritize chemical scaffolds and optimize druglike properties simultaneously with pharmacological activity, thereby identifying structure–property relationships (SPRs) in addition to SARs.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> This multidimensional optimization strategy has led to a decrease in the number of compounds terminated from clinical trials for unsatisfactory pharmacokinetics.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Pharma Challenges</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">It became apparent by the early 2000s that the general business model followed by most of big Pharma needed adjustment.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> Dramatic changes in the economic and regulatory environments, the increased complexity of the diseases in need of treatment, a stagnation in the number of new drugs receiving approval despite increased R&D spending (relative to the 1990s), and fierce competition from generics began taking a toll on the pharmaceutical industry so that it could no longer ignore or deal with using a business as usual approach. A number of challenges needed to be addressed if the industry was to survive. Ironically, some of the initial responses by big Pharma have led to additional challenges rather than solutions. Those challenges and the strategies that the pharmaceutical industry has pursued to address those challenges are discussed below.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Mergers and Acquisitions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To the outside observer, mergers and acquisitions (M&As) in the pharmaceutical industry seem like a routine occurrence these days. However, the truth is that they are anything but routine. According to a recent story by Kathlyn Stone<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and on the basis of data from Irving Levin Associates, Inc.,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> during the period 2000–2009, 1345 M&A deals took place, with a total value exceeding $690 billion. These M&A’s have played a significant role in the loss of over 300 000 pharmaceutical jobs since 2000. Although they may have looked beneficial to both upper management and stock holders in the short term, the long-term consequences may have been detrimental to big pharmaceutical companies’ R&D efforts, as succinctly described in articles written by Pharma insiders such as John LaMattina,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Raymond Firestone,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and Bernard Munos<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> as well as outside business observers such as Comanor and Scherer.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">As a result of M&A activity, the number of biopharmaceutical companies has decreased dramatically. In 1988, big Pharma members of the Pharmaceutical Research and Manufacturing Association (PhRMA) totaled 42 (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). By the year 2011, that number was down to 11, although one of the 1988 members, Roche, left PhRMA out of choice rather than loss of identity from an acquisition. For the most part, that period saw small-to-midsized companies swallowed up by the big Pharma giants. However, big Pharma was not immune, with a number of large companies being acquired by their competitors. Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> provide a summary of pharmaceutical company M&A’s from 2000–2012 in which the value of the deal exceeded $2 billion. In particular, Pfizer was one of the most active M&A protagonists for deals in this price range, although Abbott and Novartis also executed several multibillion dollar deals as well. A number of mega-deals received ample publicity during this time, including GlaxoWellcome’s acquisition of SmithKlineBeecham to form GlaxoSmithKline in 2000, Pharmacia/Upjohn’s merger with Monsanto to form Pharmacia in 2000, Pfizer’s acquisitions of Warner Lambert in 2000, Pharmacia in 2002, and Wyeth in 2009, Sanofi-Synthalabo’s acquisition of Aventis in 2004, Roche’s complete acquisition of Genentech in 2008, Merck’s acquisition of Schering-Plough in 2009, and Novartis’ acquisition of Alcon in 2010. The value of each of these deals exceeded $40 billion. Since 2010, no further mega-mergers have occurred. However, many analysts believe that more multibillion dollar M&A’s may be on the horizon, spurred by the completion of ongoing restructuring activities, a need to boost revenues, continued low research productivity, and the availability of large cash reserves. Big Pharma may not be the only player in the M&A game now that many biotech companies like Amgen, Celgene, and Gilead are valued at greater than $10 billion. In fact, Amgen recently announced that it will acquire Onyx for $10 billion.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Furthermore, M&A activity has now become common in many international markets (such as the Indian pharmaceutical market) as well as the generic market. Thus, it appears likely that the trend will continue.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Comparison of PhRMA Members in 1998 and 2011.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Timeline of mergers and acquisitions with values ≥$2 billion that occurred from 2000 to 2012.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. List of Mergers and Acquisitions with Values ≥$2 Billion That Occurred from 2000 to 2012</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">date</th><th class="colsep0 rowsep0" align="center">companies<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">approx. value (billions of dollars)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">2000</td><td class="colsep0 rowsep0" align="left">Pfizer–Warner Lambert</td><td class="colsep0 rowsep0" align="left">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GlaxoWellcome–SKB</td><td class="colsep0 rowsep0" align="left">74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P&U–Monsanto</td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">2001</td><td class="colsep0 rowsep0" align="left">J&J–Alza</td><td class="colsep0 rowsep0" align="left">12.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS–Dupont Pharma</td><td class="colsep0 rowsep0" align="left">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abbott–Knoll</td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Shire–Biochem Pharma</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2002</td><td class="colsep0 rowsep0" align="left">Pfizer–Pharmacia</td><td class="colsep0 rowsep0" align="left">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">2003</td><td class="colsep0 rowsep0" align="left">Biogen–Idec</td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Teva–Secor</td><td class="colsep0 rowsep0" align="left">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" align="left">2004</td><td class="colsep0 rowsep0" align="left">Sanofi Synthelabo–Aventis</td><td class="colsep0 rowsep0" align="left">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GE–Amersham</td><td class="colsep0 rowsep0" align="left">10.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Yamanuchi–Fujisawa</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mylan–King</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Roche–Bayer OTC</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">UCB–Celltech</td><td class="colsep0 rowsep0" align="left">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="7" align="left">2005</td><td class="colsep0 rowsep0" align="left">J&J–Guidant</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Teva–Ivax</td><td class="colsep0 rowsep0" align="left">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sankyo–Daiichi</td><td class="colsep0 rowsep0" align="left">7.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Novartis–Eon</td><td class="colsep0 rowsep0" align="left">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Novartis–Chiron</td><td class="colsep0 rowsep0" align="left">5.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Novartis–Hexal</td><td class="colsep0 rowsep0" align="left">5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Allergan–Inamed</td><td class="colsep0 rowsep0" align="left">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">2006</td><td class="colsep0 rowsep0" align="left">Bayer AG–Schering AG</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">J&J–Pfizer Consumer</td><td class="colsep0 rowsep0" align="left">16.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">2007</td><td class="colsep0 rowsep0" align="left">Schering-Plough–Organon</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AstraZeneca–Medimune</td><td class="colsep0 rowsep0" align="left">15.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="7" align="left">2008</td><td class="colsep0 rowsep0" align="left">Roche–Genentech</td><td class="colsep0 rowsep0" align="left">44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Teva–Barr</td><td class="colsep0 rowsep0" align="left">8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Takeda–Millenium</td><td class="colsep0 rowsep0" align="left">8.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lilly–Imclone</td><td class="colsep0 rowsep0" align="left">6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Daiiche–Rambaxy</td><td class="colsep0 rowsep0" align="left">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Easai–MGI</td><td class="colsep0 rowsep0" align="left">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fresenius–APP</td><td class="colsep0 rowsep0" align="left">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">2009</td><td class="colsep0 rowsep0" align="left">Pfizer–Wyeth</td><td class="colsep0 rowsep0" align="left">68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Merck–Schering-Plough</td><td class="colsep0 rowsep0" align="left">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dainippon–Sepracor</td><td class="colsep0 rowsep0" align="left">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">2010</td><td class="colsep0 rowsep0" align="left">Novartis–Alcon</td><td class="colsep0 rowsep0" align="left">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abbott–Solvay</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abbott–Piramal</td><td class="colsep0 rowsep0" align="left">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pfizer–King</td><td class="colsep0 rowsep0" align="left">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">2011</td><td class="colsep0 rowsep0" align="left">Gilead–Pharmasset</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Takeda–Nycomed</td><td class="colsep0 rowsep0" align="left">9.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Teva–Cephalon</td><td class="colsep0 rowsep0" align="left">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">2012</td><td class="colsep0 rowsep0" align="left">BMS–Amylin</td><td class="colsep0 rowsep0" align="left">5.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSK–Human Genome</td><td class="colsep0 rowsep0" align="left">3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Abbreviations: GE, General Electric; J&J, Johnson & Johnson; OTC, Over the Counter; P&U, Pharmacia and Upjohn; SKB, SmithKlineBeecham; BMS, Bristol-Myers Squibb; and GSK, GlaxoSmithKline.</p></div></div></div><div class="NLM_p">Analysts agree that mergers, and especially acquisitions, occur in response to financial and business pressures, not for the sake of enhancing research capacity.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Grabowski and Kyle have recently categorized the motives for M&As into five major catagories (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> For example, the primary motivations believed to be behind Pfizer’s acquisition of Wyeth in 2009 were Pfizer’s desire to acquire capacity in biological therapeutics and vaccines (a strength for Wyeth) and their desire to obtain Wyeth’s clinical and late-phase pipeline, which was felt by many to be one of the best in the industry at the time.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> On the surface, M&A’s appear attractive. For a pharmaceutical company with a weak pipeline, M&A’s are a relatively quick way to acquire products and late-stage development candidates that enhance the company’s value for shareholders, at least in the short term. However, data suggest that the long-term impact of M&A’s on R&D, especially in large pharmaceutical companies, is not as beneficial. A certain amount of streamlining can occur, with synergies identified, duplications eliminated, and costs cut. These measures appeal to stockholders because they immediately affect the bottom line of the company but do not necessarily translate into a more efficient, productive R&D operation. For example, one measure of long-term value, the identification of new molecular entities (NME’s) approved by the Food and Drug Administration was analyzed by Munos in 2009.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> This analysis of six large pharmaceutical companies involved in mergers, 10 large companies involved in acquisitions, and 14 small (biotech) companies involved in acquisitions showed that, for large companies, mergers did little to increase the average output of NME’s and acquisitions resulted in a significant 70% decrease in NME output. Small companies fared better, with a 118% increase in average NME output following 80% of the acquisitions analyzed. Thus, on average, acquisitions may boost small-company output but, at least for the companies analyzed, do little to enhance large-company productivity. This observation is corroborated by LaMattina,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> who noted that advancement of Pfizer’s internal (i.e., nonacquired) clinical pipeline compounds slowed following their acquisition of Wyeth in 2008.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Motives for M&As in the Pharmaceutical Industry<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">response to industry-wide or company-wide shocks</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">economics of sales and scope</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">access to new technology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">expansion to foreign markets and other stages of the drug distribution chain</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">increased market power and size</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Source: ref <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">41</a>.</p></div></div></div><div class="NLM_p">The negative impact of M&A’s on R&D productivity can be felt at all stages of the drug discovery and development process. In the interest of cutting costs and eliminating duplications, projects are routinely terminated, divisions are dismantled, whole research sites are eliminated, and, of course, R&D scientists are laid off. Although in theory such endeavors offer the opportunity to retain and concentrate the best and brightest scientists, the painful truth is that often, in the name of cost cutting, the more experienced and higher-paid scientists (especially at the bench levels) are among the first to go. Since 2000, over 300 000 pharmaceutical employees have lost their jobs, many to M&A’s and company downsizing. Some have found new jobs with other pharmaceutical or biotech companies, but there are no accurate reports detailing how many displaced Pharma scientists remained in the biopharmaceutical industry versus the number that had to venture outside of the private sector or change their careers to find employment. One must wonder how much of the creativity that led to many of the blockbuster drugs of the 1990s was retained when the companies that discovered those blockbusters were acquired during the 2000s. With fewer scientists to execute projects, it follows that the average number of research projects must be smaller. This reduction in human resources plays a role in how many compounds advance to development. Research budget is another factor. One would think that a merger of two large companies would lead a larger annual research budget for the combined entity. A number of studies, including a 2006 U.S. Congressional Budget Office study (summarized by Tjandrawinata and Simanjuntak<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>) suggest that higher R&D investment correlates with profitability and competitiveness of a company. However, until recently, increased spending has not correlated with an increase in the number of NCE approvals by the FDA. A number of merged entities have reportedly cut back on their research budgets to numbers significantly lower than the combined research budget of the two separate companies. For example, the combined research budget for Pfizer and Wyeth in 2008 was over $11 billion, whereas the 2012 research budget for the merged entity was around $7 billion.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Even merged companies that originally sought to retain a significant portion of their combined research budget, like Merck/Schering-Plough,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> have come under criticism from Wall Street critics and have recently executed major downsizing activities and R&D budget cuts.</div><div class="NLM_p">Fewer drug discovery scientists in the pharmaceutical industry means fewer internal projects, leading to a decreased number of home-grown compounds advancing to development. Later, we will discuss how today’s big Pharma companies are trying to deal with the lost productivity and innovation that comes from reduced numbers of drug discovery scientists. However, the discovery phase of a clinical candidate represents a relatively small portion of the budget compared to the cost of developing that clinical candidate once it is identified. Companies must possess the financial resources to support costly clinical trials to get a new drug to market and into the hands of patients. Although the number of midsized biotech companies with the resources to support a limited number of clinical trials has increased since the 1990s, the number of big Pharma companies with the ability to support multiple clinical trials on multiple candidates has decreased significantly. Some data suggest that when a merger or acquisition occurs between two large companies the number of pipeline candidates advancing into clinical trials can increase, at least in the short term.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> However, it has been argued by others<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> that clinical advancement does not necessarily represent a true measure of productivity, and, as stated earlier, there is testimony from one Pharma insider that acquisition of one large company by another can lead to a slowing of clinical advancement for the pipeline candidates that originated with the acquirer. Regardless of the source of clinical candidates, logic dictates that fewer companies with the financial ability to support multiple clinical trials means less compounds undergoing clinical trials, which has to result in fewer new drugs being developed and brought to market.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> To this point, LaMattina makes a valid observation.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> When critics of the pharmaceutical industry discuss the reductions in numbers of drugs approved each year by the FDA, they often compare the mid- to late-2000s with the 1990s. The truth is that there were fewer large pharmaceutical companies during the mid-to-late 2000s compared to the 1990s, which surely contributed to the reduction in number of new drug approvals.</div><div class="NLM_p last">M&A’s obviously take a toll on the employees who lose their jobs in the process. However, negative impacts can also be felt by employees who are retained, and these negative “vibes” can have detrimental effects on the innovation and productivity of the emerging new corporate entity. During the merger or acquisition, preclinical research, especially for the partner undergoing acquisition, slows or stops completely as the fate of the acquired people and projects is determined. The review process takes several months and has an immeasurable but significant effect on morale and productivity. Both the acquired and the acquiring staff are affected as they worry about their futures. Many begin to seek new employment even before their role in the new company (or lack thereof) is determined. The onus continues for employees who are kept on after the initial acquisition activities are completed because the staff-reduction process often occurs in sequential waves that take upward of a year to complete. Retained scientists may be tempted to shift their research efforts away from risky endeavors that might lead to real breakthroughs to activities intended to enhance the job security so that they will be kept on in the event of future M&A’s or staff reductions. In the current drug discovery environment, safe research that leads to incremental improvements of known therapies may not be enough to ensure the success of companies as they struggle to overcome the patent cliff, the changing world market, and the greater regulatory requirements. Unfortunately, it is these little victories that are perceived as building researcher reputations and ensuring job security in the environment of a merger or acquisition. Going forward, companies must encourage, retain, and reward those scientists who take chances with the goal of discovering breakthrough drugs.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Patent Cliff</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The concept of the patent cliff is well-known to anyone with interest in drug development and the pharmaceutical industry. Starting in 2010, a number of blockbuster drugs (originally defined as drugs selling more than $1 billion per year, although $4 to 4.5 billion in annual sales is now considered blockbuster by most big Pharma companies) began losing patent protection (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Over $68 billion in worldwide sales of branded prescription drugs was lost because of patent expirations and resulting generic competition during the period of 2010–2012,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and some estimates suggest that over $290 billion in sales may be at risk for the period of 2012–2018.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The impact on the branded industry, as a whole, is obvious. However, the damage of losing the majority of sales from a blockbuster drug on an individual company can be devastating. Following the expiration of patent coverage on Lipitor (atorvastatin) in November of 2011, Pfizer lost 59% of its worldwide sales (81% of U.S. sales) in 2012 despite major efforts to maintain those sales and soften the blow from the loss (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Other classic examples of loss in branded sales following patent expiration can be seen with Merck’s Fosamax (alendronate) and Eli Lilly’s Prozac (fluoxetine). Following a successful Paragraph IV challenge in 2008 by Teva (four years before the Fosamax patents were scheduled to expire), Fosamax sales dropped by 50% in 2009.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> A similar successful patent challenge by Barr in 2001 eroded market share of branded Prozac, which fell to generic fluoxetine by 65% in the first two months. By the end of 6 months, branded Prozac accounted for only 16% of the prescriptions written for the popular antidepressant drug.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Blockbuster Drug Patent Expirations between 2011 and 2016<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">year</th><th class="colsep0 rowsep0" align="center">brand name</th><th class="colsep0 rowsep0" align="center">2010 sales (billions of dollars)<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">company</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">Actos<sup>®</sup></td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">Takeda</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">Zyprexa<sup>®</sup></td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">Eli Lilly</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2011</td><td class="colsep0 rowsep0" align="left">Lipitor<sup>®</sup></td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">Pfizer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">Levaquin<sup>®</sup></td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">Janssen</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">Lexapro<sup>®</sup></td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">Forest</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">Seroquel<sup>®</sup></td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">Plavix<sup>®</sup></td><td class="colsep0 rowsep0" align="left">9.1</td><td class="colsep0 rowsep0" align="left">BMS<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a>/ Sanofi</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">Singulair<sup>®</sup></td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">Merck</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2012</td><td class="colsep0 rowsep0" align="left">Diovan<sup>®</sup></td><td class="colsep0 rowsep0" align="left">6.1</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">Cymbalta<sup>®</sup></td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">Eli Lilly</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">OxyContin<sup>®</sup></td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">Purdue</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2013</td><td class="colsep0 rowsep0" align="left">Zometa<sup>®</sup></td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">Nexium<sup>®</sup></td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">Celebrex<sup>®</sup></td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">Prizer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2014</td><td class="colsep0 rowsep0" align="left">Sandostatin<sup>®</sup></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2015</td><td class="colsep0 rowsep0" align="left">Abilify<sup>®</sup></td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">BMS<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2015</td><td class="colsep0 rowsep0" align="left">Gleevec<sup>®</sup></td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">Novartis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2016</td><td class="colsep0 rowsep0" align="left">Crestor<sup>®</sup></td><td class="colsep0 rowsep0" align="left">6.1</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">Source: ref <a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">49</a>.</p></div><div class="footnote" id="t3fn1"><sup>b</sup><p class="last">World-wide sales.</p></div><div class="footnote" id="t3fn2"><sup>c</sup><p class="last">BMS, Bristol-Myers Squibb.</p></div></div></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of introduction of generic Atorvastatin on U.S. Lipitor sales (source: ref <a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">50</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharma has responded to the patent cliff and impending loss of revenue in a number of ways. We have already discussed the dramatic increase in mergers and acquisitions (including a number of mega-acquisitions) that occurred in the period of 2000–2012 as large companies anticipated the unprecedented number of patent expirations and strove to replace their shrinking pipelines with those of other companies. Different companies have embraced the acquisition arena with varying degrees of enthusiasm. Some companies, with Pfizer being the notable example, have chosen inorganic growth through mergers and acquisitions as a major part of their solution to declining revenues. Other companies, such as Eli Lilly, have avoided major M&As. As discussed earlier, M&As offer a short-term solution to the patent cliff issue but may actually hurt long-term growth through their detrimental effects on internal research and development. Growing internal R&D capacity is, in theory, a more favorable solution for long-term growth provided that internal growth successfully leads to the identification and development of innovative new drugs. Only time will tell which strategy, if either, is better.</div><div class="NLM_p">Apart from M&As and increasing internal R&D capacity, other avenues for weathering the patent cliff are being pursued by today’s pharmaceutical companies as they look for the new business models that will help them survive and thrive in today’s changing economic environment. A recent analysis of drug company portfolios from 2008 revealed that, with a few exceptions, most companies were not in a position to replace effectively the revenues soon to be lost to blockbuster patent expirations in the short term.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> To overcome this weakness, companies have considered a number of approaches. We will now discuss some of those approaches.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Abandoning the Blockbuster Mentality</h3><div class="NLM_p last">Some companies have shifted focus away from a preference for identifying and developing potential blockbuster drugs (the so-called blockbuster mentality) to pursuing a greater number of more focused drugs whose separate sales may not reach blockbuster levels but whose combined sales may compensate for the loss of those blockbusters. The cardiovascular drug area is a good example of this strategy. Despite the financial success of a number of cardiovascular drugs (e.g., Actos, Plavix, and Lovenox), investors and companies alike have hungered for a new drug with the level of success seen with the statins, most notably, atorvastatin, whose annual sales exceeded $12 billion for several years. Some companies have now reconsidered that approach. For example, SanofiAventis recently discussed its plans to replace Plavix and Lovenox with a range of drugs with more focused roles such as Multaq, Zaltrap, and Kynamro.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> However, although the past 2 years has seen an increase in the number of FDA approvals of drugs with limited applications in smaller numbers of patients such as targeted cancer drugs, this approach is not without risk. Such specialty drugs rarely move through the approval process any faster than drugs with broader application, and the cost of developing such drugs still approaches $1 billion or more. The result is that the price of such targeted drugs once they reach the market, especially in the U.S., is high because of the limited exclusivity time available to recoup the investment in the drug. For example, Vertex’s Kalydeco, a drug targeting the underlying cause of cystic fibrosis (30 000 cases in the U.S., with 1000 new cases diagnosed annually), costs around $294 000 per year. The high price of such drugs, particularly for politically charged disease areas such as HIV infection and cancer, continues to face criticism and challenge from government officials, lawmakers, insurers, patients, and advocate groups. Thus, this avenue for recouping lost blockbuster revenues may see limited success.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Therapeutic Focus</h3><div class="NLM_p">In addition to a move away from the blockbuster mentality, pharmaceutical companies have been actively seeking new business models that will enhance the chances for survival in the changing environment. Two adaptations that have received significant attention are therapeutic area focus and diversification. For example, in the late 2000s, Pfizer announced their intent to focus on six invest-to-win therapeutic areas (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). These areas were identified on the basis of market, unmet medical need, and the relative difficulty of getting new drugs approved in light of heightened regulatory requirements that new drugs not only be efficacious but also be better than currently available drugs for the same indication. Several other big Pharma companies have developed similar strategies based on the relative rates of success within the various therapeutic areas, and it is evident from Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> that there is a tremendous degree of overlap between big Pharma companies as to which areas they feel offer the best opportunities for growth. It is also evident that some therapeutic areas, like antibiotics (the term anti-infectives in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> refers primarily to virology), have been abandoned by many big companies because of the increased difficulty in getting new drugs approved.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Therapeutic Areas of Focus for Representative Big Pharmaceutical Companies<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">therapeutic areas of focus</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">oncology, pain, diabetes, AD, inflammation, psychoses</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">cardiovascular, diabetes/endocrinology, neuroscience/ophthalmology, oncology, respiratory/immunology, infectious disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">hypertension, metabolism, virology/anti-infectives, neuroscience, oncology, ophthalmology, respiratory, transplantation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td><td class="colsep0 rowsep0" align="left">cardiovascular/metabolic, inflammation, infectious disease, neuroscience, oncology, ophthalmology, respiratory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Eli Lilly</td><td class="colsep0 rowsep0" align="left">neuroscience, urology, cardiovascular, autoimmunity, musculoskeletal, diabetes, oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abbott</td><td class="colsep0 rowsep0" align="left">chronic kidney disease, multiple sclerosis, antivirals, oncology, women’s health, immunology, neuroscience/pain</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS</td><td class="colsep0 rowsep0" align="left">cardiovascular, immunology, metabolics, oncology, virology, neuroscience</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">cardiovascular, anti-infectives, oncology, gastrointestinal, neuroscience, respiratory/inflammation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Takeda</td><td class="colsep0 rowsep0" align="left">cardiovascular, metabolic, neuroscience, respiratory/immunology, oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Johnson and Johnson</td><td class="colsep0 rowsep0" align="left">cardiovascular/metabolic, immunology, anti-infectives, neuroscience/pain, oncology</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last"> Source: company websites.</p></div></div></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Product Diversification</h3><div class="NLM_p last">Although most of the large companies are focusing their pharmaceutical R&D efforts in areas which they hope will foster success, there seems to be a difference in opinion concerning diversification. The 1960s and 1970s saw a wave of diversification by pharmaceutical companies as they sought to maintain revenue flow. This trend was reversed in the 1980s as a result of the success of a number of blockbuster drugs and a move toward the blockbuster mentality paradigm. Today, many pharmaceutical companies own business units that are not based directly on branded pharmaceuticals such as animal health, consumer health, medical devices, and so forth. With the mission of focusing efforts in mind, some companies have begun spinning off some of their satellite business units. Notable examples include Pfizer, who recently spun off their animal health care unit Zoetis, and Abbott, who recently announced that they would separate their medical products and pharmaceutical units into two separate companies. Both of these moves were well-received by investors as indicated by an increase in stock price. However, other companies have taken the opposite path and have embraced diversification as a means of boosting profits and remaining solvent as they work to reinvent their ethical pharmaceuticals business model. Johnson and Johnson, a broadly diversified company, cites that diversified portfolio as one of the elements of its continued success. Companies such as Merck and SanofiAventis have recently cited diversification as an important part of surviving the patent cliff. For example, Bayer (an already diverse company) recently expanded into the vitamins arena with a $1.2 billion purchase of Schiff, and Novartis acquired the ophthalmology company Alcon in 2011 (a $51 billion mega-merger). However, the two major areas of diversification that several big pharmaceutical companies have embraced are biologicals and branded generics (discussed in the section on generic competition).</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Patent Extensions</h3><div class="NLM_p last">A common method of avoiding patent expiration is to extend the patent life for drugs. We have already covered this topic in Part 1 of this series,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and readers are referred to that manuscript for a detailed discussion of the subject. The Hatch–Waxman Act of 1984 provides for patent extensions in recognition of the long development times required for bringing a new drug to market. Up to 50% of the time spent in initial clinical trials and 100% of the time spent in regulatory evaluation can be added to the life of a patent, provided the applicant did not cause undue delay in either of these two processes. However, other patent strategies are routinely used by pharmaceutical companies to extend the exclusivity period of their products, a process referred to by critics of the practice as evergreening.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> These include patenting optimal physicochemical forms of the drug, additional indications, new formulations, active enantiomers of racemates, and branded fixed-dose combinations of the drug (for example, the multiple drug combinations used in HAART treatment of HIV infection). Patent extensions are not always successful. Paragraph IV patent challenges are becoming more common, and a number of noncomposition of matter patents have fallen under litigation, such as the patent covering Norvasc, the besylate salt of the calcium channel blocker amlodipine. Generic companies are beginning to achieve a level of success with their abbreviated new drug applications (ANDAs) by carving out patented uses of drugs from their generic labels. Given the ability of physicians to prescribe a drug for a nonlabeled use in the U.S. (off-label prescribing), companies relying on use patents to protect their branded drug may be forced to police generic company’s public marketing strategies to minimize off-label prescribing of generics for proprietary uses.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Emerging Markets</h3><div class="NLM_p">Another avenue that pharmaceutical companies have pursued in response to declining sales and lost revenue due to the patent cliff is expansion into emerging markets. The topic has recently been discussed in detail in a briefing from the global management firm Booz & Co.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Defined as countries with social or business activity in the process of rapid growth and industrialization, the pharmaceutical concept of emerging markets divides them into three tiers: the BRICMT group (Brazil, Russia, India, China, Mexico, and Turkey), the second-tier group (a diverse group of more mature economies from Eastern Europe, former Soviet bloc nations, and Southeast Asia), and Africa. As opposed to that in the U.S. and EU5 countries, the emerging markets are expected to grow significantly over the next 5 years (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Pharmaceutical companies have already pursued these markets in the past as a source of additional income and continue to do so with renewed vigor in the wake of the patent cliff. The BRICMT nations will likely continue to draw most of the attention because of their stable economic systems and their relatively higher standard of living, although second-tier nations are now being viewed as tempting emerging markets.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharma market development, 2006–2016.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2008, infectious diseases, especially those caused by the HIV virus and chronic parasite-based neglected diseases, made up a significant portion of the disease patterns seen in second-tier and African nations. Pharma’s response to the AIDs epidemic in developing nations has already been discussed in the previous part of this series.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Highly active antiretroviral therapy (HAART) involving combinations of various drugs shows promise in the ongoing battle against AIDS, but the high cost of such combination therapies, especially those whose components are still under patent protection, has become a major issue both in developing countries and in the U.S., where yearly costs for HAART can easily exceed $25 000/year. Contrary to popular criticism, pharmaceutical companies have made some efforts to combat chronic infectious diseases such as trypanosomiasis, leishmaniasis, Dengue fever, and lymphatic filariasis. This aid came in the form of donations of existing drugs and tiered pricing to facilitate drug purchase by foreign governments and involved medical groups. Concern over an inability to recoup investment dissuaded (and continues to dissuade) most companies from engaging in novel drug discovery targeting these diseases, despite their prevalence and devastating impact on victims. A shift in disease patterns in emerging markets is predicted to occur over the next 5 years (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). The prevalence of infectious diseases, particularly HIV/AIDS, is expected to decline and to be replaced by diseases that are already an issue in the U.S. and Europe. In fact, examination of the predicted future disease patterns for the emerging market countries show that their growth coincides with the therapeutic area focus strategies that almost all of the big pharmaceutical companies have already embraced, suggesting that the promise of emerging markets has been incorporated into the new R&D models. However, one issue that remains uncertain is how problematic treatment-resistant bacterial infection will become in the next 20 years. As the FDA comes under renewed pressure to relax approval criteria for new antibiotic candidates, big Pharma continues to withdraw from antibiotic drug discovery, viewing it as too risky. It remains to be seen if the current level of antibiotic research can keep up with the proliferation of multi-drug-resistant strains of bacteria.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Disease patterns in 2008 compared to predicted patterns in 2030 (source: WHO, Booz & Company).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">However, despite the promise of untapped revenue, efforts to exploit those emerging markets by companies have realized limited success and have not reaped the profits originally expected. It became apparent that to be successful in emerging market countries, companies needed to establish themselves locally, either by building internal capacity in the country in question or by partnering with existing resources. A major hindrance to that goal was the inability to identify and recruit qualified local talent. Even today, in countries like China and India where the quality and quantity of local expertise have grown significantly, continuing competition makes it difficult to retain that talent as personnel regularly change positions to move up the corporate ladder. Other challenges also continue to hinder growth into emerging markets. Lack of a good health-care infrastructure in many countries makes it difficult to reach much of the population. Companies will need to work with governments to identify or build systems that identify patients in need of treatment, match those patients with the right drugs, and get those drugs into the hands of the patients. Despite growing economies, cost is still a major issue in emerging markets, especially for new drugs. Many developing countries do not have a prescription cost reimbursement system. Governments and internal health associations are already cognizant of the power of negotiated mass purchasing and many are already moving toward a value-driven drug-pricing system. Costs will have to be kept within the range that the emerging markets can afford to pay and, at the same time, ensure an adequate return on the investment for the companies. Cost-containment measures like local manufacturing may become necessary. Intellectual property considerations are also hindering expansion into emerging markets. This topic will be discussed further when we address competition from generics, but the same patent cliff that is driving companies to look toward emerging markets has become a challenge to tapping into those markets. Increased competition from generics as drugs lose patent protection will be a problem in developing countries just as it is in the U.S. and Western Europe, compounded by a trend toward disregarding patent protection altogether in many developing countries. All of the above-mentioned issues will have to be successfully navigated if the promise of emerging markets is to be turned into reality.</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Cost Cutting</h3><div class="NLM_p">In response to declining revenues as drugs lose patent protection, companies have implemented cost-cutting initiatives to maintain value for investors as they adapt to replace those lost revenues. We have already discussed the short- and long-term impacts of M&As on companies. Consolidation, elimination of redundancy, closure of sites, and reduction in scientific work force all appear to benefit the bottom line in the short term and are usually viewed positively by stockholders. However, there is concern over the negative long-term effects that such activities may have on R&D and the ability to put new drugs on the market going forward. The plain truth is that, with few exceptions, big Pharma is significantly cutting back on internal research and is looking to fill that gap in a number of ways.</div><div class="NLM_p">Arguably, one of the most debated cost-cutting measures that big Pharma has embraced is outsourcing, especially to developing countries like China and India. What started as a strategy to supplement internal resources occasionally has become a means of replacing much of those internal resources and cutting expenses because of the lower cost of doing business. The global pharmaceutical and chemical outsourcing business has grown into an impressive market. Commonly cited figures place the current market value at around $25 billion, with continued growth of 15% expected for several years.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> However, one study by the Tufts University Center for the Study of Drug Development suggests that the contract R&D market could exceed $200 billion.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The term virtual drug discovery has become prevalent. In the early years of pharmaceutical outsourcing, contract research organizations (CROs) would be engaged to synthesize compounds assigned to them by Pharma scientists or to test compounds sent to them in an effort to supplement man power. That model has now grown to one where, oftentimes, a small number of scientists within a pharmaceutical company manage whole drug discovery projects that are now fully executed by the CRO. Additionally, medicinal chemistry and pharmacology are not the only fields to feel the effect of outsourcing. Manufacturing, formulation, ADME, safety, toxicology, and many other functions historically maintained in-house by big pharmaceutical companies are now routinely outsourced.</div><div class="NLM_p">The lure, of course, has always been the reduced cost of supporting these activities in economic climates where the cost of living is relatively low. However, that promise of reduced expenditures has come with some challenges. Selecting a contract service provider and establishing a productive outsourcing collaboration requires significant due diligence and the establishment of a strong interorganization relationship. In the past, issues with cost overruns, quality, failure to deliver services or products, and concerns over confidentiality and intellectual property have arisen. Communication across 10–12 time zones can be difficult and inefficient. To facilitate effective contact and management, some companies have funded or built dedicated facilities for partnered CROs and have embedded company personnel at those facilities, especially in China and India (captive market outsourcing). However, recent court decisions in India to overturn or circumvent patent protection on certain expensive drugs have caused some to question the wisdom of future investment by big Pharma in foreign R&D infrastructure.</div><div class="NLM_p last">Recent changes in the economics of outsourcing has also caused big pharmaceutical companies to rethink their outsourcing strategy. The cost of outsourcing has increased significantly in the past few years as the economies of the developing countries have grown. The gap between the cost of an outsourced full-time equivalent (FTE) in Asia and one maintained internally by a pharmaceutical company has narrowed, and some companies are considering a shift away from an FTE-based outsourcing model to ones where payment is provided for whole projects (project-based outsourcing) or deliverables (value-based outsourcing). It is up to the CRO to provide adequate resources to accomplish the job or project successfully. This model is appealing on the surface because it rewards success. However, significant governance, trust, and effective management is still required, and the potential advantage of having dedicated personnel and facilities is lost as CROs must now manage their own budgets and projects competing for their internal resources. Other outsourcing models that are starting to gain popularity involve paying bonuses above and beyond the basic funding agreement for projects that exceed expectations (incentive-based outsourcing) and sharing the cost of the project with the CRO, who reaps additional rewards if the project become successful (shared risk/shared reward outsourcing). Some companies have elected to insource some R&D rather than outsource it. Downsizing of internal work forces leaves vacant infrastructure, which is filled on a temporary basis by CRO-managed personnel who work on the company’s R&D projects. The concept of insourcing was publicized within the scientific community when Lilly and Albany Molecular Research, Inc. (AMRI) announced a 6 year deal to insource 40 medicinal chemists in 2011. However, other companies had already been employing insourcing, such as J&J and Pfizer, at their research site in Sandwich, U.K. One advantage cited for the Lilly/AMRI collaboration was maximizing real-time exchange of scientific information. The significant growth of U.S.-based scientific CROs in the past 2 years suggests that insourcing may grow in popularity, assuming that adequate numbers of qualified local scientists can still be identified and recruited in the wake of the devastating numbers of jobs lost and careers reinvented over the past 13 years.</div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Partnerships</h3><div class="NLM_p">As the cost and risk of drug development has skyrocketed, the business models for how big Pharma companies interact with smaller biotech tech companies and with each other have also changed. The reductions in research capacity caused by the patent cliff have made companies rethink their ability to stand alone and bear the escalating costs of bringing a drug to market. Now more than ever, companies are looking outside of their own shops to feed their pipelines and for ways to mitigate risk and cost. Although acquisitions of whole companies or subdivisions and licensing of interesting drug candidates still continues to be a viable business model in some cases, the establishment of shared risk/shared reward strategic partnerships has increased dramatically.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In many cases, upfront payments are giving way to smaller initial compensation coupled with milestone payments and the guarantee of royalties if the subject of the partnership advances to market. Of course, there are a number of motivations for the formation of strategic alliances, but cost reduction and risk mitigation figure prominently among these motivations.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p">The partnership model is not limited to big Pharma’s interaction with smaller biotech companies. The past 15 years has seen the establishment of a number of development, marketing, and research alliances between major pharmaceutical corporations. Some examples of co-marketed drugs are given in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Research alliances are also on the rise. Perhaps the best known research alliance among big Pharma companies is the Roche/Genentech alliance, touted by many to be one of the most successful alliances to date, although Roche ultimately acquired Genetech in 2009. Today, even companies like Merck, who historically took a position of independence and self-reliance, are now embracing alliances and partnerships. Merck recently won Deloitte Recap’s 2013 ALLICENSE Breakthrough Alliance Award for their partnership with AiCuris, a German biotech company developing drugs to treat human cytomegalovirus.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Examples of Co-Marketed Drugs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">companies</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">indications</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb, Sanofi</td><td class="colsep0 rowsep0" align="left">Plavix®</td><td class="colsep0 rowsep0" align="left">anticoagulant</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb, Gilead, Merck</td><td class="colsep0 rowsep0" align="left">Atripla®</td><td class="colsep0 rowsep0" align="left">HIV therapy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb, Pfizer</td><td class="colsep0 rowsep0" align="left">Eliquis®</td><td class="colsep0 rowsep0" align="left">anticoagulant</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb, Novartis</td><td class="colsep0 rowsep0" align="left">Zelmac®</td><td class="colsep0 rowsep0" align="left">irritable bowel syndrome</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Briston-Myers Squibb, Otsuka</td><td class="colsep0 rowsep0" align="left">Abilify®</td><td class="colsep0 rowsep0" align="left">antipsychotic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb, AstraZeneca</td><td class="colsep0 rowsep0" align="left">Onglyza®</td><td class="colsep0 rowsep0" align="left">diabetes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb, Sanofi</td><td class="colsep0 rowsep0" align="left">Plavix®</td><td class="colsep0 rowsep0" align="left">anticoagulant</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Merck, Schering Plough</td><td class="colsep0 rowsep0" align="left">Vytorin®</td><td class="colsep0 rowsep0" align="left">high cholesterol</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Merck, Roche</td><td class="colsep0 rowsep0" align="left">Victrelis®</td><td class="colsep0 rowsep0" align="left">hepatitis C</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abbott, Takeda</td><td class="colsep0 rowsep0" align="left">Lurpon®<br /></br>Prevacid®</td><td class="colsep0 rowsep0" align="left">GnRH agonist ulcers, GERD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abbott, Solvay</td><td class="colsep0 rowsep0" align="left">Simcor®</td><td class="colsep0 rowsep0" align="left">high cholesterol</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pfizer, Boeringher Ingelheim</td><td class="colsep0 rowsep0" align="left">Spireva®</td><td class="colsep0 rowsep0" align="left">COPD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pfizer, Easai</td><td class="colsep0 rowsep0" align="left">Aricept®</td><td class="colsep0 rowsep0" align="left">Alzheimer’s disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Johnson & Johnson, Easai</td><td class="colsep0 rowsep0" align="left">AcipHex®</td><td class="colsep0 rowsep0" align="left">ulcer, GERD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bayer, Onyx</td><td class="colsep0 rowsep0" align="left">Stivarga®</td><td class="colsep0 rowsep0" align="left">colon cancer</td></tr></tbody></table></div></div><div class="NLM_p last">The flexibility of the alliance model is being tested in other ways as well. In 2008, Critical Path Institute established the Coalition Against Major Diseases (CAMD), a consortium of industry, government, and academic partners dedicated to the treatment of Alzheimer’s and Parkinson’s diseases. In 2010, CAMD partnered with Johnson & Johnson, Sanofi-Aventis, GlaxoSmithKline, AstraZeneca, and Abbott Laboratories to accumulate and make available the data from Alzheimer’s disease clinical trials in the hopes of better understanding and overcoming the failure of drugs examined to date. TransCelerate Biopharma, a consortium composed of Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech, and Sanofi, was launched in 2012. The initial focus of this collaboration was the enhancement and improvement of clinical study execution. Plans are in place to share encouraging results with other alliances such as CAMD. Another recent publicized partnership is Enlight Biosciences. This consortium, backed by Abbott, Merck, J&J, Lilly, Novartis, and Pfizer, seeks out early innovation from academia and biotech, which is shared between the partners. In some cases, companies are even beginning to share screening libraries as part of alliances to enhance the chances of identifying viable hits for new targets. An example of this unprecedented action is the sharing of HTS libraries by Sanofi, AstraZeneca, and Easai as part of the Tuburculosis Drug Accellerator Partnership. The establishment of strategic alliances in their various forms seems to be on the rise, and it is hoped that this new business model of cooperation and collaboration will help the industry to survive, evolve, and continue to pursue its essential mission of delivering innovative new medicines to treat unmet medical needs.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Fierce Generic Competition</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anyone associated with pharmaceutical research is aware of the impact that generic competition has had on the branded drug industry. In 2011, the generic drug market reached a new high, with 80% of prescriptions being filled with a generic.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> We have already mentioned the loss in worldwide branded drug sales for the period of 2010–2012 because of the introduction of generics ($68 billion) and the sales that may be at risk for the period of 2012–2018 ($290 billion). Market analysis estimates that the global generic market value in 2011 was $225 billion, and future predictions suggest that the global generic market could be as high as $385 billion by 2016. Today’s generic companies are focused, savvy, and organized, and the generic industry has matured to the point where mergers and acquisitions are now occurring as larger generic firms maneuver for dominance in the market.</div><div class="NLM_p">The rise of generics, touted by governments, insurers, and special interest groups as a key factor for keeping the cost of drugs down, have not only been encouraged but also have been facilitated. The Paragraph IV certification of the 1984 Hatch–Waxman Act allows generic drug companies to attempt to invalidate patents and file Abbreviated New Drug Applications (ANDAs) as soon as 4 years after a new drug is approved and provides protection and limited risk of liability from infringement. Paragraph IV challenges have become a core business strategy for many generic companies. From the data shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, it is evident that the number of ANDA-related litigations has trended upward since 1995.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> On average, roughly 55% of these cases are decided favorably for the ANDA sponsor in recent years, and the issue is not limited only to U.S. drug sales. India, one of the largest producers of generic drugs, began issuing pharmaceutical patents only in 2005. However, three recent court decisions have implications on branded drug sales, not only in India but also in the rest of the world. In 2006, the Indian patent appeal board revoked an awarded patent on Roche’s antiviral drug Pegasys, the first pharmaceutical patent awarded in India. In 2012, the Indian government issued a compulsory license to Natco Pharma to manufacture and sell a generic version of Nexavar, an anticancer drug comarketed by Bayer and Onyx. The high price and the need for access to the drug by Indian patients was cited as the justification for the license. Most recently, the Indian Supreme Court ruled against patent protection for Novartis’ anticancer drug Gleevec. These decisions have paved the way for manufacture and distribution of these drugs, not only in India but also throughout much of the world where patent enforcement is not acknowledged or vigorously pursued. Issues such as these raise concern over how impactful the emerging markets will actually be if generic versions are immediately available to compete with new branded drugs, especially in markets where the economies already dictate the need for reduced prices.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Court decisions from ANDA trials (source: ref <a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">62</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because of the dramatic impact that increased generic competition has had on revenues, branded pharmaceutical companies have instituted a number of strategies for mitigating the damage that this challenge has caused. We have already discussed patent life extension strategies such as patenting new indications, active enantiomers, new formulations, and fixed dose combinations. These approaches have met with mixed success in litigation proceedings, and generic companies have learned to carve out<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> newly patented indications from their ANDA applications and rely on off-label prescribing to support sales of the generic. In Part 1 of this series, we also discussed the pay for delay strategy whereby owners of branded drug owners pay generic companies to delay their ANDA applications. In fiscal year 2012, the Federal Trade Commission (FTC) received notice of 140 final settlements between branded drug companies and generic challengers. Forty of these settlements involved payments or promises not to market authorized generics in exchange for delayed generic entry into the market.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The FTC contends that this practice is unethical but has realized limited success in litigating against such pay for delay settlements. On June 17, 2013, the U.S. Supreme Court reversed a decision by the Eleventh Circuit Court of Appeals that a pay for delay agreement struck between Solvay and Watson (now known as Actavis) over Androgel (a testosterone supplement) was lawful but rejected the FTC’s suggestion that such reverse payments be considered unlawful. In essence, the court opened the way for future litigation on the subject but did not render a definitive opinion on the lawfulness of the practice. Apart from patenting strategies and business arrangements, big Pharma has embraced two major R&D initiatives to address the challenge of increased generic competition. Those two initiatives, biopharmaceuticals and authorized generics, will be discussed in more detail in the following sections.</div><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Authorized Generics</h3><div class="NLM_p">When a generic pharmaceutical company successfully prosecutes a Paragraph IV challenge, the first to file the ANDA receives a 180 day exclusivity period during which no other generic companies can market their own generic version of the drug in question. The price of the generic drug during this exclusivity period is usually higher (on average, 82–86% of the pre-entry branded price) than when additional generic competition begins after the 180 day period, which is an incentive for being the first to file an ANDA. However, this proviso in the Hatch–Waxman Act does not apply to the original owner of the branded drug, who can market their own authorized generic version of the drug during the exclusivity period. The authorized generic version contains both active and inactive ingredients that are identical to those of the branded form. This differs from other generic versions, which only contain the identical active agent. The branded company usually commissions a generic company to market the authorized generic drug under their name, although some companies such as Abbott, Novartis, Sanofi, and AstraZeneca have chosen to establish or purchase their own generic subsidiaries to support the regional or worldwide marketing of branded generics. A current list of authorized generic drugs can be found on the U.S. FDA’s web site.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p">Branded pharmaceutical companies contend that the driving force for authorized generics is the maintenance of revenues following patent expiration or Paragraph IV challenge. Generic companies and critics of the pharmaceutical industry contend that the major reason for the practice is to discourage generic competition by eliminating the profit for the generic company, a position also held by the FTC. However, although the practice of marketing authorized generics may be perceived as unethical by the FTC, the patient population apparently does not agree with that assessment. According to a 2005 public survey carried out by Roper Public Affairs & Media for Prasco Laboratories, an authorized generic drug company, over 80% of Americans want the option of choosing authorized generics.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Interestingly, what could be perceived as bad for generic competition may actually contribute to lower generic costs during the 180 day first to file exclusivity period, according to the 2011 report from the FTC.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> On average, the retail cost of generic drugs during the first 180 days was 4–8% lower in the face of authorized generic competition.</div><div class="NLM_p last">Internal records from generic companies do not specifically discuss how the threat of authorized generics affects their Paragraph IV strategies, and the steady increase in Paragraph IV challenges suggests that the threat is not a significant deterrent. However, the FTC’s analysis does suggest that authorized generics do have a significant impact on the revenues of competing generic firms during the 180 day exclusivity period. Depending on how the data are analyzed, the presence of authorized generic competition reduced the revenues of the ANDA first filer by 40–52% on average. Additional evidence for the impact of authorized generics can be found in a 2012 follow-up analysis to the 2011 FTC report.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Of the 40 pay for delay settlements reported to the FTC in 2012, 19 of them involved compensation in the form of a no-authorized-generic commitment (up from the 11 no-authorized-generic settlements reported in 2011). Regardless of the driving force, authorized generics seem to be one of the more successful strategies for addressing the challenge of increased generic competition.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Biopharmaceuticals</h3><div class="NLM_p">Another strategy that the branded pharmaceutical industry has undertaken to counter the challenge of increased generic competition is expansion into the area of biopharmaceuticals.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(68)</a> This general class of drug comprises proteins derived from recombinant DNA technology. Examples of marketed biopharmaceuticals include cytokines, clotting factors, hormones, enzymes, antibodies, vaccines, and cell- and tissue-based therapies. The first biopharmaceutical approved for human use was Humulin (recombinant human insulin), developed by Genentech and marketed by Lilly in 1982. Since that time, the biopharmaceutical market has grown significantly. In 2011, biopharmaceuticals accounted for nearly 16% of the global pharmaceutical market (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>), and some estimates suggest that the biopharmaceutical market could grow to over $320 billion by 2020.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(69)</a></div><div class="NLM_p">The biopharmaceutical industry has come a long way since the introduction of Humulin. For example, the therapeutic antibody field has realized success, particularly in the areas of cancer and immunological disorders. In the cardiovascular field, recent clinical results show that REGN727/SAR236553, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), reduces low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia patients, including those on stable statin therapy and those intolerant to statin therapy.<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(70, 71)</a> Today, thousands of companies worldwide are associated with or focus specifically on biopharmaceutical R&D, manufacture, and development. A list of the top 10 biopharmaceutical companies based on 2012 revenues from sales of biopharmaceuticals is given in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Many of these companies started life as small biotech firms but have grown significantly. In addition, a number of big Pharma companies with a history of focus in small molecules has expanded into biopharmaceuticals, partly as a way of countering the onslaught of generic competition. For example, Roche initially partnered with and ultimately acquired Genentech and now considers itself to be essentially a biopharmaceutical company. One of the primary motivations for Pfizer’s purchase of Wyeth was to acquire its biopharmaceutical R&D resources and pipeline. Analysts predict that the scramble to establish or acquire biopharmaceutical capacity will continue over the next several years, with smaller low-valuation companies being the target of M&As throughout the world.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(72)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Percentage of biopharmaceuticals in the pharmaceutical market, 2001–2011 (source: ref <a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">69</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Top 10 Biopharmaceutical Companies in 2012<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">company</th><th class="colsep0 rowsep0" align="center">2012 biopharma revenues (billions of dollars)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">Roche/Genentech</td><td class="colsep0 rowsep0" align="left">37.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">Amgen</td><td class="colsep0 rowsep0" align="left">17.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">Novo Nordisk</td><td class="colsep0 rowsep0" align="left">13.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">Merck Serono</td><td class="colsep0 rowsep0" align="left"> 8.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">Baxter</td><td class="colsep0 rowsep0" align="left">6.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">Biogen Idec</td><td class="colsep0 rowsep0" align="left">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">CSL Behring</td><td class="colsep0 rowsep0" align="left">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">Allergan</td><td class="colsep0 rowsep0" align="left">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">Alexion</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">Regeneron</td><td class="colsep0 rowsep0" align="left">0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last">Source: company annual reports.</p></div></div></div><div class="NLM_p">Because of their complex structures, biopharmaceuticals are produced by living organisms. Specialized techniques and facilities are required to generate the quantities of GMP-quality biopharmaceuticals needed to market one of these agents as a drug. It is their structural complexity that also gives biopharmaceuticals their appeal as a means of staving off generic competition. That structural complexity makes them difficult to reproduce exactly, and that aspect is what has attracted the branded pharmaceutical companies. The process for producing any given biopharmaceutical is specific, and the conditions, cell lines, and reagents used can affect the outcome. Often, the process for preparing a marketed biopharmaceutical is patented along with the actual drug. Although a version of the biological agent in question produced via different conditions may have the same primary-structural sequence, secondary-structural features such as glycosylation pattern can vary, and those subtle variations can affect safety and clinical efficacy. For these reasons, there are no biogenerics, which, by definition, contain the identical active agent. Rather, the biological generic industry has been left with the pursuit of similar agents with similar clinical profiles. These agents have come to be known as follow-on biologicals or biosimilars.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(73)</a></div><div class="NLM_p">Apart from the difficulty in production and the expense, a significant competitive advantage for biopharmaceuticals comes from the regulatory requirements imposed on biosimilars. Generic approvals require only that bioequivalence is achieved and that safety and tolerance is demonstratred. This can usually be accomplished with phase I clinical trials at an average development cost of $1–5 million. Development times are relatively short, and postmarketing pharmacovigilance is not required. Biosimilars do not contain the exact active agent as the branded biopharmaceutical that they are trying to replace and are treated more like new chemical entities (NCEs). Both safety/tolerance and efficacy must be demonstrated in clinical trials, with development times often running 6–10 years and development costs exceeding $100 million. Like NCEs, postlaunch safety updates and pharmacovigilance are required for biosimilars. Another added incentive is that, unlike traditional generics, biosimilars cannot be automatically substituted for the branded biopharmaceutical that they intend to replace by the pharmacy or insurance provider. They must be specifically prescribed. This gives the branded pharmaceutical company the opportunity to maintain market share by cultivating prescriber and patient loyalty.</div><div class="NLM_p">However, it is not clear how long the biopharmaceutical sector will continue to be a safe haven for branded pharmaceutical exclusivity. With the realization that biopharmaceuticals can be effective drugs that sometimes treat conditions and diseases that small molecules do not has come pressure to facilitate the availability of lower-priced biosimilars. Regulatory agencies throughout the world are beginning to issue guidelines for accelerated approval of biosimilar agents,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(74)</a> and some biosimilars have already reached the market such as Sandoz’s Omnitrope (marketed in the European Union in 2006). In the U.S., President Obama signed the Patient Protection and Affordable Care Act on March 23, 2010.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(75)</a> This Act contained the Biological Price Competition and Innovation Act, which established an abbreviated approval pathway for biosimilars in the U.S. This pathway requires that biosimilar agents meet two basic criteria: (1) the biosimilar must be highly similar to the reference product not withstanding minor differences in minor inactive components and (2) no clinically meaningful differences can exist between the biosimilar and the reference product in terms of safety, purity, and potency. Also, it must be shown that the biosimilar has the same indication, route of administration, dosage form, and strength as the reference product.</div><div class="NLM_p last">The Patient Protection and Affordable Care Act was designed to facilitate the approval of biosimilars. However, it does provide the owner of the original branded biopharmaceutical considerable protection, which is an added incentive for using biopharmaceuticals to counter generic competition. An abbreviated Biological License Application (BLA) cannot be filed by the biosimilar drug’s applicant less than 4 years following approval of the reference product, and the FDA must wait at least 12 years following original licensing of the reference product before a BLA on a biosimilar can be approved. As with ANDAs, the first to file a BLA on a biosimilar is awarded an exclusivity period during which no other biosimilars can be introduced. The FDA has established the Biosimilar Implementation Committee, but the committee has not issues guidelines on what specific clinical data will be required for approval of biosimilars. Thus, at present, investment in biopharmaceuticals remains an effective business strategy, especially in the U.S. However, the generic industry in the rest of the world has already expanded into the biosimilars arena, especially in Europe, India, and other emerging market countries. There is growing pressure on the FDA to clear the way for biosimilar approvals. Thus, it is unclear how long biopharmaceutical investment will remain an effective tool in the branded pharmaceutical company’s arsenal of tools to counter generic competition.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Stagnant Success Rate</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65016" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65016" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The data shown in Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> have been presented many times. Some argue that new drug approvals may not be the best way to judge productivity, but the data in Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> speak clearly to one of the issues facing the pharmaceutical industry: a stagnant return on increased R&D spending and new drugs whose earnings will not be able to replace the lost revenue of blockbusters going off-patent. This discrepancy has been dubbed the innovation gap. The recent increase in FDA approvals in 2011 and 2012 has been cited as an encouraging trend that could signify that the new drug drought may be coming to an end. However, an examination of those 2011 to 2012 approvals (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>) suggests that the vast majority of new small-molecule drugs approved during that time period are intended for limited use in smaller numbers of patients. Similar trends can be seen for compounds in phase III clinical trials in 2012.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(76)</a> Many of these new drugs and drug candidates have orphan drug status. Thus, despite the higher cost of many of these agents,<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(77)</a> they will not likely recoup revenues to match those of blockbuster drugs like atorvastatin. So, apart from fewer major players in the field, why are no more drugs crossing the finish line despite a 4-fold increase in spending? Several factors are believed to contribute to the lack of correlation between R&D spending and the number of new drug approvals. Some of these factors are discussed in the following sections.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Correlation of R&D spending by PhRMA members and number of new chemical entities approved by the FDA from 1995 to 2012 (source: PhRMA web site).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Increased Cost</h3><div class="NLM_p last">First and most obviously, salaries and the cost of developing drugs have gone up significantly since the early 1990s. The U.S. Bureau of Labor Statistics estimates that the cost of living has increased by over 65% since 1992. The fees for a U.S. NDA in 1995 were in the range of $200 000. In 2012, those fees exceeded $1.8 million.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(78)</a> Second, as discussed earlier, the number of large pharmaceutical companies capable of supporting several multiple-site clinical trials has declined. Examination of Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a> shows that 64% of the NMEs approved by the FDA in 2012 were developed by smaller companies. This is in contrast to 1996 (the year when a record-setting 53 NMEs were approved), where big Pharma companies accounted for over 50% of NME approvals and several companies had multiple approvals in that year. In fact, the data in Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> suggest that the 53 NMEs approved in 1996 and the 36 NMEs approved in 2004 are, in fact, aberrations and that 20–25 NME approvals per year is a more realistic average. Still, despite a 3- to 4-fold increase in R&D spending since the early 1990s, the number of NMEs approved each year has remained roughly the same, and it is this apparent stagnation in productivity that has many interests within the biomedical arena concerned.</div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Higher Safety Hurdles</h3><div class="NLM_p">Another reason for a stagnant success rate is the difference in the requirements for a NME to be approved today compared to 15 years ago. Safety hurdles for new drugs are much higher than they were back in the 1990s. That is not to say that unsafe drugs were approved back then. Rather, following a pair of high-profile drug recalls in the 2000s (Wyeth’s fenfluramine, part of the Fen-Phen anti-obesity drug combination and Merck’s anti-inflammatory drug Vioxx) and elevated safety concerns over Wyeth’s conjugated estrogens drug Premarin, the FDA began postponing or rejecting significantly more NDAs based on safety concerns. There was a dramatic increase in the number of approvable letters issued by FDA review committees, requiring additional costly clinical trials for NDA applications that might otherwise have been approved 5 years earlier. This increase in safety requirements resulted in a number of companies dropping late-stage development of drugs after having invested hundreds of millions of dollars.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(79)</a> The obvious question that follows is, if safety requirements are much more stringent now, then how was it possible to get 30 NMEs approved in 2011 and 39 in 2012? The first answer to this question lies in a policy change by the FDA. In 2008, the FDA announced that it would replace the approvable letter with a clear response delineating what was needed to approve an NDA.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(80)</a> The frustration and lack of a path forward experienced by NDA applicants was now replaced by guidance that helped companies continue to move late-stage programs forward. The second answer lies in the indications for those 69 recent NME approvals. From Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>, it can be seen that the majority of the NMEs approved in 2011 and 2012 were for life-threatening diseases or for orphan diseases where no other drugs exist. In those cases, some risk can be tolerated. In contrast, many of the NDAs filed just after the post-recall debacle in 2002–2004 were for drugs intended to treat big-market diseases. There were drugs already approved for many of these indications. The presence of existing safe, effective treatments for these diseases made it easier for the FDA to delay or deny second-generation or me-too drugs that did not display exceedingly good safety profiles.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Small Molecule New Chemical Entities Approved by the FDA in 2011 and 2012<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">2011 company</th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">2012 company</th><th class="colsep0 rowsep0" align="center">indication</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Adcetris<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Seattle Genetics</td><td class="colsep0 rowsep0" align="left">Hodgkin lymphoma</td><td class="colsep0 rowsep0" align="left">Amyvid<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Avid</td><td class="colsep0 rowsep0" align="left">PET imaging</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Arcapta<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">COPD</td><td class="colsep0 rowsep0" align="left">Aubagio®</td><td class="colsep0 rowsep0" align="left">Sanofi</td><td class="colsep0 rowsep0" align="left">multiple sclerosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Benzysta®</td><td class="colsep0 rowsep0" align="left">GSK/Human Genome</td><td class="colsep0 rowsep0" align="left">lupus</td><td class="colsep0 rowsep0" align="left">Belviq®</td><td class="colsep0 rowsep0" align="left">Arena</td><td class="colsep0 rowsep0" align="left">obesity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Brilinta<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">acute coronary syndrome</td><td class="colsep0 rowsep0" align="left">Bosulif®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">CML</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caprelsa®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">thyroid cancer</td><td class="colsep0 rowsep0" align="left">Choline C11 Injection</td><td class="colsep0 rowsep0" align="left">Mayo Clinic</td><td class="colsep0 rowsep0" align="left">PET imaging</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Daliresp®</td><td class="colsep0 rowsep0" align="left">Forest</td><td class="colsep0 rowsep0" align="left">COPD</td><td class="colsep0 rowsep0" align="left">Cometriq<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Exelixis</td><td class="colsep0 rowsep0" align="left">thyroid cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DaTscan<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">GE</td><td class="colsep0 rowsep0" align="left">SPECT imaging</td><td class="colsep0 rowsep0" align="left">Elelyso<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Prizer/Protalix</td><td class="colsep0 rowsep0" align="left">Gaucher disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dificid®</td><td class="colsep0 rowsep0" align="left">Optimer</td><td class="colsep0 rowsep0" align="left">Clostridium-associated diarrhea</td><td class="colsep0 rowsep0" align="left">Eliquis®</td><td class="colsep0 rowsep0" align="left">Pfizer/BMS</td><td class="colsep0 rowsep0" align="left">anticoagulant</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Edarbi<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Takeda</td><td class="colsep0 rowsep0" align="left">hypertension</td><td class="colsep0 rowsep0" align="left">Erivedge®</td><td class="colsep0 rowsep0" align="left">Genentech</td><td class="colsep0 rowsep0" align="left">basal cell carcinoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Edurant®</td><td class="colsep0 rowsep0" align="left">Jannsen</td><td class="colsep0 rowsep0" align="left">HIV</td><td class="colsep0 rowsep0" align="left">Fulyazq<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Salix</td><td class="colsep0 rowsep0" align="left">HIV-associated diarrhea</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Erwinaze<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">EUSA</td><td class="colsep0 rowsep0" align="left">ALL</td><td class="colsep0 rowsep0" align="left">Fycompa®</td><td class="colsep0 rowsep0" align="left">Eisai</td><td class="colsep0 rowsep0" align="left">epilepsy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Eylea®</td><td class="colsep0 rowsep0" align="left">Regeneron</td><td class="colsep0 rowsep0" align="left">macular degeneration</td><td class="colsep0 rowsep0" align="left">Gattex®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">NPS</td><td class="colsep0 rowsep0" align="left">short bowel syndrome</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ferriprox®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ApoPharma</td><td class="colsep0 rowsep0" align="left">thalassemia</td><td class="colsep0 rowsep0" align="left">Iclusig<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Ariad</td><td class="colsep0 rowsep0" align="left">CML</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Firazyr®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Shire</td><td class="colsep0 rowsep0" align="left">angioedema</td><td class="colsep0 rowsep0" align="left">Inlyta®</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">kidney cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gadavist<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Bayer</td><td class="colsep0 rowsep0" align="left">CNS imaging</td><td class="colsep0 rowsep0" align="left">Jetrea®</td><td class="colsep0 rowsep0" align="left">ThromboGenics</td><td class="colsep0 rowsep0" align="left">symptomatic vitreomacular adhesion</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Horizant<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">GSK/Xenoport</td><td class="colsep0 rowsep0" align="left">restless legs syndrome</td><td class="colsep0 rowsep0" align="left">Juxtapid<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Aegerion</td><td class="colsep0 rowsep0" align="left">familial hypercholesterolmia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Incivek<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Vertex</td><td class="colsep0 rowsep0" align="left">hepatitis C</td><td class="colsep0 rowsep0" align="left">Kalydico<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Vertex</td><td class="colsep0 rowsep0" align="left">cystic fibrosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Jakafi<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Incyte</td><td class="colsep0 rowsep0" align="left">myelofibrosis</td><td class="colsep0 rowsep0" align="left">Kyprolis®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Onyx</td><td class="colsep0 rowsep0" align="left">myeloma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Natroba<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">ParaPRO</td><td class="colsep0 rowsep0" align="left">head lice</td><td class="colsep0 rowsep0" align="left">Linzess<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Ironwood</td><td class="colsep0 rowsep0" align="left">IBS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Nulojix®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">BMS</td><td class="colsep0 rowsep0" align="left">transplant rejection</td><td class="colsep0 rowsep0" align="left">Myrbetriq®</td><td class="colsep0 rowsep0" align="left">Astellas</td><td class="colsep0 rowsep0" align="left">overactive bladder</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Onfi<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Lundbeck</td><td class="colsep0 rowsep0" align="left">Lennox-Gastaut syndrome</td><td class="colsep0 rowsep0" align="left">Neutroval<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Sicor/Teva</td><td class="colsep0 rowsep0" align="left">neutropenia from kidney disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Protiga<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">GSK/Valient</td><td class="colsep0 rowsep0" align="left">seizures</td><td class="colsep0 rowsep0" align="left">Omontys®</td><td class="colsep0 rowsep0" align="left">Affymax</td><td class="colsep0 rowsep0" align="left">anemia from kidney disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tradjenta<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Boehringer</td><td class="colsep0 rowsep0" align="left">type-2 diabetes</td><td class="colsep0 rowsep0" align="left">Perjeta®</td><td class="colsep0 rowsep0" align="left">Genentech</td><td class="colsep0 rowsep0" align="left">breast cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Victrelis<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">hepatitis C</td><td class="colsep0 rowsep0" align="left">Picato®</td><td class="colsep0 rowsep0" align="left">LEO</td><td class="colsep0 rowsep0" align="left">actinic keratosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Viibryd®</td><td class="colsep0 rowsep0" align="left">Forest</td><td class="colsep0 rowsep0" align="left">depression</td><td class="colsep0 rowsep0" align="left">Prepopik<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Ferring</td><td class="colsep0 rowsep0" align="left">colonoscopy preparation</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Xalkori®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">lung cancer</td><td class="colsep0 rowsep0" align="left">Abthrax<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Human Genome/GSK</td><td class="colsep0 rowsep0" align="left">anthrax</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Xarelto®</td><td class="colsep0 rowsep0" align="left">Jannsen</td><td class="colsep0 rowsep0" align="left">anticoagulant</td><td class="colsep0 rowsep0" align="left">Signifor®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">Cushing’s disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Yervoy<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">BMS</td><td class="colsep0 rowsep0" align="left">melanoma</td><td class="colsep0 rowsep0" align="left">Sirturo<sup>TM,</sup><a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Johnson & Johnson</td><td class="colsep0 rowsep0" align="left">tuburculosis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Zelboraf®</td><td class="colsep0 rowsep0" align="left">Genentech</td><td class="colsep0 rowsep0" align="left">melanoma</td><td class="colsep0 rowsep0" align="left">Stendra<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Vivus</td><td class="colsep0 rowsep0" align="left">erectile dysfunction</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Zytiga®</td><td class="colsep0 rowsep0" align="left">Janssen</td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">Stivarga®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Bayer</td><td class="colsep0 rowsep0" align="left">colorectal cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Stribild®</td><td class="colsep0 rowsep0" align="left">Gilead</td><td class="colsep0 rowsep0" align="left">HIV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Surfaxin®</td><td class="colsep0 rowsep0" align="left">Discovery Laboratories</td><td class="colsep0 rowsep0" align="left">respiratory distress</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Synribo®</td><td class="colsep0 rowsep0" align="left">Teva</td><td class="colsep0 rowsep0" align="left">CML</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Tudorza<sup>TM</sup><br /></br>Pressair<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Forest</td><td class="colsep0 rowsep0" align="left">COPD</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Voraxaze®<a class="ref internalNav" href="#t7fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">BTG</td><td class="colsep0 rowsep0" align="left">methotrexate toxicity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Xeljanz®</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">arthritis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Xtandi®</td><td class="colsep0 rowsep0" align="left">Astellas</td><td class="colsep0 rowsep0" align="left">prostate cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Zaltrap®</td><td class="colsep0 rowsep0" align="left">Gilead</td><td class="colsep0 rowsep0" align="left">HIV</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Zioptan<sup>TM</sup></td><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">glaucoma</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">Abbreviations: ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; COPD, chronic obstructive pulmonary disorder; HIV, human immunodeficiency syndrome; IBS, irritable bowel syndrome; PET, positron emission topography; and SPECT, single photon emission computed tomography. Source: FDA website (fda.gov).</p></div><div class="footnote" id="t7fn1"><sup>b</sup><p class="last">Signifies orphan drug status.</p></div></div></div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Need for Differentiation</h3><div class="NLM_p">Another reason for the apparent decrease in NME approvals is the increased demand not only for efficacy but also for differentiation from existing treatment options. A 2012 commentary by Light and Lexchin, while quite critical of the pharmaceutical industry, did present some interesting figures on the percent of drugs approved since the mig-1970s that were considered as important therapeutic gains.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(81)</a> In the 1990s, approval was contingent on the drug being safe and showing efficacy. In fact, physicians expressed approval for having several options in treating their patients because of idiosyncratic differences in how patients responded to a particular drug class, structural scaffold, or individual drug. Times have changed. Although the FDA says that no regulations have changed for drug approvals, they are now using comparative data to make some decisions and are scrutinizing noninferiority data in NDAs, according to a 2010 report by the U.S. Government Accountability Office.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(82)</a> The scrutiny does not stop at the regulatory level. In today’s economy, payers, health care providers, and even patients are reluctant to pay for new drugs that do not provide significant benefits to patients, especially those with high price tags. International health care assessment agencies such as the U.K.’s National Institute for Health and Clinical Excellence and Germany’s Institute for Quality and Efficiency in Health Care are having considerable influence on a drug’s commercial potential as well as the FDA’s decision on whether or not to approve it. Drug approvals are increasingly becoming dependent on value.</div><div class="NLM_p last">In response to these heightened regulatory and economic hurdles, the industry has modified a number of its development strategies. Portfolio management within companies has begun embracing the concept of value-driven drug development, focusing efforts on drugs that demonstrate value to the many stakeholders that now influence the commercial potential and regulatory approval process, including payers, insurers, health care providers, and even patients.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(83)</a> Efficient project management with clear goals, go/no-go points, and advancement criteria are critical for this approach to have a meaningful impact. Some companies use a clinical utility index or medical differentiation index,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(84)</a> a mathematical algorithm that weighs a number of characteristics and compares them to those of competing drugs that are already on the market. The concept of differentiation is being introduced earlier in the drug discovery process. Marketing and regulatory team members are becoming involved earlier in projects as well. Drug candidates that are less likely to meet safety or differentiation criteria are being dropped from development earlier, before costly phase III clinical trials begin. Consulting agencies have sprung up that provide guidance and insight on how to differentiate new drug candidates from currently existing products.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(85, 86)</a> Phrases like “streamlined clinical trials” and “if you must fail, then fail early” have become commonplace and reinforce the fact that the industry has finally begun to accept the need for increased efficiency and a change in its development strategy.</div></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Decrease in Preclinical R&D Innovation</h3><div class="NLM_p">The wave of consolidation and downsizing that the industry has experienced in the past 10 years has led to one undeniable conclusion: there are less preclinical drug discovery scientists, which means less internal capacity for discovering new drugs. Although internal basic research into new drug targets was a part of some companies’ business models in the 1980s, that trend declined throughout the 1990s. Companies came to rely on government, academic, and biotech research as the source of their targets. In fact, many companies have begun downsizing or spinning off their preclinical discovery R&D groups in an effort to focus on the development phase. With the loss of over 300 000 pharmaceutical jobs since 2001, it is reasonably accurate to assert that little basic research is now performed internally in major pharmaceutical company laboratories. This is relevant in light of the fact that the regulatory agencies and stakeholders who impact the pharmaceutical industry are beginning to demand an increase in the true therapeutic value of the new drugs coming to market. The untreated or poorly treated diseases of today seem to be more complicated. For example, it has become increasingly obvious that there will probably be no one universal drug to treat cancer because each cancer type has its own individual characteristics. Despite decades of drug discovery and development for Alzheimer’s disease, no drug exists that can halt the progression of this devastating disease. Finding effective drugs for these and other treatment-defying diseases will require innovation and breakthroughs in our basic understanding of the disease processes. That innovation has to come from somewhere if the industry is to survive.</div><div class="NLM_p">One source of the much needed innovation is the highly focused biotech industry, where companies tend to specialize in one disease area or drug target. The synergy between big Pharma and the biotech industry has been discussed in many venues and is well-known. The one change in that relationship that merits comment here is the approach that big Pharma has adapted in their deals with biotech companies. Because of the cost of development and the increased risk, many big Pharma companies have moved away from the traditional licensing arrangements of the 1980–1990s in favor of codevelopment agreements where both the cost of development and the rewards of success are shared. From Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>, it can be seen that five of such codeveloped drugs received FDA approval in the past 2 years.</div><div class="NLM_p">Another source of innovation and basic research that big Pharma has embraced is academic laboratories. Pharmaceutical companies have made investments in academic research and continue to do so, although at a significantly diminished level because of cost constraints. Historically, academic laboratories have focused on basic research because they were primarily funded by public money in the form of government grants. The ideas coming out of academia were innovative (they had to be to compete successfully for grant money) but still required significant work to turn them into viable drug targets. This translation from concept to target was the subject of much of the basic research that was being done internally by big Pharma in the 1980–1990s. However, as internal basic research diminished, so did their capacity for turning basic discoveries from academia into drug discovery projects.</div><div class="NLM_p">However, a new entity has arisen that hopes to help fill the innovation gap left behind by the downsizing of Pharma preclinical research groups. That entity is the academic drug discovery group. One of the primary missions of an academic drug discovery group is to help academic scientists with innovative ideas turn those ideas into something that will appeal to an industrial partner. A few academic groups have been successful at getting whole research projects funded by pharmaceutical companies, but for the majority of academic research, the term “appealing to an industrial partner” is synonymous with “clinical candidate”. Academic drug discovery groups provide the early discovery capacity to help mold innovative findings into tangible products that can be patented and licensed to development partners.</div><div class="NLM_p">Recently, a group from the University of North Carolina at Chapel Hill (UNC) conducted a survey of 78 academic drug discovery groups and compiled some intriguing responses and statistics.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(87)</a> What started out as a modest effort (<25% of the survey responders founded before 2004) accelerated rapidly in the past 9 years. Often led and staffed by scientists with industry experience, today’s academic drug discovery centers possess the skills, experience, and resources needed to execute successfully all phases of early drug discovery, including target validation, hit-to-lead, and lead optimization. Resources originally associated with an industrial setting, such as high-throughput screening and in vivo efficacy profiling, are now carried out in half of the academic facilities surveyed. Universities have recognized the potential of academic drug discovery and have significantly expanded patenting activity and their internal support of drug discovery groups. University technology transfer groups have grown in size and experience and now proactively shop around their university’s intellectual property rather than wait for companies to come looking for them. To facilitate the technology transfer process, some universities have commissioned dedicated incubator space, facilities that can be offered to university groups with potentially valuable commodities so that they can form start-up companies around those commodities. Although some still debate whether a university is the appropriate setting for such endeavors, the growing number of new academic drug discovery groups suggests that many university administrations and boards of trustees see the combination of potential revenue and faculty members with practical experience as a win–win situation.</div><div class="NLM_p">Some critics of academic drug discovery question how impactful these groups will be in the drug development arena. Academic groups will inevitably face the same risk and drop-out rate that has hindered drug discovery in the industrial setting. Certainly, most academic drug discovery groups lack the funding needed to advance a compound to clinical trials. The NIH has responded to a certain extent by establishing programs that provide IND-enabling resources to projects that align with its priorities, but the availability of these resources is limited and cannot provide the funding needed to advance all of the deserving advanced leads coming out of academia. Additionally, relatively few government grant programs target the early stages of drug discovery such as lead identification or hit-to-lead activities. Most government grants focus either on basic research or final lead optimization, even though they are only part of the drug discovery paradigm.</div><div class="NLM_p">Opinions also vary over what role academic drug discovery groups should play. Some feel that academic groups should limit their endeavors to the special expertise that their faculty members possess and that the industrial mind set (team- and goal-oriented) does not fit well with the academic atmosphere.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(88)</a> Some question the reliability of target validation performed in an academic setting and its translatability to the industry environment.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(89)</a> Others believe that academic drug discovery laboratories should take on more of the activities historically based in the industrial setting.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(90)</a> Many wonder whether the goal driven, project-managed environment that is important for drug discovery can meld with the environment of academic freedom that is key to a university. It has been these authors’ experience that some academic colleagues are able to think and work in a team-oriented environment and some are not. This is the essence of academic freedom: in academia you do not have to collaborate with any given person or group. You can choose to do so or not to do so. For academic drug discovery groups to be successful, they must identify collaborators who can adapt to a work model that has the best chance for identifying a drug candidate. In fact, we have found that many of our academic collaborators are amazed by how much can be accomplished when team work and project management are incorporated into the research plan. In addition, the immigration of industry scientists to academia as a result of job loses has been beneficial on multiple fronts. Several universities are now reaping the rewards of employing faculty that not only can teach biomedical science and research from a practical, industrial point of view but also naturally fit in with the operating model that academic drug discovery groups employ.</div><div class="NLM_p last">As far as the impact that academic research groups have had on drug development, it is certainly true that academic groups have contributed to early-stage basic research by identifying biological tool molecules as summed up in a recent article.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(91)</a> However, the UNC survey showed that academic drug discovery laboratories are involved with many high-profile therapeutic areas as well as orphan diseases and less well validated targets that are of interest to pharmaceutical companies. Companies certainly recognize the potential of tapping into academic research. For example, Merck recently formed the California Institute for Biomedical Research (Calibr), a facility dedicated to academic partnerships. In a 2011 follow-up interview to the UNC survey,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(92)</a> a number of universities confirmed that they have seen an increase in the number of deals made with Pharma. Furthermore, projects started in academia have successfully delivered clinical candidates and even marketed drugs. Scripps Institute’s agreement with Receptos in 2009 led to a clinical candidate. In 2011, Scripps’ sphingosine-1-phosphate receptor-1 agonist RPC1063 entered phase I trials for multiple sclerosis. That compound advanced to phase II/III pivotal trials in 2012. Dennis Liotta’s group at Emory University discovered Emtriva. Vorinostat came out of Ron Breslow’s group at Columbia University, and Richard Silverman’s group at Northwestern University invented Lyrica. What the future holds is uncertain, but as the pharmaceutical industry continues to downsize staff and eliminate projects (especially ones that are considered high risk), it is hoped that academic drug discovery will continue to serve as a source of new projects and products that will help big Pharma overcome the innovation gap.</div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Clinical Drop-Out</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Another challenge faced by the pharmaceutical industry is the failure rate for compounds entering clinical trials. Costs escalate dramatically as clinical candidates move from preclinical development through safety and tolerance studies (phase I) and into phase II and phase III efficacy trials. More recent figures could not be found in the public domain, but 2008 numbers suggest that the greatest percentage of clinical candidates today fail in phase II, when preliminary efficacy and differentiation data become available (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>a).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(93)</a> Although the rate of attrition has remained similar over the past 20 years, some of the reasons for clinical failure have changed (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>b,c).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(94)</a> For example, in 1991, poor pharmacokinetics accounted for nearly 40% of clinical failures. That number had decreased to roughly 9% by 2000. Unfortunately, the encouraging results for PK-associated failures seem to have been countered by increases in failure resulting from commercial considerations (which likely included cost to the patient and differentiation concerns) and increased toxicology as crowded intellectual space forced companies to pursue more complex structural scaffolds that were still patentable.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Clinical attrition statistics: (a) attrition rate by stage of development, (b) reasons for clinical failure in 1991, and (c) reasons for clinical failure in 2000 (source: refs <a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">93</a> and <a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">94</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The obvious place to start addressing clinical dropout is by designing cost-effective, more efficient clinical trials, ones that facilitate good go/no-go decisions. When possible (as in cancer), genetic typing is being employed to target new clinical candidates to trial subjects that stand the best chance of responding. Many companies are now incorporating small efficacy arms into their advanced safety/tolerance studies (the ones run in actual patients) and are analyzing those safety studies for potential signs of short-term efficacy. Of course, these results cannot match the accuracy of those obtained from larger, statistically powered phase III clinical trials, but they can be used to help in deciding whether or not to advance the drug to the next more costly stage. Clinical research has become more sophisticated in response to the changing pharmaceutical environment, but how has preclinical research responded to the challenges? Below we discuss some of the preclinical tactics that the industry has employed in its attempt to improve the success rate.</div><div class="NLM_p">One outstanding feature in the data presented in Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a> is the decline in the number of clinical failures because of unacceptable PK properties from 1991 to 2000. The reason for this is straightforward: PK became important earlier in a clinical candidate’s evolution. Spurred on by a pivotal paper by Prentis et al. in 1988,<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(95)</a> medicinal chemists began thinking about PK and bioavailability as early as the hit identification stage, and project teams started routinely incorporating PK considerations into their decision-making process from that stage forward. In vivo PK studies, formerly prioritized to advanced leads being considered for IND-enabling studies, were now deployed during the course of hit-to-lead and lead optimization campaigns. However, during this time many companies did not have the infrastructure and personnel required to take on this increased workload and still support predevelopment and clinical projects. Outsourcing of PK studies took some of the added burden off of preclinical research resources, but the advent of a breakthrough concept provided pharmaceutical companies with a new way of tackling the issue of PK. That concept was the high-throughput in vitro screening of compounds for druglike properties.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> High-Throughput Screening for Druglike Properties</h3><div class="NLM_p">Since the revelation of Lipinski’s rule of five,<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(96)</a> several analyses have confirmed the undeniable fact that pharmacokinetics and toxicology are dependent on the physicochemical properties of compounds (for a recent review, see ref <a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">97</a>). It stands to reason that a clinical candidate that possesses both good pharmacological activity and druglike properties will have a better chance of making it to market than one that has suboptimal properties. To facilitate the ability of medicinal chemists to incorporate druglike properties into their drug design on a routine basis, companies have invested a great deal of time and money into developing batteries of in vitro high-throughput assays that monitor physicochemical parameters. Properties like solubility, stability, and permeability through cellular membranes (or artificial membranes) are now assessed in HTS plate format and rapidly monitored using LC/MS/MS or fluorescent-based quantitation. Similar technologies have been used to develop PK- and toxicology-specific HTS assays such as plasma stability (a predictor of hydrolysis metabolism), stability in liver microsomes (a predictor of phase I/phase II hepatic metabolism and in vivo half-life), and inhibition of human liver cytochrome P450 enzymes (a predictor of drug–drug interactions). HTS assays for monitoring p-glycoprotein (P-gp), breast cancer-related protein (BCRP), and other xenobiotic transporter activities provide input on potential issues with oral absorption, tissue penetration (especially the CNS), and liver toxicity (OATP’s, OCT’s, OAT’s, etc.). Even specific toxicity targets like the human ether-related a-go-go ion channel can be assessed in high-throughput binding and functional assays. More importantly, the high-throughput nature of these assays (usually performed in 96- or 384-well plates) means that every target molecule synthesized by chemists on a project can be screened for multiple druglike properties and the data can be generated and returned to the chemist in a timely manner so that the resulting information can be used to address any physicochemical/ADME/toxicity issues that exist. Most of today’s pharmaceutical chemists are very familiar with the typical traffic light spreadsheet shown in Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>, which classifies a compounds’ measured or calculated properties into druglike catagories (red, poor; yellow, moderate; and green, good). This concept has been dubbed multidimensional optimization or multiparameter optimization and has undoubtedly contributed to the reduction in clinical failures resulting from poor PK since 1991.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Typical traffic light spreadsheet used to report in vitro physicochemical/ADME data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The advances in HTS-based in vitro screening of physicochemical/ADME/toxicology parameters have been paralleled by significant advances in virtual in silico methods for predicting druglike parameters, although some warn against relying solely on these ranking methods for compound triage.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(98)</a>·<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(99)</a> Of course, algorithms for calculationg logP and topological polar surface area (TPSA) have been available for some time. However, today’s drug discovery scientists have access to software platforms and algorithms capable of predicting permeability,<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(100)</a> metabolism,<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(101)</a> off-target liabilities,<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(102)</a> potential toxicology,<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(103)</a> and even aqueous solubility.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(104, 105)</a> The incorporation of ligand efficiencies<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(106)</a> and other discoveries into their SAR design and analogue synthesis provides a quantifiable metric that medicinal chemists can use to prioritize lead molecules that have a greater chance of surviving the multitude of development challenges. The original concept,<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(107)</a> a ratio of the potency of the molecule to the size of the molecule, has been extended to include other parameters such as number of heteroatoms, number of rotatable bonds, lipophilicity,<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(108)</a> and, more recently, organizational factors such as fraction of sp<sup>3</sup>-hybridized carbons (Fsp<sup>3</sup>) and ratio of aromatic carbons to sp<sup>3</sup> carbons (Ar-sp<sup>3</sup>).<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(109)</a> Support for the validity and usefulness of ligand efficiencies has been provided in the form of retroanalysis studies similar to the one that led to the Lipinski rules.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(110, 111)</a> Analysis of successful drugs and the lead molecules from which they evolved shows that, for the most part, the drugs possessed superior ligand efficiency indices compared to their corresponding leads. This trend held true for a number of physicochemical parameters including molecular weight and lipophilicity. Although in vitro predictors may not be a replacement for the intuition that comes from experience in medicinal chemistry, they have become invaluable tools that help medicinal chemists efficiently identify clinical candidates that have a better chance of making it across the finish line.</div></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Translational Medicine</h3><div class="NLM_p">Another field that has emerged in the quest to reduce clinical dropout is translational medicine.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(112)</a> The term translational medicine means different things to different stakeholders in the pharmaceutical industry, but one of the important goals of this field is to increase the predictability of preclinical research in order to enhance the chances that a clinical candidate will cross the finish line and effectively treat a disease or condition. The concept has been popularized in the term bench to bedside, which has been associated with numerous research centers and projects and has even been used to designate an NIH funding program.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(113)</a> Two major components of enhancing clinical predictability that have received significant attention are (1) establishing biomarkers and (2) genetic targeting of drug candidates to patient populations more likely to respond (personalized medicine).</div><div class="NLM_p">The development of reproducible, objective biomarkers to establish a correlation between target modulation and clinical outcome and to confirm target engagement has become a cornerstone of modern drug discovery.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(114)</a> The concept of a biomarker was formalized at the turn of the 2000s by the NIH’s Biomarkers Definitions Working Group.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(115)</a> Pharmaceutical companies and clinical research groups embraced the concept, and biomarker identification and development eventually became a staple in the clinical and preclinical research paradigms. In an attempt to overcome the confusion over the roles of biomarkers in the scheme of drug development,<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(116)</a> a number of groups have proposed classification systems for biomarkers based on their use such as the one shown in Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(117)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Utilitarian classification of biomarkers<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(117)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Arguably, a tool that has had one of the greatest impacts in translational medicine in the past 20 years is imaging. Imaging techniques have been used to confirm target validation, to monitor target engagement, and to assess the effectiveness of treatment. Well-known imaging techniques such as X-ray and X-ray-based computer-assisted topography (CAT) have become commonplace in today’s clinical setting and are used to diagnose diseases and to monitor the progress of drug treatment. However, the routine use of PET (positron emission tomography) and SPECT (single-photon emission computed tomography) imaging agents have allowed preclinical and clinical scientists to establish whether advancing drug candidates reach and engage the biological target at high enough concentrations to correlate with the in vitro concentrations that are thought to be therapeutically meaningful and that target engagement is maintained for the desired period of time.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(118)</a> Using such data, researchers can correlate pharmacokinetics with the expected pharmacodynamics predicted from animal efficacy models and increase the efficiency of clinical trials through proper dose and dosing regimen selection. Alternatively, if unacceptable target engagement is identified, then development of the compound can be halted prior to incurring the cost of further clinical trials. A plethora of published examples of PET and SPECT biomarkers use to drive go/no-go decisions exists in the literature, and it is beyond the scope of this manuscript to discuss them in detail. Notable examples (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>) of the use of PET imaging biomarkers include confirming the role of 5-HT<sub>2A</sub> antagonism in the neuroleptic activity of atypical antipsychotics,<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(119)</a> demonstrating that poor receptor occupancy was not the reason for a lack of human efficacy seen with the neurokinin-1 antagonist aprepitant,<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(120, 121)</a> and monitoring glucose utilization with the PET ligand <sup>18</sup>F-fluorodeoxyglucose<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(122)</a> in a myriad of preclinical and clinical applications.<a onclick="showRef(event, 'ref125 ref126'); return false;" href="javascript:void(0);" class="ref ref125 ref126">(123, 124)</a> SPECT imaging has also found use in a number of applications. The use of technetium-99 for bone and brain scans is well-known, and its incorporation into tissue-specific chelates or attachment to antibodies has broadened its impact as a biomarker to additional fields such as cardiovascular, metabolic, and oncology medicine. One of the most recent examples is ProstaScint (capromab pendetide), an antibody for prostate specific membrane antigen labeled with indium-111 used to diagnose prostate cancer and to monitor tumor response to treatment.<a onclick="showRef(event, 'ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref127 ref128">(125, 126)</a> Of course, radioisotope-based imaging is not the only methodology that has had significant impact in translational medicine. For example, magnetic resonance imaging (MRI) has become a critical tool in the stroke drug development field and is critical for the diagnosis of stroke in the clinical setting and determination of whether or not the patient is a candidate for the only approved intervention for stroke, thrombolytic therapy. Additionally, combining radioisotope and nonradioisotope techniques can provide greater detail and image resolution.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Representative PET and SPECT biomarker imaging agents and their biological targets.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The authors’ backgrounds in CNS drug discovery, perhaps, bias them toward an appreciation of radioisotope-based imaging; however, we would be remiss not to acknowledge the considerable contributions to drug discovery that non-imaging-based biomarkers have made. For example, focused use of distal and proximal biomarkers such as plasma glucose levels and plasma dipeptidyl-peptidase IV activity allowed Merck to move the type 2 diabetes drug sitagliptin (Januvia) from phase I to phase III in 60% of the average time for most clinical candidates.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(127)</a> Prostate specific antigen remains an invaluable plasma biomarker for prostate cancer diagnosis and monitoring tumor progression and treatment.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(128)</a> In addition, efficacy and target engagement are not the only drug properties that can be monitored through the use of biomarkers. Safety is another critical aspect of drug development that has benefited from the use of biomarkers. For example, the association of a prolongation in the QTc interval seen in electrocardiograms with an increased risk for sudden cardiac death (i.e., Torsades de pointes) led to the recognition of blockade of the human KI<sub>R</sub> current (associated, in part with the Kv11.1 potassium channel encoded by the notorious human ether-a-go-go related gene hERG) as a potential safety concern. As a result, the U.S. Food and Drug Administration (FDA) released guidance in 2005 on what hERG-related data were expected in IND applications.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(129)</a> It cannot be denied that the concept of biomarkers and their application have had beneficial impacts on drug discovery.</div><div class="NLM_p">However, despite significant advances, there is an unmet medical need for predictive biomarkers in many areas. Two neurodegenerative diseases that come to mind are Alzheimer’s disease (AD) and Parkinson’s disease (PD). The challenge for AD biomarker research has been to identify biomarkers that can help to diagnose the disease in its early stages and to monitor accurately the effect of the drug on the progression of the disease process. Significant progress has been made in AD biomarker research both in imaging (e.g., whole-brain imaging, <sup>18</sup>F-fluorodeoxyglucose, and Lilly’s recently marketed amyloid plaque imaging agent AMYViD)<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(130)</a> and in plasma and cerebrospinal fluid biomarkers.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(131)</a> It remains to be seen whether these biomarkers accurately correlate with disease presence and progression, especially in light of the doubt cast on the amyloid hypothesis by the recent clinical failures of the gamma secretase inhibitors semagacestat and avagacestat. Identifying a viable biomarker for PD is an ongoing priority for many groups, including the National Institute of Neurological Disorders and Stroke and the Michael J. Fox Foundation. Preliminary data with the SPECT imaging agent [<sup>123</sup>I][β]-CIT (2β-carbomethoxy-3β-(4-iodophenyl)tropane) suggested that clinical outcome of recently diagnosed PD patients correlated with striatal dopamine transporter density.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(132)</a> Under appropriate assay conditions, decreased cerebrospinal fluid levels of α-synuclein and Parkinson Protein 7 (PARK7, aka, DJ-1) correlates with the existence of PD, although there was no association between biomarker levels and disease severity.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(133)</a> Although these tools may find greater use in PD, what is ultimately needed is reliable biomarkers that can help diagnose PD early in this devastating disease where much of the substantia nigra has been destroyed before the typical symptoms begin to manifest.</div><div class="NLM_p">An extension of the use of biomarkers is the concept of targeted or personalized medicine. With the sequencing of the human genome came the ability to use genetic information to identify patients whose diseases would be particularly responsive to a given drug both in clinical trials and in the patient population once the drug is approved. At the forefront of the biomarker-driven personalized medicine arena has been the field of oncology. A key turning point for the acceptance of genetic biomarkers was Herceptin, a drug targeted through genetic profiling to breast cancer patients whose tumors overexpress the HER2/neu receptor.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(134)</a> Since that time, a number of cancer-associated genetic biomarkers have been identified that have potential clinical utility,<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(135)</a> and several drugs have entered focused, biomarker-driven clinical trials.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(136)</a> The subject of genetic biomarkers recently received significant public attention. In February, 2013, American actress Angelina Jolie announced that she had elected to undergo a preventive double mastectomy after learning from a genetic screen that she possessed a mutation in her BRCA1 gene that significantly elevated her risk for developing aggressive breast cancer. Although various sides continue to debate the merit of Jolie’s decision and, more importantly, publicity of the event, it cannot be denied that the event has raised public awareness of genetic screening and the use of genetic biomarkers to make health decisions.</div><div class="NLM_p last">Unfortunately, other therapeutic areas have lagged behind the oncology field. For example, in CNS drug discovery, only two diseases have seen significant genetic biomarker research. In AD, it has been recognized that patients carrying the apolipoprotein E4 (ApoE4) allele, especially the E4/E4 gene pair, are at higher risk for developing the late-onset form of the disease (reviewed by Sadigh-Eteghad et al.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(137)</a>) and may respond differently to treatment. Unfortunately, this discovery has had limited impact on the identification of a drug that can halt the progression of the disease. Extensive genotyping of schizophrenic patients has been pursued in an attempt to differentiate the 20% of patients who respond well to an antipsychotic drug from the 80% who respond less well or show no response. However, the unexpectedly large number of genes underlying the disease has proven to be challenging to analyze.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(138)</a> As research into genetic biomarkers continues, an underlying concern with the concept of personalized medicine is that of cost. Despite the savings that focusing clinical trials toward smaller numbers of treatment-susceptible patients may provide, the overall cost of developing a personalized drug is still going to be substantial. Smaller numbers of target patients means that the cost of the drug will have to be high to recover the R&D investment. This concern has already become a reality, with the yearly cost of many personalized cancer drugs exceeding $10 000/year and a few, like the biological anticancer drugs Yervoy and Provenge, expected to approach $100 000/year. Provenge, in some ways, can be considered the epitome of personalized medicine because it is an antiprostate cancer vaccine that is prepared individually for each patient. Some insurers have already refused to pay for some high-cost personalized drugs targeting small patient populations, essentially denying access of these to drugs to patients who stand the best chance of benefiting from them. Without the ability to make back the money that they laid out developing such focused drugs, it stands to reason that most companies will not be able to afford developing such drugs, even if good genetic biomarkers are available to guide patient selection. The ability of the pharmaceutical industry and the market to reach a mutually beneficial compromise between patient cost and investment recovery will likely play a major role in the future of personalized medicine.</div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Pharma’s Commitment to Innovation: Success Stories from the Authors’ Past</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71361" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71361" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite the challenges discussed above, the industry continues to embark on a range of initiatives and projects to address unmet medical needs or to identify superior drugs in place of ones with weaknesses, risks, or less than desirable efficacy. Attempts to identify additional indications for drugs or drug classes, superior formulations that make taking the drug more convenient (thus enhancing patient compliance), or drug combinations that treat diseases better than the separate components have all been criticized as evergreening exercises or franchise maintenance. However, in an environment where many of the most pressing unmet medical needs like neurodegenerative diseases and stroke have yet to yield to pharmaceutical intervention, even small innovations can be useful as the greater goals are being pursued, and these are often taken for granted by critics of the industry. For example, although not a disease cure, the advent of highly active antiretroviral therapy (HAART) and the use of drug combinations has brought hope to numerous HIV sufferers. It will be the small innovations that sustain the industry as the scientific community continues to search for the keys to unlock the secrets of diseases like AD.</div><div class="NLM_p">In the following sections, we will briefly describe three success stories from our past association with Wyeth. Their inclusion in this Perspective does not mean that we believe that these successes overshadow others. The industry as a whole has realized many innovative successes throughout the past 30 years, both big and small. The ones that we present below are simply most familiar to us. The first example, the small-molecule antidepressant Pristiq, describes how attempts to overcome the weaknesses with a blockbuster drug led to a follow-on agent that is much more convenient to use. The second example, natural product-derived immunophilins, presents how the search for follow-on agents with improved physicochemical properties led to new indications and even new biological targets. The final example from the vaccines platform, Prevnar13, shows how an attempt to address a biological issue caused by a predecessor agent has provided an innovative therapy that jump-started one company’s vaccines program and has demonstrated that, like small molecules, vaccines can achieve blockbuster status.</div><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Pristiq (Desvenlavaxine)</h3><div class="NLM_p">In 1993, Wyeth marketed the first nontricyclic serotonin/norepinephrine reuptake inhibitor (SNRI) antidepressant Effexor (venlafaxine, Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(139)</a> The clinical efficacy seen with venlafaxine has benefited over 20 milllion patients, and studies have shown that patients resistant to treatment with other antidepressants often respond to venlafaxine.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(140)</a> The success of venlafaxine encouraged the discovery of other nontricyclic SNRIs, including Cymbalta (duloxetine), Savella (milnacipran), and, most recently, the active enantiomer of milnacipran, Fetzima (levomilnacipran). Venlafaxine is metabolized in man by cytochrome P450 2D6 to give the major active O-desmethyl metabolite desvenlafaxine (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>). Desvenlafaxine is also a mixed serotonin/norepinephrine reuptake inhibitor, although the compound is somewhat more selective for the serotonin transporter than venlafaxine (desvenlafaxine is 10-fold more potent at inhibiting serotonin uptake<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(141)</a> than norepinephrine, whereas venlafaxine is 3-fold more selective for serotonin uptake<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(142)</a>). Because of genetic polymorphisms in the 2D6 subtype, different people metabolize via 2D6 at different rates, leading to phenotypic classifications such as poor metabolizers (PM) and extensive metabolizers (EM). Clinical data (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>, left) revealed that significantly higher plasma levels of desvenlavaxine (both in terms of <i>C</i><sub>max</sub> and AUC) were seen in EMs than in PMs following administration of Effexor.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(143)</a> As a result, the dose of venlafaxine for patients initiating treatment has to be titrated until steady-state plasma levels of both the drug and active metabolite are reached. To overcome this issue, Wyeth developed the active metabolite desvenlafaxine as a follow-on to venlafaxine. From the data shown on the right in Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>, it can be seen that direct administration of desvenlafaxine results in similar plasma levels in both EMs and PMs. Additionally, the lack of a role for 2D6 in desvanlafaxine’s metabolism translates to a reduced risk for 2D6-associated drug–drug interactions, including those likely to occur with other antidepressant drugs that inhibit CYP 2D6 such as paroxetine. This is pertinent because depressed patients are often cotreated with multiple antidepressant drugs. Wyeth marketed the succinate salt of desvanlafaxine as Pristiq in 2008. Since Pristiq’s introduction, sales have grown to approximately $500 million per year. However, beginning earlier this year, nonbranded versions of desvenlafaxine became available outside of the U.S. despite the fact that patents on the drug are not scheduled to expire until the 2022–2027 time frame. In light of this fierce generic competition (including generic venlafaxine itself), it remains to be seen if Pristiq will achieve the blockbuster status once enjoyed by its predecessor Effexor.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures of venlafaxine (Effexor) and desvenlafaxine (Pristiq) and pharmacokinetic data for administration of the two drugs. EM, extensive metabolizers; PM, poor metabolizers. (Data taken from ref <a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">143</a>.)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Immunophilins</h3><div class="NLM_p">The history that led from the discovery of Rapamune (rapamycin) to Torisel (temsirolimus) and then on to the innovative experimental agent ILS-920 (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>) has been told by us<a onclick="showRef(event, 'ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref146 ref147">(144, 145)</a> and others.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(146)</a> Therefore, in this Perspective, we will only summarize the details that can be found in other manuscripts. The journey from rapamycin to <b>1</b> is a good example of how a class of molecules can have multiple therapeutic applications.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of immunosuppresive and nonimmunosuppresive immunophilins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Rapamycin (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>) was an innovative product in its own right. It was the tool molecule that led to the discovery of mammalian target of rapamycin (mTOR), a new drug target and the center of a pair of previously unknown signaling pathways. Rapamycin’s immunosuppressant activity is well-known and has been discussed elsewhere.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(147)</a> Rapamycin was the first in its class and finds utility in the treatment of organ-transplant rejection and as a restenosis-preventing agent in coronary stents. However, its development for cancer was never prioritized despite the pivotal role that one of the mTOR pathways holds in many cancers.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(148)</a> Rapamycin’s relatively poor water solubility was perceived to be a weakness, and a medicinal chemistry program was initiated to identify more soluble semisynthetic analogues of rapamycin that could be targeted for the cancer indication.<a onclick="showRef(event, 'ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref151 ref152">(149, 150)</a> An X-ray cocrystal structure of rapamycin bound to the FKBP12/mTOR complex revealed that the region of the molecule surrounding the C-42 hydroxyl was relatively solvent-exposed and could be altered without affecting the terniary complex.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(151)</a> Thus, a series of aqueous solubility-promoting substituents were appended to the C-42 hydroxyl to give compounds that retained immunosuppressant and antiproliferative activity. In 2007, Wyeth marketed temsirolemus for the treatment of advanced renal cell carcinoma, a disease that routinely possessed a poor prognosis following diagnosis. Temsirolemus was one of the first drugs to improve statistically the overall survival time for renal cell carcinioma patients and validated mTOR as a relevant therapeutic target for cancer. Its success ultimately led other companies to develop and market similar water-soluble anticancer rapamycin analogues such as everolimus and ridaforolimus.</div><div class="NLM_p">The discovery of <b>1</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>) began with a few key observations. Both rapamycin and the structurally related FK506 (<b>2</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>) were reported to show neuroprotective effects in vitro. However, although the in vitro activity translated into efficacy in a rodent model of ischemic stroke for <b>2</b>, rapamycin was not effective in the same study. It was generally accepted that the immunosuppressive activity shown by <b>2</b> precluded it from development for stroke. Other immunophilins that bound to FKBP12 such as GPI-1046 (<b>3</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>) also demonstrated some neuroprotective activity in vitro but were not immunosuppressant, leading some to hypothesize that the neuroprotective activity seen with FK506 and GPI-1046 may be the result of binding to other targets. A breakthrough for Wyeth came with the isolation of a macrocyclic derivative structurally related to rapamycin, 3-normyridamycin (Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>). 3-Normyridamycin showed little binding to FKBP12 and no immunosuppressant activity but was potently neuroprotective and neuroregenerative in a cellular model of Parkinson’s-like neurodegeneration.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(152)</a> These results encouraged Wyeth to embark on a reassessment of their immunophilin analogue library using a pair of phenotypic assays that assessed neuroprotective and neuroregenerative potential. Hits were cross-screened for immunosuppressant activity. This exercise identified the nonimmunosuppressive rapamycin analogue WAY-124466 (<b>4</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>), a derivative where the polyene moiety thought to interact with mTOR had been modified using Diels–Alder chemistry.</div><div class="NLM_p last">A focused medicinal chemistry campaign concentrating on Diels–Alder adducts of rapamycin led to <b>1</b>, which advanced to clinical trials for stroke in 2008. The detailed biological profile of <b>1</b> has been published elsewhere.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(153)</a> This nonimmunosuppressive macrocyclic derivative showed potent neuroprotective and neuroregenerative activity in vitro as well as reduction of infarct volume and enhanced functional recovery in animal models of ischemic stroke. Affinity purification experiments suggested that the biological targets for <b>1</b> were the β1-subunit of the L-type calcium channel and FKBP52, a target associated with neuroregenerative activity. Thus, the initial discovery of a natural product from a soil sample from Easter Island ultimately led not only to additional drugs with different indications but also to the discovery of new signaling pathways that remain an area of intense research and new discoveries even today.</div></div><div id="sec10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Prevnar 13</h3><div class="NLM_p">In 2000, Wyeth introduced Prevnar, a vaccine targeting <i>Streptococcus pneumoniae</i>, the leading cause of serious infections in children, including pneumonia, meningitis, and sepsis as well as less invasive infections such otitis media and sinusitis. Prevnar targeted seven of the most common serotypes of <i>S. pneumoniae</i> (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>). Prevnar was different from many vaccines in that it targeted cell surface polysaccharides rather than proteins because <i>S. pneumoniae</i> is encapsulated in a polysaccharide coat, which is its major virulence factor. To elicit a suitable response, protein-conjugation technology was employed to produce Prevnar. By 2001, the number of new cases of <i>S. pneumoniae</i> in the U.S. (mainly in the form of otitis media) had dropped by nearly 70%. However, as a result of the use of Prevnar, the incidence of serotypes of <i>S. pneumoniae</i> not covered by the vaccine increased, especially the virulent 19A serotype.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(154)</a> An agent with broader coverage was needed.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. <i>S. pneumoniae</i> serotypes covered by Prevnar and Prevnar 13 (data taken from ref <a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">155</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Wyeth began research soon afterward to extend the coverage of Prevnar. In 2009, they submitted the BLA for Prevnar 13, a vaccine targeting 13 <i>S. pneumoniae</i> serotypes, including A19 (Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>). The new vaccine was marketed in 2010,<a onclick="showRef(event, 'ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref156 ref157">(154, 155)</a> and has been a gratifying success. As of 2012, Prevnar 13 was licensed in over 90 countries for use in children and has become part of national immunization programs in over 50 countries worldwide.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(156)</a> It is commonly held that the Prevnar franchise and Wyeth’s vaccine development capabilities were one of the primary driving forces behind Pfizer’s acquisition of Wyeth in 2009, and the investment has paid off. Prevnar 13 was the first vaccine to achieve blockbuster status, with sales of over $1.8 billion in 2012.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(157)</a> In essence, Prevnar 13 has done for the vaccines platform what Tagamet did for the small-molecules platform: demonstrate that good, innovative products can reap significant rewards for the companies who take the risk and invest in their development. Prevnar 13 has shown that vaccines can be blockbuster products too.</div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60005" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60005" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">So where does the pharmaceutical industry stand? We previously discussed the various criticisms levied at Pharma and concluded that although many of those criticisms are the result of misconceptions or unavoidable some are at least partly valid and deserved. A similar conclusion can be reached regarding the many challenges that the industry faces today in its quest to develop new medicines. Some of today’s challenges are the result of changes that the industry could not have been predicted 20 years ago. The hurdles that must be cleared to achieve regulatory approval are higher today, thanks in part to some high-profile cases of unexpected adverse events surfacing after the drugs in question were marketed and administered to large numbers of patients. Some initiatives, such as multidimensional optimization and translational research, are helping to increase the success rate both at the preclinical and clinical stages, but the high price of clinical development requires that even greater efforts are made to ensure that compounds entering clinical trials cross the finishing line.</div><div class="NLM_p">Generic competition today is fiercer than ever. Not only are generic companies encouraged to bust the patents of branded drugs in order to market cheaper generic versions earlier but also they are protected from much of the liability that would otherwise result in the event that their activities are ruled to be infringement. Additionally, the hope of expanding into international markets to compensate for stagnant revenues in the U.S. is being threatened by the apparent willingness of generic-producing countries to deny or bypass patents in those countries, opening the way for generic versions of drugs to be made available in developing markets before their patent lives have ended. To withstand the onslaught of generics, many big Pharma companies have expanded their biopharmaceutical efforts, and a significant number of new drugs approved in the last 5 years have been therapeutic proteins and antibodies. Many of these biotherapeutics represent personalized medicine approaches and hold promise for specifically targeting diseases that will be particularly susceptible. However, the high price tag of many of these biotherapeutics (partly because biotherapeutic drugs are inherently more expensive than small molecules and partly because of the small market share expected from targeted therapy) are running afoul of the current political and economic environments that are pushing back against high prices. That same environment is also turning its back on purely me-too second- and third-generation drugs that offer little advantage over currently available therapies. Going forward, new drugs will have to offer something unavailable or at least significantly superior to receive approval and a guarantee of insurer’s support.</div><div class="NLM_p">Yet, some of the challenges that the industry faces today are at least partly of their own making. A focus on the development of blockbuster drugs ultimately contributed to the patent cliff that has received so much attention and has impacted significantly on the future of Pharma. Although many analysts feel that the worst of the patent cliff is over, the industry is left trying to develop business models that will shield them from such situations in the future. Another challenge that the industry must address is how to compensate for the loss of talent and capacity in the wake of the massive layoffs that have occurred over the past 13 years. At the time that this Perspective was being revised, two companies just announced additional multithousand employee layoffs, with a number of other companies already having executed smaller layoffs in 2013. One company, rather than reduce staff, has elected to freeze employee base pay for 2014. Outsourcing has compensated, to some extent, for the loss in manpower, but innovation has stagnated, partly because of the resistance of companies to tackle high-risk targets, but also because of the loss of scientists who are the source of the innovation. To insource innovation while minimizing risk, companies are changing their approach to how they partner with biotech companies and academic research groups. To facilitate the transfer of innovative ideas from academia to Pharma, many universities have supported the establishment of academic drug discovery groups who can help academic scientists craft their innovative ideas into the products that will appeal to an industrial partner. The challenges for these groups include overcoming the same risk and drop-out rate faced by industrial research groups and identifying funding after the initial investment made by the university. Most government grants and foundation awards target early basic research or late-stage drug discovery where the identification and optimization of a preclinical candidate has already occurred. Relatively few requests for applications (RFAs) specifically address the early lead identification and hit-to-lead stages, not nearly enough to support the many innovative and promising projects that are going on in today’s academic laboratories. If academic drug discovery is to play a relevant role in boosting pharmaceutical innovation, a supportive funding system will need to be established so that good ideas have a chance to become realities.</div><div class="NLM_p last">Despite all of today’s challenges, pharmaceutical companies continue to develop innovative new products, as summarized in a recent article by Chemical and Engineering News writer Rick Mullin.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(158)</a> Some of the worst may be over, but the quest to rise from the ashes of last century’s Phoenix continues. Regardless of the inevitable fact that pharmaceutical companies are for-profit entities, the need for their successful navigation of today’s uncertain times impacts us all. The industry must find a path forward so that we can all continue to enjoy the irreplaceable benefits that pharmaceuticals offer.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm401564r" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16303" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Magid Abou-Gharbia</span> - <span class="hlFld-Affiliation affiliation">Moulder
Center for Drug Discovery
Research, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6203000d170f03052216070f120e074c070617"><span class="__cf_email__" data-cfemail="7312111c061e12143307161e031f165d161706">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wayne E. Childers</span> - <span class="hlFld-Affiliation affiliation">Moulder
Center for Drug Discovery
Research, Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, Pennsylvania 19140, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors worked for several years in the pharmaceutical sector; however, they are not spokesmen for the pharmaceutical industry. The views expressed in this perspective are entirely their own. The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12153" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12153" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Magid Abou-Gharbia</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=BIO-d2204e2571-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Magid Abou-Gharbia</b> received his B.Sc. in Pharmacy and his M.Sc. in Medicinal Chemistry from Cairo University in 1971 and 1974, respectively, and his Ph.D. in Organic Chemistry from the University of Pennsylvania in 1979. Following an NIH postdoctoral fellowship at Temple University, Magid joined Wyeth Pharmaceuticals in 1982, where he was ultimately promoted to Senior Vice President of Chemical and Screening Sciences. His team’s efforts led to the identification of eight marketed drugs and several clinical candidates. In 2008, Magid joined Temple University School of Pharmacy as Professor of Pharmaceutical Sciences, Associate Director of Research, and Director of the Molder Center for Drug Discovery Research. Magid serves on the Scientific Advisory Board of several companies and professional societies and has adjunct professor appointments at several universities.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Wayne E. Childers</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=BIO-d2204e2576-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wayne E. Childers</b> received his B.A. in Chemistry from Vanderbilt University in 1975 and his Ph.D. in Organic Chemistry from the University of Georgia in 1984. While pursuing his Ph.D. studies, Wayne served as Assistant Adjunct Professor at Bucknell University from 1982–1984. Following a postdoctoral fellowship at Johns Hopkins University School of Medicine, Wayne joined Wyeth in 1987, where he led CNS-directed project teams that advanced four new chemical entities to clinical trials. In 2010, Wayne joined Temple University School of Pharmacy to serve as Associate Professor of Pharmaceutical Sciences and Associate Director of the Molder Center for Drug Discovery Research. Wayne’s research interests involve applying state-of-the-art techniques to the identification and development of new chemical entities for treating unmet medical needs.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i39" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i39"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i40" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i40"> Abbreviations Used</h2><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and elimination</p></td></tr><tr><td class="NLM_term">AMRI</td><td class="NLM_def"><p class="first last">Albany Molecular Research, Inc.</p></td></tr><tr><td class="NLM_term">ANDA</td><td class="NLM_def"><p class="first last">abbreviated new drug application</p></td></tr><tr><td class="NLM_term">ApoE4</td><td class="NLM_def"><p class="first last">apolipoprotein E4</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">BLA</td><td class="NLM_def"><p class="first last">biological license application</p></td></tr><tr><td class="NLM_term">BRICMT</td><td class="NLM_def"><p class="first last">Brazil, Russia, India, China, Mexico, Turkey</p></td></tr><tr><td class="NLM_term">Calibr</td><td class="NLM_def"><p class="first last">California Institute for Biomedical Research</p></td></tr><tr><td class="NLM_term">CAMD</td><td class="NLM_def"><p class="first last">Coalition Against Major Diseases</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CRO</td><td class="NLM_def"><p class="first last">contract research organization</p></td></tr><tr><td class="NLM_term">CT</td><td class="NLM_def"><p class="first last">computed tomography</p></td></tr><tr><td class="NLM_term">EM</td><td class="NLM_def"><p class="first last">extensive metabolizers</p></td></tr><tr><td class="NLM_term">EU</td><td class="NLM_def"><p class="first last">European Union</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FKBP12</td><td class="NLM_def"><p class="first last">FK506 binding protein-12</p></td></tr><tr><td class="NLM_term">FKBP52</td><td class="NLM_def"><p class="first last">FK506 binding protein-52</p></td></tr><tr><td class="NLM_term">FTC</td><td class="NLM_def"><p class="first last">Federal Trade Commission</p></td></tr><tr><td class="NLM_term">FTE</td><td class="NLM_def"><p class="first last">full-time equivalent</p></td></tr><tr><td class="NLM_term">GMP</td><td class="NLM_def"><p class="first last">good manufacturing practice</p></td></tr><tr><td class="NLM_term">HAART</td><td class="NLM_def"><p class="first last">highly active antiretroviral therapy</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-related a go-go</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screen</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigational new drug</p></td></tr><tr><td class="NLM_term">J&J</td><td class="NLM_def"><p class="first last">Johnson and Johnson</p></td></tr><tr><td class="NLM_term">LC/MS/MS</td><td class="NLM_def"><p class="first last">liquid chromatography–tandem mass spectroscopy</p></td></tr><tr><td class="NLM_term">M&A</td><td class="NLM_def"><p class="first last">merger and acquisition</p></td></tr><tr><td class="NLM_term">MRI</td><td class="NLM_def"><p class="first last">magnetic resonance imaging</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NDA</td><td class="NLM_def"><p class="first last">new drug application</p></td></tr><tr><td class="NLM_term">NIH</td><td class="NLM_def"><p class="first last">National Institutes of Health</p></td></tr><tr><td class="NLM_term">OAT</td><td class="NLM_def"><p class="first last">organic anion transporter</p></td></tr><tr><td class="NLM_term">OATP</td><td class="NLM_def"><p class="first last">organic anion transporting polypeptide</p></td></tr><tr><td class="NLM_term">OCT</td><td class="NLM_def"><p class="first last">organic cation transporter</p></td></tr><tr><td class="NLM_term">PCI</td><td class="NLM_def"><p class="first last">percutaneous coronary intervention</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PhRMA</td><td class="NLM_def"><p class="first last">Pharmaceutical Research and Manufacturing Association</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PM</td><td class="NLM_def"><p class="first last">poor metabolizers</p></td></tr><tr><td class="NLM_term">R&D</td><td class="NLM_def"><p class="first last">research and development</p></td></tr><tr><td class="NLM_term">RFA</td><td class="NLM_def"><p class="first last">request for applications</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small interfering ribonucleic acid</p></td></tr><tr><td class="NLM_term">SPECT</td><td class="NLM_def"><p class="first last">single-photon emission computed tomography</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">structure–property relationship</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">UNC</td><td class="NLM_def"><p class="first last">University of North Carolina (Chapel Hill)</p></td></tr><tr><td class="NLM_term">U.K.</td><td class="NLM_def"><p class="first last">United Kingdom</p></td></tr><tr><td class="NLM_term">U.S.</td><td class="NLM_def"><p class="first last">United States</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 158 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Arlington, S.</span>From Vision to Decision: Pharma 2020. Technical Report from PricewaterhouseCoopers:<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.pwc.com/jp/ja/japan-knowledge/archive/assets/pdf/pharma-2020-vision-to-decision.pdf" class="extLink">http://www.pwc.com/jp/ja/japan-knowledge/archive/assets/pdf/pharma-2020-vision-to-decision.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=S.+Arlington&title=From+Vision+to+Decision%3A+Pharma+2020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DArlington%26aufirst%3DS.%26jtitle%3DFrom%2520Vision%2520to%2520Decision%253A%2520Pharma%25202020%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Childers, W. E.</span><span> </span><span class="NLM_article-title">Discovery of innovative therapeutics: Today’s realities and tomorrow’s visions. 1. Criticisms faced by the pharmaceutical industry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5659</span><span class="NLM_x">–</span> <span class="NLM_lpage">5672</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400330j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5659-5672&author=M.+Abou-Gharbiaauthor=W.+E.+Childers&title=Discovery+of+innovative+therapeutics%3A+Today%E2%80%99s+realities+and+tomorrow%E2%80%99s+visions.+1.+Criticisms+faced+by+the+pharmaceutical+industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm400330j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400330j%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DChilders%26aufirst%3DW.%2BE.%26atitle%3DDiscovery%2520of%2520innovative%2520therapeutics%253A%2520Today%25E2%2580%2599s%2520realities%2520and%2520tomorrow%25E2%2580%2599s%2520visions.%25201.%2520Criticisms%2520faced%2520by%2520the%2520pharmaceutical%2520industry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5659%26epage%3D5672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalindjian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, K.</span><span> </span><span class="NLM_article-title">Principals of early drug discovery</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">1239</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1111%2Fj.1476-5381.2010.01127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21091654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=1239-1249&author=J.+Hughesauthor=S.+Reesauthor=S.+Kalindjianauthor=K.+Philpott&title=Principals+of+early+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of early drug discovery</span></div><div class="casAuthors">Hughes, J. P.; Rees, S.; Kalindjian, S. B.; Philpott, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1239-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion.  The idea for a target can come from a variety of sources including academic and clin. research and from the com. sector.  It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery program.  Once a target was chosen, the pharmaceutical industry and more recently some academic centers have streamlined a no. of early processes to identify mols. which possess suitable characteristics to make acceptable drugs.  This review will look at key preclin. stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate mol. for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCc74_F_90rVg90H21EOLACvtfcHk0ljMCEc5-q3egQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D&md5=05a0016f45b155f9fb5822f5c7bcc35d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01127.x%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DKalindjian%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DK.%26atitle%3DPrincipals%2520of%2520early%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D1239%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Grech, E.</span><span> </span><span class="NLM_article-title">ABC of interventional cardiology. Percutaneous coronary intervention. I: History and development</span> <span class="citation_source-journal">Brit. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">1082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1136%2Fbmj.326.7382.180" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2003&pages=180-1082&author=E.+Grech&title=ABC+of+interventional+cardiology.+Percutaneous+coronary+intervention.+I%3A+History+and+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1136%2Fbmj.326.7382.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.326.7382.180%26sid%3Dliteratum%253Aachs%26aulast%3DGrech%26aufirst%3DE.%26atitle%3DABC%2520of%2520interventional%2520cardiology.%2520Percutaneous%2520coronary%2520intervention.%2520I%253A%2520History%2520and%2520development%26jtitle%3DBrit.%2520Med.%2520J.%26date%3D2003%26volume%3D326%26spage%3D180%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhindi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khachigian, L.</span><span> </span><span class="NLM_article-title">Recent developments in drug-eluting stents</span> <span class="citation_source-journal">J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs00109-011-0729-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21279500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtl2lsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=545-553&author=Y.+Liauthor=R.+Bhindiauthor=L.+Khachigian&title=Recent+developments+in+drug-eluting+stents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in drug-eluting stents</span></div><div class="casAuthors">Li, Yue; Bhindi, Ravinay; Khachigian, Levon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-553</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Percutaneous coronary intervention (PCI) is an important treatment approach in the management of symptomatic coronary artery disease (CAD).  A significant development in PCI in the mid 1970s was balloon angioplasty, followed by bare-metal stents a decade later, and now, the widespread use of drug-eluting stents (DES).  While PCI has conferred remarkable benefit to millions of CAD patients, restenosis, and late stent thrombosis assocd. with DES remain problematic, and improvements are keenly sought.  This article reviews recent developments in DES.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQrKeB11Xcx7Vg90H21EOLACvtfcHk0ljMCEc5-q3egQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtl2lsbc%253D&md5=80f5c20ee3321a6f0bdd51921485b874</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00109-011-0729-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-011-0729-3%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBhindi%26aufirst%3DR.%26aulast%3DKhachigian%26aufirst%3DL.%26atitle%3DRecent%2520developments%2520in%2520drug-eluting%2520stents%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2011%26volume%3D89%26spage%3D545%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Harikumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, G.</span><span> </span><span class="NLM_article-title">Formulation tactics for the delivery of poorly soluble drugs</span> <span class="citation_source-journal">Int. J. PharmTech Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">914</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ejtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=914-923&author=R.+Harikumarauthor=G.+Aggarwal&title=Formulation+tactics+for+the+delivery+of+poorly+soluble+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Formulation tactics for the delivery of poorly soluble drugs</span></div><div class="casAuthors">Ritika; Harikumar, S. L.; Aggarwal, Geeta</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of PharmTech Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">914-923</span>CODEN:
                <span class="NLM_cas:coden">IJPRIF</span>;
        ISSN:<span class="NLM_cas:issn">0974-4304</span>.
    
            (<span class="NLM_cas:orgname">Sphinx Knowledge House</span>)
        </div><div class="casAbstract">A review.  As an upshot of modern drug discovery techniques like combinatorial chem. research and inventive high throughput screening, no. of new drug candidates developing, are often lipophilic.  For poorly sol. drugs, a good bioavailability is typically needed to evaluate the therapeutic index and aptness of the compd. for tech. formulation development.  This challenges drug delivery institutions to develop carrier systems for optimal oral and parentral administration of these drugs.  Comprehensive physicochem. characterization of poorly water sol. compds. can provide the key for outcome of successful formulation development, serving as guide for risk benefit assessment of delivery technol.  The higher levels of difficulties are confronted by formulation specialists when these drugs have to be delivered at specific site.  The present review addresses the emerging and promising formulation design options for the optimal administration of poorly water sol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUL6MiCfGSrVg90H21EOLACvtfcHk0ljMCEc5-q3egQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ejtL3I&md5=275259c3e77188eb22847555cd020a5f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarikumar%26aufirst%3DR.%26aulast%3DAggarwal%26aufirst%3DG.%26atitle%3DFormulation%2520tactics%2520for%2520the%2520delivery%2520of%2520poorly%2520soluble%2520drugs%26jtitle%3DInt.%2520J.%2520PharmTech%2520Res.%26date%3D2012%26volume%3D4%26spage%3D914%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Alvarez-Lueje, A.; Perez, M.; Zapata, C.</span><span> </span><span class="NLM_article-title">Electrochemical methods for the in vitro assessment of drug metabolism</span>. In  <span class="citation_source-book">Topics on Drug Metabolism</span>; <span class="NLM_contrib-group">Paxton, J.</span>, Ed.; <span class="NLM_publisher-name">InTech</span>, <span class="NLM_publisher-loc">Rijeka, Croatia</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Chapter 9.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Alvarez-Lueje&author=M.+Perez&author=C.+Zapataauthor=J.+Paxton&title=Topics+on+Drug+Metabolism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Lueje%26aufirst%3DA.%26atitle%3DElectrochemical%2520methods%2520for%2520the%2520in%2520vitro%2520assessment%2520of%2520drug%2520metabolism%26btitle%3DTopics%2520on%2520Drug%2520Metabolism%26aulast%3DPaxton%26aufirst%3DJ.%26pub%3DInTech%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Nordstrom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewensohn, R.</span><span> </span><span class="NLM_article-title">Metabolomics: Moving to the clinic</span> <span class="citation_source-journal">J. Neuroimmune Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs11481-009-9156-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19399626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BC3c7htlegsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=4-17&author=A.+Nordstromauthor=R.+Lewensohn&title=Metabolomics%3A+Moving+to+the+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomics: moving to the clinic</span></div><div class="casAuthors">Nordstrom Anders; Lewensohn Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Assessment of a biological system by means of global and non-targeted metabolite profiling--metabolomics or metabonomics--provides the investigator with molecular information that is close to the phenotype in question in the sense that metabolites are an ultimate product of gene, mRNA, and protein activity.  Over the last few years, there has been a rapidly growing number of metabolomics applications aimed at finding biomarkers which could assist diagnosis, provide therapy guidance, and evaluate response to therapy for particular diseases.  Also, within the fields of drug discovery, drug toxicology, and personalized pharmacology, metabolomics is emerging as a powerful tool.  This review seeks to update the reader on analytical strategies, biomarker findings, and implications of metabolomics for the clinic.  Particular attention is paid to recent biomarkers found related to neurological, cardiovascular, and cancer diseases.  Moreover, the impact of metabolomics in the drug discovery and development process is examined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrpv7XSde-J2PgL4LrC-0VfW6udTcc2eblJgSJeQn35bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7htlegsw%253D%253D&md5=57cbca331a903ebbe6c0d6ef88310fdf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs11481-009-9156-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11481-009-9156-4%26sid%3Dliteratum%253Aachs%26aulast%3DNordstrom%26aufirst%3DA.%26aulast%3DLewensohn%26aufirst%3DR.%26atitle%3DMetabolomics%253A%2520Moving%2520to%2520the%2520clinic%26jtitle%3DJ.%2520Neuroimmune%2520Pharmacol.%26date%3D2010%26volume%3D5%26spage%3D4%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ametamey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubiger, P.</span><span> </span><span class="NLM_article-title">Molecular imaging with PET</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">1501</span><span class="NLM_x">–</span> <span class="NLM_lpage">1516</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0782426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=1501-1516&author=S.+Ametameyauthor=M.+Honerauthor=P.+Schubiger&title=Molecular+imaging+with+PET"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Imaging with PET</span></div><div class="casAuthors">Ametamey, Simon M.; Honer, Michael; Schubiger, Pius August</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1501-1516</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgtMhO_aTjrVg90H21EOLACvtfcHk0ljNoPehzKHBmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFShtL0%253D&md5=513a2a8c8779c207122a8c23586fd016</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fcr0782426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0782426%26sid%3Dliteratum%253Aachs%26aulast%3DAmetamey%26aufirst%3DS.%26aulast%3DHoner%26aufirst%3DM.%26aulast%3DSchubiger%26aufirst%3DP.%26atitle%3DMolecular%2520imaging%2520with%2520PET%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D1501%26epage%3D1516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Bailey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willowson, K.</span><span> </span><span class="NLM_article-title">An evidence-based review of quantitative SPECT imaging and potential clinical applications</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=83-89&author=D.+Baileyauthor=K.+Willowson&title=An+evidence-based+review+of+quantitative+SPECT+imaging+and+potential+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DD.%26aulast%3DWillowson%26aufirst%3DK.%26atitle%3DAn%2520evidence-based%2520review%2520of%2520quantitative%2520SPECT%2520imaging%2520and%2520potential%2520clinical%2520applications%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2013%26volume%3D54%26spage%3D83%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Mariani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruselli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flotats, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Israel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, N.</span><span> </span><span class="NLM_article-title">A review on the clinical uses of SPECT/CT</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1959</span><span class="NLM_x">–</span> <span class="NLM_lpage">1985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs00259-010-1390-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=20182712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpsFektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=1959-1985&author=G.+Marianiauthor=L.+Bruselliauthor=T.+Kuwertauthor=E.+Kimauthor=A.+Flotatsauthor=O.+Israelauthor=M.+Dondiauthor=N.+Watanabe&title=A+review+on+the+clinical+uses+of+SPECT%2FCT"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A review on the clinical uses of SPECT/CT</span></div><div class="casAuthors">Mariani Giuliano; Bruselli Laura; Kuwert Torsten; Kim Edmund E; Flotats Albert; Israel Ora; Dondi Maurizio; Watanabe Naoyuki</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1959-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the era when positron emission tomography (PET) seems to constitute the most advanced application of nuclear medicine imaging, still the conventional procedure of single photon emission computed tomography (SPECT) is far from being obsolete, especially if combined with computed tomography (CT).  In fact, this dual modality imaging technique (SPECT/CT) lends itself to a wide variety of useful diagnostic applications whose clinical impact is in most instances already well established, while the evidence is growing for newer applications.  The increasing availability of new hybrid SPECT/CT devices with advanced technology offers the opportunity to shorten acquisition time and to provide accurate attenuation correction and fusion imaging.  In this review we analyse and discuss the capabilities of SPECT/CT for improving sensitivity and specificity in the imaging of both oncological and non-oncological diseases.  The main advantages of SPECT/CT are represented by better attenuation correction, increased specificity, and accurate depiction of the localization of disease and of possible involvement of adjacent tissues.  Endocrine and neuroendocrine tumours are accurately localized and characterized by SPECT/CT, as also are solitary pulmonary nodules and lung cancers, brain tumours, lymphoma, prostate cancer, malignant and benign bone lesions, and infection.  Furthermore, hybrid SPECT/CT imaging is especially suited to support the increasing applications of minimally invasive surgery, as well as to precisely define the diagnostic and prognostic profile of cardiovascular patients.  Finally, the applications of SPECT/CT to other clinical disorders or malignant tumours is currently under extensive investigation, with encouraging results in terms of diagnostic accuracy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxqGMXy1jiKyEJCPKhJPuqfW6udTcc2eb2Vu35aDzG9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpsFektQ%253D%253D&md5=9c3a713b083c2b412fd92eaee6f3042f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00259-010-1390-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-010-1390-8%26sid%3Dliteratum%253Aachs%26aulast%3DMariani%26aufirst%3DG.%26aulast%3DBruselli%26aufirst%3DL.%26aulast%3DKuwert%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DFlotats%26aufirst%3DA.%26aulast%3DIsrael%26aufirst%3DO.%26aulast%3DDondi%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DN.%26atitle%3DA%2520review%2520on%2520the%2520clinical%2520uses%2520of%2520SPECT%252FCT%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2010%26volume%3D37%26spage%3D1959%26epage%3D1985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span>Drug Discovery and Development: Understanding the R&D Process; Report from the Pharmaceutical Research and Manufacturers of America: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="http://www.innovation.org/drug_discovery/objects/pdf/RD_Brochure.pdf" class="extLink">http://www.innovation.org/drug_discovery/objects/pdf/RD_Brochure.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drug+Discovery+and+Development%3A+Understanding+the+R%26D+Process%3B+Report+from+the+Pharmaceutical+Research+and+Manufacturers+of+America%3A+Washington%2C+DC%2C+2007%3B+http%3A%2F%2Fwww.innovation.org%2Fdrug_discovery%2Fobjects%2Fpdf%2FRD_Brochure.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520and%2520Development%253A%2520Understanding%2520the%2520R%2526D%2520Process%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Overington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A.</span><span> </span><span class="NLM_article-title">How many drug targets are there?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">996</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=993-996&author=J.+Overingtonauthor=B.+Al-Lazikaniauthor=A.+Hopkins&title=How+many+drug+targets+are+there%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOverington%26aufirst%3DJ.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHopkins%26aufirst%3DA.%26atitle%3DHow%2520many%2520drug%2520targets%2520are%2520there%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D993%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hopkins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C.</span><span> </span><span class="NLM_article-title">The druggable genome</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=12209152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslamtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=727-730&author=A.+Hopkinsauthor=C.+Groom&title=The+druggable+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: The druggable genome</span></div><div class="casAuthors">Hopkins, Andrew L.; Groom, Colin R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">727-730</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  An assessment of the no. of mol. targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry.  Now that we know the size of the human genome, it is interesting to consider just how many mol. targets this opportunity represents.  We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Uvqi8O9wzrVg90H21EOLACvtfcHk0lg-kJJlmHb2Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslamtrY%253D&md5=d6dc7c67822661fe03e920695def1329</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd892%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%26aulast%3DGroom%26aufirst%3DC.%26atitle%3DThe%2520druggable%2520genome%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D727%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kubiyni, H.</span><span> </span><span class="NLM_article-title">Drug research myths: Hype and reality</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=665-668&author=H.+Kubiyni&title=Drug+research+myths%3A+Hype+and+reality"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKubiyni%26aufirst%3DH.%26atitle%3DDrug%2520research%2520myths%253A%2520Hype%2520and%2520reality%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D665%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalindjian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, K.</span><span> </span><span class="NLM_article-title">Principals of early drug discovery</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">1239</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1111%2Fj.1476-5381.2010.01127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21091654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=1239-1249&author=J.+Hughesauthor=S.+Reesauthor=S.+Kalindjianauthor=K.+Philpott&title=Principals+of+early+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of early drug discovery</span></div><div class="casAuthors">Hughes, J. P.; Rees, S.; Kalindjian, S. B.; Philpott, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1239-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion.  The idea for a target can come from a variety of sources including academic and clin. research and from the com. sector.  It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery program.  Once a target was chosen, the pharmaceutical industry and more recently some academic centers have streamlined a no. of early processes to identify mols. which possess suitable characteristics to make acceptable drugs.  This review will look at key preclin. stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate mol. for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCc74_F_90rVg90H21EOLACvtfcHk0lg-kJJlmHb2Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D&md5=05a0016f45b155f9fb5822f5c7bcc35d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01127.x%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DKalindjian%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DK.%26atitle%3DPrincipals%2520of%2520early%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D1239%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lounkine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoichet, B.</span><span> </span><span class="NLM_article-title">Identifying mechanism-of-action targets for drugs and probes</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">11178</span><span class="NLM_x">–</span> <span class="NLM_lpage">11183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=11178-11183&author=E.+Gregori-Puigjaneauthor=V.+Setolaauthor=J.+Hertauthor=B.+Crewsauthor=J.+Irwinauthor=E.+Lounkineauthor=L.+Marnettauthor=B.+Rothauthor=B.+Schoichet&title=Identifying+mechanism-of-action+targets+for+drugs+and+probes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DB.%26aulast%3DIrwin%26aufirst%3DJ.%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DMarnett%26aufirst%3DL.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DSchoichet%26aufirst%3DB.%26atitle%3DIdentifying%2520mechanism-of-action%2520targets%2520for%2520drugs%2520and%2520probes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D11178%26epage%3D11183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Boguski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandl, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukhatme, V.</span><span> </span><span class="NLM_article-title">Drug discovery, repurposing with a difference</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">324</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1394-1395&author=M.+Boguskiauthor=K.+Mandlauthor=V.+Sukhatme&title=Drug+discovery%2C+repurposing+with+a+difference"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoguski%26aufirst%3DM.%26aulast%3DMandl%26aufirst%3DK.%26aulast%3DSukhatme%26aufirst%3DV.%26atitle%3DDrug%2520discovery%252C%2520repurposing%2520with%2520a%2520difference%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1394%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Plenge, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolnick, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altshuler, D.</span><span> </span><span class="NLM_article-title">Validating therapeutic targets through human genetics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=581-594&author=R.+M.+Plengeauthor=E.+M.+Scolnickauthor=D.+Altshuler&title=Validating+therapeutic+targets+through+human+genetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlenge%26aufirst%3DR.%2BM.%26aulast%3DScolnick%26aufirst%3DE.%2BM.%26aulast%3DAltshuler%26aufirst%3DD.%26atitle%3DValidating%2520therapeutic%2520targets%2520through%2520human%2520genetics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D581%26epage%3D594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Chen, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, G.-H.</span><span> </span><span class="NLM_article-title">Target validation: A door to drug discovery</span> <span class="citation_source-journal">Drug Discovery Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BC38rltFKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=23-29&author=X.-P.+Chenauthor=G.-H.+Du&title=Target+validation%3A+A+door+to+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Target validation: A door to drug discovery</span></div><div class="casAuthors">Chen X P; Du G H</div><div class="citationInfo"><span class="NLM_cas:title">Drug discoveries & therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-9</span>
        ISSN:<span class="NLM_cas:issn">1881-7831</span>.
    </div><div class="casAbstract">From ancient times to today, drug discovery transitioned from serendipity to rationality over its long history.  Proper drug target selection and validation are crucial to the discovery of new drugs.  This review discusses the definition of drug targets and proposes several characteristics for drug targets.  The limitations of the term 'target' itself are summarized.  The drug target validation process is also discussed in detail and pitfalls during this process are outlined.  Small active chemical compounds obtained from the target validation process are useful tools in target validation and target function research.  The validation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) as a new potential anti-atherosclerotic drug target is cited as an example in order to elucidate the target validation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJpC8lwbV7IS86Js-BCLiifW6udTcc2eZl5DBlOKP9-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rltFKgsA%253D%253D&md5=25518dab9534f81a769975698075efc1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.-P.%26aulast%3DDu%26aufirst%3DG.-H.%26atitle%3DTarget%2520validation%253A%2520A%2520door%2520to%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Ther.%26date%3D2007%26volume%3D1%26spage%3D23%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Brunschweiger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J.</span><span> </span><span class="NLM_article-title">A decade of the human genome sequence – how does the medicinal chemist benefit?</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=194-203&author=A.+Brunschweigerauthor=J.+Hall&title=A+decade+of+the+human+genome+sequence+%E2%80%93+how+does+the+medicinal+chemist+benefit%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DHall%26aufirst%3DJ.%26atitle%3DA%2520decade%2520of%2520the%2520human%2520genome%2520sequence%2520%25E2%2580%2593%2520how%2520does%2520the%2520medicinal%2520chemist%2520benefit%253F%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D194%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Halgren, T.</span><span> </span><span class="NLM_article-title">Identifying and characterizing binding sites and assessing druggability</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci800324m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=377-389&author=T.+Halgren&title=Identifying+and+characterizing+binding+sites+and+assessing+druggability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Characterizing Binding Sites and Assessing Druggability</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification and characterization of binding sites is key in the process of structure-based drug design.  In some cases there may not be any information about the binding site for a target of interest.  In other cases, a putative binding site has been identified by computational or exptl. means, but the druggability of the target is not known.  Even when a site for a given target is known, it may be desirable to find addnl. sites whose targeting could produce a desired biol. response.  A new program, called SiteMap, is presented for identifying and analyzing binding sites and for predicting target druggability.  In a large-scale validation, SiteMap correctly identifies the known binding site as the top-ranked site in 86% of the cases, with best results (>98%) coming for sites that bind ligands with subnanomolar affinity.  In addn., a modified version of the score employed for binding-site identification allows SiteMap to accurately classify the druggability of proteins as measured by their ability to bind passively absorbed small mols. tightly.  In characterizing binding sites, SiteMap provides quant. and graphical information that can help guide efforts to critically assess virtual hits in a lead-discovery application or to modify ligand structure to enhance potency or improve phys. properties in a lead-optimization context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfAt0-gvcXDLVg90H21EOLACvtfcHk0lgXCUL0sx2pyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D&md5=f03c7b27e30ae03d10e4127ed1f1ed3c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fci800324m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800324m%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%26atitle%3DIdentifying%2520and%2520characterizing%2520binding%2520sites%2520and%2520assessing%2520druggability%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D377%26epage%3D389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Skolnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Interplay of physics and evolution in the likely origin of protein biochemical function</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">9344</span><span class="NLM_x">–</span> <span class="NLM_lpage">9349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=9344-9349&author=J.+Skolnickauthor=M.+Gao&title=Interplay+of+physics+and+evolution+in+the+likely+origin+of+protein+biochemical+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnick%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DInterplay%2520of%2520physics%2520and%2520evolution%2520in%2520the%2520likely%2520origin%2520of%2520protein%2520biochemical%2520function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D9344%26epage%3D9349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Campbell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaulton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bichko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brouwer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harland, L.</span><span> </span><span class="NLM_article-title">Visualizing the drug target landscape</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=3-15&author=S.+Campbellauthor=A.+Gaultonauthor=J.+Marshallauthor=D.+Bichkoauthor=S.+Martinauthor=C.+Brouwerauthor=L.+Harland&title=Visualizing+the+drug+target+landscape"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DJ.%26aulast%3DBichko%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DBrouwer%26aufirst%3DC.%26aulast%3DHarland%26aufirst%3DL.%26atitle%3DVisualizing%2520the%2520drug%2520target%2520landscape%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D3%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Z.</span><span> </span><span class="NLM_article-title">A practical view of ‘druggability’</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.cbpa.2006.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=16814592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlGitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=357-361&author=T.+Kellerauthor=A.+Pichotaauthor=Z.+Yin&title=A+practical+view+of+%E2%80%98druggability%E2%80%99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A practical view of druggability</span></div><div class="casAuthors">Keller, Thomas H.; Pichota, Arkadius; Yin, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">357-361</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The introduction of Lipinski's Rule of Five has initiated a profound shift in the thinking paradigm of medicinal chemists.  Understanding the difference between biol. active small mols. and drugs became a priority in the drug discovery process, and the importance of addressing pharmacokinetic properties early during lead optimization is a clear result.  These concepts of drug-likeness and druggability have been extended to proteins and genes for target identification and selection.  How should these concepts be integrated practically into the drug discovery process.  This review summarizes the recent advances in the field and examines the usefulness of the rules of the game in practice from a medicinal chemist's standpoint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorq2g5GWthbrVg90H21EOLACvtfcHk0lgXCUL0sx2pyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlGitbs%253D&md5=b9cef8a80f8867a568d2edd3444b73b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2006.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2006.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DPichota%26aufirst%3DA.%26aulast%3DYin%26aufirst%3DZ.%26atitle%3DA%2520practical%2520view%2520of%2520%25E2%2580%2598druggability%25E2%2580%2599%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D10%26spage%3D357%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Lipinski, C.</span><span> </span><span class="NLM_article-title">Lead- and drug-like compounds: The rule-of-five revolution</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-341&author=C.+Lipinski&title=Lead-+and+drug-like+compounds%3A+The+rule-of-five+revolution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%26atitle%3DLead-%2520and%2520drug-like%2520compounds%253A%2520The%2520rule-of-five%2520revolution%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D1%26spage%3D337%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Merritt, A.</span><span> </span><span class="NLM_article-title">High throughput chemistry in drug discovery</span>. In  <span class="citation_source-book">New Synthetic Technologies in Medicinal Chemistry</span>; <span class="NLM_contrib-group">Farrant, E.</span>, Ed.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span>, Chapter 2.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=6-41&author=A.+Merrittauthor=E.+Farrant&title=New+Synthetic+Technologies+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMerritt%26aufirst%3DA.%26atitle%3DHigh%2520throughput%2520chemistry%2520in%2520drug%2520discovery%26btitle%3DNew%2520Synthetic%2520Technologies%2520in%2520Medicinal%2520Chemistry%26aulast%3DFarrant%26aufirst%3DE.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D6%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Kerns, E.; Di, L.</span> <span class="citation_source-book">Drug-Like Properties: Concepts, Structure Design and Methods</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FB978-012369520-8.50020-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Kerns&author=L.+Di&title=Drug-Like+Properties%3A+Concepts%2C+Structure+Design+and+Methods"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FB978-012369520-8.50020-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-012369520-8.50020-6%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%26btitle%3DDrug-Like%2520Properties%253A%2520Concepts%252C%2520Structure%2520Design%2520and%2520Methods%26pub%3DAcademic%2520Press%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Gleeson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannongbua, S.</span><span> </span><span class="NLM_article-title">In-silico ADME models: A general assessment of their utility in drug discovery applications</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.2174%2F156802611794480927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21320065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=358-381&author=M.+Gleesonauthor=A.+Herseyauthor=S.+Hannongbua&title=In-silico+ADME+models%3A+A+general+assessment+of+their+utility+in+drug+discovery+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">In-silico ADME models: a general assessment of their utility in drug discovery applications</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Hannongbua, Supa</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">358-381</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  ADME prediction is an extremely challenging area as many of the properties we try to predict are a result of multiple physiol. processes.  In this review we consider how in-silico predictions of ADME processes can be used to help bias medicinal chem. into more ideal areas of property space, minimizing the no. of compds. needed to be synthesized to obtain the required biochem./physico-chem. profile.  While such models are not sufficiently accurate to act as a replacement for in-vivo or in-vitro methods, in-silico methods nevertheless can help us to understand the underlying physico-chem. dependencies of the different ADME properties, and thus can give us inspiration on how to optimize them.  Many global in-silico ADME models (i.e generated on large, diverse datasets) have been reported in the literature.  In this paper we selectively review representatives from each distinct class and discuss their relative utility in drug discovery.  For each ADME parameter, we limit our discussion to the most recent, most predictive or most insightful examples in the literature to highlight the current state of the art.  In each case we briefly summarize the different types of models available for each parameter (i.e simple rules, physico-chem. and 3D based QSAR predictions), their overall accuracy and the underlying SAR.  We also discuss the utility of the models as related to lead generation and optimization phases of discovery research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNyakFYvcjtrVg90H21EOLACvtfcHk0lhESDSiQGIEtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSnur4%253D&md5=5ca56a568815370a3b04833db45c0a9b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F156802611794480927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480927%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DHannongbua%26aufirst%3DS.%26atitle%3DIn-silico%2520ADME%2520models%253A%2520A%2520general%2520assessment%2520of%2520their%2520utility%2520in%2520drug%2520discovery%2520applications%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D358%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-715&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Gilbert, J.; Henske, P.; Singh, A.</span><span> </span><span class="NLM_article-title">Rebuilding big pharma’s business model</span>.  <span class="citation_source-journal">In Vivo Bus. Med. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&author=J.+Gilbert&author=P.+Henske&author=A.+Singh&title=Rebuilding+big+pharma%E2%80%99s+business+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DJ.%26atitle%3DRebuilding%2520big%2520pharma%25E2%2580%2599s%2520business%2520model%26jtitle%3DIn%2520Vivo%2520Bus.%2520Med.%2520Rep.%26date%3D2003%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kleemann, A.</span><span> </span><span class="NLM_article-title">Metamorphosis of the pharmaceutical industry</span> <span class="citation_source-journal">Pharm. Ind.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">562</span><span class="NLM_x">–</span> <span class="NLM_lpage">574</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=562-574&author=A.+Kleemann&title=Metamorphosis+of+the+pharmaceutical+industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKleemann%26aufirst%3DA.%26atitle%3DMetamorphosis%2520of%2520the%2520pharmaceutical%2520industry%26jtitle%3DPharm.%2520Ind.%26date%3D2013%26volume%3D75%26spage%3D562%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Stone, K.</span> Big pharma’s merger mania. <i>About.com</i>; <a href="http://pharma.about.com/od/BigPharma/tp/Big-Pharmas-Merger-Mania.htm" class="extLink">http://pharma.about.com/od/BigPharma/tp/Big-Pharmas-Merger-Mania.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Stone%2C+K.+Big+pharma%E2%80%99s+merger+mania.+About.com%3B+http%3A%2F%2Fpharma.about.com%2Fod%2FBigPharma%2Ftp%2FBig-Pharmas-Merger-Mania.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DK." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span>Deal Search Online Home Page, Irving Levin Associates, Inc.; <a href="http://www.levinassociates.com/dealsearch/" class="extLink">http://www.levinassociates.com/dealsearch/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Deal+Search+Online+Home+Page%2C+Irving+Levin+Associates%2C+Inc.%3B+http%3A%2F%2Fwww.levinassociates.com%2Fdealsearch%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Lamattina, J.</span><span> </span><span class="NLM_article-title">The impact of mergers on pharmaceutical R&D</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">560</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd3514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21804580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=559-560&author=J.+Lamattina&title=The+impact+of+mergers+on+pharmaceutical+R%26D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of mergers on pharmaceutical R&D</span></div><div class="casAuthors">LaMattina, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-560</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mergers and acquisitions in the pharmaceutical industry have substantially reduced the no. of major companies over the past 15 years.  The short-term business rationale for this extensive consolidation might have been reasonable, but at what cost to research and development productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQG-hMf2r3PLVg90H21EOLACvtfcHk0ljKCqnyacP_UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKqtLc%253D&md5=9760460d349c12265be4c2e04c7dabb4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnrd3514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3514%26sid%3Dliteratum%253Aachs%26aulast%3DLamattina%26aufirst%3DJ.%26atitle%3DThe%2520impact%2520of%2520mergers%2520on%2520pharmaceutical%2520R%2526D%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D559%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Firestone, R.</span><span> </span><span class="NLM_article-title">Lessons from 54 years of pharmaceutical research</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=963&author=R.+Firestone&title=Lessons+from+54+years+of+pharmaceutical+research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFirestone%26aufirst%3DR.%26atitle%3DLessons%2520from%252054%2520years%2520of%2520pharmaceutical%2520research%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Munos, B.</span><span> </span><span class="NLM_article-title">Lessons from 60 years of pharmaceutical innovation</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">959</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd2961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19949401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2gtrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=959-968&author=B.+Munos&title=Lessons+from+60+years+of+pharmaceutical+innovation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from 60 years of pharmaceutical innovation</span></div><div class="casAuthors">Munos, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">959-968</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite unprecedented investment in pharmaceutical research and development (R&D), the no. of new drugs approved by the US Food and Drug Administration (FDA) remains low.  To help understand this conundrum, this article investigates the record of pharmaceutical innovation by analyzing data on the companies that introduced the ∼1,200 new drugs that have been approved by the FDA since 1950.  This anal. shows that the new-drug output from pharmaceutical companies in this period has essentially been const., and remains so despite the attempts to increase it.  This suggests that, contrary to common perception, the new-drug output is not depressed, but may simply reflect the limitations of the current R&D model.  The implications of these findings and options to achieve sustain-ability for the pharmaceutical industry are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5CrUftSjUirVg90H21EOLACvtfcHk0ljKCqnyacP_UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2gtrbK&md5=dd36497b2a0788257333322f77df81bc</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrd2961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2961%26sid%3Dliteratum%253Aachs%26aulast%3DMunos%26aufirst%3DB.%26atitle%3DLessons%2520from%252060%2520years%2520of%2520pharmaceutical%2520innovation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D959%26epage%3D968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Comanor, W.; Scherer, F.</span><span> </span><span class="NLM_article-title">Mergers and innovation in the pharmaceutical industry</span>. Harvard Kennedy School Faculty Research Working Paper Series,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="https://research.hks.harvard.edu/publications/workingpapers/citation.aspx?PubId=8053&amp;type=FN&amp;PersonId=219" class="extLink">https://research.hks.harvard.edu/publications/workingpapers/citation.aspx?PubId=8053&type=FN&PersonId=219</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=W.+Comanor&author=F.+Scherer&title=Mergers+and+innovation+in+the+pharmaceutical+industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DComanor%26aufirst%3DW.%26atitle%3DMergers%2520and%2520innovation%2520in%2520the%2520pharmaceutical%2520industry%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span>Amgen Press Release, Aug 25, 2013; <a href="http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1849611" class="extLink">http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1849611</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Amgen+Press+Release%2C+Aug+25%2C+2013%3B+http%3A%2F%2Fwww.amgen.com%2Fmedia%2Fmedia_pr_detail.jsp%3FreleaseID%3D1849611."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Scannell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blankley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, B.</span><span> </span><span class="NLM_article-title">Diagnosing the decline in pharmaceutical R&D efficiency</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&author=J.+Scannellauthor=A.+Blankleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0ljKCqnyacP_UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%26aulast%3DBlankley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520decline%2520in%2520pharmaceutical%2520R%2526D%2520efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Grabowski, H.; Kyle, M.</span><span> </span><span class="NLM_article-title">Mergers, acquisitions and alliances</span>. In  <span class="citation_source-book">The Oxford Handbook of The Economics of the Biopharmaceutical Industry</span>; <span class="NLM_contrib-group">Danzon, P.; Nicholson, S.</span>, Eds.; <span class="NLM_publisher-name">Oxford University Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">552</span><span class="NLM_x">–</span> <span class="NLM_lpage">577</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=552-577&author=H.+Grabowski&author=M.+Kyleauthor=P.+Danzon&author=S.+Nicholson&title=The+Oxford+Handbook+of+The+Economics+of+the+Biopharmaceutical+Industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGrabowski%26aufirst%3DH.%26atitle%3DMergers%252C%2520acquisitions%2520and%2520alliances%26btitle%3DThe%2520Oxford%2520Handbook%2520of%2520The%2520Economics%2520of%2520the%2520Biopharmaceutical%2520Industry%26aulast%3DDanzon%26aufirst%3DP.%26pub%3DOxford%2520University%2520Press%26date%3D2012%26spage%3D552%26epage%3D577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kumar, B.</span><span> </span><span class="NLM_article-title">Mergers and acquisitions in the pharmaceutical industry</span>. In  <span class="citation_source-book">Mega Mergers and Acquisitions: Case Studies from Key Industries</span>; <span class="NLM_publisher-name">Palgrave MacMillan</span>: <span class="NLM_publisher-loc">Hampshire, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">, </span>’ pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1057%2F9781137005908" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-59&author=B.+Kumar&title=Mega+Mergers+and+Acquisitions%3A+Case+Studies+from+Key+Industries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1057%2F9781137005908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1057%252F9781137005908%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DB.%26atitle%3DMergers%2520and%2520acquisitions%2520in%2520the%2520pharmaceutical%2520industry%26btitle%3DMega%2520Mergers%2520and%2520Acquisitions%253A%2520Case%2520Studies%2520from%2520Key%2520Industries%26pub%3DPalgrave%2520MacMillan%26date%3D2012%26spage%3D1%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Tjandrawinata, R.; Simanjuntak, D.</span><span> </span><span class="NLM_article-title">The impact of mergers and acquisitions in research-based pharmaceutical companies on productivity</span>. <span class="NLM_publisher-name">Social Science Research Network</span>: <span class="NLM_publisher-loc">Rochester, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1981889" class="extLink">http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1981889</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Tjandrawinata&author=D.+Simanjuntak&title=The+impact+of+mergers+and+acquisitions+in+research-based+pharmaceutical+companies+on+productivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DTjandrawinata%26aufirst%3DR.%26atitle%3DThe%2520impact%2520of%2520mergers%2520and%2520acquisitions%2520in%2520research-based%2520pharmaceutical%2520companies%2520on%2520productivity%26pub%3DSocial%2520Science%2520Research%2520Network%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">LaMattina, J.</span> A holiday gift from Merck’s Ken Frazier. Drug Truths, Dec 20,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://johnlamattina.wordpress.com/2011/12/20/a-holiday-gift-from-mercks-ken-frazier/" class="extLink">http://johnlamattina.wordpress.com/2011/12/20/a-holiday-gift-from-mercks-ken-frazier/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+LaMattina&title=Drug+Truths"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DLaMattina%26aufirst%3DJ.%26jtitle%3DDrug%2520Truths%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Weaver, C.</span> Merck CEO defends strategy to pursue new drugs, research. Wall Street Journal, Dec 13,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://online.wsj.com/article/BT-CO-20111213-711338.html" class="extLink">http://online.wsj.com/article/BT-CO-20111213-711338.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=C.+Weaver&title=Wall+Street+Journal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DWeaver%26aufirst%3DC.%26jtitle%3DWall%2520Street%2520Journal%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Danzon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, S.</span><span> </span><span class="NLM_article-title">Mergers and acquisitions in the pharmaceutical and biotech industries</span> <span class="citation_source-journal">Managerial and Decision Economics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=307-328&author=P.+Danzonauthor=A.+Epsteinauthor=S.+Nicholson&title=Mergers+and+acquisitions+in+the+pharmaceutical+and+biotech+industries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDanzon%26aufirst%3DP.%26aulast%3DEpstein%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DS.%26atitle%3DMergers%2520and%2520acquisitions%2520in%2520the%2520pharmaceutical%2520and%2520biotech%2520industries%26jtitle%3DManagerial%2520and%2520Decision%2520Economics%26date%3D2007%26volume%3D28%26spage%3D307%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Grabowski, H.; Kyle, M.</span><span> </span><span class="NLM_article-title">Mergers and alliances in pharmaceuticals: effects on innovation and productivity</span>. In  <span class="citation_source-book">Economics of Corporate Governance and Mergers</span>; <span class="NLM_contrib-group">Gugler, K.; Yurtoglu, B.</span>, Eds.; <span class="NLM_publisher-name">Edward Elgar</span>: <span class="NLM_publisher-loc">Cheltehham, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=262-287&author=H.+Grabowski&author=M.+Kyleauthor=K.+Gugler&author=B.+Yurtoglu&title=Economics+of+Corporate+Governance+and+Mergers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGrabowski%26aufirst%3DH.%26atitle%3DMergers%2520and%2520alliances%2520in%2520pharmaceuticals%253A%2520effects%2520on%2520innovation%2520and%2520productivity%26btitle%3DEconomics%2520of%2520Corporate%2520Governance%2520and%2520Mergers%26aulast%3DGugler%26aufirst%3DK.%26pub%3DEdward%2520Elgar%26date%3D2008%26spage%3D262%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Davis, P. J.</span><span> </span><span class="NLM_article-title">Beyond the patent cliff – signs of recovery in biopharma’s new normal</span>. Accenture Life Sciences,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture-Life-Sciences-Beyond-The-Patent-Cliff-Signs-Of-Recovery-in-Biopharmas-New-Normal.pdf" class="extLink">http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture-Life-Sciences-Beyond-The-Patent-Cliff-Signs-Of-Recovery-in-Biopharmas-New-Normal.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.+J.+Davis&title=Beyond+the+patent+cliff+%E2%80%93+signs+of+recovery+in+biopharma%E2%80%99s+new+normal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DP.%2BJ.%26atitle%3DBeyond%2520the%2520patent%2520cliff%2520%25E2%2580%2593%2520signs%2520of%2520recovery%2520in%2520biopharma%25E2%2580%2599s%2520new%2520normal%26jtitle%3DAccenture%2520Life%2520Sciences%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span>World preview 2018: Embracing the patent cliff. EvaluatePharma,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://info.evaluatepharma.com/WP2018_ELS_LP.html" class="extLink">http://info.evaluatepharma.com/WP2018_ELS_LP.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+preview+2018%3A+Embracing+the+patent+cliff.+EvaluatePharma%2C+2012%3B+http%3A%2F%2Finfo.evaluatepharma.com%2FWP2018_ELS_LP.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DEvaluatePharma%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span>Lipitor sales data. <i>Drugs.com</i>; <a href="http://www.drugs.com/stats/lipitor" class="extLink">http://www.drugs.com/stats/lipitor</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lipitor+sales+data.+Drugs.com%3B+http%3A%2F%2Fwww.drugs.com%2Fstats%2Flipitor."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S.</span><span> </span><span class="NLM_article-title">Balancing innovation and access: Patent challenges tip the scales</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">–</span> <span class="NLM_lpage">371</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2009&pages=370-371&author=M.+Higginsauthor=S.+Grahamauthor=M.+Higginsauthor=S.+Graham&title=Balancing+innovation+and+access%3A+Patent+challenges+tip+the+scales"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DS.%26atitle%3DBalancing%2520innovation%2520and%2520access%253A%2520Patent%2520challenges%2520tip%2520the%2520scales%26jtitle%3DScience%26date%3D2009%26volume%3D326%26spage%3D370%26epage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span>Paragraph four explained: Why generic drug companies challenge patents. <span class="NLM_publisher-name">Parry Ashfold, Inc.</span>: <span class="NLM_publisher-loc">Exton, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://paragraphfour.com/explained/why_challenge.html" class="extLink">http://paragraphfour.com/explained/why_challenge.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Paragraph+four+explained%3A+Why+generic+drug+companies+challenge+patents.+Parry+Ashfold%2C+Inc.%3A+Exton%2C+PA%2C+2012%3B+http%3A%2F%2Fparagraphfour.com%2Fexplained%2Fwhy_challenge.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26pub%3DParry%2520Ashfold%252C%2520Inc%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Harrison, C.</span><span> </span><span class="NLM_article-title">The patent cliff steepens</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=12-13&author=C.+Harrison&title=The+patent+cliff+steepens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26atitle%3DThe%2520patent%2520cliff%2520steepens%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D12%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Powers, M.</span> Despite short-term revenue hit, Sanofi manages patent cliff. <i>BioWorld</i>; <a href="http://www.bioworld.com/content/despite-short-term-revenue-hit-sanofi-manages-patent-cliff-0" class="extLink">http://www.bioworld.com/content/despite-short-term-revenue-hit-sanofi-manages-patent-cliff-0</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Powers%2C+M.+Despite+short-term+revenue+hit%2C+Sanofi+manages+patent+cliff.+BioWorld%3B+http%3A%2F%2Fwww.bioworld.com%2Fcontent%2Fdespite-short-term-revenue-hit-sanofi-manages-patent-cliff-0."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Hitchings, A.; Baker, E.; Khong, T.</span><span> </span><span class="NLM_article-title">Making medicines evergreen</span>.  <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">e7941</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2012&pages=e7941&author=A.+Hitchings&author=E.+Baker&author=T.+Khong&title=Making+medicines+evergreen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHitchings%26aufirst%3DA.%26atitle%3DMaking%2520medicines%2520evergreen%26jtitle%3DBr.%2520Med.%2520J.%26date%3D2012%26volume%3D345%26spage%3De7941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Buente, M.; Danner, S.; Weissbacker, S.; Ramme, C.</span> Pharma emerging markets 2.0. How emerging markets are driving the transformation of the pharmaceutical industry. <i>Booz & Co</i>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.booz.com/media/file/BoozCo_Pharma-Emerging-Markets-2.0.pdf" class="extLink">http://www.booz.com/media/file/BoozCo_Pharma-Emerging-Markets-2.0.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Buente%2C+M.%3B+Danner%2C+S.%3B+Weissbacker%2C+S.%3B+Ramme%2C+C.+Pharma+emerging+markets+2.0.+How+emerging+markets+are+driving+the+transformation+of+the+pharmaceutical+industry.+Booz+%26+Co%2C+2013%3B+http%3A%2F%2Fwww.booz.com%2Fmedia%2Ffile%2FBoozCo_Pharma-Emerging-Markets-2.0.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DBuente%26aufirst%3DM.%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Schumacher, C.</span><span> </span><span class="NLM_article-title">CRAMS outsourcing in pharmaceutical and chemical research and manufacturing</span>, part II. <i>StepChange Innovations GmbH</i>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://blog.stepchange-innovations.com/2012/08/crams-outsourcing-in-pharmaceutical-and-chemical-research-and-manufacturing-part-ii/#_edn1" class="extLink">http://blog.stepchange-innovations.com/2012/08/crams-outsourcing-in-pharmaceutical-and-chemical-research-and-manufacturing-part-ii/#_edn1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Schumacher&title=CRAMS+outsourcing+in+pharmaceutical+and+chemical+research+and+manufacturing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DC.%26atitle%3DCRAMS%2520outsourcing%2520in%2520pharmaceutical%2520and%2520chemical%2520research%2520and%2520manufacturing%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Getz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamberti, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stergiopoulis, S.</span><span> </span><span class="NLM_article-title">Resizing the global R&D contract service market</span> <span class="citation_source-journal">Contract Pharma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=54&author=K.+Getzauthor=M.+J.+Lambertiauthor=A.+Mathiasauthor=S.+Stergiopoulis&title=Resizing+the+global+R%26D+contract+service+market"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGetz%26aufirst%3DK.%26aulast%3DLamberti%26aufirst%3DM.%2BJ.%26aulast%3DMathias%26aufirst%3DA.%26aulast%3DStergiopoulis%26aufirst%3DS.%26atitle%3DResizing%2520the%2520global%2520R%2526D%2520contract%2520service%2520market%26jtitle%3DContract%2520Pharma%26date%3D2012%26volume%3D14%26spage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Roijakkers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagedoorn, J.</span><span> </span><span class="NLM_article-title">Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns and networks</span> <span class="citation_source-journal">Res. Policy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.respol.2006.01.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2006&pages=431-446&author=N.+Roijakkersauthor=J.+Hagedoorn&title=Inter-firm+R%26D+partnering+in+pharmaceutical+biotechnology+since+1975%3A+Trends%2C+patterns+and+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.respol.2006.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.respol.2006.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DRoijakkers%26aufirst%3DN.%26aulast%3DHagedoorn%26aufirst%3DJ.%26atitle%3DInter-firm%2520R%2526D%2520partnering%2520in%2520pharmaceutical%2520biotechnology%2520since%25201975%253A%2520Trends%252C%2520patterns%2520and%2520networks%26jtitle%3DRes.%2520Policy%26date%3D2006%26volume%3D35%26spage%3D431%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">McCutchen, W. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swamidass, P. M.</span><span> </span><span class="NLM_article-title">Motivations for strategic alliances in the pharmaceutical/biotech industry: Some new findings</span> <span class="citation_source-journal">J. High Technol. Manage. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.hitech.2004.03.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=197-204&author=W.+W.+McCutchenauthor=P.+M.+Swamidass&title=Motivations+for+strategic+alliances+in+the+pharmaceutical%2Fbiotech+industry%3A+Some+new+findings"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.hitech.2004.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hitech.2004.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DMcCutchen%26aufirst%3DW.%2BW.%26aulast%3DSwamidass%26aufirst%3DP.%2BM.%26atitle%3DMotivations%2520for%2520strategic%2520alliances%2520in%2520the%2520pharmaceutical%252Fbiotech%2520industry%253A%2520Some%2520new%2520findings%26jtitle%3DJ.%2520High%2520Technol.%2520Manage.%2520Res.%26date%3D2004%26volume%3D15%26spage%3D197%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span>The use of medicines in the United States: Review of 2011. IMS Institute for Healthcare Informatics, April<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf" class="extLink">http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+use+of+medicines+in+the+United+States%3A+Review+of+2011.+IMS+Institute+for+Healthcare+Informatics%2C+April+2012%3B+http%3A%2F%2Fwww.imshealth.com%2Fims%2FGlobal%2FContent%2FInsights%2FIMS%2520Institute%2520for%2520Healthcare%2520Informatics%2FIHII_Medicines_in_U.S_Report_2011.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DIMS%2520Institute%2520for%2520Healthcare%2520Informatics%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Barry, C.; Arad, R.; Johnston, A.; Parent, A.; Ansell, L.; Arnold, M.</span><span class="NLM_x"> (</span><span class="NLM_year">2012</span><span class="NLM_x">) </span>patent litigation study. PricewaterhouseCoopers, Sept 2012; <a href="http://www.pwc.com/us/en/forensic-services/publications/2012-patent-litigation-study.jhtml" class="extLink">http://www.pwc.com/us/en/forensic-services/publications/2012-patent-litigation-study.jhtml</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Barry&author=R.+Arad&author=A.+Johnston&author=A.+Parent&author=L.+Ansell&author=M.+Arnold&title=PricewaterhouseCoopers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DC.%26date%3D2012%26jtitle%3DPricewaterhouseCoopers" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Rai, A.</span><span> </span><span class="NLM_article-title">Use patents, carve-outs, and incentives – a new battle in the drug-patent wars</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1056%2FNEJMp1206573" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2012&pages=491-493&author=A.+Rai&title=Use+patents%2C+carve-outs%2C+and+incentives+%E2%80%93+a+new+battle+in+the+drug-patent+wars"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1206573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1206573%26sid%3Dliteratum%253Aachs%26aulast%3DRai%26aufirst%3DA.%26atitle%3DUse%2520patents%252C%2520carve-outs%252C%2520and%2520incentives%2520%25E2%2580%2593%2520a%2520new%2520battle%2520in%2520the%2520drug-patent%2520wars%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D376%26spage%3D491%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span>Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement and Moderinization Act of 2003: Overview of agreements filed filed in FY 2012; A report by the Bureau of Competition, Federal Trade Commission: <span class="NLM_publisher-loc">Washington, DC</span>, Jan<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.ftc.gov/os/2013/01/130117mmareport.pdf" class="extLink">http://www.ftc.gov/os/2013/01/130117mmareport.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Agreements+filed+with+the+Federal+Trade+Commission+under+the+Medicare+Prescription+Drug%2C+Improvement+and+Moderinization+Act+of+2003%3A+Overview+of+agreements+filed+filed+in+FY+2012%3B+A+report+by+the+Bureau+of+Competition%2C+Federal+Trade+Commission%3A+Washington%2C+DC%2C+Jan+2013%3B+http%3A%2F%2Fwww.ftc.gov%2Fos%2F2013%2F01%2F130117mmareport.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span> </span><span class="NLM_article-title">List of authorized generic drugs</span>. <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Washington , DC</span>; <a href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm126389.htm" class="extLink">http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm126389.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=List+of+authorized+generic+drugs.+U.S.+Food+and+Drug+Administration%3A+Washington+%2C+DC%3B+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDevelopmentApprovalProcess%2FHowDrugsareDevelopedandApproved%2FApprovalApplications%2FAbbreviatedNewDrugApplicationANDAGenerics%2Fucm126389.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DList%2520of%2520authorized%2520generic%2520drugs%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span>More than eight in ten Americans want the option of choosing authorized generic prescription drugs. Roper Public Affairs & Media,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span><a href="http://www.prasco.com/wp-content/uploads/2012/03/Roper_Poll.pdf" class="extLink">http://www.prasco.com/wp-content/uploads/2012/03/Roper_Poll.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=More+than+eight+in+ten+Americans+want+the+option+of+choosing+authorized+generic+prescription+drugs.+Roper+Public+Affairs+%26+Media%2C+2005%3B+http%3A%2F%2Fwww.prasco.com%2Fwp-content%2Fuploads%2F2012%2F03%2FRoper_Poll.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DRoper%2520Public%2520Affairs%2520%2526%2520Media%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span> </span><span class="NLM_article-title">Authorized generic drugs: Short-term effects and long-term impact</span>. <span class="NLM_publisher-name">Federal Trade Commission</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Authorized+generic+drugs%3A+Short-term+effects+and+long-term+impact.+Federal+Trade+Commission%3A+Washington%2C+DC%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26atitle%3DAuthorized%2520generic%2520drugs%253A%2520Short-term%2520effects%2520and%2520long-term%2520impact%26pub%3DFederal%2520Trade%2520Commission%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Ryu, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D. H.</span><span> </span><span class="NLM_article-title">Current status and perspectives of biopharmaceutical drugs</span> <span class="citation_source-journal">Biotechnol. Bioprocess Eng.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs12257-012-0095-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGitb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=900-911&author=J.+K.+Ryuauthor=H.+S.+Kimauthor=D.+H.+Nam&title=Current+status+and+perspectives+of+biopharmaceutical+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Current status and perspectives of biopharmaceutical drugs</span></div><div class="casAuthors">Ryu, Jae Kuk; Kim, Hyo Sun; Nam, Doo Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology and Bioprocess Engineering</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">BBEIAU</span>;
        ISSN:<span class="NLM_cas:issn">1226-8372</span>.
    
            (<span class="NLM_cas:orgname">Korean Society for Biotechnology and Bioengineering</span>)
        </div><div class="casAbstract">A review.  Since the first approval of recombinant human insulin 3 decades ago, more than 150 biopharmaceutical drugs were marketed, and some of them became blockbuster drugs in market size.  The patent expiration of the oldest biopharmaceutical drugs resulted in the development of biosimilar drugs.  However the short serum half-life of biopharmaceutical drugs incurs a frequent injection to maintain a target clin. outcome in patients.  The other major crit. concern of biopharmaceutical drugs is immunogenicity producing anti-drug antibodies.  These antibodies may reduce clin. efficacy by neutralizing biol. activity, and may not only cause a severe allergic reaction but also other serious adverse reactions by blocking endogenous proteins.  In order to improve pharmaceutical properties and reduce immunogenicity, the next generation biobetter drugs were achieved by glycoengineering technol., Pegylation technol. and protein engineering technol.  Other biobetter drugs having optimized binding sites were also generated by in vitro display technol.  Many of those biobetter drugs were developed and/or are under development, and come into the clin. field in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMjGJLYcIF2LVg90H21EOLACvtfcHk0ljA8DR8SSfnMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGitb%252FP&md5=0b16e6c413ae1119005cdd029e836a7c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs12257-012-0095-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12257-012-0095-1%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DNam%26aufirst%3DD.%2BH.%26atitle%3DCurrent%2520status%2520and%2520perspectives%2520of%2520biopharmaceutical%2520drugs%26jtitle%3DBiotechnol.%2520Bioprocess%2520Eng.%26date%3D2012%26volume%3D17%26spage%3D900%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit70"><span>Global biopharmaceutical market expected to reach $320 billion by 2020. <i>Global Information, Inc.</i>, Oct 4,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.giiresearch.com/press/6805.shtml" class="extLink">http://www.giiresearch.com/press/6805.shtml</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+biopharmaceutical+market+expected+to+reach+%24320+billion+by+2020.+Global+Information%2C+Inc.%2C+Oct+4%2C+2012%3B+http%3A%2F%2Fwww.giiresearch.com%2Fpress%2F6805.shtml."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Stein, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gipe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pordy, R.</span><span> </span><span class="NLM_article-title">Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimebe therapy: A phase 2 randomized controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=7-13&author=E.+A.+Steinauthor=D.+Gipeauthor=J.+Bergeronauthor=D.+Gaudetauthor=R.+Weissauthor=R.+Dufourauthor=R.+Wuauthor=R.+Pordy&title=Effect+of+a+monoclonal+antibody+to+PCSK9%2C+REGN727%2FSAR236553%2C+to+reduce+low-density+lipoprotein+cholesterol+in+patients+with+heterozygous+familial+hypercholesterolaemia+on+stable+statin+dose+with+or+without+ezetimebe+therapy%3A+A+phase+2+randomized+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DE.%2BA.%26aulast%3DGipe%26aufirst%3DD.%26aulast%3DBergeron%26aufirst%3DJ.%26aulast%3DGaudet%26aufirst%3DD.%26aulast%3DWeiss%26aufirst%3DR.%26aulast%3DDufour%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DPordy%26aufirst%3DR.%26atitle%3DEffect%2520of%2520a%2520monoclonal%2520antibody%2520to%2520PCSK9%252C%2520REGN727%252FSAR236553%252C%2520to%2520reduce%2520low-density%2520lipoprotein%2520cholesterol%2520in%2520patients%2520with%2520heterozygous%2520familial%2520hypercholesterolaemia%2520on%2520stable%2520statin%2520dose%2520with%2520or%2520without%2520ezetimebe%2520therapy%253A%2520A%2520phase%25202%2520randomized%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D7%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Sullivan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebski, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, E. A.</span><span> </span><span class="NLM_article-title">Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">2497</span><span class="NLM_x">–</span> <span class="NLM_lpage">2506</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=2497-2506&author=D.+Sullivanauthor=A.+G.+Olssonauthor=R.+Scottauthor=J.+B.+Kimauthor=A.+Xueauthor=V.+Gebskiauthor=S.+M.+Wassermanauthor=E.+A.+Stein&title=Effect+of+a+monoclonal+antibody+to+PCSK9+on+low-density+lipoprotein+cholesterol+levels+in+statin-intolerant+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DOlsson%26aufirst%3DA.%2BG.%26aulast%3DScott%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BB.%26aulast%3DXue%26aufirst%3DA.%26aulast%3DGebski%26aufirst%3DV.%26aulast%3DWasserman%26aufirst%3DS.%2BM.%26aulast%3DStein%26aufirst%3DE.%2BA.%26atitle%3DEffect%2520of%2520a%2520monoclonal%2520antibody%2520to%2520PCSK9%2520on%2520low-density%2520lipoprotein%2520cholesterol%2520levels%2520in%2520statin-intolerant%2520patients%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D2497%26epage%3D2506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Herd, T.; Sheehy, D. A.; Ural, A.</span><span> </span><span class="NLM_article-title">Mergers & acquisitions: A strategy for focused growth in the biopharmaceutical industry during uncertain times</span>. Accenture,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture_A_Strategy_for_Focused_Growth.pdf" class="extLink">http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture_A_Strategy_for_Focused_Growth.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=T.+Herd&author=D.+A.+Sheehy&author=A.+Ural&title=Mergers+%26+acquisitions%3A+A+strategy+for+focused+growth+in+the+biopharmaceutical+industry+during+uncertain+times"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DHerd%26aufirst%3DT.%26atitle%3DMergers%2520%2526%2520acquisitions%253A%2520A%2520strategy%2520for%2520focused%2520growth%2520in%2520the%2520biopharmaceutical%2520industry%2520during%2520uncertain%2520times%26jtitle%3DAccenture%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Kanase, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavhane, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khandakar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurav, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, A. V.</span><span> </span><span class="NLM_article-title">Biosimilar: an overview</span> <span class="citation_source-journal">Int. J. Pharm. Sci Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2132</span><span class="NLM_x">–</span> <span class="NLM_lpage">2144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCmsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2132-2144&author=S.+J.+Kanaseauthor=Y.+N.+Gavhaneauthor=A.+Khandakarauthor=A.+S.+Guravauthor=A.+V.+Yadav&title=Biosimilar%3A+an+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Biosimilar: an overview</span></div><div class="casAuthors">Kanase, Sagar J.; Gavhane, Yogesh N.; Khandekar, Ashok; Gurav, Atul S.; Yadav, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutical Sciences and Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2132-2144</span>CODEN:
                <span class="NLM_cas:coden">IJPSTT</span>;
        ISSN:<span class="NLM_cas:issn">0975-8232</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Pharmaceutical Sciences and Research</span>)
        </div><div class="casAbstract">A review.  Biosimilars are defined as officially approved new version of innovator bio-therapeutic products for which the patent has expired.  Biosimilars the 'generic' versions of biopharmaceuticals, continue to enter Indian pharmaceutical market, to treat a variety of diseases.  Biosimilars available in India include monoclonal antibodies for treating various malignant and immunol. disorders, growth factors like erythropoietin and granulocyte colony stimulating factor (GCSF), human insulins for treating diabetes mellitus etc.  In the recent scenario, there is an increasing demand for biol. drugs.  The development and prodn. of biosimilars are boosted by existing manufg. technol.  Due to no investment in phase I-II of clin. trials, biosimilars are available at cheaper prices than the ref. products, so that it has low market risk.  The main goal of this review is that the phase I-II trials are typically not required for biosimilar approval unless it is found necessary in special cases.  Phase III trials with a min. of 100 patients are mandatory for establishing bioequivalence.  Therefore, the total cost to develop a biosimilar in India can range from $10-20 million, which helps Indian companies to offer their products at a 25-40 % cheaper price than the innovator biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopX552zvQzy7Vg90H21EOLACvtfcHk0lhqaQiId3Os2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCmsrzE&md5=7aee98dddc7d24ea65bf02615b8f025a</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKanase%26aufirst%3DS.%2BJ.%26aulast%3DGavhane%26aufirst%3DY.%2BN.%26aulast%3DKhandakar%26aufirst%3DA.%26aulast%3DGurav%26aufirst%3DA.%2BS.%26aulast%3DYadav%26aufirst%3DA.%2BV.%26atitle%3DBiosimilar%253A%2520an%2520overview%26jtitle%3DInt.%2520J.%2520Pharm.%2520Sci%2520Res.%26date%3D2013%26volume%3D4%26spage%3D2132%26epage%3D2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Kay, J.</span><span> </span><span class="NLM_article-title">Biosimilars: A regulatory perspective from America</span> <span class="citation_source-journal">Arthritis Res Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1186%2Far3310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21586106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlKlsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=112&author=J.+Kay&title=Biosimilars%3A+A+regulatory+perspective+from+America"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Biosimilars: a regulatory perspective from America</span></div><div class="casAuthors">Kay, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">112</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Biosimilars are protein products that are sufficiently similar to a biopharmaceutical already approved by a regulatory agency.  Several biotechnol. companies and generic drug manufacturers in Asia and Europe are developing biosimilars of tumor necrosis factor inhibitors and rituximab.  A biosimilar etanercept is already being marketed in Colombia and China.  In the US, several natural source products and recombinant proteins have been approved as generic drugs under Section 505(b)(2) of the Food, Drug, and Cosmetic Act.  However, because the complexity of large biopharmaceuticals makes it difficult to demonstrate that a biosimilar is structurally identical to an already approved biopharmaceutical, this Act does not apply to biosimilars of large biopharmaceuticals.  Section 7002 of the Patient Protection and Affordable Care Act of 2010, which is referred to as the Biologics Price Competition and Innovation Act of 2009, amends Section 351 of the Public Health Service Act to create an abbreviated pathway that permits a biosimilar to be evaluated by comparing it with only a single ref. biol. product.  This paper reviews the processes for approval of biosimilars in the US and the European Union and highlights recent changes in federal regulations governing the approval of biosimilars in the US.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpREyZ8F7bZJbVg90H21EOLACvtfcHk0lhPMdLgIK_a2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlKlsrY%253D&md5=ec491be9188ca2c24956da2291ed3a72</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1186%2Far3310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far3310%26sid%3Dliteratum%253Aachs%26aulast%3DKay%26aufirst%3DJ.%26atitle%3DBiosimilars%253A%2520A%2520regulatory%2520perspective%2520from%2520America%26jtitle%3DArthritis%2520Res%2520Ther.%26date%3D2011%26volume%3D13%26spage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit76"><span>Patient Protection and Affordable Care Act of 2009, Pub. L. No. 111-148, Title VII, Subtitle A Biologics Price Competition and Innovation Act of 2009, §7001-7003; <a href="http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf" class="extLink">http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Patient+Protection+and+Affordable+Care+Act+of+2009%2C+Pub.+L.+No.+111-148%2C+Title+VII%2C+Subtitle+A+Biologics+Price+Competition+and+Innovation+Act+of+2009%2C+%C2%A77001-7003%3B+http%3A%2F%2Fwww.gpo.gov%2Ffdsys%2Fpkg%2FBILLS-111hr3590enr%2Fpdf%2FBILLS-111hr3590enr.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Notte, G. T.</span><span> </span><span class="NLM_article-title">New chemical entities entering phase III clinical trials in 2012</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_contrib-group">Bronston, J.; Desai, M. C.</span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Waltham, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">451</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=451-469&author=G.+T.+Notteauthor=J.+Bronston&author=M.+C.+Desai&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNotte%26aufirst%3DG.%2BT.%26atitle%3DNew%2520chemical%2520entities%2520entering%2520phase%2520III%2520clinical%2520trials%2520in%25202012%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DBronston%26aufirst%3DJ.%26pub%3DAcademic%2520Press%26date%3D2013%26spage%3D451%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Jarvis, L. M.</span><span> </span><span class="NLM_article-title">A bountiful year</span> <span class="citation_source-journal">Chem. Eng. News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=15-17&author=L.+M.+Jarvis&title=A+bountiful+year"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJarvis%26aufirst%3DL.%2BM.%26atitle%3DA%2520bountiful%2520year%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2013%26spage%3D15%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">LaMattina, J.</span> When it comes to NDA approvals, is 30 the new 50? <i>Drug Truths</i>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://johnlamattina.wordpress.com/2012/01/17/when-it-comes-to-nda-approvals-is-30-the-new-50/" class="extLink">http://johnlamattina.wordpress.com/2012/01/17/when-it-comes-to-nda-approvals-is-30-the-new-50/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LaMattina%2C+J.+When+it+comes+to+NDA+approvals%2C+is+30+the+new+50%3F+Drug+Truths%2C+2012%3B+http%3A%2F%2Fjohnlamattina.wordpress.com%2F2012%2F01%2F17%2Fwhen-it-comes-to-nda-approvals-is-30-the-new-50%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DLaMattina%26aufirst%3DJ.%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Armstrong, W.</span> FDA’s approvable problem. <i>Pharmaceutical Executive</i>, Nov 1,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="http://www.pharmexec.com/pharmexec/PE+Features/FDAs-Approvable-Problem/ArticleStandard/Article/detail/469652" class="extLink">http://www.pharmexec.com/pharmexec/PE+Features/FDAs-Approvable-Problem/ArticleStandard/Article/detail/469652</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Armstrong%2C+W.+FDA%E2%80%99s+approvable+problem.+Pharmaceutical+Executive%2C+Nov+1%2C+2007%3B+http%3A%2F%2Fwww.pharmexec.com%2Fpharmexec%2FPE%2BFeatures%2FFDAs-Approvable-Problem%2FArticleStandard%2FArticle%2Fdetail%2F469652."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DW.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit81"><span><span> </span><span class="NLM_article-title">FDA revised process for responding to drug applications</span>; Press Release by the U.S. Food and Drug Administration, July 8,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116920.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116920.htm</a>. Complete <a href="http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2004-N-0510-nfr.pdf" class="extLink">http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2004-N-0510-nfr.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+revised+process+for+responding+to+drug+applications%3B+Press+Release+by+the+U.S.+Food+and+Drug+Administration%2C+July+8%2C+2008%3B+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2F2008%2Fucm116920.htm.+Complete+http%3A%2F%2Fwww.fda.gov%2FOHRMS%2FDOCKETS%2F98fr%2FFDA-2004-N-0510-nfr.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520revised%2520process%2520for%2520responding%2520to%2520drug%2520applications%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Light, D.; Lexchin, J. R.</span><span> </span><span class="NLM_article-title">Pharmaceutical research and development – what do we get for all that money?</span> <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">e4348</span>. <a href="http://www.bmj.com/content/345/bmj.e4348.pdf%2Bhtml" class="extLink">http://www.bmj.com/content/345/bmj.e4348.pdf%2Bhtml</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2012&pages=e4348&author=D.+Light&author=J.+R.+Lexchin&title=Pharmaceutical+research+and+development+%E2%80%93+what+do+we+get+for+all+that+money%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLight%26aufirst%3DD.%26atitle%3DPharmaceutical%2520research%2520and%2520development%2520%25E2%2580%2593%2520what%2520do%2520we%2520get%2520for%2520all%2520that%2520money%253F%26jtitle%3DBr.%2520Med.%2520J.%26date%3D2012%26volume%3D344%26spage%3De4348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit83"><span>FDA’s consideration of evidence from certain clinical trials. <i>United States Government Accountability Office</i>, July<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span><a href="http://www.gao.gov/assets/310/308301.pdf" class="extLink">http://www.gao.gov/assets/310/308301.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA%E2%80%99s+consideration+of+evidence+from+certain+clinical+trials.+United+States+Government+Accountability+Office%2C+July+2010%3B+http%3A%2F%2Fwww.gao.gov%2Fassets%2F310%2F308301.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Bode-Greuel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickisch, K. J.</span><span> </span><span class="NLM_article-title">Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development – commonalities and differences in portfolio management practice</span> <span class="citation_source-journal">J. Commer. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1057%2Fjcb.2008.6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=307-325&author=K.+Bode-Greuelauthor=K.+J.+Nickisch&title=Value-driven+project+and+portfolio+management+in+the+pharmaceutical+industry%3A+Drug+discovery+versus+drug+development+%E2%80%93+commonalities+and+differences+in+portfolio+management+practice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1057%2Fjcb.2008.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1057%252Fjcb.2008.6%26sid%3Dliteratum%253Aachs%26aulast%3DBode-Greuel%26aufirst%3DK.%26aulast%3DNickisch%26aufirst%3DK.%2BJ.%26atitle%3DValue-driven%2520project%2520and%2520portfolio%2520management%2520in%2520the%2520pharmaceutical%2520industry%253A%2520Drug%2520discovery%2520versus%2520drug%2520development%2520%25E2%2580%2593%2520commonalities%2520and%2520differences%2520in%2520portfolio%2520management%2520practice%26jtitle%3DJ.%2520Commer.%2520Biotechnol.%26date%3D2008%26volume%3D14%26spage%3D307%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Poland, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemen, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagnar, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykstra, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishna, R.</span><span> </span><span class="NLM_article-title">The clinical utility index as a practical multiattribute approach to drug development decisions</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fclpt.2009.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19458614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvis1GgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2009&pages=105-108&author=B.+Polandauthor=F.+L.+Hodgeauthor=A.+Kahnauthor=R.+T.+Clemenauthor=J.+A.+Wagnarauthor=K.+Dykstraauthor=R.+Krishna&title=The+clinical+utility+index+as+a+practical+multiattribute+approach+to+drug+development+decisions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical utility index as a practical multiattribute approach to drug development decisions</span></div><div class="casAuthors">Poland B; Hodge F L; Khan A; Clemen R T; Wagner J A; Dykstra K; Krishna R</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We identify some innovative approaches to predicting overall patient benefit from investigational drugs to support development decisions.  We then illustrate calculation of a probabilistic clinical utility index (CUI), an implementation of multiattribute utility that focuses on clinical attributes.  We recommend use of the CUI for the support of early drug development decisions because of its practicality, reasonable accuracy, and transparency to decision makers, at stages in which financial factors that may dominate later-phase decisions are less critical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgPD5PSdNKJL0AGQpJZWpJfW6udTcc2eaZFfMC-kwJWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvis1GgtQ%253D%253D&md5=31b2a128e00a6fe6ef653c27d7082ff7</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.71%26sid%3Dliteratum%253Aachs%26aulast%3DPoland%26aufirst%3DB.%26aulast%3DHodge%26aufirst%3DF.%2BL.%26aulast%3DKahn%26aufirst%3DA.%26aulast%3DClemen%26aufirst%3DR.%2BT.%26aulast%3DWagnar%26aufirst%3DJ.%2BA.%26aulast%3DDykstra%26aufirst%3DK.%26aulast%3DKrishna%26aufirst%3DR.%26atitle%3DThe%2520clinical%2520utility%2520index%2520as%2520a%2520practical%2520multiattribute%2520approach%2520to%2520drug%2520development%2520decisions%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2009%26volume%3D86%26spage%3D105%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Sartori, V.; Steinmann, M.; Evers, M.; Jantzer, P.</span> Value-driven drug development – unlocking the value of your pipeline. McKinsey Quarterly,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.mckinsey.com/Search.aspx?q=sartori&amp;l=Insights%20%26%20Publications" class="extLink">http://www.mckinsey.com/Search.aspx?q=sartori&l=Insights%20%26%20Publications</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=V.+Sartori&author=M.+Steinmann&author=M.+Evers&author=P.+Jantzer&title=McKinsey+Quarterly"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DSartori%26aufirst%3DV.%26jtitle%3DMcKinsey%2520Quarterly%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Dykstra, K.; Hodge, L.; Poland, B.; Carrothers, T. J.</span> Methods for developing differentiated drug products. Pharsight,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span><a href="http://www.pharsight.com/library/Methods%20for%20Developing%20Differentiated%20Drug%20Products.pdf" class="extLink">http://www.pharsight.com/library/Methods%20for%20Developing%20Differentiated%20Drug%20Products.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Dykstra&author=L.+Hodge&author=B.+Poland&author=T.+J.+Carrothers&title=Pharsight"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DDykstra%26aufirst%3DK.%26jtitle%3DPharsight%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Frye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juliano, E.</span><span> </span><span class="NLM_article-title">US academic drug discovery</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=409-410&author=S.+Fryeauthor=M.+Crosbyauthor=T.+Edwardsauthor=E.+Juliano&title=US+academic+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrye%26aufirst%3DS.%26aulast%3DCrosby%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DT.%26aulast%3DJuliano%26aufirst%3DE.%26atitle%3DUS%2520academic%2520drug%2520discovery%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D409%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Huryn, D. H.</span><span> </span><span class="NLM_article-title">Drug discovery in an academic setting: Playing to the strengths</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml400012g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=313-315&author=D.+H.+Huryn&title=Drug+discovery+in+an+academic+setting%3A+Playing+to+the+strengths"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fml400012g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400012g%26sid%3Dliteratum%253Aachs%26aulast%3DHuryn%26aufirst%3DD.%2BH.%26atitle%3DDrug%2520discovery%2520in%2520an%2520academic%2520setting%253A%2520Playing%2520to%2520the%2520strengths%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D313%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Prinz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlange, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asadullah, K.</span><span> </span><span class="NLM_article-title">Believe it or not: How much can we rely on published data on potential drug targets?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=713&author=F.+Prinzauthor=T.+Schlangeauthor=K.+Asadullah&title=Believe+it+or+not%3A+How+much+can+we+rely+on+published+data+on+potential+drug+targets%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPrinz%26aufirst%3DF.%26aulast%3DSchlange%26aufirst%3DT.%26aulast%3DAsadullah%26aufirst%3DK.%26atitle%3DBelieve%2520it%2520or%2520not%253A%2520How%2520much%2520can%2520we%2520rely%2520on%2520published%2520data%2520on%2520potential%2520drug%2520targets%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Silber, B. M.</span><span> </span><span class="NLM_article-title">Driving drug discovery: The fundamental role of academic labs</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">30cm16-1</span><span class="NLM_x">–</span> <span class="NLM_lpage">30cm16-6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1126%2Fscitranslmed.3000169" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=30cm16-1-30cm16-6&author=B.+M.+Silber&title=Driving+drug+discovery%3A+The+fundamental+role+of+academic+labs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000169%26sid%3Dliteratum%253Aachs%26aulast%3DSilber%26aufirst%3DB.%2BM.%26atitle%3DDriving%2520drug%2520discovery%253A%2520The%2520fundamental%2520role%2520of%2520academic%2520labs%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D30cm16-1%26epage%3D30cm16-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Huryn, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resnick, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wipf, P.</span><span> </span><span class="NLM_article-title">Contributions of academic laboratories to the discovery and development of chemical biology tools</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7161</span><span class="NLM_x">–</span> <span class="NLM_lpage">7176</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400132d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7161-7176&author=D.+H.+Hurynauthor=L.+O.+Resnickauthor=P.+Wipf&title=Contributions+of+academic+laboratories+to+the+discovery+and+development+of+chemical+biology+tools"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm400132d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400132d%26sid%3Dliteratum%253Aachs%26aulast%3DHuryn%26aufirst%3DD.%2BH.%26aulast%3DResnick%26aufirst%3DL.%2BO.%26aulast%3DWipf%26aufirst%3DP.%26atitle%3DContributions%2520of%2520academic%2520laboratories%2520to%2520the%2520discovery%2520and%2520development%2520of%2520chemical%2520biology%2520tools%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7161%26epage%3D7176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Kotz, J.</span><span> </span><span class="NLM_article-title">Small (molecule) thinking in academia</span> <span class="citation_source-journal">SciBX</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fscibx.2011.559" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=1-4&author=J.+Kotz&title=Small+%28molecule%29+thinking+in+academia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fscibx.2011.559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fscibx.2011.559%26sid%3Dliteratum%253Aachs%26aulast%3DKotz%26aufirst%3DJ.%26atitle%3DSmall%2520%2528molecule%2529%2520thinking%2520in%2520academia%26jtitle%3DSciBX%26date%3D2011%26volume%3D4%26spage%3D1%26epage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Donatella, V.</span><span> </span><span class="NLM_article-title">Predictive methods as a powerful tool in drug discovery</span> <span class="citation_source-journal">Biochemica Medica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">318</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=314-318&author=V.+Donatella&title=Predictive+methods+as+a+powerful+tool+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDonatella%26aufirst%3DV.%26atitle%3DPredictive%2520methods%2520as%2520a%2520powerful%2520tool%2520in%2520drug%2520discovery%26jtitle%3DBiochemica%2520Medica%26date%3D2010%26volume%3D20%26spage%3D314%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-715&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Prentis, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, S. R.</span><span> </span><span class="NLM_article-title">Pharmaceutical innovation by the seven UK-owned pharmaceutical companies</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1111%2Fj.1365-2125.1988.tb03318.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=3358900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADyaL1c7ptlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1988&pages=387-396&author=R.+A.+Prentisauthor=Y.+Lisauthor=S.+R.+Walker&title=Pharmaceutical+innovation+by+the+seven+UK-owned+pharmaceutical+companies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)</span></div><div class="casAuthors">Prentis R A; Lis Y; Walker S R</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-96</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">1 A total of three hundred and nineteen new chemical entities (NCEs) were investigated in man for the first time between 1964 and 1985 by seven UK-owned pharmaceutical companies.  The majority (96.2%), were self-originated by the UK company or one of its overseas subsidiaries. 2 There was an increase in the number of NCEs investigated each year in man, doubling from an average of 12 per year up to 1980, to over 20 per year between 1981 and 1985.  The majority of first drug evaluations in human volunteers were carried out in the UK (92.2%), in contrast to evaluation of new medicines in patients, where 42.9% were first tested outside the UK. 3 The majority of NCEs evaluated in man (78%), were in four therapeutic classes: anti-infectives (32%), anti-allergics (22%), drugs acting on the central nervous system (13%) and cardiovascular system agents (11%). 4 By the end of 1985, 49 (15.4%) of these NCEs had been marketed in the UK and 198 (62.0%) discontinued from further development.  The main reasons for termination were inappropriate pharmacokinetics in man (39.4%), and lack of clinical efficacy (29.3%). 5 Average development times increased from less than 2 years between 1964 and 1965, to around 8 years in the 1980s with a consequent reduction in the effective patent life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa4QASkgAlyfx2phytoz6_fW6udTcc2ebAwAn9zridKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c7ptlShtQ%253D%253D&md5=5648b42a95dca30156b601835fcaf1bd</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1988.tb03318.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1988.tb03318.x%26sid%3Dliteratum%253Aachs%26aulast%3DPrentis%26aufirst%3DR.%2BA.%26aulast%3DLis%26aufirst%3DY.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26atitle%3DPharmaceutical%2520innovation%2520by%2520the%2520seven%2520UK-owned%2520pharmaceutical%2520companies%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1988%26volume%3D25%26spage%3D387%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Lapinski, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=P.+A.+Lapinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLapinski%26aufirst%3DP.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Res.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Gleeson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J.</span><span> </span><span class="NLM_article-title">Probing the links between in vitro potency, ADMET and physicochemical parameters</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21358739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=197-208&author=M.+P.+Gleesonauthor=A.+Herseyauthor=D.+Montanariauthor=J.+Overington&title=Probing+the+links+between+in+vitro+potency%2C+ADMET+and+physicochemical+parameters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the links between in vitro potency, ADMET and physicochemical parameters</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Montanari, Dino; Overington, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A common underlying assumption in current drug discovery strategies is that compds. with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics.  This has led to the development of screening cascades with in vitro potency embedded as an early filter.  However, this approach is beginning to be questioned, given the bias in physicochem. properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochem. parameters assocd. with high in vitro potency and those assocd. with desirable absorption, distribution, metab., excretion and toxicity (ADMET) characteristics.  Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compds.  Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on av.); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose.  These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOslFSgIkUbVg90H21EOLACvtfcHk0lg2saZd5Eu8Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D&md5=e275044516e9b0245b71c9603477ef74</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnrd3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3367%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DOverington%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520links%2520between%2520in%2520vitro%2520potency%252C%2520ADMET%2520and%2520physicochemical%2520parameters%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D197%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Shultz, M. D.</span><span> </span><span class="NLM_article-title">Setting expectations in molecular optimizations: strengths and limitations of commonly used composit parameters</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5980</span><span class="NLM_x">–</span> <span class="NLM_lpage">5991</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5980-5991&author=M.+D.+Shultz&title=Setting+expectations+in+molecular+optimizations%3A+strengths+and+limitations+of+commonly+used+composit+parameters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520expectations%2520in%2520molecular%2520optimizations%253A%2520strengths%2520and%2520limitations%2520of%2520commonly%2520used%2520composit%2520parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5980%26epage%3D5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Kenny, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, C. A.</span><span> </span><span class="NLM_article-title">Inflation of correlation in the pursuit of drug-likeness</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs10822-012-9631-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=23306465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1SrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1-13&author=P.+W.+Kennyauthor=C.+A.+Montanari&title=Inflation+of+correlation+in+the+pursuit+of+drug-likeness"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Inflation of correlation in the pursuit of drug-likeness</span></div><div class="casAuthors">Kenny, Peter W.; Montanari, Carlos A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Drug-likeness is a frequently invoked, although not always precisely defined, concept in drug discovery.  Opinions on drug-likeness are to a large extent shaped by the relationships that are obsd. between surrogate measures of drug-likeness (e.g. aq. soly.; permeability; pharmacol. promiscuity) and fundamental physicochem. properties (e.g. lipophilicity; mol. size).  This article draws on examples from the literature to highlight approaches to data anal. that exaggerate trends in data and the term correlation inflation is introduced in the context of drug discovery.  Averaging groups of data points prior to anal. is a common cause of correlation inflation and results from anal. of binned continuous data should always be treated with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGcOTh1EJCrVg90H21EOLACvtfcHk0lg2saZd5Eu8Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1SrtbY%253D&md5=e8542e2402b11cfb2fd98ae8a5185f46</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9631-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9631-5%26sid%3Dliteratum%253Aachs%26aulast%3DKenny%26aufirst%3DP.%2BW.%26aulast%3DMontanari%26aufirst%3DC.%2BA.%26atitle%3DInflation%2520of%2520correlation%2520in%2520the%2520pursuit%2520of%2520drug-likeness%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2013%26volume%3D27%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Refsgaard, H. H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockhoff, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padkhaer, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buldbrandt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, M. S.</span><span> </span><span class="NLM_article-title">In silico prediction of membrane permeability from calculated molecular parameters</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049661n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=805-811&author=H.+H.+F.+Refsgaardauthor=B.+F.+Jensenauthor=P.+B.+Brockhoffauthor=S.+B.+Padkhaerauthor=M.+Buldbrandtauthor=M.+S.+Christensen&title=In+silico+prediction+of+membrane+permeability+from+calculated+molecular+parameters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjm049661n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049661n%26sid%3Dliteratum%253Aachs%26aulast%3DRefsgaard%26aufirst%3DH.%2BH.%2BF.%26aulast%3DJensen%26aufirst%3DB.%2BF.%26aulast%3DBrockhoff%26aufirst%3DP.%2BB.%26aulast%3DPadkhaer%26aufirst%3DS.%2BB.%26aulast%3DBuldbrandt%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DM.%2BS.%26atitle%3DIn%2520silico%2520prediction%2520of%2520membrane%2520permeability%2520from%2520calculated%2520molecular%2520parameters%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D805%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Peach, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaknarov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugliese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallqlvist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicklaus, M. C.</span><span> </span><span class="NLM_article-title">Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.4155%2Ffmc.12.150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=23088273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCqtrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1907-1932&author=M.+L.+Peachauthor=A.+V.+Zaknarovauthor=R.+Liuauthor=A.+Puglieseauthor=G.+Tawaauthor=A.+Wallqlvistauthor=M.+C.+Nicklaus&title=Computational+tools+and+resources+for+metabolism-related+property+predictions.+1.+Overview+of+publicly+available+%28free+and+commercial%29+databases+and+software"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software</span></div><div class="casAuthors">Peach, Megan L.; Zakharov, Alexey V.; Liu, Ruifeng; Pugliese, Angelo; Tawa, Gregory; Wallqvist, Anders; Nicklaus, Marc C.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1907-1932</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Metab. has been identified as a defining factor in drug development success or failure because of its impact on many aspects of drug pharmacol., including bioavailability, half-life and toxicity.  In this article, we provide an outline and descriptions of the resources for metab.-related property predictions that are currently either freely or com. available to the public.  These resources include databases with data on, and software for prediction of, several end points: metabolite formation, sites of metabolic transformation, binding to metabolizing enzymes and metabolic stability.  We attempt to place each tool in historical context and describe, wherever possible, the data it was based on.  For predictions of interactions with metabolizing enzymes, we show a typical set of results for a small test set of compds.  Our aim is to give a clear overview of the areas and aspects of metab. prediction in which the currently available resources are useful and accurate, and the areas in which they are inadequate or missing entirely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlJNQ-tDEqYrVg90H21EOLACvtfcHk0lir7eB7qvlGmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCqtrvP&md5=73a6e90caa7df9d457dde7eae3368e4c</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.150%26sid%3Dliteratum%253Aachs%26aulast%3DPeach%26aufirst%3DM.%2BL.%26aulast%3DZaknarov%26aufirst%3DA.%2BV.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DPugliese%26aufirst%3DA.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DWallqlvist%26aufirst%3DA.%26aulast%3DNicklaus%26aufirst%3DM.%2BC.%26atitle%3DComputational%2520tools%2520and%2520resources%2520for%2520metabolism-related%2520property%2520predictions.%25201.%2520Overview%2520of%2520publicly%2520available%2520%2528free%2520and%2520commercial%2529%2520databases%2520and%2520software%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1907%26epage%3D1932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">AbdulHameed, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sing, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallqvist, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawa, G. J.</span><span> </span><span class="NLM_article-title">Exploring polypharmacology using a ROCS-based target fishing approach</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">492</span><span class="NLM_x">–</span> <span class="NLM_lpage">505</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci2003544" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Oju7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=492-505&author=M.+D.+AbdulHameedauthor=S.+Chaudhuryauthor=N.+Singauthor=S.+H.+Wallqvistauthor=G.+J.+Tawa&title=Exploring+polypharmacology+using+a+ROCS-based+target+fishing+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring Polypharmacology Using a ROCS-Based Target Fishing Approach</span></div><div class="casAuthors">AbdulHameed, Mohamed Diwan M.; Chaudhury, Sidhartha; Singh, Narender; Sun, Hongmao; Wallqvist, Anders; Tawa, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">492-505</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. has emerged as a new theme in drug discovery.  In this paper, we studied polypharmacol. using a ligand-based target fishing (LBTF) protocol.  To implement the protocol, we first generated a chemogenomic database that links individual protein targets with a specified set of drugs or target representatives.  Target profiles were then generated for a given query mol. by computing maximal shape/chem. overlap between the query mol. and the drug sets assigned to each protein target.  The overlap was computed using the program ROCS (Rapid Overlay of Chem. Structures).  We validated this approach using the Directory of Useful Decoys (DUD).  DUD contains 2950 active compds., each with 36 property-matched decoys, against 40 protein targets.  We chose a set of known drugs to represent each DUD target, and we carried out ligand-based virtual screens using data sets of DUD actives seeded into DUD decoys for each target.  We computed Receiver Operator Characteristic (ROC) curves and assocd. area under the curve (AUC) values.  For the majority of targets studied, the AUC values were significantly better than for the case of a random selection of compds.  In a second test, the method successfully identified off-targets for drugs such as remantadine, propranolol, and domperidone that were consistent with those identified by recent expts.  The results from our ROCS-based target fishing approach are promising and have potential application in drug repurposing for single and multiple targets, identifying targets for orphan compds., and adverse effect prediction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlyFxT_WLxY7Vg90H21EOLACvtfcHk0lir7eB7qvlGmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Oju7zN&md5=8158d3042eee891660426077bfdbe163</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fci2003544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2003544%26sid%3Dliteratum%253Aachs%26aulast%3DAbdulHameed%26aufirst%3DM.%2BD.%26aulast%3DChaudhury%26aufirst%3DS.%26aulast%3DSing%26aufirst%3DN.%26aulast%3DWallqvist%26aufirst%3DS.%2BH.%26aulast%3DTawa%26aufirst%3DG.%2BJ.%26atitle%3DExploring%2520polypharmacology%2520using%2520a%2520ROCS-based%2520target%2520fishing%2520approach%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D492%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Valerio, L. G.</span><span> </span><span class="NLM_article-title">In silico toxicology for the pharmaceutical sciences</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">241</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.taap.2009.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19716836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=2009&pages=356-370&author=L.+G.+Valerio&title=In+silico+toxicology+for+the+pharmaceutical+sciences"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">In silico toxicology for the pharmaceutical sciences</span></div><div class="casAuthors">Valerio, Luis G.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">356-370</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The applied use of in silico technologies (a.k.a. computational toxicol., in silico toxicol., computer-assisted tox, e-tox, i-drug discovery, predictive ADME, etc.) for predicting preclin. toxicol. endpoints, clin. adverse effects, and metab. of pharmaceutical substances has become of high interest to the scientific community and the public.  The increased accessibility of these technologies for scientists and recent regulations permitting their use for chem. risk assessment supports this notion.  The scientific community is interested in the appropriate use of such technologies as a tool to enhance product development and safety of pharmaceuticals and other xenobiotics, while ensuring the reliability and accuracy of in silico approaches for the toxicol. and pharmacol. sciences.  For pharmaceutical substances, this means active and impurity chems. in the drug product may be screened using specialized software and databases designed to cover these substances through a chem. structure-based screening process and algorithm specific to a given software program.  A major goal for use of these software programs is to enable industry scientists not only to enhance the discovery process but also to ensure the judicious use of in silico tools to support risk assessments of drug-induced toxicities and in safety evaluations.  However, a great amt. of applied research is still needed, and there are many limitations with these approaches which are described in this review.  Currently, there is a wide range of endpoints available from predictive quant. structure-activity relationship models driven by many different computational software programs and data sources, and this is only expected to grow.  For example, there are models based on non-proprietary and/or proprietary information specific to assessing potential rodent carcinogenicity, in silico screens for ICH genetic toxicity assays, reproductive and developmental toxicity, theor. prediction of human drug metab., mechanisms of action for pharmaceuticals, and newer models for predicting human adverse effects.  How accurate are these approaches is both a statistical issue and challenge in toxicol.  In this review, fundamental concepts and the current capabilities and limitations of this technol. will be critically addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzkrrxfkNNVrVg90H21EOLACvtfcHk0lhKqjg-xBwKdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrsbvO&md5=70e08282b489f0472b9522bc2422aefb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2009.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2009.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DValerio%26aufirst%3DL.%2BG.%26atitle%3DIn%2520silico%2520toxicology%2520for%2520the%2520pharmaceutical%2520sciences%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2009%26volume%3D241%26spage%3D356%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Hewitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enoch, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madden, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearden, J. C.</span><span> </span><span class="NLM_article-title">In silico prediction of aqueous solubility: the solubility challenge</span> <span class="citation_source-journal">J Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2572</span><span class="NLM_x">–</span> <span class="NLM_lpage">2587</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci900286s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtleqtLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2572-2587&author=M.+Hewittauthor=M.+T.+D.+Croninauthor=S.+J.+Enochauthor=J.+C.+Maddenauthor=D.+W.+Robertsauthor=J.+C.+Dearden&title=In+silico+prediction+of+aqueous+solubility%3A+the+solubility+challenge"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Prediction of Aqueous Solubility: The Solubility Challenge</span></div><div class="casAuthors">Hewitt, M.; Cronin, M. T. D.; Enoch, S. J.; Madden, J. C.; Roberts, D. W.; Dearden, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2572-2587</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dissoln. of a chem. into water is a process fundamental to both chem. and biol.  The persistence of a chem. within the environment and the effects of a chem. within the body are dependent primarily upon aq. soly.  With the well-documented limitations hindering the accurate exptl. detn. of aq. soly., the utilization of predictive methods have been widely investigated and employed.  The setting of a soly. challenge by this journal proved an excellent opportunity to explore several different modeling methods, utilizing a supplied dataset of high-quality aq. soly. measurements.  Four contrasting approaches (simple linear regression, artificial neural networks, category formation, and available in silico models) were utilized within our lab. and the quality of these predictions was assessed.  These were chosen to span the multitude of modeling methods now in use, while also allowing for the evaluation of existing com. soly. models.  The conclusions of this study were surprising, in that a simple linear regression approach proved to be superior over more-complex modeling methods.  Possible explanations for this observation are discussed and also recommendations are made for future soly. prediction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuHCgKjzGtE7Vg90H21EOLACvtfcHk0lhKqjg-xBwKdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtleqtLvE&md5=7983f8d3133655a4d8967d5b7e9fbdbd</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fci900286s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900286s%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DM.%26aulast%3DCronin%26aufirst%3DM.%2BT.%2BD.%26aulast%3DEnoch%26aufirst%3DS.%2BJ.%26aulast%3DMadden%26aufirst%3DJ.%2BC.%26aulast%3DRoberts%26aufirst%3DD.%2BW.%26aulast%3DDearden%26aufirst%3DJ.%2BC.%26atitle%3DIn%2520silico%2520prediction%2520of%2520aqueous%2520solubility%253A%2520the%2520solubility%2520challenge%26jtitle%3DJ%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D2572%26epage%3D2587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Davis, A. M.; Bruneau, P.</span><span> </span><span class="NLM_article-title">In silico prediction of solubility</span>. In:  <span class="citation_source-book">Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability</span>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group">van de WaterBeemd, H.; Testa, B.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">40</span> , pp  <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=53-68&author=A.+M.+Davis&author=P.+Bruneauauthor=H.+van+de+WaterBeemd&author=B.+Testa&title=Drug+Bioavailability%3A+Estimation+of+Solubility%2C+Permeability%2C+Absorption+and+Bioavailability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DA.%2BM.%26atitle%3DIn%2520silico%2520prediction%2520of%2520solubility%26btitle%3DDrug%2520Bioavailability%253A%2520Estimation%2520of%2520Solubility%252C%2520Permeability%252C%2520Absorption%2520and%2520Bioavailability%26aulast%3Dvan%2Bde%2BWaterBeemd%26aufirst%3DH.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2009%26volume%3D40%26spage%3D53%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Abad-Zapatero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, J. T.</span><span> </span><span class="NLM_article-title">Ligand efficiency indices as guideposts for drug discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FS1359-6446%2805%2903386-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=15809192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=464-469&author=C.+Abad-Zapateroauthor=J.+T.+Metz&title=Ligand+efficiency+indices+as+guideposts+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices as guideposts for drug discovery</span></div><div class="casAuthors">Abad-Zapatero Cele; Metz James T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">464-9</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHqVfZXUq224qdXsLcGTEUfW6udTcc2eb1S4z6veemJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D&md5=1720f263a306122c86a57463e5a39287</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903386-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903386-6%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DMetz%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520efficiency%2520indices%2520as%2520guideposts%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D464%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eb1S4z6veemJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Abad-Zapatero, C.</span> <span class="citation_source-book">Ligand Efficiency Indices for Drug Discovery: Towards an Atlas-Guided Paradigm</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=C.+Abad-Zapatero&title=Ligand+Efficiency+Indices+for+Drug+Discovery%3A+Towards+an+Atlas-Guided+Paradigm"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26btitle%3DLigand%2520Efficiency%2520Indices%2520for%2520Drug%2520Discovery%253A%2520Towards%2520an%2520Atlas-Guided%2520Paradigm%26pub%3DAcademic%2520Press%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St.-Gallay, S. A.</span><span> </span><span class="NLM_article-title">The influence of the ‘organizational factor’ on compound quality in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=749-765&author=P.+D.+Leesonauthor=S.+A.+St.-Gallay&title=The+influence+of+the+%E2%80%98organizational+factor%E2%80%99+on+compound+quality+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSt.-Gallay%26aufirst%3DS.%2BA.%26atitle%3DThe%2520influence%2520of%2520the%2520%25E2%2580%2598organizational%2520factor%25E2%2580%2599%2520on%2520compound%2520quality%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D749%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Perola, E.</span><span> </span><span class="NLM_article-title">An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2986</span><span class="NLM_x">–</span> <span class="NLM_lpage">2997</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100118x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2986-2997&author=E.+Perola&title=An+analysis+of+the+binding+efficiencies+of+drugs+and+their+leads+in+successful+drug+discovery+programs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">An Analysis of the Binding Efficiencies of Drugs and their Leads in Successful Drug Discovery Programs</span></div><div class="casAuthors">Perola, Emanuele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2986-2997</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to investigate the evolution of binding efficiency in successful drug discovery programs, a data set of 60 lead/drug pairs with known binding affinities has been compiled and analyzed.  Low-end thresholds for the binding efficiencies of viable leads and drugs have been derived.  On av., the drugs in the set are significantly larger and more potent but have similar lipophilicity relative to their originating leads, suggesting that the ability to maintain low levels of lipophilicity while increasing mol. wt. is one of the keys to a successful drug discovery program.  A no. of examples demonstrate that large increases in binding efficiency from leads to more elaborate drugs sharing the same scaffold can be achieved.  The importance of dissecting a lead structure to identify the most efficient fragments and the option of sacrificing binding efficiency to optimize other properties are discussed, and relevant examples are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRqzYFBuX2Q7Vg90H21EOLACvtfcHk0liatC274zzsqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D&md5=a7eaad792f1518d093588951df64d22f</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Fjm100118x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100118x%26sid%3Dliteratum%253Aachs%26aulast%3DPerola%26aufirst%3DE.%26atitle%3DAn%2520analysis%2520of%2520the%2520binding%2520efficiencies%2520of%2520drugs%2520and%2520their%2520leads%2520in%2520successful%2520drug%2520discovery%2520programs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2986%26epage%3D2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span> </span><span class="NLM_article-title">Is there a difference between leads and drugs? A historical perspective</span> <span class="citation_source-journal">J. Chem. Inf. Comput. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1308</span><span class="NLM_x">–</span> <span class="NLM_lpage">1315</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci010366a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Okt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=1308-1315&author=T.+I.+Opreaauthor=A.+D.+Davisauthor=S.+J.+Teagueauthor=P.+D.+Leeson&title=Is+there+a+difference+between+leads+and+drugs%3F+A+historical+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Is There a Difference between Leads and Drugs? A Historical Perspective</span></div><div class="casAuthors">Oprea, Tudor I.; Davis, Andrew M.; Teague, Simon J.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1308-1315</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To be considered for further development, lead structures should display the following properties: (1) simple chem. features, amenable for chem. optimization; (2) membership to an established SAR series; (3) favorable patent situation; and (4) good absorption, distribution, metab., and excretion (ADME) properties.  There are two distinct categories of leads: those that lack any therapeutic use (i.e., "pure" leads), and those that are marketed drugs themselves but have been altered to yield novel drugs.  We have previously analyzed the design of leadlike combinatorial libraries starting from 18 lead and drug pairs of structures (S. J. Teague et al. Angew. Chem., Int. Ed. Engl. 1999, 38, 3743-3748).  Here, we report results based on an extended dataset of 96 lead-drug pairs, of which 62 are lead structures that are not marketed as drugs, and 75 are drugs that are not presumably used as leads.  We examd. the following properties: MW (mol. wt.), CMR (the calcd. mol. refractivity), RNG (the no. of rings), RTB (the no. of rotatable bonds), the no. of hydrogen bond donors (HDO) and acceptors (HAC), the calcd. logarithm of the n-octanol/water partition (CLogP), the calcd. logarithm of the distribution coeff. at pH 7.4 (LogD74), the Daylight-fingerprint druglike score (DFPS), and the property and pharmacophore features score (PPFS).  The following differences were obsd. between the medians of drugs and leads: ΔMW = 69; ΔCMR = 1.8; ΔRNG = ΔHAC =1; ΔRTB = 2; ΔCLogP = 0.43; ΔLogD74 = 0.97; ΔHDO = 0; ΔDFPS = 0.15; ΔPPFS = 0.12.  Lead structures exhibit, on the av., less mol. complexity (less MW, less no. of rings and rotatable bonds), are less hydrophobic (lower CLogP and LogD74), and less druglike (lower druglike scores).  These findings indicate that the process of optimizing a lead into a drug results in more complex structures.  This information should be used in the design of novel combinatorial libraries that are aimed at lead discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG4E0R8n7tLrVg90H21EOLACvtfcHk0liatC274zzsqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Okt7s%253D&md5=422b9cf937168d9c2f3d1c8429648ea0</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fci010366a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci010366a%26sid%3Dliteratum%253Aachs%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DDavis%26aufirst%3DA.%2BD.%26aulast%3DTeague%26aufirst%3DS.%2BJ.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DIs%2520there%2520a%2520difference%2520between%2520leads%2520and%2520drugs%253F%2520A%2520historical%2520perspective%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2001%26volume%3D41%26spage%3D1308%26epage%3D1315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Shahzad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLachlan, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohrs, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wangb, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, G.</span><span> </span><span class="NLM_article-title">Global translational medicine initiatives and programs</span> <span class="citation_source-journal">Transl. Biomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=1-7&author=A.+Shahzadauthor=C.+S.+McLachlanauthor=J.+Gaultauthor=R.+J.+Cohrsauthor=X.+Wangbauthor=G.+Kohler&title=Global+translational+medicine+initiatives+and+programs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShahzad%26aufirst%3DA.%26aulast%3DMcLachlan%26aufirst%3DC.%2BS.%26aulast%3DGault%26aufirst%3DJ.%26aulast%3DCohrs%26aufirst%3DR.%2BJ.%26aulast%3DWangb%26aufirst%3DX.%26aulast%3DKohler%26aufirst%3DG.%26atitle%3DGlobal%2520translational%2520medicine%2520initiatives%2520and%2520programs%26jtitle%3DTransl.%2520Biomed.%26date%3D2011%26volume%3D2%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit115"><span>NIH Bench-to-Bedside Program Home Page. <a href="http://clinicalcenter.nih.gov/ccc/btb/" class="extLink">http://clinicalcenter.nih.gov/ccc/btb/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+Bench-to-Bedside+Program+Home+Page.+http%3A%2F%2Fclinicalcenter.nih.gov%2Fccc%2Fbtb%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargreaves, R.</span><span> </span><span class="NLM_article-title">Clinical biomarkers in drug discovery and development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=566-580&author=R.+Frankauthor=R.+Hargreaves&title=Clinical+biomarkers+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DHargreaves%26aufirst%3DR.%26atitle%3DClinical%2520biomarkers%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D566%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Biomarkers Definitions Working Group</span><span> </span><span class="NLM_article-title">Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1067%2Fmcp.2001.113989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=11240971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2001&pages=89-95&author=Biomarkers+Definitions+Working+Group&title=Biomarkers+and+surrogate+endpoints%3A+Preferred+definitions+and+conceptual+framework"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2001.113989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2001.113989%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DBiomarkers%2520and%2520surrogate%2520endpoints%253A%2520Preferred%2520definitions%2520and%2520conceptual%2520framework%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D69%26spage%3D89%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Strimbu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travel, J. A.</span><span> </span><span class="NLM_article-title">What are biomarkers?</span> <span class="citation_source-journal">Curr. Opin. HIV AIDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1097%2FCOH.0b013e32833ed177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=20978388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BC3cbisFSgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=463-466&author=K.+Strimbuauthor=J.+A.+Travel&title=What+are+biomarkers%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">What are biomarkers?</span></div><div class="casAuthors">Strimbu Kyle; Tavel Jorge A</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in HIV and AIDS</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">463-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  This article provides working definitions and a conceptual framework to understand the roles of biomarkers in clinical research.  RECENT FINDINGS:  The definitions of the terms discussed in this article--medical signs, symptoms, biomarkers, surrogate endpoints, clinical endpoints, validation--are still under discussion, as are their relationships to each other, but broad consensus has developed in the past decade and a half about the necessity of distinguishing between, in particular, surrogate and clinical endpoints.  SUMMARY:  This article outlines the major definitions of the key terms in this field and considers select cases in which misunderstandings about the terms led to flawed research conclusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTK-9zJcAGcuLt9HypzAgQfW6udTcc2eZbtkhVb5WQwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbisFSgtQ%253D%253D&md5=3884ee39f4923e3a592f7ead3551f4f4</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1097%2FCOH.0b013e32833ed177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0b013e32833ed177%26sid%3Dliteratum%253Aachs%26aulast%3DStrimbu%26aufirst%3DK.%26aulast%3DTravel%26aufirst%3DJ.%2BA.%26atitle%3DWhat%2520are%2520biomarkers%253F%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2010%26volume%3D5%26spage%3D463%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Day, M.; Rutkowski, J. L.; Feuerstein, G. Z.</span><span> </span><span class="NLM_article-title">Translational medicine – a paradigm shift in modern drug discovery and development: The role of biomarkers</span>. In  <span class="citation_source-book">Pharmaceutical Biotechnology: Advances in Experimental Biology and Medicine</span>; <span class="NLM_contrib-group">Guzman, C. A.; Feuerstein, G. Z.</span>, Eds.; <span class="NLM_publisher-name">Springer Verlag</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">655</span>, pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2F978-1-4419-1132-2_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=1-12&author=M.+Day&author=J.+L.+Rutkowski&author=G.+Z.+Feuersteinauthor=C.+A.+Guzman&author=G.+Z.+Feuerstein&title=Pharmaceutical+Biotechnology%3A+Advances+in+Experimental+Biology+and+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1007%2F978-1-4419-1132-2_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4419-1132-2_1%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DM.%26atitle%3DTranslational%2520medicine%2520%25E2%2580%2593%2520a%2520paradigm%2520shift%2520in%2520modern%2520drug%2520discovery%2520and%2520development%253A%2520The%2520role%2520of%2520biomarkers%26btitle%3DPharmaceutical%2520Biotechnology%253A%2520Advances%2520in%2520Experimental%2520Biology%2520and%2520Medicine%26aulast%3DGuzman%26aufirst%3DC.%2BA.%26pub%3DSpringer%2520Verlag%26date%3D2009%26volume%3D655%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Lee, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farde, L.</span><span> </span><span class="NLM_article-title">Using positron emission tomography tro facilitate CNS drug development</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">310</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=310-316&author=C.-M.+Leeauthor=L.+Farde&title=Using+positron+emission+tomography+tro+facilitate+CNS+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.-M.%26aulast%3DFarde%26aufirst%3DL.%26atitle%3DUsing%2520positron%2520emission%2520tomography%2520tro%2520facilitate%2520CNS%2520drug%2520development%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D310%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zipursky, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remington, G.</span><span> </span><span class="NLM_article-title">Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=9989565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADyaK1M7kt1Kksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1999&pages=286-293&author=S.+Kapurauthor=R.+B.+Zipurskyauthor=G.+Remington&title=Clinical+and+theoretical+implications+of+5-HT2+and+D2+receptor+occupancy+of+clozapine%2C+risperidone+and+olanzapine+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia</span></div><div class="casAuthors">Kapur S; Zipursky R B; Remington G</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">286-93</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Dopamine D2 receptor occupancy measurements provide a valid predictor of antipsychotic response, extrapyramidal side effects, and elevation of prolactin levels.  The new antipsychotics clozapine, risperidone, and olanzapine obtain antipsychotic response with few extrapyramidal side effects and little prolactin elevation.  The purpose of this study was to compare the D2 and serotonin 5-HT2 receptor occupancies of these drugs in patients receiving multiple-dose, steady-state regimens.  METHOD:  Forty-four patients with schizophrenia (16 taking risperidone, 2-12 mg/day; 17 taking olanzapine, 5-60 mg/day; and 11 taking clozapine, 75-900 mg/day) had their D2 and 5-HT2 occupancies determined with the use of [11C]raclopride and [18F]setoperone, respectively, and positron emission tomography imaging.  RESULTS:  Clozapine showed a much lower D2 occupancy (16%-68%) than risperidone (63%-89%) and olanzapine (43%-89%).  Risperidone and olanzapine gave equal D2 occupancies at doses of 5 and 20 mg/day, respectively.  All three drugs showed greater 5-HT2 than D2 occupancy at all doses, although the difference was greatest for clozapine.  CONCLUSIONS:  Clozapine, at doses known to be effective in routine clinical settings, showed a D2 occupancy clearly lower than that of typical antipsychotics, while risperidone and olanzapine at their usual clinical doses gave the same level of D2 occupancy as low-dose typical antipsychotics.  The results also suggest that some previous clinical comparisons of antipsychotics may have been confounded by different levels of D2 occupancy.  Clinical comparisons of these drugs, matching for D2 occupancy, may provide a better measure of their true "atypicality" and will help in understanding the contribution of non-D2 receptors to antipsychotic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8__ZcHLPhBjW1zwg2yUK5fW6udTcc2eaDJEqdbLgoSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7kt1Kksw%253D%253D&md5=30cdcea9c4ae28aa2e8a978635baa894</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DZipursky%26aufirst%3DR.%2BB.%26aulast%3DRemington%26aufirst%3DG.%26atitle%3DClinical%2520and%2520theoretical%2520implications%2520of%25205-HT2%2520and%2520D2%2520receptor%2520occupancy%2520of%2520clozapine%252C%2520risperidone%2520and%2520olanzapine%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1999%26volume%3D156%26spage%3D286%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Chawla, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunburg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gralla, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesketh, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rittenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmer, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carides, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horgan, K. J.</span><span> </span><span class="NLM_article-title">Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">2290</span><span class="NLM_x">–</span> <span class="NLM_lpage">2300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2003&pages=2290-2300&author=S.+P.+Chawlaauthor=S.+Grunburgauthor=R.+J.+Grallaauthor=P.+J.+Heskethauthor=C.+Rittenbergauthor=M.+E.+Elmerauthor=C.+Schmidtauthor=A.+Taylorauthor=A.+D.+Caridesauthor=J.+K.+Evansauthor=K.+J.+Horgan&title=Establishing+the+dose+of+the+oral+NK1+antagonist+aprepitant+for+the+prevention+of+chemotherapy-induced+nausea+and+vomiting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChawla%26aufirst%3DS.%2BP.%26aulast%3DGrunburg%26aufirst%3DS.%26aulast%3DGralla%26aufirst%3DR.%2BJ.%26aulast%3DHesketh%26aufirst%3DP.%2BJ.%26aulast%3DRittenberg%26aufirst%3DC.%26aulast%3DElmer%26aufirst%3DM.%2BE.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DCarides%26aufirst%3DA.%2BD.%26aulast%3DEvans%26aufirst%3DJ.%2BK.%26aulast%3DHorgan%26aufirst%3DK.%2BJ.%26atitle%3DEstablishing%2520the%2520dose%2520of%2520the%2520oral%2520NK1%2520antagonist%2520aprepitant%2520for%2520the%2520prevention%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DCancer%26date%3D2003%26volume%3D97%26spage%3D2290%26epage%3D2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Keller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snavely, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargreaves, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hietala, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lines, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reines, S.</span><span> </span><span class="NLM_article-title">Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">216</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.biopsych.2005.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=16248986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlaqu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=216-223&author=M.+Kellerauthor=S.+Montgomeryauthor=W.+Ballauthor=M.+Morrisonauthor=D.+Snavelyauthor=G.+Liuauthor=R.+Hargreavesauthor=J.+Hietalaauthor=C.+Linesauthor=K.+Beebeauthor=S.+Reines&title=Lack+of+efficacy+of+the+substance+P+%28neurokinin1+receptor%29+antagonist+aprepitant+in+the+treatment+of+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder</span></div><div class="casAuthors">Keller, Martin; Montgomery, Stuart; Ball, William; Morrison, Mary; Snavely, Duane; Liu, Guanghan; Hargreaves, Richard; Hietala, Jarmo; Lines, Christopher; Beebe, Katherine; Reines, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-223</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">An early clin. trial suggested that the substance P (neurokinin1 receptor) antagonist, aprepitant, might provide a unique mechanism of antidepressant activity.  Phase III trials were conducted to confirm these findings.  Five 8-wk, randomized, double-blind, parallel-groups, placebo-controlled, multicenter trials in outpatients with Major Depressive Disorder were performed.  Aprepitant 160 mg and placebo were included in all trials.  Aprepitant 80 mg and paroxetine 20 mg (active comparator) were included in three trials.  Approx. 150 patients were enrolled per treatment group in each trial.  The primary end point was the mean change-from-baseline of the first 17 items of the Hamilton Rating Scale for Depression (HAM-D17) score at 8 wk.  A positron emission tomog. (PET) study was also performed in normal subjects to det. the relationship between neurokinin1 receptor occupancy and aprepitant plasma concns. in dosing regimens relevant to the trials.  No statistically significant differences from placebo on the HAM-D17 were obsd. at week 8 for either dose of aprepitant in any of the trials, whereas paroxetine 20 mg was significantly (p ≤ .05) more effective than placebo at week 8 in each of the three trials in which it was included.  Results from the PET study indicated that the aprepitant dosing regimens provided continuously high levels of neurokinin1 receptor blockade over 8 wk.  Because the methodol. employed confirmed the antidepressant efficacy of paroxetine, the absence of an effect for aprepitant indicates that it was not an effective treatment for depression.  The concept of neurokinin1 receptor antagonism as an antidepressant mechanism was not supported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9V3m5cxalq7Vg90H21EOLACvtfcHk0ljc6SztBR2W0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlaqu74%253D&md5=3b757ca50e7e72151af389acf17f94e2</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DS.%26aulast%3DBall%26aufirst%3DW.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DSnavely%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DHietala%26aufirst%3DJ.%26aulast%3DLines%26aufirst%3DC.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DReines%26aufirst%3DS.%26atitle%3DLack%2520of%2520efficacy%2520of%2520the%2520substance%2520P%2520%2528neurokinin1%2520receptor%2529%2520antagonist%2520aprepitant%2520in%2520the%2520treatment%2520of%2520major%2520depressive%2520disorder%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D216%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Schirmer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calimia, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klauser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvarani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moncayo, R.</span><span> </span><span class="NLM_article-title"><sup>18</sup>F-fluorodeoxyglucose-positron emission topography: A new explorative perspective</span> <span class="citation_source-journal">Exp. Gerentol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FS0531-5565%2802%2900267-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=12670633" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=463-470&author=M.+Schirmerauthor=K.+T.+Calimiaauthor=M.+Wengerauthor=A.+Klauserauthor=C.+Salvaraniauthor=R.+Moncayo&title=18F-fluorodeoxyglucose-positron+emission+topography%3A+A+new+explorative+perspective"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2FS0531-5565%2802%2900267-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0531-5565%252802%252900267-X%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmer%26aufirst%3DM.%26aulast%3DCalimia%26aufirst%3DK.%2BT.%26aulast%3DWenger%26aufirst%3DM.%26aulast%3DKlauser%26aufirst%3DA.%26aulast%3DSalvarani%26aufirst%3DC.%26aulast%3DMoncayo%26aufirst%3DR.%26atitle%3D18F-fluorodeoxyglucose-positron%2520emission%2520topography%253A%2520A%2520new%2520explorative%2520perspective%26jtitle%3DExp.%2520Gerentol.%26date%3D2003%26volume%3D38%26spage%3D463%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Bhatnager, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hustinx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alavi, A.</span><span> </span><span class="NLM_article-title">Nuclear imaging methods for non-invasive drug monitoring</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=41-54&author=A.+Bhatnagerauthor=R.+Hustinxauthor=A.+Alavi&title=Nuclear+imaging+methods+for+non-invasive+drug+monitoring"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhatnager%26aufirst%3DA.%26aulast%3DHustinx%26aufirst%3DR.%26aulast%3DAlavi%26aufirst%3DA.%26atitle%3DNuclear%2520imaging%2520methods%2520for%2520non-invasive%2520drug%2520monitoring%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2000%26volume%3D41%26spage%3D41%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Aboagye, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T.</span><span> </span><span class="NLM_article-title">In vivo pharmacokinetics and pharmacodynamics in drug development using positron emission topography</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=293-302&author=E.+O.+Aboagyeauthor=P.+M.+Priceauthor=T.+Jones&title=In+vivo+pharmacokinetics+and+pharmacodynamics+in+drug+development+using+positron+emission+topography"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DPrice%26aufirst%3DP.%2BM.%26aulast%3DJones%26aufirst%3DT.%26atitle%3DIn%2520vivo%2520pharmacokinetics%2520and%2520pharmacodynamics%2520in%2520drug%2520development%2520using%2520positron%2520emission%2520topography%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2001%26volume%3D6%26spage%3D293%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Taneja, S. S.</span><span> </span><span class="NLM_article-title">ProstaScint® scan: Contemporary use in clinical practice</span> <span class="citation_source-journal">Rev. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">S19</span><span class="NLM_x">–</span> <span class="NLM_lpage">S28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=16985928" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=S19-S28&author=S.+S.+Taneja&title=ProstaScint%C2%AE+scan%3A+Contemporary+use+in+clinical+practice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaneja%26aufirst%3DS.%2BS.%26atitle%3DProstaScint%25C2%25AE%2520scan%253A%2520Contemporary%2520use%2520in%2520clinical%2520practice%26jtitle%3DRev.%2520Urol.%26date%3D2004%26volume%3D6%26spage%3DS19%26epage%3DS28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Schettino, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taneja, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabhan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepor, H.</span><span> </span><span class="NLM_article-title">Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer</span> <span class="citation_source-journal">Am. J. Roentgenol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.2214%2Fajr.183.2.1830519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD2czmsVagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2004&pages=519-524&author=C.+J.+Schettinoauthor=E.+L.+Kramerauthor=M.+E.+Noxauthor=S.+Tanejaauthor=P.+Padmanabhanauthor=H.+Lepor&title=Impact+of+fusion+of+indium-111+capromab+pendetide+volume+data+sets+with+those+from+MRI+or+CT+in+patients+with+recurrent+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer</span></div><div class="casAuthors">Schettino Chris J; Kramer Elissa L; Noz Marilyn E; Taneja Samir; Padmanabhan Priya; Lepor Herbert</div><div class="citationInfo"><span class="NLM_cas:title">AJR. American journal of roentgenology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">519-24</span>
        ISSN:<span class="NLM_cas:issn">0361-803X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Our goal was to evaluate the impact of image fusion on the interpretation of indium-111 Prosta-Scint SPECT scans.  MATERIALS AND METHODS:  Sixty-seven consecutive patients referred for rising prostate-specific antigen (PSA) levels after initial therapy for primary prostate cancer underwent SPECT 96 hr after infusion of (111)In Prosta-Scint, with simultaneous technetium-99m blood pool imaging.  Volume data sets from the SPECT scans were then fused with those from CT and MR images of the pelvis using a 3D landmark-based warping program.  The SPECT scans were initially interpreted without benefit of MRI or CT fusion.  The fused Prosta-Scint MRI-CT volumes were reevaluated by a nuclear radiologist and an MRI radiologist.  Independent reviews before and after fusion were available in these patients.  Validation of results after fusion was performed through correlation with PSA changes after radiation therapy.  RESULTS:  Six patients with sites that could not be evaluated and three without their original Prosta-Scint scanning reports were excluded; thus, 58 patients were studied clinically.  Seventy-four of 161 prefusion-positive sites were found to be negative after fusion.  These 74 sites subsequently were identified primarily as showing bowel, vessel, or marrow uptake after fusion.  In two patients, nodal disease was identified although the review before perfusion indicated none.  Twenty-five patients previously thought to have nodal disease appeared to have only local disease after fusion.  After local radiation therapy, PSA levels decreased in 12 of 25 patients, increased in five, and were unavailable in eight.  CONCLUSION:  Although Prosta-Scint SPECT alone can help in the proper management of recurrent prostate cancer, fusion with MRI-CT of the pelvis can improve the specificity of the examination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlMjqKVyHdC8jl5L8hwNX0fW6udTcc2eaa-WZfAKnc67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czmsVagtA%253D%253D&md5=a4dced9a7901e17e009ef48fc51a66d3</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.2214%2Fajr.183.2.1830519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2214%252Fajr.183.2.1830519%26sid%3Dliteratum%253Aachs%26aulast%3DSchettino%26aufirst%3DC.%2BJ.%26aulast%3DKramer%26aufirst%3DE.%2BL.%26aulast%3DNox%26aufirst%3DM.%2BE.%26aulast%3DTaneja%26aufirst%3DS.%26aulast%3DPadmanabhan%26aufirst%3DP.%26aulast%3DLepor%26aufirst%3DH.%26atitle%3DImpact%2520of%2520fusion%2520of%2520indium-111%2520capromab%2520pendetide%2520volume%2520data%2520sets%2520with%2520those%2520from%2520MRI%2520or%2520CT%2520in%2520patients%2520with%2520recurrent%2520prostate%2520cancer%26jtitle%3DAm.%2520J.%2520Roentgenol.%26date%3D2004%26volume%3D183%26spage%3D519%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Krishna, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nerman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. A.</span><span> </span><span class="NLM_article-title">Accellerating drug development using biomarkers: A case study with sitagliptin, a novel DPP4 inhibior for type 2 diabetes</span> <span class="citation_source-journal">AAPS J</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=401-409&author=R.+Krishnaauthor=G.+Nermanauthor=J.+A.+Wagner&title=Accellerating+drug+development+using+biomarkers%3A+A+case+study+with+sitagliptin%2C+a+novel+DPP4+inhibior+for+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrishna%26aufirst%3DR.%26aulast%3DNerman%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26atitle%3DAccellerating%2520drug%2520development%2520using%2520biomarkers%253A%2520A%2520case%2520study%2520with%2520sitagliptin%252C%2520a%2520novel%2520DPP4%2520inhibior%2520for%2520type%25202%2520diabetes%26jtitle%3DAAPS%2520J%26date%3D2008%26volume%3D10%26spage%3D401%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Velonas, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dos Remedios, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assinder, S. J.</span><span> </span><span class="NLM_article-title">Current status of biomarkers for prostate cancer</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">11034</span><span class="NLM_x">–</span> <span class="NLM_lpage">11060</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.3390%2Fijms140611034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=23708103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2jsbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=11034-11060&author=V.+M.+Velonasauthor=H.+H.+Wooauthor=C.+G.+dos+Remediosauthor=S.+J.+Assinder&title=Current+status+of+biomarkers+for+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of biomarkers for prostate cancer</span></div><div class="casAuthors">Velonas, Vicki M.; Woo, Henry H.; dos Remedios, Cristobal G.; Assinder, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">11034-11060, 27 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Prostate cancer (PCa) is a leading cause of cancer-related death of men globally.  Since its introduction, there has been intense debate as to the effectiveness of the prostate specific antigen (PSA) test as a screening tool for PCa.  It is now evident that the PSA test produces unacceptably high rates of false pos. results and is not prognostic.  Here we review the current status of mol. biomarkers that promise to be prognostic and that might inform individual patient management.  It highlights current efforts to identify biomarkers obtained by minimally invasive methods and discusses current knowledge with regard to gene fusions, mRNA and microRNAs, immunol., and cancer-assocd. microparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsPVUX_K_4rVg90H21EOLACvtfcHk0lg3qHTmSDzMnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2jsbbI&md5=bae975612dcef03909f95d5313a56ab6</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.3390%2Fijms140611034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms140611034%26sid%3Dliteratum%253Aachs%26aulast%3DVelonas%26aufirst%3DV.%2BM.%26aulast%3DWoo%26aufirst%3DH.%2BH.%26aulast%3Ddos%2BRemedios%26aufirst%3DC.%2BG.%26aulast%3DAssinder%26aufirst%3DS.%2BJ.%26atitle%3DCurrent%2520status%2520of%2520biomarkers%2520for%2520prostate%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D11034%26epage%3D11060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit131"><span>Guidance for Industry: S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. U.S. Food and Drug Administration, Oct<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span><a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074963.pdf" class="extLink">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074963.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Guidance+for+Industry%3A+S7B+nonclinical+evaluation+of+the+potential+for+delayed+ventricular+repolarization+%28QT+interval+prolongation%29+by+human+pharmaceuticals.+U.S.+Food+and+Drug+Administration%2C+Oct+2005%3B+http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fucm074963.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Hampel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teipel, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herholz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokde, A. L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoessler, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanhai, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodcock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blennow, K.</span><span> </span><span class="NLM_article-title">Biomarkers for Alzheimer’s disease: academic industry and regulatory perspectives</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">574</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=560-574&author=H.+Hampelauthor=R.+Frankauthor=K.+Broichauthor=S.+J.+Teipelauthor=R.+G.+Katzauthor=J.+Hardyauthor=K.+Herholzauthor=A.+L.+W.+Bokdeauthor=F.+Jessenauthor=Y.+C.+Hoesslerauthor=W.+R.+Sanhaiauthor=H.+Zetterbergauthor=J.+Woodcockauthor=K.+Blennow&title=Biomarkers+for+Alzheimer%E2%80%99s+disease%3A+academic+industry+and+regulatory+perspectives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHampel%26aufirst%3DH.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DBroich%26aufirst%3DK.%26aulast%3DTeipel%26aufirst%3DS.%2BJ.%26aulast%3DKatz%26aufirst%3DR.%2BG.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DHerholz%26aufirst%3DK.%26aulast%3DBokde%26aufirst%3DA.%2BL.%2BW.%26aulast%3DJessen%26aufirst%3DF.%26aulast%3DHoessler%26aufirst%3DY.%2BC.%26aulast%3DSanhai%26aufirst%3DW.%2BR.%26aulast%3DZetterberg%26aufirst%3DH.%26aulast%3DWoodcock%26aufirst%3DJ.%26aulast%3DBlennow%26aufirst%3DK.%26atitle%3DBiomarkers%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520academic%2520industry%2520and%2520regulatory%2520perspectives%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D560%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Rosen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blennow, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterberg, H.</span><span> </span><span class="NLM_article-title">Fluid biomarkers in Alzheimer’s disease – current concepts</span> <span class="citation_source-journal">Mol. Neurodegener.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">20-1</span><span class="NLM_x">–</span> <span class="NLM_lpage">20-11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1186%2F1750-1326-8-20" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=20-1-20-11&author=C.+Rosenauthor=O.+Hanssonauthor=K.+Blennowauthor=H.+Zetterberg&title=Fluid+biomarkers+in+Alzheimer%E2%80%99s+disease+%E2%80%93+current+concepts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1186%2F1750-1326-8-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1326-8-20%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DC.%26aulast%3DHansson%26aufirst%3DO.%26aulast%3DBlennow%26aufirst%3DK.%26aulast%3DZetterberg%26aufirst%3DH.%26atitle%3DFluid%2520biomarkers%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520%25E2%2580%2593%2520current%2520concepts%26jtitle%3DMol.%2520Neurodegener.%26date%3D2013%26volume%3D8%26spage%3D20-1%26epage%3D20-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Ravine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurlan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascherio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galpem, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoulson, I.</span><span> </span><span class="NLM_article-title">Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease</span> <span class="citation_source-journal">Mov. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1392</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=1392-1397&author=B.+Ravineauthor=K.+Marekauthor=S.+Eberlyauthor=D.+Oakesauthor=R.+Kurlanauthor=A.+Ascherioauthor=F.+Bealauthor=J.+Beckauthor=E.+Flaggauthor=W.+R.+Galpemauthor=J.+Harmanauthor=A.+E.+Langauthor=M.+Schwarzschildauthor=C.+Tannerauthor=I.+Shoulson&title=Dopamine+transporter+imaging+is+associated+with+long-term+outcomes+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRavine%26aufirst%3DB.%26aulast%3DMarek%26aufirst%3DK.%26aulast%3DEberly%26aufirst%3DS.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DKurlan%26aufirst%3DR.%26aulast%3DAscherio%26aufirst%3DA.%26aulast%3DBeal%26aufirst%3DF.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DFlagg%26aufirst%3DE.%26aulast%3DGalpem%26aufirst%3DW.%2BR.%26aulast%3DHarman%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DSchwarzschild%26aufirst%3DM.%26aulast%3DTanner%26aufirst%3DC.%26aulast%3DShoulson%26aufirst%3DI.%26atitle%3DDopamine%2520transporter%2520imaging%2520is%2520associated%2520with%2520long-term%2520outcomes%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2012%26volume%3D27%26spage%3D1392%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Hong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesking, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankovic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabetian, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverenz, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, U. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease</span> <span class="citation_source-journal">Brain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2010&pages=713-726&author=Z.+Hongauthor=M.+Shiauthor=K.+A.+Chungauthor=J.+F.+Quinnauthor=E.+R.+Peskingauthor=D.+Galaskoauthor=J.+Jankovicauthor=C.+P.+Zabetianauthor=J.+B.+Leverenzauthor=G.+Bairdauthor=T.+J.+Montineauthor=A.+M.+Hancockauthor=J.+Hwangauthor=C.+Panauthor=J.+Bradnerauthor=U.+J.+Kangauthor=P.+H.+Jensenauthor=J.+Zhang&title=DJ-1+and+%CE%B1-synuclein+in+human+cerebrospinal+fluid+as+biomarkers+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DK.%2BA.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26aulast%3DPesking%26aufirst%3DE.%2BR.%26aulast%3DGalasko%26aufirst%3DD.%26aulast%3DJankovic%26aufirst%3DJ.%26aulast%3DZabetian%26aufirst%3DC.%2BP.%26aulast%3DLeverenz%26aufirst%3DJ.%2BB.%26aulast%3DBaird%26aufirst%3DG.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DHancock%26aufirst%3DA.%2BM.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DU.%2BJ.%26aulast%3DJensen%26aufirst%3DP.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DDJ-1%2520and%2520%25CE%25B1-synuclein%2520in%2520human%2520cerebrospinal%2520fluid%2520as%2520biomarkers%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DBrain%26date%3D2010%26volume%3D133%26spage%3D713%26epage%3D726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albanell, J.</span><span> </span><span class="NLM_article-title">Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2825</span><span class="NLM_x">–</span> <span class="NLM_lpage">2831</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=2825-2831&author=J.+Baselgaauthor=L.+Nortonauthor=J.+Albanell&title=Recombinant+humanized+anti-HER-2+antibody+%28Herceptin%29+enhances+the+antitumor+activity+of+paclitaxel+and+doxorubicin+against+HER2%2Fneu+overexpressing+human+breast+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DAlbanell%26aufirst%3DJ.%26atitle%3DRecombinant%2520humanized%2520anti-HER-2%2520antibody%2520%2528Herceptin%2529%2520enhances%2520the%2520antitumor%2520activity%2520of%2520paclitaxel%2520and%2520doxorubicin%2520against%2520HER2%252Fneu%2520overexpressing%2520human%2520breast%2520cancer%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D2825%26epage%3D2831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Schilsky, R. L.</span><span> </span><span class="NLM_article-title">Personalized medicine in oncology: The future is now</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=363-366&author=R.+L.+Schilsky&title=Personalized+medicine+in+oncology%3A+The+future+is+now"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchilsky%26aufirst%3DR.%2BL.%26atitle%3DPersonalized%2520medicine%2520in%2520oncology%253A%2520The%2520future%2520is%2520now%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D363%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Chiang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Million, R. P.</span><span> </span><span class="NLM_article-title">Personalized medicine in oncology: Next generation</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=895-896&author=A.+Chiangauthor=R.+P.+Million&title=Personalized+medicine+in+oncology%3A+Next+generation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DMillion%26aufirst%3DR.%2BP.%26atitle%3DPersonalized%2520medicine%2520in%2520oncology%253A%2520Next%2520generation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D895%26epage%3D896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Sadigh-Eteghad, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talebi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farhoudi, M.</span><span> </span><span class="NLM_article-title">Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer’s disease. A meta-analysis</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=321-326&author=S.+Sadigh-Eteghadauthor=M.+Talebiauthor=M.+Farhoudi&title=Association+of+apolipoprotein+E+epsilon+4+allele+with+sporadic+late+onset+Alzheimer%E2%80%99s+disease.+A+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSadigh-Eteghad%26aufirst%3DS.%26aulast%3DTalebi%26aufirst%3DM.%26aulast%3DFarhoudi%26aufirst%3DM.%26atitle%3DAssociation%2520of%2520apolipoprotein%2520E%2520epsilon%25204%2520allele%2520with%2520sporadic%2520late%2520onset%2520Alzheimer%25E2%2580%2599s%2520disease.%2520A%2520meta-analysis%26jtitle%3DNeuroscience%26date%3D2012%26volume%3D17%26spage%3D321%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Harrison, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D.</span><span> </span><span class="NLM_article-title">Schizophrenia genes, gene expression and neuropathology: on the matter of their convergence</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fsj.mp.4001558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=15263907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=40-68&author=P.+Harrisonauthor=D.+Weinberger&title=Schizophrenia+genes%2C+gene+expression+and+neuropathology%3A+on+the+matter+of+their+convergence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence</span></div><div class="casAuthors">Harrison, P. J.; Weinberger, D. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-68</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This review critically summarizes the neuropathol. and genetics of schizophrenia, the relationship between them, and speculates on their functional convergence.  The morphol. correlates of schizophrenia are subtle, and range from a slight redn. in brain size to localized alterations in the morphol. and mol. compn. of specific neuronal, synaptic, and glial populations in the hippocampus, dorsolateral prefrontal cortex, and dorsal thalamus.  These findings have fostered the view of schizophrenia as a disorder of connectivity and of the synapse.  Although attractive, such concepts are vague, and differentiating primary events from epiphenomena has been difficult.  A way forward is provided by the recent identification of several putative susceptibility genes (including neuregulin, dysbindin, COMT, DISC1, RGS4, GRM3, and G72).  We discuss the evidence for these and other genes, along with what is known of their expression profiles and biol. roles in brain and how these may be altered in schizophrenia.  The evidence for several of the genes is now strong.  However, for none, with the likely exception of COMT, has a causative allele or the mechanism by which it predisposes to schizophrenia been identified.  Nevertheless, we speculate that the genes may all converge functionally upon schizophrenia risk via an influence upon synaptic plasticity and the development and stabilization of cortical microcircuitry.  NMDA receptor-mediated glutamate transmission may be esp. implicated, though there are also direct and indirect links to dopamine and GABA signaling.  Hence, there is a correspondence between the putative roles of the genes at the mol. and synaptic levels and the existing understanding of the disorder at the neural systems level.  Characterization of a core mol. pathway and a genetic cytoarchitecture' would be a profound advance in understanding schizophrenia, and may have equally significant therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEeG0dw3pqdbVg90H21EOLACvtfcHk0lg4APepVK80lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3N&md5=6e69aab6f45644278ca29a89ea03724a</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001558%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DP.%26aulast%3DWeinberger%26aufirst%3DD.%26atitle%3DSchizophrenia%2520genes%252C%2520gene%2520expression%2520and%2520neuropathology%253A%2520on%2520the%2520matter%2520of%2520their%2520convergence%26jtitle%3DMol.%2520Psychiatry%26date%3D2005%26volume%3D10%26spage%3D40%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Abou-Gharbia, M. A.; Childers, W. E.</span><span> </span><span class="NLM_article-title">The discovery of Effexor® and Pristiq®</span>. In  <span class="citation_source-book">Analogue-Based Drug Discovery II</span>; <span class="NLM_contrib-group">Fischer, J.; Ganellin, C. R.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1002%2F9783527630035.ch21" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=507-524&author=M.+A.+Abou-Gharbia&author=W.+E.+Childersauthor=J.+Fischer&author=C.+R.+Ganellin&title=Analogue-Based+Drug+Discovery+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2F9783527630035.ch21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527630035.ch21%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%2BA.%26atitle%3DThe%2520discovery%2520of%2520Effexor%25C2%25AE%2520and%2520Pristiq%25C2%25AE%26btitle%3DAnalogue-Based%2520Drug%2520Discovery%2520II%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%26date%3D2010%26spage%3D507%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Nelson, J. C.</span><span> </span><span class="NLM_article-title">Managing treatment-resistant major depression</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.4088%2FJCP.v64n0301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=12625799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1Wqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=5-12&author=J.+C.+Nelson&title=Managing+treatment-resistant+major+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Managing treatment-resistant major depression</span></div><div class="casAuthors">Nelson, J. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">5-12</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">A review.  A sizable proportion of patients suffering from nonpsychotic unipolar depression experience only partial or no clin. response to antidepressant treatment.  Switching, augmenting, and combining various pharmaceutical agents can be effective strategies for patients with treatment-resistant depression.  The empirical evidence supporting these approaches is inconsistent, however, and there is a paucity of controlled studies to support their efficacy.  Addnl., it has been difficult to demonstrate the advantages of these strategies over increasing the dose or duration of the initial drug treatment.  This article will review available evidence and clin. considerations regarding switching, augmenting, and combining various agents in the treatment of patients suffering from nonpsychotic unipolar depression who have failed adequate courses of antidepressant treatment.  More research is needed that controls for continued time on the initial agent, that compares different strategies, and that dets. which patients are the best candidates for which treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN5ZLGjxOZQLVg90H21EOLACvtfcHk0lh4VrnBL8mJWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1Wqtrk%253D&md5=4184177f5193d20a0134cc7387786033</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.4088%2FJCP.v64n0301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.v64n0301%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%2BC.%26atitle%3DManaging%2520treatment-resistant%2520major%2520depression%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2003%26volume%3D64%26spage%3D5%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Deecher, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andree, T. H.</span><span> </span><span class="NLM_article-title">Desvenlavaxine succinate: a new serotonin and norepinephrine reuptake inhibitor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1124%2Fjpet.106.103382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=16675639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslOlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2006&pages=657-665&author=D.+C.+Deecherauthor=C.+E.+Beyerauthor=G.+Johnstonauthor=J.+Brayauthor=S.+Shahauthor=M.+Abou-Gharbiaauthor=T.+H.+Andree&title=Desvenlavaxine+succinate%3A+a+new+serotonin+and+norepinephrine+reuptake+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor</span></div><div class="casAuthors">Deecher, Darlene C.; Beyer, Chad E.; Johnston, Grace; Bray, Jenifer; Shah, S.; Abou-Gharbia, M.; Andree, Terrance H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">657-665</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The purpose of this study was to characterize a new chem. entity, desvenlafaxine succinate (DVS).  DVS is a novel salt form of the isolated major active metabolite of venlafaxine.  Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with Ki values for DVS of 40.2±1.6 and 558.4±121.6 nM, resp.  DVS showed weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter.  Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3±19.4 and 531.3±113.0 nM, resp.  DVS (10 μM), examd. at a large no. of nontransporter targets, showed no significant activity.  DVS (30 mg/kg orally) rapidly penetrated the male rat brain and hypothalamus.  DVS (30 mg/kg orally) significantly increased extracellular NE levels compared with baseline in the male rat hypothalamus but had no effect on DA levels using microdialysis.  To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT1A autoreceptors, a 5-HT1A antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).  5-HT increased 78% compared with baseline with no addnl. increase in NE or DA levels.  In conclusion, DVS is a new 5-HT and NE reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios, suggesting utility in a variety of central nervous system-related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkQZEaoTYCvrVg90H21EOLACvtfcHk0lh4VrnBL8mJWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslOlsbw%253D&md5=3aee610641ebcc865d849d7e400f1ea5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.103382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.103382%26sid%3Dliteratum%253Aachs%26aulast%3DDeecher%26aufirst%3DD.%2BC.%26aulast%3DBeyer%26aufirst%3DC.%2BE.%26aulast%3DJohnston%26aufirst%3DG.%26aulast%3DBray%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26atitle%3DDesvenlavaxine%2520succinate%253A%2520a%2520new%2520serotonin%2520and%2520norepinephrine%2520reuptake%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D318%26spage%3D657%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Yardley, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husbands, G. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bicksler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muth, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andree, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, H. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleleck, A. R.</span><span> </span><span class="NLM_article-title">2-Phenyl-2-(1-hydroxycycloalkyl)ethyl)amine derivatives: Synthesis and antidepressant activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2899</span><span class="NLM_x">–</span> <span class="NLM_lpage">2905</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00172a035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=2899-2905&author=J.+P.+Yardleyauthor=G.+E.+M.+Husbandsauthor=G.+Stackauthor=J.+Butchauthor=J.+Bickslerauthor=J.+A.+Moyerauthor=E.+A.+Muthauthor=T.+Andreeauthor=H.+F.+Fletcherauthor=M.+N.+G.+Jamesauthor=A.+R.+Sleleck&title=2-Phenyl-2-%281-hydroxycycloalkyl%29ethyl%29amine+derivatives%3A+Synthesis+and+antidepressant+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fjm00172a035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00172a035%26sid%3Dliteratum%253Aachs%26aulast%3DYardley%26aufirst%3DJ.%2BP.%26aulast%3DHusbands%26aufirst%3DG.%2BE.%2BM.%26aulast%3DStack%26aufirst%3DG.%26aulast%3DButch%26aufirst%3DJ.%26aulast%3DBicksler%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BA.%26aulast%3DMuth%26aufirst%3DE.%2BA.%26aulast%3DAndree%26aufirst%3DT.%26aulast%3DFletcher%26aufirst%3DH.%2BF.%26aulast%3DJames%26aufirst%3DM.%2BN.%2BG.%26aulast%3DSleleck%26aufirst%3DA.%2BR.%26atitle%3D2-Phenyl-2-%25281-hydroxycycloalkyl%2529ethyl%2529amine%2520derivatives%253A%2520Synthesis%2520and%2520antidepressant%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D2899%26epage%3D2905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Preskorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patroneva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isler, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burczynski, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, A. I.</span><span> </span><span class="NLM_article-title">Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1097%2FJCP.0b013e318192e4c1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19142106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FmvFOmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=39-43&author=S.+Preskornauthor=A.+Patronevaauthor=H.+Silmanauthor=Q.+Jiangauthor=J.+A.+Islerauthor=M.+E.+Burczynskiauthor=S.+Ahmedauthor=J.+Paulauthor=A.+I.+Nichols&title=Comparison+of+the+pharmacokinetics+of+venlafaxine+extended+release+and+desvenlafaxine+in+extensive+and+poor+cytochrome+P450+2D6+metabolizers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers</span></div><div class="casAuthors">Preskorn Sheldon; Patroneva Albena; Silman Heather; Jiang Qin; Isler Jennifer A; Burczynski Michael E; Ahmed Saeeduddin; Paul Jeffrey; Nichols Alice I</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical psychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The goal of this study was to evaluate the impact of cytochrome P450 2D6 extensive metabolizer (EM) or poor metabolizer (PM) status on the pharmacokinetics of single doses of venlafaxine extended release (ER) and desvenlafaxine (administered as desvenlafaxine succinate) in healthy adults.  METHODS:  In an open-label, crossover study, 14 healthy volunteers (aged 18-55 years; 7 EMs and 7 PMs) received, in randomized sequence, single doses of venlafaxine ER 75 mg/d or desvenlafaxine 100 mg/d.  Cytochrome P450 2D6 genotyping was performed, and plasma drug levels were measured.  The arithmetic means and standard deviation (SD) for area under the plasma concentration-versus-time curve (AUC) and peak plasma concentration (Cmax) were calculated.  Comparisons of AUC and Cmax between cytochrome P450 2D6 EMs and PMs were calculated using a Wilcoxon exact test.  RESULTS:  After administration of venlafaxine ER, mean Cmax and AUC of venlafaxine were significantly greater in PMs compared with EMs, whereas mean Cmax and AUC of its metabolite, desvenlafaxine, were significantly lower for PMs than for EMs (P = 0.001, all comparisons).  In contrast, mean Cmax and AUC of desvenlafaxine after administration of desvenlafaxine were comparable between EMs and PMs.  CONCLUSIONS:  Cytochrome P450 2D6 genetic polymorphisms had no discernible impact on exposure to desvenlafaxine after desvenlafaxine administration; in contrast, compared with an EM phenotype, a PM phenotype had a significant effect on venlafaxine and desvenlafaxine plasma concentrations after venlafaxine ER administration.  This reduced pharmacokinetic variability of desvenlafaxine may translate into better uniformity of response for patients receiving desvenlafaxine versus venlafaxine, but additional studies are required to test this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYAEo4W4qorty3lHz94U-GfW6udTcc2eYCz7fVVO82E7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FmvFOmsw%253D%253D&md5=abea14db55147faaa9e2a0f2fc57cb63</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1097%2FJCP.0b013e318192e4c1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0b013e318192e4c1%26sid%3Dliteratum%253Aachs%26aulast%3DPreskorn%26aufirst%3DS.%26aulast%3DPatroneva%26aufirst%3DA.%26aulast%3DSilman%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DIsler%26aufirst%3DJ.%2BA.%26aulast%3DBurczynski%26aufirst%3DM.%2BE.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DA.%2BI.%26atitle%3DComparison%2520of%2520the%2520pharmacokinetics%2520of%2520venlafaxine%2520extended%2520release%2520and%2520desvenlafaxine%2520in%2520extensive%2520and%2520poor%2520cytochrome%2520P450%25202D6%2520metabolizers%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2009%26volume%3D29%26spage%3D39%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span> </span><span class="NLM_article-title">Discovery of innovative small molecule therapeutics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8012823" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2-9&author=M.+Abou-Gharbia&title=Discovery+of+innovative+small+molecule+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm8012823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012823%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520innovative%2520small%2520molecule%2520therapeutics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Childers, W.</span><span> </span><span class="NLM_article-title">Targeting neurodegenerative diseases: Drug discovery in a challenging arena</span> <span class="citation_source-journal">Pure Appl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1543</span><span class="NLM_x">–</span> <span class="NLM_lpage">1556</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=1543-1556&author=M.+Abou-Gharbiaauthor=W.+Childers&title=Targeting+neurodegenerative+diseases%3A+Drug+discovery+in+a+challenging+arena"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DChilders%26aufirst%3DW.%26atitle%3DTargeting%2520neurodegenerative%2520diseases%253A%2520Drug%2520discovery%2520in%2520a%2520challenging%2520arena%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2012%26volume%3D84%26spage%3D1543%26epage%3D1556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Graziani, E. I.</span><span> </span><span class="NLM_article-title">Uncoupling neuroprotection from immunosuppression: The discovery of ILS-920</span>. In  <span class="citation_source-book">Accounts in Drug Discovery</span>; <span class="NLM_contrib-group">Barrish, J. C.; Carter, P. H.; Cheng, P. T. W.; Zahler, R.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">331</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=316-331&author=E.+I.+Grazianiauthor=J.+C.+Barrish&author=P.+H.+Carter&author=P.+T.+W.+Cheng&author=R.+Zahler&title=Accounts+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3DUncoupling%2520neuroprotection%2520from%2520immunosuppression%253A%2520The%2520discovery%2520of%2520ILS-920%26btitle%3DAccounts%2520in%2520Drug%2520Discovery%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26pub%3DRSC%2520Publishing%26date%3D2011%26spage%3D316%26epage%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Saunders, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, M. L.</span><span> </span><span class="NLM_article-title">Rapamycin in transplantation: A review of the evidence</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1046%2Fj.1523-1755.2001.00460.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=11135052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot1yguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2001&pages=3-16&author=R.+N.+Saundersauthor=M.+S.+Metcalfeauthor=M.+L.+Nicholson&title=Rapamycin+in+transplantation%3A+A+review+of+the+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin in transplantation: A review of the evidence</span></div><div class="casAuthors">Saunders, Richard N.; Metcalfe, Mathew S.; Nicholson, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">A review with 125 refs.  The calcineurin inhibitors have been the mainstays of immunosuppression for solid organ transplantation over the last two decades, but nephrotoxicity limits their therapeutic benefit.  Rapamycin is a new drug with both immunosuppressant and antiproliferative properties that has a unique mechanism of action distinct from that of the calcineurin inhibitors.  It has a role as a maintenance immunosuppressant either alone or in combination with a calcineurin inhibitor and can also be used to treat refractory acute rejection.  Theor. evidence suggests that it may limit the development and progression of chronic rejection in transplant recipients, but this has yet to be confirmed.  This review examines the current in vitro animal and human work underlying the use of rapamycin and, in addn., comments on the pharmacokinetics and side-effect profile of this promising new agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXwUZLv9en7Vg90H21EOLACvtfcHk0lhT6EvuohPaBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot1yguw%253D%253D&md5=d94b7d45cd50461178347a8868dbe6ff</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1755.2001.00460.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1755.2001.00460.x%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DR.%2BN.%26aulast%3DMetcalfe%26aufirst%3DM.%2BS.%26aulast%3DNicholson%26aufirst%3DM.%2BL.%26atitle%3DRapamycin%2520in%2520transplantation%253A%2520A%2520review%2520of%2520the%2520evidence%26jtitle%3DKidney%2520Int.%26date%3D2001%26volume%3D59%26spage%3D3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Faiver, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Current development of mTOR inhibitors as anticancer agents</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">688</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=671-688&author=S.+Faiverauthor=G.+Kroemerauthor=E.+Raymond&title=Current+development+of+mTOR+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaiver%26aufirst%3DS.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DCurrent%2520development%2520of%2520mTOR%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D671%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Skotnicki, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou-Gharbia, M. A.</span><span> </span><span class="NLM_article-title"> Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: The identification of CCI-779</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3749S</span><span class="NLM_x">–</span> <span class="NLM_lpage">3750S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=3749S-3750S&author=J.+S.+Skotnickiauthor=C.+L.+Leoneauthor=A.+L.+Smithauthor=Y.+L.+Palmerauthor=K.+Yuauthor=C.+M.+Discafaniauthor=J.+J.+Gibbonsauthor=P.+Frostauthor=M.+A.+Abou-Gharbia&title=+Design%2C+synthesis+and+biological+evaluation+of+C-42+hydroxyesters+of+rapamycin%3A+The+identification+of+CCI-779"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkotnicki%26aufirst%3DJ.%2BS.%26aulast%3DLeone%26aufirst%3DC.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DPalmer%26aufirst%3DY.%2BL.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%2BA.%26atitle%3D%2520Design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520C-42%2520hydroxyesters%2520of%2520rapamycin%253A%2520The%2520identification%2520of%2520CCI-779%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D3749S%26epage%3D3750S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Rini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Temsirolimus</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=599-600&author=B.+Riniauthor=S.+Karauthor=P.+Kirkpatrick&title=Temsirolimus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRini%26aufirst%3DB.%26aulast%3DKar%26aufirst%3DS.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DTemsirolimus%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D599%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clardy, J.</span><span> </span><span class="NLM_article-title">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP12-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0lj2SeSgPOuKYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP12-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26spage%3D239%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Summers, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, E. I.</span><span> </span><span class="NLM_article-title">3-Normeridamycin: A potent non-immunosuppresive immunophilin ligand is neuroprotective in dopaminergic neurons</span> <span class="citation_source-journal">J. Antibiot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=184-189&author=M.+Y.+Summersauthor=M.+Leightonauthor=D.+Liuauthor=K.+Pongauthor=E.+I.+Graziani&title=3-Normeridamycin%3A+A+potent+non-immunosuppresive+immunophilin+ligand+is+neuroprotective+in+dopaminergic+neurons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSummers%26aufirst%3DM.%2BY.%26aulast%3DLeighton%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPong%26aufirst%3DK.%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3D3-Normeridamycin%253A%2520A%2520potent%2520non-immunosuppresive%2520immunophilin%2520ligand%2520is%2520neuroprotective%2520in%2520dopaminergic%2520neurons%26jtitle%3DJ.%2520Antibiot.%26date%3D2006%26volume%3D59%26spage%3D184%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Ruan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowlby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crozier, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercado, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaleska, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magolda, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skotnicki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pangalos, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehn, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, E. I.</span><span> </span><span class="NLM_article-title">Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=33-38&author=B.+Ruanauthor=K.+Pongauthor=F.+Jowauthor=M.+Bowlbyauthor=R.+A.+Crozierauthor=D.+Liuauthor=S.+Liangauthor=Y.+Chenauthor=M.+L.+Mercadoauthor=X.+Fengauthor=F.+Bennettauthor=D.+van+Schackauthor=L.+McDonaldauthor=M.+M.+Zaleskaauthor=A.+Woodauthor=P.+H.+Reinhardtauthor=R.+L.+Magoldaauthor=J.+Skotnickiauthor=M.+N.+Pangalosauthor=F.+E.+Koehnauthor=G.+T.+Carterauthor=M.+Abou-Gharbiaauthor=E.+I.+Graziani&title=Binding+of+rapamycin+analogs+to+calcium+channels+and+FKBP52+contributes+to+their+neuroprotective+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuan%26aufirst%3DB.%26aulast%3DPong%26aufirst%3DK.%26aulast%3DJow%26aufirst%3DF.%26aulast%3DBowlby%26aufirst%3DM.%26aulast%3DCrozier%26aufirst%3DR.%2BA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMercado%26aufirst%3DM.%2BL.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3Dvan%2BSchack%26aufirst%3DD.%26aulast%3DMcDonald%26aufirst%3DL.%26aulast%3DZaleska%26aufirst%3DM.%2BM.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DReinhardt%26aufirst%3DP.%2BH.%26aulast%3DMagolda%26aufirst%3DR.%2BL.%26aulast%3DSkotnicki%26aufirst%3DJ.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26aulast%3DKoehn%26aufirst%3DF.%2BE.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3DBinding%2520of%2520rapamycin%2520analogs%2520to%2520calcium%2520channels%2520and%2520FKBP52%2520contributes%2520to%2520their%2520neuroprotective%2520activities%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D33%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Dinleyici, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yargic, Z. A.</span><span> </span><span class="NLM_article-title">Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine</span> <span class="citation_source-journal">Expert Rev. Vaccines</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">986</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1586%2Ferv.09.68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19627181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFOls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=977-986&author=E.+C.+Dinleyiciauthor=Z.+A.+Yargic&title=Current+knowledge+regarding+the+investigational+13-valent+pneumococcal+conjugate+vaccine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine</span></div><div class="casAuthors">Dinleyici, Ener Cagri; Yargic, Zeynel Abidin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Vaccines</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">977-986</span>CODEN:
                <span class="NLM_cas:coden">ERVXAX</span>;
        ISSN:<span class="NLM_cas:issn">1476-0584</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The introduction of a 7-valent pneumococcal conjugate vaccine (PCV-7) into the routine childhood vaccination schedule has been shown to be effective in preventing invasive pneumococcal disease (IPD), pneumonia, otitis media and meningitis in infants and young children as detd. by epidemiol. surveillance studies.  There has been a rise in IPD due to nonvaccine serotypes; however, this rise is small compared with the overall redn. in IPD.  Non-PCV-7 serotypes and vaccine-related serotypes, such as serotypes 1, 5, 7F, 6A and 19A, have also been reported to cause IPD in some parts of the world where morbidity and mortality from pneumococcal disease are higher.  An investigational 13-valent pneumococcal conjugate vaccine (PCV-13) uses CRM197 as a carrier, similar to the current PCV-7, and covers serotypes 1, 3, 5, 6A, 7F and 19A, in addn. to the serotypes of PCV-7 (serotype 4, 6B, 9V, 14, 18C, 19F and 23F).  PCV-13 is safe and well tolerated with other pediatric vaccines in infants according to clin. trials.  IgG anticapsular polysaccharide-binding concns. and opsonophagocytic assay responses are similar and noninferior between PCV-13 and PCV-7 and, according to immunogenicity studies, PCV-13 has more potential to protect against pneumococcal diseases with the addnl. six serotypes.  With the addn. of these new serotypes, it could be possible to cover potential pneumococcal serotypes causing IPD throughout the world.  The cost of the vaccine, its length of duration, optimal scheduling, combination and boosting with PCV-7 are still unresolved issues.  Assessment of the vaccine's effectiveness and efficacy following potential licensure will require carefully designed cohort and case-control studies that can assess the indirect effects of PCV-13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpppav-RL6wv7Vg90H21EOLACvtfcHk0ljnqce_8cJvxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFOls7o%253D&md5=24483a3712b533806afc15a508accc9c</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1586%2Ferv.09.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Ferv.09.68%26sid%3Dliteratum%253Aachs%26aulast%3DDinleyici%26aufirst%3DE.%2BC.%26aulast%3DYargic%26aufirst%3DZ.%2BA.%26atitle%3DCurrent%2520knowledge%2520regarding%2520the%2520investigational%252013-valent%2520pneumococcal%2520conjugate%2520vaccine%26jtitle%3DExpert%2520Rev.%2520Vaccines%26date%3D2009%26volume%3D8%26spage%3D977%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Sucher, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chahine, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sucher, B. J.</span><span> </span><span class="NLM_article-title">Prevnar13, the new 13-valent pneumococcal conjugate vaccine</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1516</span><span class="NLM_x">–</span> <span class="NLM_lpage">1524</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2011&pages=1516-1524&author=A.+J.+Sucherauthor=E.+B.+Chahineauthor=M.+Nelsonauthor=B.+J.+Sucher&title=Prevnar13%2C+the+new+13-valent+pneumococcal+conjugate+vaccine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSucher%26aufirst%3DA.%2BJ.%26aulast%3DChahine%26aufirst%3DE.%2BB.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DSucher%26aufirst%3DB.%2BJ.%26atitle%3DPrevnar13%252C%2520the%2520new%252013-valent%2520pneumococcal%2520conjugate%2520vaccine%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2011%26volume%3D45%26spage%3D1516%26epage%3D1524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Gruber, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emini, E. A.</span><span> </span><span class="NLM_article-title">Development and clinical evaluation of of Prevnar 13, a 13-valent pneumococcal CRM<sub>197</sub> conjugate vaccine</span> <span class="citation_source-journal">Ann. N.Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1263</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1263&publication_year=2012&pages=15-26&author=W.+C.+Gruberauthor=D.+A.+Scottauthor=E.+A.+Emini&title=Development+and+clinical+evaluation+of+of+Prevnar+13%2C+a+13-valent+pneumococcal+CRM197+conjugate+vaccine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGruber%26aufirst%3DW.%2BC.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DEmini%26aufirst%3DE.%2BA.%26atitle%3DDevelopment%2520and%2520clinical%2520evaluation%2520of%2520of%2520Prevnar%252013%252C%2520a%252013-valent%2520pneumococcal%2520CRM197%2520conjugate%2520vaccine%26jtitle%3DAnn.%2520N.Y.%2520Acad.%2520Sci.%26date%3D2012%26volume%3D1263%26spage%3D15%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Brant, A.</span> 20 top selling vaccines – H1, 2012. <i>FierceVaccines</i>, Sept 25,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.fiercevaccines.com/special-report/20-top-selling-vaccines/2012-09-25" class="extLink">http://www.fiercevaccines.com/special-report/20-top-selling-vaccines/2012-09-25</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Brant%2C+A.+20+top+selling+vaccines+%E2%80%93+H1%2C+2012.+FierceVaccines%2C+Sept+25%2C+2012%3B+http%3A%2F%2Fwww.fiercevaccines.com%2Fspecial-report%2F20-top-selling-vaccines%2F2012-09-25."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DBrant%26aufirst%3DA.%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Mullin, R.</span><span> </span><span class="NLM_article-title">The future is now</span> <span class="citation_source-journal">Chem. Eng. News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2013&pages=12-17&author=R.+Mullin&title=The+future+is+now"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullin%26aufirst%3DR.%26atitle%3DThe%2520future%2520is%2520now%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2013%26volume%3D91%26spage%3D12%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 31 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lewis D. Pennington, Brian M. Aquila, Younggi Choi, Roman A. Valiulin, <span class="NLM_string-name hlFld-ContribAuthor">Ingo Muegge</span>. </span><span class="cited-content_cbyCitation_article-title">Positional Analogue Scanning: An Effective Strategy for Multiparameter Optimization in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 8956-8976. <a href="https://doi.org/10.1021/acs.jmedchem.9b02092" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02092%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPositional%252BAnalogue%252BScanning%25253A%252BAn%252BEffective%252BStrategy%252Bfor%252BMultiparameter%252BOptimization%252Bin%252BDrug%252BDesign%26aulast%3DPennington%26aufirst%3DLewis%2BD.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D16122019%26date%3D24042020%26volume%3D63%26issue%3D17%26spage%3D8956%26epage%3D8976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ignacio  Aliagas</span>, <span class="hlFld-ContribAuthor ">Raphaëlle  Berger</span>, <span class="hlFld-ContribAuthor ">Kristin  Goldberg</span>, <span class="hlFld-ContribAuthor ">Rachel T.  Nishimura</span>, <span class="hlFld-ContribAuthor ">John  Reilly</span>, <span class="hlFld-ContribAuthor ">Paul  Richardson</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Edward C.  Sherer</span>, <span class="hlFld-ContribAuthor ">Brian A.  Sparling</span>, and <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>  . </span><span class="cited-content_cbyCitation_article-title">Sustainable Practices in Medicinal Chemistry Part 2: Green by Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (14)
                                     , 5955-5968. <a href="https://doi.org/10.1021/acs.jmedchem.6b01837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSustainable%252BPractices%252Bin%252BMedicinal%252BChemistry%252BPart%252B2%25253A%252BGreen%252Bby%252BDesign%26aulast%3DAliagas%26aufirst%3DIgnacio%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D14122016%26date%3D12042017%26date%3D27072017%26date%3D04042017%26volume%3D60%26issue%3D14%26spage%3D5955%26epage%3D5968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Laura  Bolognesi</span>, <span class="hlFld-ContribAuthor ">Annachiara  Gandini</span>, <span class="hlFld-ContribAuthor ">Federica  Prati</span>, and <span class="hlFld-ContribAuthor ">Elisa  Uliassi</span>  . </span><span class="cited-content_cbyCitation_article-title">From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer’s Disease?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (17)
                                     , 7759-7770. <a href="https://doi.org/10.1021/acs.jmedchem.6b00151" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00151%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFrom%252BCompanion%252BDiagnostics%252Bto%252BTheranostics%25253A%252BA%252BNew%252BAvenue%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%25253F%26aulast%3DBolognesi%26aufirst%3DMaria%2BLaura%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D29012016%26date%3D06052016%26date%3D08092016%26date%3D28042016%26volume%3D59%26issue%3D17%26spage%3D7759%26epage%3D7770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Costantino</span> and <span class="hlFld-ContribAuthor ">Daniela  Barlocco</span>  . </span><span class="cited-content_cbyCitation_article-title">Ten Years of Medicinal Chemistry (2005–2014) in the Journal of Medicinal Chemistry: Country of Contributors, Topics, and Public–Private Partnerships. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (16)
                                     , 7352-7359. <a href="https://doi.org/10.1021/acs.jmedchem.5b01349" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01349</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01349%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTen%252BYears%252Bof%252BMedicinal%252BChemistry%252B%2525282005%2525E2%252580%2525932014%252529%252Bin%252Bthe%252BJournal%252Bof%252BMedicinal%252BChemistry%25253A%252BCountry%252Bof%252BContributors%25252C%252BTopics%25252C%252Band%252BPublic%2525E2%252580%252593Private%252BPartnerships%26aulast%3DCostantino%26aufirst%3DLuca%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D01092015%26date%3D05042016%26date%3D25082016%26date%3D23032016%26volume%3D59%26issue%3D16%26spage%3D7352%26epage%3D7359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2016,</strong> <em>29 </em>
                                    (4)
                                     , 564-616. <a href="https://doi.org/10.1021/acs.chemrestox.6b00043" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.6b00043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DImproving%252BDrug%252BDesign%25253A%252BAn%252BUpdate%252Bon%252BRecent%252BApplications%252Bof%252BEfficiency%252BMetrics%25252C%252BStrategies%252Bfor%252BReplacing%252BProblematic%252BElements%25252C%252Band%252BCompounds%252Bin%252BNontraditional%252BDrug%252BSpace%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03022016%26date%3D14032016%26date%3D18042016%26volume%3D29%26issue%3D4%26spage%3D564%26epage%3D616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benoît  Métayer</span>, <span class="hlFld-ContribAuthor ">Guillaume  Compain</span>, <span class="hlFld-ContribAuthor ">Kévin  Jouvin</span>, <span class="hlFld-ContribAuthor ">Agnès  Martin-Mingot</span>, <span class="hlFld-ContribAuthor ">Christian  Bachmann</span>, <span class="hlFld-ContribAuthor ">Jérôme  Marrot</span>, <span class="hlFld-ContribAuthor ">Gwilherm  Evano</span>, and <span class="hlFld-ContribAuthor ">Sébastien  Thibaudeau</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemo- and Stereoselective Synthesis of Fluorinated Enamides from Ynamides in HF/Pyridine: Second-Generation Approach to Potent Ureas Bioisosteres. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>80 </em>
                                    (7)
                                     , 3397-3410. <a href="https://doi.org/10.1021/jo502699y" title="DOI URL">https://doi.org/10.1021/jo502699y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo502699y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo502699y%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DChemo-%252Band%252BStereoselective%252BSynthesis%252Bof%252BFluorinated%252BEnamides%252Bfrom%252BYnamides%252Bin%252BHF%25252FPyridine%25253A%252BSecond-Generation%252BApproach%252Bto%252BPotent%252BUreas%252BBioisosteres%26aulast%3DM%25C3%25A9tayer%26aufirst%3DBeno%25C3%25AEt%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D27112014%26date%3D23012015%26date%3D03042015%26date%3D08012015%26volume%3D80%26issue%3D7%26spage%3D3397%26epage%3D3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keith D  Wing</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmaceutical technologies with potential application to insecticide discovery
              †. </span><span class="cited-content_cbyCitation_journal-name">Pest Management Science</span><span> <strong>2021,</strong> <em>77 </em>
                                    (8)
                                     , 3617-3625. <a href="https://doi.org/10.1002/ps.6075" title="DOI URL">https://doi.org/10.1002/ps.6075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ps.6075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fps.6075%26sid%3Dliteratum%253Aachs%26jtitle%3DPest%2520Management%2520Science%26atitle%3DPharmaceutical%252Btechnologies%252Bwith%252Bpotential%252Bapplication%252Bto%252Binsecticide%252Bdiscovery%252B%2525E2%252580%2525A0%26aulast%3DWing%26aufirst%3DKeith%2BD%26date%3D2021%26date%3D2020%26volume%3D77%26issue%3D8%26spage%3D3617%26epage%3D3625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roland E.  Dolle</span>, <span class="hlFld-ContribAuthor ">Denise  Barrault</span>, <span class="hlFld-ContribAuthor ">Neil  Carragher</span>, <span class="hlFld-ContribAuthor ">Paul  Andrews</span>, <span class="hlFld-ContribAuthor ">Daniel  Ebner</span>, <span class="hlFld-ContribAuthor ">Andrew  Hopkins</span>, <span class="hlFld-ContribAuthor ">Hirotatsu  Kojima</span>, <span class="hlFld-ContribAuthor ">Stephen  Frye</span>, <span class="hlFld-ContribAuthor ">Al  Edwards</span>, <span class="hlFld-ContribAuthor ">Peter I.  Dosa</span>, <span class="hlFld-ContribAuthor ">Gunda I.  Georg</span>, <span class="hlFld-ContribAuthor ">Vadim J.  Gurvich</span>, <span class="hlFld-ContribAuthor ">Jon E.  Hawkinson</span>, <span class="hlFld-ContribAuthor ">Michael A.  Walters</span>, <span class="hlFld-ContribAuthor ">Anna‐Lena  Gustavsson</span>, <span class="hlFld-ContribAuthor ">Erik  Chorell</span>, <span class="hlFld-ContribAuthor ">Richard E.  Taylor</span>, <span class="hlFld-ContribAuthor ">Denton  Hoyer</span>, <span class="hlFld-ContribAuthor ">Michael R.  Myers</span>. </span><span class="cited-content_cbyCitation_article-title">Experiences in Academic and Industry Partnerships – Forging a Path to Translational Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-101. <a href="https://doi.org/10.1002/0471266949.bmc292" title="DOI URL">https://doi.org/10.1002/0471266949.bmc292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc292%26sid%3Dliteratum%253Aachs%26atitle%3DExperiences%252Bin%252BAcademic%252Band%252BIndustry%252BPartnerships%252B%2525E2%252580%252593%252BForging%252Ba%252BPath%252Bto%252BTranslational%252BDrug%252BDiscovery%26aulast%3DDolle%26aufirst%3DRoland%2BE.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D101%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin E.  Blass</span>. </span><span class="cited-content_cbyCitation_article-title">Organizational consideration and trends in the pharmaceutical industry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 561-593. <a href="https://doi.org/10.1016/B978-0-12-817214-8.00012-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-817214-8.00012-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-817214-8.00012-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-817214-8.00012-9%26sid%3Dliteratum%253Aachs%26atitle%3DOrganizational%252Bconsideration%252Band%252Btrends%252Bin%252Bthe%252Bpharmaceutical%252Bindustry%26aulast%3DBlass%26aufirst%3DBenjamin%2BE.%26date%3D2021%26spage%3D561%26epage%3D593%26pub%3DElsevier%26atitle%3DBasic%252BPrinciples%252Bof%252BDrug%252BDiscovery%252Band%252BDevelopment%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele de Medeiros  Rocha</span>, <span class="hlFld-ContribAuthor ">Emmanuel Paiva  de Andrade</span>, <span class="hlFld-ContribAuthor ">Edna Ribeiro  Alves</span>, <span class="hlFld-ContribAuthor ">João Carlos  Cândido</span>, <span class="hlFld-ContribAuthor ">Marcello de Miranda  Borio</span>. </span><span class="cited-content_cbyCitation_article-title">Access to innovative medicines by pharma companies: Sustainable initiatives for global health or useful advertisement?. </span><span class="cited-content_cbyCitation_journal-name">Global Public Health</span><span> <strong>2020,</strong> <em>15 </em>
                                    (6)
                                     , 777-789. <a href="https://doi.org/10.1080/17441692.2020.1729391" title="DOI URL">https://doi.org/10.1080/17441692.2020.1729391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17441692.2020.1729391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17441692.2020.1729391%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Public%2520Health%26atitle%3DAccess%252Bto%252Binnovative%252Bmedicines%252Bby%252Bpharma%252Bcompanies%25253A%252BSustainable%252Binitiatives%252Bfor%252Bglobal%252Bhealth%252Bor%252Buseful%252Badvertisement%25253F%26aulast%3DRocha%26aufirst%3DMichele%2Bde%2BMedeiros%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D6%26spage%3D777%26epage%3D789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander N.  Phillipou</span>, <span class="hlFld-ContribAuthor ">Charles S.  Lay</span>, <span class="hlFld-ContribAuthor ">Charlotte E.  Carver</span>, <span class="hlFld-ContribAuthor ">Cassie  Messenger</span>, <span class="hlFld-ContribAuthor ">John P.  Evans</span>, <span class="hlFld-ContribAuthor ">Antonia J.  Lewis</span>, <span class="hlFld-ContribAuthor ">Laurie J.  Gordon</span>, <span class="hlFld-ContribAuthor ">Mahnoor  Mahmood</span>, <span class="hlFld-ContribAuthor ">Luke A.  Greenhough</span>, <span class="hlFld-ContribAuthor ">Douglas  Sammon</span>, <span class="hlFld-ContribAuthor ">Aaron T.  Cheng</span>, <span class="hlFld-ContribAuthor ">Syandan  Chakraborty</span>, <span class="hlFld-ContribAuthor ">Emma J.  Jones</span>, <span class="hlFld-ContribAuthor ">Simon C. C.  Lucas</span>, <span class="hlFld-ContribAuthor ">Kelly M.  Gatfield</span>, <span class="hlFld-ContribAuthor ">David J.  Brierley</span>, <span class="hlFld-ContribAuthor ">Peter D.  Craggs</span>. </span><span class="cited-content_cbyCitation_article-title">Cellular Target Engagement Approaches to Monitor Epigenetic Reader Domain Interactions. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 163-175. <a href="https://doi.org/10.1177/2472555219896278" title="DOI URL">https://doi.org/10.1177/2472555219896278</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555219896278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555219896278%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DCellular%252BTarget%252BEngagement%252BApproaches%252Bto%252BMonitor%252BEpigenetic%252BReader%252BDomain%252BInteractions%26aulast%3DPhillipou%26aufirst%3DAlexander%2BN.%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D2%26spage%3D163%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhavishya  Mittal</span>. </span><span class="cited-content_cbyCitation_article-title">Healthcare. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-25. <a href="https://doi.org/10.1016/B978-0-12-816813-4.00001-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-816813-4.00001-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816813-4.00001-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816813-4.00001-5%26sid%3Dliteratum%253Aachs%26atitle%3DHealthcare%26aulast%3DMittal%26aufirst%3DBhavishya%26date%3D2020%26spage%3D1%26epage%3D25%26pub%3DElsevier%26atitle%3DHow%252Bto%252BIntegrate%252BQuality%252Bby%252BEfficient%252BDesign%252B%252528QbED%252529%252Bin%252BProduct%252BDevelopment%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhavishya  Mittal</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmaceutical productivity. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 59-86. <a href="https://doi.org/10.1016/B978-0-12-816813-4.00003-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-816813-4.00003-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816813-4.00003-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816813-4.00003-9%26sid%3Dliteratum%253Aachs%26atitle%3DPharmaceutical%252Bproductivity%26aulast%3DMittal%26aufirst%3DBhavishya%26date%3D2020%26spage%3D59%26epage%3D86%26pub%3DElsevier%26atitle%3DHow%252Bto%252BIntegrate%252BQuality%252Bby%252BEfficient%252BDesign%252B%252528QbED%252529%252Bin%252BProduct%252BDevelopment%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivan  Babic</span>, <span class="hlFld-ContribAuthor ">Santosh  Kesari</span>, <span class="hlFld-ContribAuthor ">Elmar  Nurmemmedov</span>. </span><span class="cited-content_cbyCitation_article-title">Cellular target engagement: a new paradigm in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (14)
                                     , 1641-1644. <a href="https://doi.org/10.4155/fmc-2018-0139" title="DOI URL">https://doi.org/10.4155/fmc-2018-0139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0139%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DCellular%252Btarget%252Bengagement%25253A%252Ba%252Bnew%252Bparadigm%252Bin%252Bdrug%252Bdiscovery%26aulast%3DBabic%26aufirst%3DIvan%26date%3D2018%26volume%3D10%26issue%3D14%26spage%3D1641%26epage%3D1644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Svetlana  Borukhova</span>, <span class="hlFld-ContribAuthor ">Volker  Hessel</span>. </span><span class="cited-content_cbyCitation_article-title">Continuous Manufacturing of Active Pharmaceutical Ingredients via Flow Technology. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 127-167. <a href="https://doi.org/10.1002/9781119001348.ch4" title="DOI URL">https://doi.org/10.1002/9781119001348.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119001348.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119001348.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DContinuous%252BManufacturing%252Bof%252BActive%252BPharmaceutical%252BIngredients%252Bvia%252BFlow%252BTechnology%26aulast%3DBorukhova%26aufirst%3DSvetlana%26date%3D2017%26date%3D2017%26spage%3D127%26epage%3D167%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DContinuous%252BManufacturing%252Bof%252BPharmaceuticals%26aulast%3DKleinebudde%26aufirst%3DPeter%26date%3D2017%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John S.  Morrison</span>, <span class="hlFld-ContribAuthor ">Michael J.  Hageman</span>. </span><span class="cited-content_cbyCitation_article-title">Outlook for the Future. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 421-447. <a href="https://doi.org/10.1007/978-3-319-50042-3_14" title="DOI URL">https://doi.org/10.1007/978-3-319-50042-3_14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-50042-3_14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-50042-3_14%26sid%3Dliteratum%253Aachs%26atitle%3DOutlook%252Bfor%252Bthe%252BFuture%26aulast%3DMorrison%26aufirst%3DJohn%2BS.%26date%3D2017%26date%3D2017%26spage%3D421%26epage%3D447%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DTranslating%252BMolecules%252Binto%252BMedicines%26aulast%3DBhattachar%26aufirst%3DShobha%2BN.%26date%3D2017%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy B.  Durham</span>, <span class="hlFld-ContribAuthor ">Michael R.  Wiley</span>. </span><span class="cited-content_cbyCitation_article-title">Target Engagement Measures in Preclinical Drug Discovery: Theory, Methods, and Case Studies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 41-80. <a href="https://doi.org/10.1007/978-3-319-50042-3_3" title="DOI URL">https://doi.org/10.1007/978-3-319-50042-3_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-50042-3_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-50042-3_3%26sid%3Dliteratum%253Aachs%26atitle%3DTarget%252BEngagement%252BMeasures%252Bin%252BPreclinical%252BDrug%252BDiscovery%25253A%252BTheory%25252C%252BMethods%25252C%252Band%252BCase%252BStudies%26aulast%3DDurham%26aufirst%3DTimothy%2BB.%26date%3D2017%26date%3D2017%26spage%3D41%26epage%3D80%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DTranslating%252BMolecules%252Binto%252BMedicines%26aulast%3DBhattachar%26aufirst%3DShobha%2BN.%26date%3D2017%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chloe F.  Allen</span>, <span class="hlFld-ContribAuthor ">Pamela J.  Shaw</span>, <span class="hlFld-ContribAuthor ">Laura  Ferraiuolo</span>. </span><span class="cited-content_cbyCitation_article-title">Can Astrocytes Be a Target for Precision Medicine?. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 111-128. <a href="https://doi.org/10.1007/978-3-319-60733-7_7" title="DOI URL">https://doi.org/10.1007/978-3-319-60733-7_7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-60733-7_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-60733-7_7%26sid%3Dliteratum%253Aachs%26atitle%3DCan%252BAstrocytes%252BBe%252Ba%252BTarget%252Bfor%252BPrecision%252BMedicine%25253F%26aulast%3DAllen%26aufirst%3DChloe%2BF.%26date%3D2017%26date%3D2017%26spage%3D111%26epage%3D128%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DPersonalised%252BMedicine%26aulast%3DEl-Khamisy%26aufirst%3DSherif%26date%3D2017%26volume%3D1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ken-ichiro  Kamei</span>, <span class="hlFld-ContribAuthor ">Yoshiki  Kato</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Hirai</span>, <span class="hlFld-ContribAuthor ">Shinji  Ito</span>, <span class="hlFld-ContribAuthor ">Junko  Satoh</span>, <span class="hlFld-ContribAuthor ">Atsuko  Oka</span>, <span class="hlFld-ContribAuthor ">Toshiyuki  Tsuchiya</span>, <span class="hlFld-ContribAuthor ">Yong  Chen</span>, <span class="hlFld-ContribAuthor ">Osamu  Tabata</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated heart/cancer on a chip to reproduce the side effects of anti-cancer drugs in vitro. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (58)
                                     , 36777-36786. <a href="https://doi.org/10.1039/C7RA07716E" title="DOI URL">https://doi.org/10.1039/C7RA07716E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA07716E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA07716E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DIntegrated%252Bheart%25252Fcancer%252Bon%252Ba%252Bchip%252Bto%252Breproduce%252Bthe%252Bside%252Beffects%252Bof%252Banti-cancer%252Bdrugs%252Bin%252Bvitro%26aulast%3DKamei%26aufirst%3DKen-ichiro%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D58%26spage%3D36777%26epage%3D36786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Per I.  Arvidsson</span>, <span class="hlFld-ContribAuthor ">Kristian  Sandberg</span>, <span class="hlFld-ContribAuthor ">Karin  Forsberg-Nilsson</span>. </span><span class="cited-content_cbyCitation_article-title">Open for collaboration: an academic platform for drug discovery and development at SciLifeLab. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2016,</strong> <em>21 </em>
                                    (10)
                                     , 1690-1698. <a href="https://doi.org/10.1016/j.drudis.2016.06.026" title="DOI URL">https://doi.org/10.1016/j.drudis.2016.06.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2016.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2016.06.026%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DOpen%252Bfor%252Bcollaboration%25253A%252Ban%252Bacademic%252Bplatform%252Bfor%252Bdrug%252Bdiscovery%252Band%252Bdevelopment%252Bat%252BSciLifeLab%26aulast%3DArvidsson%26aufirst%3DPer%2BI.%26date%3D2016%26volume%3D21%26issue%3D10%26spage%3D1690%26epage%3D1698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Felix  Friemann</span>, <span class="hlFld-ContribAuthor ">Paul  Schönsleben</span>. </span><span class="cited-content_cbyCitation_article-title">Reducing Global Supply Chain Risk Exposure of Pharmaceutical Companies by Further Incorporating Warehouse Capacity Planning into the Strategic Supply Chain Planning Process. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Innovation</span><span> <strong>2016,</strong> <em>11 </em>
                                    (2)
                                     , 162-176. <a href="https://doi.org/10.1007/s12247-016-9249-6" title="DOI URL">https://doi.org/10.1007/s12247-016-9249-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12247-016-9249-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12247-016-9249-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Innovation%26atitle%3DReducing%252BGlobal%252BSupply%252BChain%252BRisk%252BExposure%252Bof%252BPharmaceutical%252BCompanies%252Bby%252BFurther%252BIncorporating%252BWarehouse%252BCapacity%252BPlanning%252Binto%252Bthe%252BStrategic%252BSupply%252BChain%252BPlanning%252BProcess%26aulast%3DFriemann%26aufirst%3DFelix%26date%3D2016%26date%3D2016%26volume%3D11%26issue%3D2%26spage%3D162%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon J.F.  Macdonald</span>, <span class="hlFld-ContribAuthor ">M. Jonathan  Fray</span>, <span class="hlFld-ContribAuthor ">Thomas  McInally</span>. </span><span class="cited-content_cbyCitation_article-title">Passing on the medicinal chemistry baton: training undergraduates to be industry-ready through research projects between the University of Nottingham and GlaxoSmithKline. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2016,</strong> <em>21 </em>
                                    (6)
                                     , 880-887. <a href="https://doi.org/10.1016/j.drudis.2016.01.015" title="DOI URL">https://doi.org/10.1016/j.drudis.2016.01.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2016.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2016.01.015%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DPassing%252Bon%252Bthe%252Bmedicinal%252Bchemistry%252Bbaton%25253A%252Btraining%252Bundergraduates%252Bto%252Bbe%252Bindustry-ready%252Bthrough%252Bresearch%252Bprojects%252Bbetween%252Bthe%252BUniversity%252Bof%252BNottingham%252Band%252BGlaxoSmithKline%26aulast%3DMacdonald%26aufirst%3DSimon%2BJ.F.%26date%3D2016%26volume%3D21%26issue%3D6%26spage%3D880%26epage%3D887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  ten Holte</span>. </span><span class="cited-content_cbyCitation_article-title">Access to Compound Collections. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 61-76. <a href="https://doi.org/10.1002/9781118771723.ch3" title="DOI URL">https://doi.org/10.1002/9781118771723.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118771723.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118771723.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DAccess%252Bto%252BCompound%252BCollections%26aulast%3Dten%2BHolte%26aufirst%3DPeter%26date%3D2015%26date%3D2015%26spage%3D61%26epage%3D76%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DSmall%252BMolecule%252BMedicinal%252BChemistry%26aulast%3DCzechtizky%26aufirst%3DWerngard%26date%3D2015%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Munson</span>, <span class="hlFld-ContribAuthor ">Harvey  Lieberman</span>, <span class="hlFld-ContribAuthor ">Elina  Tserlin</span>, <span class="hlFld-ContribAuthor ">Jennifer  Rocnik</span>, <span class="hlFld-ContribAuthor ">Jie  Ge</span>, <span class="hlFld-ContribAuthor ">Maria  Fitzgerald</span>, <span class="hlFld-ContribAuthor ">Vinod  Patel</span>, <span class="hlFld-ContribAuthor ">Carlos  Garcia-Echeverria</span>. </span><span class="cited-content_cbyCitation_article-title">Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2015,</strong> <em>20 </em>
                                    (8)
                                     , 978-987. <a href="https://doi.org/10.1016/j.drudis.2015.03.010" title="DOI URL">https://doi.org/10.1016/j.drudis.2015.03.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2015.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2015.03.010%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DLead%252Boptimization%252Battrition%252Banalysis%252B%252528LOAA%252529%25253A%252Ba%252Bnovel%252Band%252Bgeneral%252Bmethodology%252Bfor%252Bmedicinal%252Bchemistry%26aulast%3DMunson%26aufirst%3DMark%26date%3D2015%26volume%3D20%26issue%3D8%26spage%3D978%26epage%3D987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marco  Lolli</span>, <span class="hlFld-ContribAuthor ">Sarah  Narramore</span>, <span class="hlFld-ContribAuthor ">Colin W.G.  Fishwick</span>, <span class="hlFld-ContribAuthor ">Klaus  Pors</span>. </span><span class="cited-content_cbyCitation_article-title">Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st Century. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2015,</strong> <em>20 </em>
                                    (8)
                                     , 1018-1026. <a href="https://doi.org/10.1016/j.drudis.2015.04.010" title="DOI URL">https://doi.org/10.1016/j.drudis.2015.04.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2015.04.010%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DRefining%252Bthe%252Bchemical%252Btoolbox%252Bto%252Bbe%252Bfit%252Bfor%252Beducational%252Band%252Bpractical%252Bpurpose%252Bfor%252Bdrug%252Bdiscovery%252Bin%252Bthe%252B21st%252BCentury%26aulast%3DLolli%26aufirst%3DMarco%26date%3D2015%26volume%3D20%26issue%3D8%26spage%3D1018%26epage%3D1026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jayme L.  Dahlin</span>, <span class="hlFld-ContribAuthor ">James  Inglese</span>, <span class="hlFld-ContribAuthor ">Michael A.  Walters</span>. </span><span class="cited-content_cbyCitation_article-title">Mitigating risk in academic preclinical drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2015,</strong> <em>14 </em>
                                    (4)
                                     , 279-294. <a href="https://doi.org/10.1038/nrd4578" title="DOI URL">https://doi.org/10.1038/nrd4578</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd4578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd4578%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DMitigating%252Brisk%252Bin%252Bacademic%252Bpreclinical%252Bdrug%252Bdiscovery%26aulast%3DDahlin%26aufirst%3DJayme%2BL.%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D4%26spage%3D279%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy B.  Durham</span>, <span class="hlFld-ContribAuthor ">Maria-Jesus  Blanco</span>. </span><span class="cited-content_cbyCitation_article-title">Target Engagement in Lead Generation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (5)
                                     , 998-1008. <a href="https://doi.org/10.1016/j.bmcl.2014.12.076" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.12.076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.12.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.12.076%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTarget%252BEngagement%252Bin%252BLead%252BGeneration%26aulast%3DDurham%26aufirst%3DTimothy%2BB.%26date%3D2015%26volume%3D25%26issue%3D5%26spage%3D998%26epage%3D1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael S.  Kinch</span>. </span><span class="cited-content_cbyCitation_article-title">Post-approval fate of pharmaceutical companies. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2015,</strong> <em>20 </em>
                                    (2)
                                     , 170-174. <a href="https://doi.org/10.1016/j.drudis.2014.10.013" title="DOI URL">https://doi.org/10.1016/j.drudis.2014.10.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2014.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2014.10.013%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DPost-approval%252Bfate%252Bof%252Bpharmaceutical%252Bcompanies%26aulast%3DKinch%26aufirst%3DMichael%2BS.%26date%3D2015%26volume%3D20%26issue%3D2%26spage%3D170%26epage%3D174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brent R.  DeGeorge</span>, <span class="hlFld-ContribAuthor ">Michael C.  Holland</span>, <span class="hlFld-ContribAuthor ">David B.  Drake</span>. </span><span class="cited-content_cbyCitation_article-title">The Impact of Conflict of Interest in Abdominal Wall Reconstruction With Acellular Dermal Matrix. </span><span class="cited-content_cbyCitation_journal-name">Annals of Plastic Surgery</span><span> <strong>2015,</strong> <em>74 </em>
                                    (2)
                                     , 242-247. <a href="https://doi.org/10.1097/SAP.0000000000000372" title="DOI URL">https://doi.org/10.1097/SAP.0000000000000372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/SAP.0000000000000372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FSAP.0000000000000372%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Plastic%2520Surgery%26atitle%3DThe%252BImpact%252Bof%252BConflict%252Bof%252BInterest%252Bin%252BAbdominal%252BWall%252BReconstruction%252BWith%252BAcellular%252BDermal%252BMatrix%26aulast%3DDeGeorge%26aufirst%3DBrent%2BR.%26date%3D2015%26volume%3D74%26issue%3D2%26spage%3D242%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Orazio  Nicolotti</span>, <span class="hlFld-ContribAuthor ">Emilio  Benfenati</span>, <span class="hlFld-ContribAuthor ">Angelo  Carotti</span>, <span class="hlFld-ContribAuthor ">Domenico  Gadaleta</span>, <span class="hlFld-ContribAuthor ">Andrea  Gissi</span>, <span class="hlFld-ContribAuthor ">Giuseppe Felice  Mangiatordi</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>. </span><span class="cited-content_cbyCitation_article-title">REACH and in silico methods: an attractive opportunity for medicinal chemists. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2014,</strong> <em>19 </em>
                                    (11)
                                     , 1757-1768. <a href="https://doi.org/10.1016/j.drudis.2014.06.027" title="DOI URL">https://doi.org/10.1016/j.drudis.2014.06.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2014.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2014.06.027%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DREACH%252Band%252Bin%252Bsilico%252Bmethods%25253A%252Ban%252Battractive%252Bopportunity%252Bfor%252Bmedicinal%252Bchemists%26aulast%3DNicolotti%26aufirst%3DOrazio%26date%3D2014%26volume%3D19%26issue%3D11%26spage%3D1757%26epage%3D1768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Drug discovery process.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Comparison of PhRMA Members in 1998 and 2011.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Timeline of mergers and acquisitions with values ≥$2 billion that occurred from 2000 to 2012.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of introduction of generic Atorvastatin on U.S. Lipitor sales (source: ref <a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">50</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharma market development, 2006–2016.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Disease patterns in 2008 compared to predicted patterns in 2030 (source: WHO, Booz & Company).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Court decisions from ANDA trials (source: ref <a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">62</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Percentage of biopharmaceuticals in the pharmaceutical market, 2001–2011 (source: ref <a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">69</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Correlation of R&D spending by PhRMA members and number of new chemical entities approved by the FDA from 1995 to 2012 (source: PhRMA web site).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Clinical attrition statistics: (a) attrition rate by stage of development, (b) reasons for clinical failure in 1991, and (c) reasons for clinical failure in 2000 (source: refs <a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">93</a> and <a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">94</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Typical traffic light spreadsheet used to report in vitro physicochemical/ADME data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Utilitarian classification of biomarkers<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(117)</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Representative PET and SPECT biomarker imaging agents and their biological targets.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures of venlafaxine (Effexor) and desvenlafaxine (Pristiq) and pharmacokinetic data for administration of the two drugs. EM, extensive metabolizers; PM, poor metabolizers. (Data taken from ref <a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">143</a>.)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of immunosuppresive and nonimmunosuppresive immunophilins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/medium/jm-2013-01564r_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. <i>S. pneumoniae</i> serotypes covered by Prevnar and Prevnar 13 (data taken from ref <a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">155</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-13/jm401564r/production/images/large/jm-2013-01564r_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401564r&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34234" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34234" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 158 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Arlington, S.</span>From Vision to Decision: Pharma 2020. Technical Report from PricewaterhouseCoopers:<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.pwc.com/jp/ja/japan-knowledge/archive/assets/pdf/pharma-2020-vision-to-decision.pdf" class="extLink">http://www.pwc.com/jp/ja/japan-knowledge/archive/assets/pdf/pharma-2020-vision-to-decision.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=S.+Arlington&title=From+Vision+to+Decision%3A+Pharma+2020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DArlington%26aufirst%3DS.%26jtitle%3DFrom%2520Vision%2520to%2520Decision%253A%2520Pharma%25202020%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Childers, W. E.</span><span> </span><span class="NLM_article-title">Discovery of innovative therapeutics: Today’s realities and tomorrow’s visions. 1. Criticisms faced by the pharmaceutical industry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5659</span><span class="NLM_x">–</span> <span class="NLM_lpage">5672</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400330j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5659-5672&author=M.+Abou-Gharbiaauthor=W.+E.+Childers&title=Discovery+of+innovative+therapeutics%3A+Today%E2%80%99s+realities+and+tomorrow%E2%80%99s+visions.+1.+Criticisms+faced+by+the+pharmaceutical+industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm400330j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400330j%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DChilders%26aufirst%3DW.%2BE.%26atitle%3DDiscovery%2520of%2520innovative%2520therapeutics%253A%2520Today%25E2%2580%2599s%2520realities%2520and%2520tomorrow%25E2%2580%2599s%2520visions.%25201.%2520Criticisms%2520faced%2520by%2520the%2520pharmaceutical%2520industry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5659%26epage%3D5672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalindjian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, K.</span><span> </span><span class="NLM_article-title">Principals of early drug discovery</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">1239</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1111%2Fj.1476-5381.2010.01127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21091654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=1239-1249&author=J.+Hughesauthor=S.+Reesauthor=S.+Kalindjianauthor=K.+Philpott&title=Principals+of+early+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of early drug discovery</span></div><div class="casAuthors">Hughes, J. P.; Rees, S.; Kalindjian, S. B.; Philpott, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1239-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion.  The idea for a target can come from a variety of sources including academic and clin. research and from the com. sector.  It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery program.  Once a target was chosen, the pharmaceutical industry and more recently some academic centers have streamlined a no. of early processes to identify mols. which possess suitable characteristics to make acceptable drugs.  This review will look at key preclin. stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate mol. for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCc74_F_90rVg90H21EOLACvtfcHk0lgFvv86OOymwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D&md5=05a0016f45b155f9fb5822f5c7bcc35d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01127.x%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DKalindjian%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DK.%26atitle%3DPrincipals%2520of%2520early%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D1239%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Grech, E.</span><span> </span><span class="NLM_article-title">ABC of interventional cardiology. Percutaneous coronary intervention. I: History and development</span> <span class="citation_source-journal">Brit. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">1082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1136%2Fbmj.326.7382.180" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2003&pages=180-1082&author=E.+Grech&title=ABC+of+interventional+cardiology.+Percutaneous+coronary+intervention.+I%3A+History+and+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1136%2Fbmj.326.7382.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.326.7382.180%26sid%3Dliteratum%253Aachs%26aulast%3DGrech%26aufirst%3DE.%26atitle%3DABC%2520of%2520interventional%2520cardiology.%2520Percutaneous%2520coronary%2520intervention.%2520I%253A%2520History%2520and%2520development%26jtitle%3DBrit.%2520Med.%2520J.%26date%3D2003%26volume%3D326%26spage%3D180%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhindi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khachigian, L.</span><span> </span><span class="NLM_article-title">Recent developments in drug-eluting stents</span> <span class="citation_source-journal">J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs00109-011-0729-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21279500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtl2lsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=545-553&author=Y.+Liauthor=R.+Bhindiauthor=L.+Khachigian&title=Recent+developments+in+drug-eluting+stents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in drug-eluting stents</span></div><div class="casAuthors">Li, Yue; Bhindi, Ravinay; Khachigian, Levon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-553</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Percutaneous coronary intervention (PCI) is an important treatment approach in the management of symptomatic coronary artery disease (CAD).  A significant development in PCI in the mid 1970s was balloon angioplasty, followed by bare-metal stents a decade later, and now, the widespread use of drug-eluting stents (DES).  While PCI has conferred remarkable benefit to millions of CAD patients, restenosis, and late stent thrombosis assocd. with DES remain problematic, and improvements are keenly sought.  This article reviews recent developments in DES.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQrKeB11Xcx7Vg90H21EOLACvtfcHk0lgFvv86OOymwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtl2lsbc%253D&md5=80f5c20ee3321a6f0bdd51921485b874</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00109-011-0729-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-011-0729-3%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBhindi%26aufirst%3DR.%26aulast%3DKhachigian%26aufirst%3DL.%26atitle%3DRecent%2520developments%2520in%2520drug-eluting%2520stents%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2011%26volume%3D89%26spage%3D545%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Harikumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, G.</span><span> </span><span class="NLM_article-title">Formulation tactics for the delivery of poorly soluble drugs</span> <span class="citation_source-journal">Int. J. PharmTech Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">914</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ejtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=914-923&author=R.+Harikumarauthor=G.+Aggarwal&title=Formulation+tactics+for+the+delivery+of+poorly+soluble+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Formulation tactics for the delivery of poorly soluble drugs</span></div><div class="casAuthors">Ritika; Harikumar, S. L.; Aggarwal, Geeta</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of PharmTech Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">914-923</span>CODEN:
                <span class="NLM_cas:coden">IJPRIF</span>;
        ISSN:<span class="NLM_cas:issn">0974-4304</span>.
    
            (<span class="NLM_cas:orgname">Sphinx Knowledge House</span>)
        </div><div class="casAbstract">A review.  As an upshot of modern drug discovery techniques like combinatorial chem. research and inventive high throughput screening, no. of new drug candidates developing, are often lipophilic.  For poorly sol. drugs, a good bioavailability is typically needed to evaluate the therapeutic index and aptness of the compd. for tech. formulation development.  This challenges drug delivery institutions to develop carrier systems for optimal oral and parentral administration of these drugs.  Comprehensive physicochem. characterization of poorly water sol. compds. can provide the key for outcome of successful formulation development, serving as guide for risk benefit assessment of delivery technol.  The higher levels of difficulties are confronted by formulation specialists when these drugs have to be delivered at specific site.  The present review addresses the emerging and promising formulation design options for the optimal administration of poorly water sol. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUL6MiCfGSrVg90H21EOLACvtfcHk0lgFvv86OOymwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ejtL3I&md5=275259c3e77188eb22847555cd020a5f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarikumar%26aufirst%3DR.%26aulast%3DAggarwal%26aufirst%3DG.%26atitle%3DFormulation%2520tactics%2520for%2520the%2520delivery%2520of%2520poorly%2520soluble%2520drugs%26jtitle%3DInt.%2520J.%2520PharmTech%2520Res.%26date%3D2012%26volume%3D4%26spage%3D914%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Alvarez-Lueje, A.; Perez, M.; Zapata, C.</span><span> </span><span class="NLM_article-title">Electrochemical methods for the in vitro assessment of drug metabolism</span>. In  <span class="citation_source-book">Topics on Drug Metabolism</span>; <span class="NLM_contrib-group">Paxton, J.</span>, Ed.; <span class="NLM_publisher-name">InTech</span>, <span class="NLM_publisher-loc">Rijeka, Croatia</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Chapter 9.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Alvarez-Lueje&author=M.+Perez&author=C.+Zapataauthor=J.+Paxton&title=Topics+on+Drug+Metabolism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Lueje%26aufirst%3DA.%26atitle%3DElectrochemical%2520methods%2520for%2520the%2520in%2520vitro%2520assessment%2520of%2520drug%2520metabolism%26btitle%3DTopics%2520on%2520Drug%2520Metabolism%26aulast%3DPaxton%26aufirst%3DJ.%26pub%3DInTech%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Nordstrom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewensohn, R.</span><span> </span><span class="NLM_article-title">Metabolomics: Moving to the clinic</span> <span class="citation_source-journal">J. Neuroimmune Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs11481-009-9156-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19399626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BC3c7htlegsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=4-17&author=A.+Nordstromauthor=R.+Lewensohn&title=Metabolomics%3A+Moving+to+the+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomics: moving to the clinic</span></div><div class="casAuthors">Nordstrom Anders; Lewensohn Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Assessment of a biological system by means of global and non-targeted metabolite profiling--metabolomics or metabonomics--provides the investigator with molecular information that is close to the phenotype in question in the sense that metabolites are an ultimate product of gene, mRNA, and protein activity.  Over the last few years, there has been a rapidly growing number of metabolomics applications aimed at finding biomarkers which could assist diagnosis, provide therapy guidance, and evaluate response to therapy for particular diseases.  Also, within the fields of drug discovery, drug toxicology, and personalized pharmacology, metabolomics is emerging as a powerful tool.  This review seeks to update the reader on analytical strategies, biomarker findings, and implications of metabolomics for the clinic.  Particular attention is paid to recent biomarkers found related to neurological, cardiovascular, and cancer diseases.  Moreover, the impact of metabolomics in the drug discovery and development process is examined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrpv7XSde-J2PgL4LrC-0VfW6udTcc2eYp1YfAylMbjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7htlegsw%253D%253D&md5=57cbca331a903ebbe6c0d6ef88310fdf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs11481-009-9156-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11481-009-9156-4%26sid%3Dliteratum%253Aachs%26aulast%3DNordstrom%26aufirst%3DA.%26aulast%3DLewensohn%26aufirst%3DR.%26atitle%3DMetabolomics%253A%2520Moving%2520to%2520the%2520clinic%26jtitle%3DJ.%2520Neuroimmune%2520Pharmacol.%26date%3D2010%26volume%3D5%26spage%3D4%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ametamey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubiger, P.</span><span> </span><span class="NLM_article-title">Molecular imaging with PET</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">1501</span><span class="NLM_x">–</span> <span class="NLM_lpage">1516</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0782426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=1501-1516&author=S.+Ametameyauthor=M.+Honerauthor=P.+Schubiger&title=Molecular+imaging+with+PET"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Imaging with PET</span></div><div class="casAuthors">Ametamey, Simon M.; Honer, Michael; Schubiger, Pius August</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1501-1516</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKgtMhO_aTjrVg90H21EOLACvtfcHk0lgsqsH3-V2USQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFShtL0%253D&md5=513a2a8c8779c207122a8c23586fd016</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fcr0782426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0782426%26sid%3Dliteratum%253Aachs%26aulast%3DAmetamey%26aufirst%3DS.%26aulast%3DHoner%26aufirst%3DM.%26aulast%3DSchubiger%26aufirst%3DP.%26atitle%3DMolecular%2520imaging%2520with%2520PET%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D1501%26epage%3D1516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Bailey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willowson, K.</span><span> </span><span class="NLM_article-title">An evidence-based review of quantitative SPECT imaging and potential clinical applications</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=83-89&author=D.+Baileyauthor=K.+Willowson&title=An+evidence-based+review+of+quantitative+SPECT+imaging+and+potential+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DD.%26aulast%3DWillowson%26aufirst%3DK.%26atitle%3DAn%2520evidence-based%2520review%2520of%2520quantitative%2520SPECT%2520imaging%2520and%2520potential%2520clinical%2520applications%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2013%26volume%3D54%26spage%3D83%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Mariani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruselli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flotats, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Israel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, N.</span><span> </span><span class="NLM_article-title">A review on the clinical uses of SPECT/CT</span> <span class="citation_source-journal">Eur. J. Nucl. Med. Mol. Imaging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1959</span><span class="NLM_x">–</span> <span class="NLM_lpage">1985</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs00259-010-1390-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=20182712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpsFektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=1959-1985&author=G.+Marianiauthor=L.+Bruselliauthor=T.+Kuwertauthor=E.+Kimauthor=A.+Flotatsauthor=O.+Israelauthor=M.+Dondiauthor=N.+Watanabe&title=A+review+on+the+clinical+uses+of+SPECT%2FCT"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A review on the clinical uses of SPECT/CT</span></div><div class="casAuthors">Mariani Giuliano; Bruselli Laura; Kuwert Torsten; Kim Edmund E; Flotats Albert; Israel Ora; Dondi Maurizio; Watanabe Naoyuki</div><div class="citationInfo"><span class="NLM_cas:title">European journal of nuclear medicine and molecular imaging</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1959-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the era when positron emission tomography (PET) seems to constitute the most advanced application of nuclear medicine imaging, still the conventional procedure of single photon emission computed tomography (SPECT) is far from being obsolete, especially if combined with computed tomography (CT).  In fact, this dual modality imaging technique (SPECT/CT) lends itself to a wide variety of useful diagnostic applications whose clinical impact is in most instances already well established, while the evidence is growing for newer applications.  The increasing availability of new hybrid SPECT/CT devices with advanced technology offers the opportunity to shorten acquisition time and to provide accurate attenuation correction and fusion imaging.  In this review we analyse and discuss the capabilities of SPECT/CT for improving sensitivity and specificity in the imaging of both oncological and non-oncological diseases.  The main advantages of SPECT/CT are represented by better attenuation correction, increased specificity, and accurate depiction of the localization of disease and of possible involvement of adjacent tissues.  Endocrine and neuroendocrine tumours are accurately localized and characterized by SPECT/CT, as also are solitary pulmonary nodules and lung cancers, brain tumours, lymphoma, prostate cancer, malignant and benign bone lesions, and infection.  Furthermore, hybrid SPECT/CT imaging is especially suited to support the increasing applications of minimally invasive surgery, as well as to precisely define the diagnostic and prognostic profile of cardiovascular patients.  Finally, the applications of SPECT/CT to other clinical disorders or malignant tumours is currently under extensive investigation, with encouraging results in terms of diagnostic accuracy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQxqGMXy1jiKyEJCPKhJPuqfW6udTcc2eYp1YfAylMbjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpsFektQ%253D%253D&md5=9c3a713b083c2b412fd92eaee6f3042f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00259-010-1390-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-010-1390-8%26sid%3Dliteratum%253Aachs%26aulast%3DMariani%26aufirst%3DG.%26aulast%3DBruselli%26aufirst%3DL.%26aulast%3DKuwert%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DFlotats%26aufirst%3DA.%26aulast%3DIsrael%26aufirst%3DO.%26aulast%3DDondi%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DN.%26atitle%3DA%2520review%2520on%2520the%2520clinical%2520uses%2520of%2520SPECT%252FCT%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2010%26volume%3D37%26spage%3D1959%26epage%3D1985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span>Drug Discovery and Development: Understanding the R&D Process; Report from the Pharmaceutical Research and Manufacturers of America: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="http://www.innovation.org/drug_discovery/objects/pdf/RD_Brochure.pdf" class="extLink">http://www.innovation.org/drug_discovery/objects/pdf/RD_Brochure.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drug+Discovery+and+Development%3A+Understanding+the+R%26D+Process%3B+Report+from+the+Pharmaceutical+Research+and+Manufacturers+of+America%3A+Washington%2C+DC%2C+2007%3B+http%3A%2F%2Fwww.innovation.org%2Fdrug_discovery%2Fobjects%2Fpdf%2FRD_Brochure.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520and%2520Development%253A%2520Understanding%2520the%2520R%2526D%2520Process%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Overington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A.</span><span> </span><span class="NLM_article-title">How many drug targets are there?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">996</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=993-996&author=J.+Overingtonauthor=B.+Al-Lazikaniauthor=A.+Hopkins&title=How+many+drug+targets+are+there%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOverington%26aufirst%3DJ.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHopkins%26aufirst%3DA.%26atitle%3DHow%2520many%2520drug%2520targets%2520are%2520there%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D993%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hopkins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C.</span><span> </span><span class="NLM_article-title">The druggable genome</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=12209152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslamtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=727-730&author=A.+Hopkinsauthor=C.+Groom&title=The+druggable+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: The druggable genome</span></div><div class="casAuthors">Hopkins, Andrew L.; Groom, Colin R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">727-730</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  An assessment of the no. of mol. targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry.  Now that we know the size of the human genome, it is interesting to consider just how many mol. targets this opportunity represents.  We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Uvqi8O9wzrVg90H21EOLACvtfcHk0ljKt71qtgvJ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslamtrY%253D&md5=d6dc7c67822661fe03e920695def1329</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd892%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%26aulast%3DGroom%26aufirst%3DC.%26atitle%3DThe%2520druggable%2520genome%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D727%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kubiyni, H.</span><span> </span><span class="NLM_article-title">Drug research myths: Hype and reality</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=665-668&author=H.+Kubiyni&title=Drug+research+myths%3A+Hype+and+reality"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKubiyni%26aufirst%3DH.%26atitle%3DDrug%2520research%2520myths%253A%2520Hype%2520and%2520reality%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D665%26epage%3D668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalindjian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, K.</span><span> </span><span class="NLM_article-title">Principals of early drug discovery</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">1239</span><span class="NLM_x">–</span> <span class="NLM_lpage">1249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1111%2Fj.1476-5381.2010.01127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21091654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=1239-1249&author=J.+Hughesauthor=S.+Reesauthor=S.+Kalindjianauthor=K.+Philpott&title=Principals+of+early+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of early drug discovery</span></div><div class="casAuthors">Hughes, J. P.; Rees, S.; Kalindjian, S. B.; Philpott, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1239-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion.  The idea for a target can come from a variety of sources including academic and clin. research and from the com. sector.  It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery program.  Once a target was chosen, the pharmaceutical industry and more recently some academic centers have streamlined a no. of early processes to identify mols. which possess suitable characteristics to make acceptable drugs.  This review will look at key preclin. stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate mol. for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCc74_F_90rVg90H21EOLACvtfcHk0ljKt71qtgvJ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D&md5=05a0016f45b155f9fb5822f5c7bcc35d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01127.x%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DKalindjian%26aufirst%3DS.%26aulast%3DPhilpott%26aufirst%3DK.%26atitle%3DPrincipals%2520of%2520early%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D1239%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Gregori-Puigjane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lounkine, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoichet, B.</span><span> </span><span class="NLM_article-title">Identifying mechanism-of-action targets for drugs and probes</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">11178</span><span class="NLM_x">–</span> <span class="NLM_lpage">11183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=11178-11183&author=E.+Gregori-Puigjaneauthor=V.+Setolaauthor=J.+Hertauthor=B.+Crewsauthor=J.+Irwinauthor=E.+Lounkineauthor=L.+Marnettauthor=B.+Rothauthor=B.+Schoichet&title=Identifying+mechanism-of-action+targets+for+drugs+and+probes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGregori-Puigjane%26aufirst%3DE.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DB.%26aulast%3DIrwin%26aufirst%3DJ.%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DMarnett%26aufirst%3DL.%26aulast%3DRoth%26aufirst%3DB.%26aulast%3DSchoichet%26aufirst%3DB.%26atitle%3DIdentifying%2520mechanism-of-action%2520targets%2520for%2520drugs%2520and%2520probes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D11178%26epage%3D11183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Boguski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandl, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sukhatme, V.</span><span> </span><span class="NLM_article-title">Drug discovery, repurposing with a difference</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">324</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1394-1395&author=M.+Boguskiauthor=K.+Mandlauthor=V.+Sukhatme&title=Drug+discovery%2C+repurposing+with+a+difference"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoguski%26aufirst%3DM.%26aulast%3DMandl%26aufirst%3DK.%26aulast%3DSukhatme%26aufirst%3DV.%26atitle%3DDrug%2520discovery%252C%2520repurposing%2520with%2520a%2520difference%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1394%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Plenge, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolnick, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altshuler, D.</span><span> </span><span class="NLM_article-title">Validating therapeutic targets through human genetics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=581-594&author=R.+M.+Plengeauthor=E.+M.+Scolnickauthor=D.+Altshuler&title=Validating+therapeutic+targets+through+human+genetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPlenge%26aufirst%3DR.%2BM.%26aulast%3DScolnick%26aufirst%3DE.%2BM.%26aulast%3DAltshuler%26aufirst%3DD.%26atitle%3DValidating%2520therapeutic%2520targets%2520through%2520human%2520genetics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D581%26epage%3D594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Chen, X.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, G.-H.</span><span> </span><span class="NLM_article-title">Target validation: A door to drug discovery</span> <span class="citation_source-journal">Drug Discovery Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BC38rltFKgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=23-29&author=X.-P.+Chenauthor=G.-H.+Du&title=Target+validation%3A+A+door+to+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Target validation: A door to drug discovery</span></div><div class="casAuthors">Chen X P; Du G H</div><div class="citationInfo"><span class="NLM_cas:title">Drug discoveries & therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-9</span>
        ISSN:<span class="NLM_cas:issn">1881-7831</span>.
    </div><div class="casAbstract">From ancient times to today, drug discovery transitioned from serendipity to rationality over its long history.  Proper drug target selection and validation are crucial to the discovery of new drugs.  This review discusses the definition of drug targets and proposes several characteristics for drug targets.  The limitations of the term 'target' itself are summarized.  The drug target validation process is also discussed in detail and pitfalls during this process are outlined.  Small active chemical compounds obtained from the target validation process are useful tools in target validation and target function research.  The validation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) as a new potential anti-atherosclerotic drug target is cited as an example in order to elucidate the target validation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJpC8lwbV7IS86Js-BCLiifW6udTcc2eYvxQmBLRSX-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rltFKgsA%253D%253D&md5=25518dab9534f81a769975698075efc1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.-P.%26aulast%3DDu%26aufirst%3DG.-H.%26atitle%3DTarget%2520validation%253A%2520A%2520door%2520to%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Ther.%26date%3D2007%26volume%3D1%26spage%3D23%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Brunschweiger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J.</span><span> </span><span class="NLM_article-title">A decade of the human genome sequence – how does the medicinal chemist benefit?</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=194-203&author=A.+Brunschweigerauthor=J.+Hall&title=A+decade+of+the+human+genome+sequence+%E2%80%93+how+does+the+medicinal+chemist+benefit%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DHall%26aufirst%3DJ.%26atitle%3DA%2520decade%2520of%2520the%2520human%2520genome%2520sequence%2520%25E2%2580%2593%2520how%2520does%2520the%2520medicinal%2520chemist%2520benefit%253F%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D194%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Halgren, T.</span><span> </span><span class="NLM_article-title">Identifying and characterizing binding sites and assessing druggability</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci800324m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=377-389&author=T.+Halgren&title=Identifying+and+characterizing+binding+sites+and+assessing+druggability"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Characterizing Binding Sites and Assessing Druggability</span></div><div class="casAuthors">Halgren, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-389</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification and characterization of binding sites is key in the process of structure-based drug design.  In some cases there may not be any information about the binding site for a target of interest.  In other cases, a putative binding site has been identified by computational or exptl. means, but the druggability of the target is not known.  Even when a site for a given target is known, it may be desirable to find addnl. sites whose targeting could produce a desired biol. response.  A new program, called SiteMap, is presented for identifying and analyzing binding sites and for predicting target druggability.  In a large-scale validation, SiteMap correctly identifies the known binding site as the top-ranked site in 86% of the cases, with best results (>98%) coming for sites that bind ligands with subnanomolar affinity.  In addn., a modified version of the score employed for binding-site identification allows SiteMap to accurately classify the druggability of proteins as measured by their ability to bind passively absorbed small mols. tightly.  In characterizing binding sites, SiteMap provides quant. and graphical information that can help guide efforts to critically assess virtual hits in a lead-discovery application or to modify ligand structure to enhance potency or improve phys. properties in a lead-optimization context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfAt0-gvcXDLVg90H21EOLACvtfcHk0lho535QG9mCrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1OhsA%253D%253D&md5=f03c7b27e30ae03d10e4127ed1f1ed3c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fci800324m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800324m%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%26atitle%3DIdentifying%2520and%2520characterizing%2520binding%2520sites%2520and%2520assessing%2520druggability%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D377%26epage%3D389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Skolnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Interplay of physics and evolution in the likely origin of protein biochemical function</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">9344</span><span class="NLM_x">–</span> <span class="NLM_lpage">9349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=9344-9349&author=J.+Skolnickauthor=M.+Gao&title=Interplay+of+physics+and+evolution+in+the+likely+origin+of+protein+biochemical+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnick%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DInterplay%2520of%2520physics%2520and%2520evolution%2520in%2520the%2520likely%2520origin%2520of%2520protein%2520biochemical%2520function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D9344%26epage%3D9349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Campbell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaulton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bichko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brouwer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harland, L.</span><span> </span><span class="NLM_article-title">Visualizing the drug target landscape</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=3-15&author=S.+Campbellauthor=A.+Gaultonauthor=J.+Marshallauthor=D.+Bichkoauthor=S.+Martinauthor=C.+Brouwerauthor=L.+Harland&title=Visualizing+the+drug+target+landscape"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DJ.%26aulast%3DBichko%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DBrouwer%26aufirst%3DC.%26aulast%3DHarland%26aufirst%3DL.%26atitle%3DVisualizing%2520the%2520drug%2520target%2520landscape%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D3%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Keller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Z.</span><span> </span><span class="NLM_article-title">A practical view of ‘druggability’</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.cbpa.2006.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=16814592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlGitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2006&pages=357-361&author=T.+Kellerauthor=A.+Pichotaauthor=Z.+Yin&title=A+practical+view+of+%E2%80%98druggability%E2%80%99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A practical view of druggability</span></div><div class="casAuthors">Keller, Thomas H.; Pichota, Arkadius; Yin, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">357-361</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The introduction of Lipinski's Rule of Five has initiated a profound shift in the thinking paradigm of medicinal chemists.  Understanding the difference between biol. active small mols. and drugs became a priority in the drug discovery process, and the importance of addressing pharmacokinetic properties early during lead optimization is a clear result.  These concepts of drug-likeness and druggability have been extended to proteins and genes for target identification and selection.  How should these concepts be integrated practically into the drug discovery process.  This review summarizes the recent advances in the field and examines the usefulness of the rules of the game in practice from a medicinal chemist's standpoint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorq2g5GWthbrVg90H21EOLACvtfcHk0lh0k_aN3-o86g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlGitbs%253D&md5=b9cef8a80f8867a568d2edd3444b73b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2006.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2006.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DPichota%26aufirst%3DA.%26aulast%3DYin%26aufirst%3DZ.%26atitle%3DA%2520practical%2520view%2520of%2520%25E2%2580%2598druggability%25E2%2580%2599%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D10%26spage%3D357%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Lipinski, C.</span><span> </span><span class="NLM_article-title">Lead- and drug-like compounds: The rule-of-five revolution</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">337</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-341&author=C.+Lipinski&title=Lead-+and+drug-like+compounds%3A+The+rule-of-five+revolution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%26atitle%3DLead-%2520and%2520drug-like%2520compounds%253A%2520The%2520rule-of-five%2520revolution%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D1%26spage%3D337%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Merritt, A.</span><span> </span><span class="NLM_article-title">High throughput chemistry in drug discovery</span>. In  <span class="citation_source-book">New Synthetic Technologies in Medicinal Chemistry</span>; <span class="NLM_contrib-group">Farrant, E.</span>, Ed.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span>, Chapter 2.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=6-41&author=A.+Merrittauthor=E.+Farrant&title=New+Synthetic+Technologies+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMerritt%26aufirst%3DA.%26atitle%3DHigh%2520throughput%2520chemistry%2520in%2520drug%2520discovery%26btitle%3DNew%2520Synthetic%2520Technologies%2520in%2520Medicinal%2520Chemistry%26aulast%3DFarrant%26aufirst%3DE.%26pub%3DRSC%2520Publishing%26date%3D2012%26spage%3D6%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Kerns, E.; Di, L.</span> <span class="citation_source-book">Drug-Like Properties: Concepts, Structure Design and Methods</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FB978-012369520-8.50020-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=E.+Kerns&author=L.+Di&title=Drug-Like+Properties%3A+Concepts%2C+Structure+Design+and+Methods"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FB978-012369520-8.50020-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-012369520-8.50020-6%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%26btitle%3DDrug-Like%2520Properties%253A%2520Concepts%252C%2520Structure%2520Design%2520and%2520Methods%26pub%3DAcademic%2520Press%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Gleeson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannongbua, S.</span><span> </span><span class="NLM_article-title">In-silico ADME models: A general assessment of their utility in drug discovery applications</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.2174%2F156802611794480927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21320065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=358-381&author=M.+Gleesonauthor=A.+Herseyauthor=S.+Hannongbua&title=In-silico+ADME+models%3A+A+general+assessment+of+their+utility+in+drug+discovery+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">In-silico ADME models: a general assessment of their utility in drug discovery applications</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Hannongbua, Supa</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">358-381</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  ADME prediction is an extremely challenging area as many of the properties we try to predict are a result of multiple physiol. processes.  In this review we consider how in-silico predictions of ADME processes can be used to help bias medicinal chem. into more ideal areas of property space, minimizing the no. of compds. needed to be synthesized to obtain the required biochem./physico-chem. profile.  While such models are not sufficiently accurate to act as a replacement for in-vivo or in-vitro methods, in-silico methods nevertheless can help us to understand the underlying physico-chem. dependencies of the different ADME properties, and thus can give us inspiration on how to optimize them.  Many global in-silico ADME models (i.e generated on large, diverse datasets) have been reported in the literature.  In this paper we selectively review representatives from each distinct class and discuss their relative utility in drug discovery.  For each ADME parameter, we limit our discussion to the most recent, most predictive or most insightful examples in the literature to highlight the current state of the art.  In each case we briefly summarize the different types of models available for each parameter (i.e simple rules, physico-chem. and 3D based QSAR predictions), their overall accuracy and the underlying SAR.  We also discuss the utility of the models as related to lead generation and optimization phases of discovery research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNyakFYvcjtrVg90H21EOLACvtfcHk0lh0k_aN3-o86g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSnur4%253D&md5=5ca56a568815370a3b04833db45c0a9b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F156802611794480927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480927%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DHannongbua%26aufirst%3DS.%26atitle%3DIn-silico%2520ADME%2520models%253A%2520A%2520general%2520assessment%2520of%2520their%2520utility%2520in%2520drug%2520discovery%2520applications%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D358%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-715&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Gilbert, J.; Henske, P.; Singh, A.</span><span> </span><span class="NLM_article-title">Rebuilding big pharma’s business model</span>.  <span class="citation_source-journal">In Vivo Bus. Med. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&author=J.+Gilbert&author=P.+Henske&author=A.+Singh&title=Rebuilding+big+pharma%E2%80%99s+business+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DJ.%26atitle%3DRebuilding%2520big%2520pharma%25E2%2580%2599s%2520business%2520model%26jtitle%3DIn%2520Vivo%2520Bus.%2520Med.%2520Rep.%26date%3D2003%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kleemann, A.</span><span> </span><span class="NLM_article-title">Metamorphosis of the pharmaceutical industry</span> <span class="citation_source-journal">Pharm. Ind.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">562</span><span class="NLM_x">–</span> <span class="NLM_lpage">574</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=562-574&author=A.+Kleemann&title=Metamorphosis+of+the+pharmaceutical+industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKleemann%26aufirst%3DA.%26atitle%3DMetamorphosis%2520of%2520the%2520pharmaceutical%2520industry%26jtitle%3DPharm.%2520Ind.%26date%3D2013%26volume%3D75%26spage%3D562%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Stone, K.</span> Big pharma’s merger mania. <i>About.com</i>; <a href="http://pharma.about.com/od/BigPharma/tp/Big-Pharmas-Merger-Mania.htm" class="extLink">http://pharma.about.com/od/BigPharma/tp/Big-Pharmas-Merger-Mania.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Stone%2C+K.+Big+pharma%E2%80%99s+merger+mania.+About.com%3B+http%3A%2F%2Fpharma.about.com%2Fod%2FBigPharma%2Ftp%2FBig-Pharmas-Merger-Mania.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DK." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span>Deal Search Online Home Page, Irving Levin Associates, Inc.; <a href="http://www.levinassociates.com/dealsearch/" class="extLink">http://www.levinassociates.com/dealsearch/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Deal+Search+Online+Home+Page%2C+Irving+Levin+Associates%2C+Inc.%3B+http%3A%2F%2Fwww.levinassociates.com%2Fdealsearch%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Lamattina, J.</span><span> </span><span class="NLM_article-title">The impact of mergers on pharmaceutical R&D</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">560</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd3514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21804580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=559-560&author=J.+Lamattina&title=The+impact+of+mergers+on+pharmaceutical+R%26D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of mergers on pharmaceutical R&D</span></div><div class="casAuthors">LaMattina, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-560</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mergers and acquisitions in the pharmaceutical industry have substantially reduced the no. of major companies over the past 15 years.  The short-term business rationale for this extensive consolidation might have been reasonable, but at what cost to research and development productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQG-hMf2r3PLVg90H21EOLACvtfcHk0liqW_7x-r-lfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKqtLc%253D&md5=9760460d349c12265be4c2e04c7dabb4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnrd3514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3514%26sid%3Dliteratum%253Aachs%26aulast%3DLamattina%26aufirst%3DJ.%26atitle%3DThe%2520impact%2520of%2520mergers%2520on%2520pharmaceutical%2520R%2526D%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D559%26epage%3D560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Firestone, R.</span><span> </span><span class="NLM_article-title">Lessons from 54 years of pharmaceutical research</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">963</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=963&author=R.+Firestone&title=Lessons+from+54+years+of+pharmaceutical+research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFirestone%26aufirst%3DR.%26atitle%3DLessons%2520from%252054%2520years%2520of%2520pharmaceutical%2520research%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Munos, B.</span><span> </span><span class="NLM_article-title">Lessons from 60 years of pharmaceutical innovation</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">959</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd2961" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19949401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2gtrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=959-968&author=B.+Munos&title=Lessons+from+60+years+of+pharmaceutical+innovation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from 60 years of pharmaceutical innovation</span></div><div class="casAuthors">Munos, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">959-968</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite unprecedented investment in pharmaceutical research and development (R&D), the no. of new drugs approved by the US Food and Drug Administration (FDA) remains low.  To help understand this conundrum, this article investigates the record of pharmaceutical innovation by analyzing data on the companies that introduced the ∼1,200 new drugs that have been approved by the FDA since 1950.  This anal. shows that the new-drug output from pharmaceutical companies in this period has essentially been const., and remains so despite the attempts to increase it.  This suggests that, contrary to common perception, the new-drug output is not depressed, but may simply reflect the limitations of the current R&D model.  The implications of these findings and options to achieve sustain-ability for the pharmaceutical industry are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5CrUftSjUirVg90H21EOLACvtfcHk0liqW_7x-r-lfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2gtrbK&md5=dd36497b2a0788257333322f77df81bc</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrd2961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2961%26sid%3Dliteratum%253Aachs%26aulast%3DMunos%26aufirst%3DB.%26atitle%3DLessons%2520from%252060%2520years%2520of%2520pharmaceutical%2520innovation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D959%26epage%3D968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Comanor, W.; Scherer, F.</span><span> </span><span class="NLM_article-title">Mergers and innovation in the pharmaceutical industry</span>. Harvard Kennedy School Faculty Research Working Paper Series,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="https://research.hks.harvard.edu/publications/workingpapers/citation.aspx?PubId=8053&amp;type=FN&amp;PersonId=219" class="extLink">https://research.hks.harvard.edu/publications/workingpapers/citation.aspx?PubId=8053&type=FN&PersonId=219</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=W.+Comanor&author=F.+Scherer&title=Mergers+and+innovation+in+the+pharmaceutical+industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DComanor%26aufirst%3DW.%26atitle%3DMergers%2520and%2520innovation%2520in%2520the%2520pharmaceutical%2520industry%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span>Amgen Press Release, Aug 25, 2013; <a href="http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1849611" class="extLink">http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1849611</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Amgen+Press+Release%2C+Aug+25%2C+2013%3B+http%3A%2F%2Fwww.amgen.com%2Fmedia%2Fmedia_pr_detail.jsp%3FreleaseID%3D1849611."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Scannell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blankley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, B.</span><span> </span><span class="NLM_article-title">Diagnosing the decline in pharmaceutical R&D efficiency</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&author=J.+Scannellauthor=A.+Blankleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0livsjebUJNIhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%26aulast%3DBlankley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520decline%2520in%2520pharmaceutical%2520R%2526D%2520efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Grabowski, H.; Kyle, M.</span><span> </span><span class="NLM_article-title">Mergers, acquisitions and alliances</span>. In  <span class="citation_source-book">The Oxford Handbook of The Economics of the Biopharmaceutical Industry</span>; <span class="NLM_contrib-group">Danzon, P.; Nicholson, S.</span>, Eds.; <span class="NLM_publisher-name">Oxford University Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">552</span><span class="NLM_x">–</span> <span class="NLM_lpage">577</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=552-577&author=H.+Grabowski&author=M.+Kyleauthor=P.+Danzon&author=S.+Nicholson&title=The+Oxford+Handbook+of+The+Economics+of+the+Biopharmaceutical+Industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGrabowski%26aufirst%3DH.%26atitle%3DMergers%252C%2520acquisitions%2520and%2520alliances%26btitle%3DThe%2520Oxford%2520Handbook%2520of%2520The%2520Economics%2520of%2520the%2520Biopharmaceutical%2520Industry%26aulast%3DDanzon%26aufirst%3DP.%26pub%3DOxford%2520University%2520Press%26date%3D2012%26spage%3D552%26epage%3D577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kumar, B.</span><span> </span><span class="NLM_article-title">Mergers and acquisitions in the pharmaceutical industry</span>. In  <span class="citation_source-book">Mega Mergers and Acquisitions: Case Studies from Key Industries</span>; <span class="NLM_publisher-name">Palgrave MacMillan</span>: <span class="NLM_publisher-loc">Hampshire, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">, </span>’ pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1057%2F9781137005908" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-59&author=B.+Kumar&title=Mega+Mergers+and+Acquisitions%3A+Case+Studies+from+Key+Industries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1057%2F9781137005908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1057%252F9781137005908%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DB.%26atitle%3DMergers%2520and%2520acquisitions%2520in%2520the%2520pharmaceutical%2520industry%26btitle%3DMega%2520Mergers%2520and%2520Acquisitions%253A%2520Case%2520Studies%2520from%2520Key%2520Industries%26pub%3DPalgrave%2520MacMillan%26date%3D2012%26spage%3D1%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Tjandrawinata, R.; Simanjuntak, D.</span><span> </span><span class="NLM_article-title">The impact of mergers and acquisitions in research-based pharmaceutical companies on productivity</span>. <span class="NLM_publisher-name">Social Science Research Network</span>: <span class="NLM_publisher-loc">Rochester, NY</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1981889" class="extLink">http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1981889</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+Tjandrawinata&author=D.+Simanjuntak&title=The+impact+of+mergers+and+acquisitions+in+research-based+pharmaceutical+companies+on+productivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DTjandrawinata%26aufirst%3DR.%26atitle%3DThe%2520impact%2520of%2520mergers%2520and%2520acquisitions%2520in%2520research-based%2520pharmaceutical%2520companies%2520on%2520productivity%26pub%3DSocial%2520Science%2520Research%2520Network%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">LaMattina, J.</span> A holiday gift from Merck’s Ken Frazier. Drug Truths, Dec 20,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://johnlamattina.wordpress.com/2011/12/20/a-holiday-gift-from-mercks-ken-frazier/" class="extLink">http://johnlamattina.wordpress.com/2011/12/20/a-holiday-gift-from-mercks-ken-frazier/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+LaMattina&title=Drug+Truths"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DLaMattina%26aufirst%3DJ.%26jtitle%3DDrug%2520Truths%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Weaver, C.</span> Merck CEO defends strategy to pursue new drugs, research. Wall Street Journal, Dec 13,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://online.wsj.com/article/BT-CO-20111213-711338.html" class="extLink">http://online.wsj.com/article/BT-CO-20111213-711338.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=C.+Weaver&title=Wall+Street+Journal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DWeaver%26aufirst%3DC.%26jtitle%3DWall%2520Street%2520Journal%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Danzon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, S.</span><span> </span><span class="NLM_article-title">Mergers and acquisitions in the pharmaceutical and biotech industries</span> <span class="citation_source-journal">Managerial and Decision Economics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=307-328&author=P.+Danzonauthor=A.+Epsteinauthor=S.+Nicholson&title=Mergers+and+acquisitions+in+the+pharmaceutical+and+biotech+industries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDanzon%26aufirst%3DP.%26aulast%3DEpstein%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DS.%26atitle%3DMergers%2520and%2520acquisitions%2520in%2520the%2520pharmaceutical%2520and%2520biotech%2520industries%26jtitle%3DManagerial%2520and%2520Decision%2520Economics%26date%3D2007%26volume%3D28%26spage%3D307%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Grabowski, H.; Kyle, M.</span><span> </span><span class="NLM_article-title">Mergers and alliances in pharmaceuticals: effects on innovation and productivity</span>. In  <span class="citation_source-book">Economics of Corporate Governance and Mergers</span>; <span class="NLM_contrib-group">Gugler, K.; Yurtoglu, B.</span>, Eds.; <span class="NLM_publisher-name">Edward Elgar</span>: <span class="NLM_publisher-loc">Cheltehham, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=262-287&author=H.+Grabowski&author=M.+Kyleauthor=K.+Gugler&author=B.+Yurtoglu&title=Economics+of+Corporate+Governance+and+Mergers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGrabowski%26aufirst%3DH.%26atitle%3DMergers%2520and%2520alliances%2520in%2520pharmaceuticals%253A%2520effects%2520on%2520innovation%2520and%2520productivity%26btitle%3DEconomics%2520of%2520Corporate%2520Governance%2520and%2520Mergers%26aulast%3DGugler%26aufirst%3DK.%26pub%3DEdward%2520Elgar%26date%3D2008%26spage%3D262%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Davis, P. J.</span><span> </span><span class="NLM_article-title">Beyond the patent cliff – signs of recovery in biopharma’s new normal</span>. Accenture Life Sciences,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture-Life-Sciences-Beyond-The-Patent-Cliff-Signs-Of-Recovery-in-Biopharmas-New-Normal.pdf" class="extLink">http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture-Life-Sciences-Beyond-The-Patent-Cliff-Signs-Of-Recovery-in-Biopharmas-New-Normal.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.+J.+Davis&title=Beyond+the+patent+cliff+%E2%80%93+signs+of+recovery+in+biopharma%E2%80%99s+new+normal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DP.%2BJ.%26atitle%3DBeyond%2520the%2520patent%2520cliff%2520%25E2%2580%2593%2520signs%2520of%2520recovery%2520in%2520biopharma%25E2%2580%2599s%2520new%2520normal%26jtitle%3DAccenture%2520Life%2520Sciences%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span>World preview 2018: Embracing the patent cliff. EvaluatePharma,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://info.evaluatepharma.com/WP2018_ELS_LP.html" class="extLink">http://info.evaluatepharma.com/WP2018_ELS_LP.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+preview+2018%3A+Embracing+the+patent+cliff.+EvaluatePharma%2C+2012%3B+http%3A%2F%2Finfo.evaluatepharma.com%2FWP2018_ELS_LP.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DEvaluatePharma%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span>Lipitor sales data. <i>Drugs.com</i>; <a href="http://www.drugs.com/stats/lipitor" class="extLink">http://www.drugs.com/stats/lipitor</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lipitor+sales+data.+Drugs.com%3B+http%3A%2F%2Fwww.drugs.com%2Fstats%2Flipitor."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S.</span><span> </span><span class="NLM_article-title">Balancing innovation and access: Patent challenges tip the scales</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">326</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">–</span> <span class="NLM_lpage">371</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2009&pages=370-371&author=M.+Higginsauthor=S.+Grahamauthor=M.+Higginsauthor=S.+Graham&title=Balancing+innovation+and+access%3A+Patent+challenges+tip+the+scales"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DS.%26atitle%3DBalancing%2520innovation%2520and%2520access%253A%2520Patent%2520challenges%2520tip%2520the%2520scales%26jtitle%3DScience%26date%3D2009%26volume%3D326%26spage%3D370%26epage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span>Paragraph four explained: Why generic drug companies challenge patents. <span class="NLM_publisher-name">Parry Ashfold, Inc.</span>: <span class="NLM_publisher-loc">Exton, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://paragraphfour.com/explained/why_challenge.html" class="extLink">http://paragraphfour.com/explained/why_challenge.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Paragraph+four+explained%3A+Why+generic+drug+companies+challenge+patents.+Parry+Ashfold%2C+Inc.%3A+Exton%2C+PA%2C+2012%3B+http%3A%2F%2Fparagraphfour.com%2Fexplained%2Fwhy_challenge.html."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26pub%3DParry%2520Ashfold%252C%2520Inc%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Harrison, C.</span><span> </span><span class="NLM_article-title">The patent cliff steepens</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=12-13&author=C.+Harrison&title=The+patent+cliff+steepens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26atitle%3DThe%2520patent%2520cliff%2520steepens%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D12%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Powers, M.</span> Despite short-term revenue hit, Sanofi manages patent cliff. <i>BioWorld</i>; <a href="http://www.bioworld.com/content/despite-short-term-revenue-hit-sanofi-manages-patent-cliff-0" class="extLink">http://www.bioworld.com/content/despite-short-term-revenue-hit-sanofi-manages-patent-cliff-0</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Powers%2C+M.+Despite+short-term+revenue+hit%2C+Sanofi+manages+patent+cliff.+BioWorld%3B+http%3A%2F%2Fwww.bioworld.com%2Fcontent%2Fdespite-short-term-revenue-hit-sanofi-manages-patent-cliff-0."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Hitchings, A.; Baker, E.; Khong, T.</span><span> </span><span class="NLM_article-title">Making medicines evergreen</span>.  <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">e7941</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=2012&pages=e7941&author=A.+Hitchings&author=E.+Baker&author=T.+Khong&title=Making+medicines+evergreen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHitchings%26aufirst%3DA.%26atitle%3DMaking%2520medicines%2520evergreen%26jtitle%3DBr.%2520Med.%2520J.%26date%3D2012%26volume%3D345%26spage%3De7941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Buente, M.; Danner, S.; Weissbacker, S.; Ramme, C.</span> Pharma emerging markets 2.0. How emerging markets are driving the transformation of the pharmaceutical industry. <i>Booz & Co</i>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.booz.com/media/file/BoozCo_Pharma-Emerging-Markets-2.0.pdf" class="extLink">http://www.booz.com/media/file/BoozCo_Pharma-Emerging-Markets-2.0.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Buente%2C+M.%3B+Danner%2C+S.%3B+Weissbacker%2C+S.%3B+Ramme%2C+C.+Pharma+emerging+markets+2.0.+How+emerging+markets+are+driving+the+transformation+of+the+pharmaceutical+industry.+Booz+%26+Co%2C+2013%3B+http%3A%2F%2Fwww.booz.com%2Fmedia%2Ffile%2FBoozCo_Pharma-Emerging-Markets-2.0.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DBuente%26aufirst%3DM.%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Schumacher, C.</span><span> </span><span class="NLM_article-title">CRAMS outsourcing in pharmaceutical and chemical research and manufacturing</span>, part II. <i>StepChange Innovations GmbH</i>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://blog.stepchange-innovations.com/2012/08/crams-outsourcing-in-pharmaceutical-and-chemical-research-and-manufacturing-part-ii/#_edn1" class="extLink">http://blog.stepchange-innovations.com/2012/08/crams-outsourcing-in-pharmaceutical-and-chemical-research-and-manufacturing-part-ii/#_edn1</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Schumacher&title=CRAMS+outsourcing+in+pharmaceutical+and+chemical+research+and+manufacturing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DC.%26atitle%3DCRAMS%2520outsourcing%2520in%2520pharmaceutical%2520and%2520chemical%2520research%2520and%2520manufacturing%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Getz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamberti, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathias, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stergiopoulis, S.</span><span> </span><span class="NLM_article-title">Resizing the global R&D contract service market</span> <span class="citation_source-journal">Contract Pharma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=54&author=K.+Getzauthor=M.+J.+Lambertiauthor=A.+Mathiasauthor=S.+Stergiopoulis&title=Resizing+the+global+R%26D+contract+service+market"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGetz%26aufirst%3DK.%26aulast%3DLamberti%26aufirst%3DM.%2BJ.%26aulast%3DMathias%26aufirst%3DA.%26aulast%3DStergiopoulis%26aufirst%3DS.%26atitle%3DResizing%2520the%2520global%2520R%2526D%2520contract%2520service%2520market%26jtitle%3DContract%2520Pharma%26date%3D2012%26volume%3D14%26spage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Roijakkers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagedoorn, J.</span><span> </span><span class="NLM_article-title">Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns and networks</span> <span class="citation_source-journal">Res. Policy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.respol.2006.01.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2006&pages=431-446&author=N.+Roijakkersauthor=J.+Hagedoorn&title=Inter-firm+R%26D+partnering+in+pharmaceutical+biotechnology+since+1975%3A+Trends%2C+patterns+and+networks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.respol.2006.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.respol.2006.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DRoijakkers%26aufirst%3DN.%26aulast%3DHagedoorn%26aufirst%3DJ.%26atitle%3DInter-firm%2520R%2526D%2520partnering%2520in%2520pharmaceutical%2520biotechnology%2520since%25201975%253A%2520Trends%252C%2520patterns%2520and%2520networks%26jtitle%3DRes.%2520Policy%26date%3D2006%26volume%3D35%26spage%3D431%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">McCutchen, W. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swamidass, P. M.</span><span> </span><span class="NLM_article-title">Motivations for strategic alliances in the pharmaceutical/biotech industry: Some new findings</span> <span class="citation_source-journal">J. High Technol. Manage. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.hitech.2004.03.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=197-204&author=W.+W.+McCutchenauthor=P.+M.+Swamidass&title=Motivations+for+strategic+alliances+in+the+pharmaceutical%2Fbiotech+industry%3A+Some+new+findings"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.hitech.2004.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hitech.2004.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DMcCutchen%26aufirst%3DW.%2BW.%26aulast%3DSwamidass%26aufirst%3DP.%2BM.%26atitle%3DMotivations%2520for%2520strategic%2520alliances%2520in%2520the%2520pharmaceutical%252Fbiotech%2520industry%253A%2520Some%2520new%2520findings%26jtitle%3DJ.%2520High%2520Technol.%2520Manage.%2520Res.%26date%3D2004%26volume%3D15%26spage%3D197%26epage%3D204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span>The use of medicines in the United States: Review of 2011. IMS Institute for Healthcare Informatics, April<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf" class="extLink">http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+use+of+medicines+in+the+United+States%3A+Review+of+2011.+IMS+Institute+for+Healthcare+Informatics%2C+April+2012%3B+http%3A%2F%2Fwww.imshealth.com%2Fims%2FGlobal%2FContent%2FInsights%2FIMS%2520Institute%2520for%2520Healthcare%2520Informatics%2FIHII_Medicines_in_U.S_Report_2011.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DIMS%2520Institute%2520for%2520Healthcare%2520Informatics%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Barry, C.; Arad, R.; Johnston, A.; Parent, A.; Ansell, L.; Arnold, M.</span><span class="NLM_x"> (</span><span class="NLM_year">2012</span><span class="NLM_x">) </span>patent litigation study. PricewaterhouseCoopers, Sept 2012; <a href="http://www.pwc.com/us/en/forensic-services/publications/2012-patent-litigation-study.jhtml" class="extLink">http://www.pwc.com/us/en/forensic-services/publications/2012-patent-litigation-study.jhtml</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Barry&author=R.+Arad&author=A.+Johnston&author=A.+Parent&author=L.+Ansell&author=M.+Arnold&title=PricewaterhouseCoopers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DBarry%26aufirst%3DC.%26date%3D2012%26jtitle%3DPricewaterhouseCoopers" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Rai, A.</span><span> </span><span class="NLM_article-title">Use patents, carve-outs, and incentives – a new battle in the drug-patent wars</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1056%2FNEJMp1206573" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2012&pages=491-493&author=A.+Rai&title=Use+patents%2C+carve-outs%2C+and+incentives+%E2%80%93+a+new+battle+in+the+drug-patent+wars"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1206573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1206573%26sid%3Dliteratum%253Aachs%26aulast%3DRai%26aufirst%3DA.%26atitle%3DUse%2520patents%252C%2520carve-outs%252C%2520and%2520incentives%2520%25E2%2580%2593%2520a%2520new%2520battle%2520in%2520the%2520drug-patent%2520wars%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D376%26spage%3D491%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span>Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement and Moderinization Act of 2003: Overview of agreements filed filed in FY 2012; A report by the Bureau of Competition, Federal Trade Commission: <span class="NLM_publisher-loc">Washington, DC</span>, Jan<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><a href="http://www.ftc.gov/os/2013/01/130117mmareport.pdf" class="extLink">http://www.ftc.gov/os/2013/01/130117mmareport.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Agreements+filed+with+the+Federal+Trade+Commission+under+the+Medicare+Prescription+Drug%2C+Improvement+and+Moderinization+Act+of+2003%3A+Overview+of+agreements+filed+filed+in+FY+2012%3B+A+report+by+the+Bureau+of+Competition%2C+Federal+Trade+Commission%3A+Washington%2C+DC%2C+Jan+2013%3B+http%3A%2F%2Fwww.ftc.gov%2Fos%2F2013%2F01%2F130117mmareport.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span> </span><span class="NLM_article-title">List of authorized generic drugs</span>. <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Washington , DC</span>; <a href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm126389.htm" class="extLink">http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm126389.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=List+of+authorized+generic+drugs.+U.S.+Food+and+Drug+Administration%3A+Washington+%2C+DC%3B+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDevelopmentApprovalProcess%2FHowDrugsareDevelopedandApproved%2FApprovalApplications%2FAbbreviatedNewDrugApplicationANDAGenerics%2Fucm126389.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DList%2520of%2520authorized%2520generic%2520drugs%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span>More than eight in ten Americans want the option of choosing authorized generic prescription drugs. Roper Public Affairs & Media,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span><a href="http://www.prasco.com/wp-content/uploads/2012/03/Roper_Poll.pdf" class="extLink">http://www.prasco.com/wp-content/uploads/2012/03/Roper_Poll.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=More+than+eight+in+ten+Americans+want+the+option+of+choosing+authorized+generic+prescription+drugs.+Roper+Public+Affairs+%26+Media%2C+2005%3B+http%3A%2F%2Fwww.prasco.com%2Fwp-content%2Fuploads%2F2012%2F03%2FRoper_Poll.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DRoper%2520Public%2520Affairs%2520%2526%2520Media%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span> </span><span class="NLM_article-title">Authorized generic drugs: Short-term effects and long-term impact</span>. <span class="NLM_publisher-name">Federal Trade Commission</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Authorized+generic+drugs%3A+Short-term+effects+and+long-term+impact.+Federal+Trade+Commission%3A+Washington%2C+DC%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26atitle%3DAuthorized%2520generic%2520drugs%253A%2520Short-term%2520effects%2520and%2520long-term%2520impact%26pub%3DFederal%2520Trade%2520Commission%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Ryu, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, D. H.</span><span> </span><span class="NLM_article-title">Current status and perspectives of biopharmaceutical drugs</span> <span class="citation_source-journal">Biotechnol. Bioprocess Eng.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs12257-012-0095-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGitb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=900-911&author=J.+K.+Ryuauthor=H.+S.+Kimauthor=D.+H.+Nam&title=Current+status+and+perspectives+of+biopharmaceutical+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Current status and perspectives of biopharmaceutical drugs</span></div><div class="casAuthors">Ryu, Jae Kuk; Kim, Hyo Sun; Nam, Doo Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology and Bioprocess Engineering</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">BBEIAU</span>;
        ISSN:<span class="NLM_cas:issn">1226-8372</span>.
    
            (<span class="NLM_cas:orgname">Korean Society for Biotechnology and Bioengineering</span>)
        </div><div class="casAbstract">A review.  Since the first approval of recombinant human insulin 3 decades ago, more than 150 biopharmaceutical drugs were marketed, and some of them became blockbuster drugs in market size.  The patent expiration of the oldest biopharmaceutical drugs resulted in the development of biosimilar drugs.  However the short serum half-life of biopharmaceutical drugs incurs a frequent injection to maintain a target clin. outcome in patients.  The other major crit. concern of biopharmaceutical drugs is immunogenicity producing anti-drug antibodies.  These antibodies may reduce clin. efficacy by neutralizing biol. activity, and may not only cause a severe allergic reaction but also other serious adverse reactions by blocking endogenous proteins.  In order to improve pharmaceutical properties and reduce immunogenicity, the next generation biobetter drugs were achieved by glycoengineering technol., Pegylation technol. and protein engineering technol.  Other biobetter drugs having optimized binding sites were also generated by in vitro display technol.  Many of those biobetter drugs were developed and/or are under development, and come into the clin. field in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMjGJLYcIF2LVg90H21EOLACvtfcHk0li8ob_5IdRKhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGitb%252FP&md5=0b16e6c413ae1119005cdd029e836a7c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs12257-012-0095-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12257-012-0095-1%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DNam%26aufirst%3DD.%2BH.%26atitle%3DCurrent%2520status%2520and%2520perspectives%2520of%2520biopharmaceutical%2520drugs%26jtitle%3DBiotechnol.%2520Bioprocess%2520Eng.%26date%3D2012%26volume%3D17%26spage%3D900%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit70"><span>Global biopharmaceutical market expected to reach $320 billion by 2020. <i>Global Information, Inc.</i>, Oct 4,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.giiresearch.com/press/6805.shtml" class="extLink">http://www.giiresearch.com/press/6805.shtml</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+biopharmaceutical+market+expected+to+reach+%24320+billion+by+2020.+Global+Information%2C+Inc.%2C+Oct+4%2C+2012%3B+http%3A%2F%2Fwww.giiresearch.com%2Fpress%2F6805.shtml."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Stein, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gipe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dufour, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pordy, R.</span><span> </span><span class="NLM_article-title">Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimebe therapy: A phase 2 randomized controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">7</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=7-13&author=E.+A.+Steinauthor=D.+Gipeauthor=J.+Bergeronauthor=D.+Gaudetauthor=R.+Weissauthor=R.+Dufourauthor=R.+Wuauthor=R.+Pordy&title=Effect+of+a+monoclonal+antibody+to+PCSK9%2C+REGN727%2FSAR236553%2C+to+reduce+low-density+lipoprotein+cholesterol+in+patients+with+heterozygous+familial+hypercholesterolaemia+on+stable+statin+dose+with+or+without+ezetimebe+therapy%3A+A+phase+2+randomized+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DE.%2BA.%26aulast%3DGipe%26aufirst%3DD.%26aulast%3DBergeron%26aufirst%3DJ.%26aulast%3DGaudet%26aufirst%3DD.%26aulast%3DWeiss%26aufirst%3DR.%26aulast%3DDufour%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DPordy%26aufirst%3DR.%26atitle%3DEffect%2520of%2520a%2520monoclonal%2520antibody%2520to%2520PCSK9%252C%2520REGN727%252FSAR236553%252C%2520to%2520reduce%2520low-density%2520lipoprotein%2520cholesterol%2520in%2520patients%2520with%2520heterozygous%2520familial%2520hypercholesterolaemia%2520on%2520stable%2520statin%2520dose%2520with%2520or%2520without%2520ezetimebe%2520therapy%253A%2520A%2520phase%25202%2520randomized%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D7%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Sullivan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebski, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, E. A.</span><span> </span><span class="NLM_article-title">Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">2497</span><span class="NLM_x">–</span> <span class="NLM_lpage">2506</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2012&pages=2497-2506&author=D.+Sullivanauthor=A.+G.+Olssonauthor=R.+Scottauthor=J.+B.+Kimauthor=A.+Xueauthor=V.+Gebskiauthor=S.+M.+Wassermanauthor=E.+A.+Stein&title=Effect+of+a+monoclonal+antibody+to+PCSK9+on+low-density+lipoprotein+cholesterol+levels+in+statin-intolerant+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DOlsson%26aufirst%3DA.%2BG.%26aulast%3DScott%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BB.%26aulast%3DXue%26aufirst%3DA.%26aulast%3DGebski%26aufirst%3DV.%26aulast%3DWasserman%26aufirst%3DS.%2BM.%26aulast%3DStein%26aufirst%3DE.%2BA.%26atitle%3DEffect%2520of%2520a%2520monoclonal%2520antibody%2520to%2520PCSK9%2520on%2520low-density%2520lipoprotein%2520cholesterol%2520levels%2520in%2520statin-intolerant%2520patients%26jtitle%3DJAMA%26date%3D2012%26volume%3D308%26spage%3D2497%26epage%3D2506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Herd, T.; Sheehy, D. A.; Ural, A.</span><span> </span><span class="NLM_article-title">Mergers & acquisitions: A strategy for focused growth in the biopharmaceutical industry during uncertain times</span>. Accenture,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture_A_Strategy_for_Focused_Growth.pdf" class="extLink">http://www.accenture.com/SiteCollectionDocuments/PDF/Accenture_A_Strategy_for_Focused_Growth.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=T.+Herd&author=D.+A.+Sheehy&author=A.+Ural&title=Mergers+%26+acquisitions%3A+A+strategy+for+focused+growth+in+the+biopharmaceutical+industry+during+uncertain+times"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DHerd%26aufirst%3DT.%26atitle%3DMergers%2520%2526%2520acquisitions%253A%2520A%2520strategy%2520for%2520focused%2520growth%2520in%2520the%2520biopharmaceutical%2520industry%2520during%2520uncertain%2520times%26jtitle%3DAccenture%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Kanase, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavhane, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khandakar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurav, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, A. V.</span><span> </span><span class="NLM_article-title">Biosimilar: an overview</span> <span class="citation_source-journal">Int. J. Pharm. Sci Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2132</span><span class="NLM_x">–</span> <span class="NLM_lpage">2144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCmsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2132-2144&author=S.+J.+Kanaseauthor=Y.+N.+Gavhaneauthor=A.+Khandakarauthor=A.+S.+Guravauthor=A.+V.+Yadav&title=Biosimilar%3A+an+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Biosimilar: an overview</span></div><div class="casAuthors">Kanase, Sagar J.; Gavhane, Yogesh N.; Khandekar, Ashok; Gurav, Atul S.; Yadav, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutical Sciences and Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2132-2144</span>CODEN:
                <span class="NLM_cas:coden">IJPSTT</span>;
        ISSN:<span class="NLM_cas:issn">0975-8232</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Pharmaceutical Sciences and Research</span>)
        </div><div class="casAbstract">A review.  Biosimilars are defined as officially approved new version of innovator bio-therapeutic products for which the patent has expired.  Biosimilars the 'generic' versions of biopharmaceuticals, continue to enter Indian pharmaceutical market, to treat a variety of diseases.  Biosimilars available in India include monoclonal antibodies for treating various malignant and immunol. disorders, growth factors like erythropoietin and granulocyte colony stimulating factor (GCSF), human insulins for treating diabetes mellitus etc.  In the recent scenario, there is an increasing demand for biol. drugs.  The development and prodn. of biosimilars are boosted by existing manufg. technol.  Due to no investment in phase I-II of clin. trials, biosimilars are available at cheaper prices than the ref. products, so that it has low market risk.  The main goal of this review is that the phase I-II trials are typically not required for biosimilar approval unless it is found necessary in special cases.  Phase III trials with a min. of 100 patients are mandatory for establishing bioequivalence.  Therefore, the total cost to develop a biosimilar in India can range from $10-20 million, which helps Indian companies to offer their products at a 25-40 % cheaper price than the innovator biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopX552zvQzy7Vg90H21EOLACvtfcHk0ljprJeeq_cWbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCmsrzE&md5=7aee98dddc7d24ea65bf02615b8f025a</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKanase%26aufirst%3DS.%2BJ.%26aulast%3DGavhane%26aufirst%3DY.%2BN.%26aulast%3DKhandakar%26aufirst%3DA.%26aulast%3DGurav%26aufirst%3DA.%2BS.%26aulast%3DYadav%26aufirst%3DA.%2BV.%26atitle%3DBiosimilar%253A%2520an%2520overview%26jtitle%3DInt.%2520J.%2520Pharm.%2520Sci%2520Res.%26date%3D2013%26volume%3D4%26spage%3D2132%26epage%3D2144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Kay, J.</span><span> </span><span class="NLM_article-title">Biosimilars: A regulatory perspective from America</span> <span class="citation_source-journal">Arthritis Res Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1186%2Far3310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21586106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlKlsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=112&author=J.+Kay&title=Biosimilars%3A+A+regulatory+perspective+from+America"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Biosimilars: a regulatory perspective from America</span></div><div class="casAuthors">Kay, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">112</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Biosimilars are protein products that are sufficiently similar to a biopharmaceutical already approved by a regulatory agency.  Several biotechnol. companies and generic drug manufacturers in Asia and Europe are developing biosimilars of tumor necrosis factor inhibitors and rituximab.  A biosimilar etanercept is already being marketed in Colombia and China.  In the US, several natural source products and recombinant proteins have been approved as generic drugs under Section 505(b)(2) of the Food, Drug, and Cosmetic Act.  However, because the complexity of large biopharmaceuticals makes it difficult to demonstrate that a biosimilar is structurally identical to an already approved biopharmaceutical, this Act does not apply to biosimilars of large biopharmaceuticals.  Section 7002 of the Patient Protection and Affordable Care Act of 2010, which is referred to as the Biologics Price Competition and Innovation Act of 2009, amends Section 351 of the Public Health Service Act to create an abbreviated pathway that permits a biosimilar to be evaluated by comparing it with only a single ref. biol. product.  This paper reviews the processes for approval of biosimilars in the US and the European Union and highlights recent changes in federal regulations governing the approval of biosimilars in the US.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpREyZ8F7bZJbVg90H21EOLACvtfcHk0ljprJeeq_cWbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlKlsrY%253D&md5=ec491be9188ca2c24956da2291ed3a72</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1186%2Far3310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far3310%26sid%3Dliteratum%253Aachs%26aulast%3DKay%26aufirst%3DJ.%26atitle%3DBiosimilars%253A%2520A%2520regulatory%2520perspective%2520from%2520America%26jtitle%3DArthritis%2520Res%2520Ther.%26date%3D2011%26volume%3D13%26spage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit76"><span>Patient Protection and Affordable Care Act of 2009, Pub. L. No. 111-148, Title VII, Subtitle A Biologics Price Competition and Innovation Act of 2009, §7001-7003; <a href="http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf" class="extLink">http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Patient+Protection+and+Affordable+Care+Act+of+2009%2C+Pub.+L.+No.+111-148%2C+Title+VII%2C+Subtitle+A+Biologics+Price+Competition+and+Innovation+Act+of+2009%2C+%C2%A77001-7003%3B+http%3A%2F%2Fwww.gpo.gov%2Ffdsys%2Fpkg%2FBILLS-111hr3590enr%2Fpdf%2FBILLS-111hr3590enr.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Notte, G. T.</span><span> </span><span class="NLM_article-title">New chemical entities entering phase III clinical trials in 2012</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_contrib-group">Bronston, J.; Desai, M. C.</span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Waltham, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">451</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=451-469&author=G.+T.+Notteauthor=J.+Bronston&author=M.+C.+Desai&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNotte%26aufirst%3DG.%2BT.%26atitle%3DNew%2520chemical%2520entities%2520entering%2520phase%2520III%2520clinical%2520trials%2520in%25202012%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DBronston%26aufirst%3DJ.%26pub%3DAcademic%2520Press%26date%3D2013%26spage%3D451%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Jarvis, L. M.</span><span> </span><span class="NLM_article-title">A bountiful year</span> <span class="citation_source-journal">Chem. Eng. News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=15-17&author=L.+M.+Jarvis&title=A+bountiful+year"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJarvis%26aufirst%3DL.%2BM.%26atitle%3DA%2520bountiful%2520year%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2013%26spage%3D15%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">LaMattina, J.</span> When it comes to NDA approvals, is 30 the new 50? <i>Drug Truths</i>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://johnlamattina.wordpress.com/2012/01/17/when-it-comes-to-nda-approvals-is-30-the-new-50/" class="extLink">http://johnlamattina.wordpress.com/2012/01/17/when-it-comes-to-nda-approvals-is-30-the-new-50/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LaMattina%2C+J.+When+it+comes+to+NDA+approvals%2C+is+30+the+new+50%3F+Drug+Truths%2C+2012%3B+http%3A%2F%2Fjohnlamattina.wordpress.com%2F2012%2F01%2F17%2Fwhen-it-comes-to-nda-approvals-is-30-the-new-50%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DLaMattina%26aufirst%3DJ.%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Armstrong, W.</span> FDA’s approvable problem. <i>Pharmaceutical Executive</i>, Nov 1,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="http://www.pharmexec.com/pharmexec/PE+Features/FDAs-Approvable-Problem/ArticleStandard/Article/detail/469652" class="extLink">http://www.pharmexec.com/pharmexec/PE+Features/FDAs-Approvable-Problem/ArticleStandard/Article/detail/469652</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Armstrong%2C+W.+FDA%E2%80%99s+approvable+problem.+Pharmaceutical+Executive%2C+Nov+1%2C+2007%3B+http%3A%2F%2Fwww.pharmexec.com%2Fpharmexec%2FPE%2BFeatures%2FFDAs-Approvable-Problem%2FArticleStandard%2FArticle%2Fdetail%2F469652."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DW.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span> </span><span class="NLM_article-title">FDA revised process for responding to drug applications</span>; Press Release by the U.S. Food and Drug Administration, July 8,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116920.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116920.htm</a>. Complete <a href="http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2004-N-0510-nfr.pdf" class="extLink">http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2004-N-0510-nfr.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+revised+process+for+responding+to+drug+applications%3B+Press+Release+by+the+U.S.+Food+and+Drug+Administration%2C+July+8%2C+2008%3B+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2F2008%2Fucm116920.htm.+Complete+http%3A%2F%2Fwww.fda.gov%2FOHRMS%2FDOCKETS%2F98fr%2FFDA-2004-N-0510-nfr.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520revised%2520process%2520for%2520responding%2520to%2520drug%2520applications%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Light, D.; Lexchin, J. R.</span><span> </span><span class="NLM_article-title">Pharmaceutical research and development – what do we get for all that money?</span> <span class="citation_source-journal">Br. Med. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">e4348</span>. <a href="http://www.bmj.com/content/345/bmj.e4348.pdf%2Bhtml" class="extLink">http://www.bmj.com/content/345/bmj.e4348.pdf%2Bhtml</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2012&pages=e4348&author=D.+Light&author=J.+R.+Lexchin&title=Pharmaceutical+research+and+development+%E2%80%93+what+do+we+get+for+all+that+money%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLight%26aufirst%3DD.%26atitle%3DPharmaceutical%2520research%2520and%2520development%2520%25E2%2580%2593%2520what%2520do%2520we%2520get%2520for%2520all%2520that%2520money%253F%26jtitle%3DBr.%2520Med.%2520J.%26date%3D2012%26volume%3D344%26spage%3De4348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit83"><span>FDA’s consideration of evidence from certain clinical trials. <i>United States Government Accountability Office</i>, July<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span><a href="http://www.gao.gov/assets/310/308301.pdf" class="extLink">http://www.gao.gov/assets/310/308301.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA%E2%80%99s+consideration+of+evidence+from+certain+clinical+trials.+United+States+Government+Accountability+Office%2C+July+2010%3B+http%3A%2F%2Fwww.gao.gov%2Fassets%2F310%2F308301.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Bode-Greuel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickisch, K. J.</span><span> </span><span class="NLM_article-title">Value-driven project and portfolio management in the pharmaceutical industry: Drug discovery versus drug development – commonalities and differences in portfolio management practice</span> <span class="citation_source-journal">J. Commer. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1057%2Fjcb.2008.6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=307-325&author=K.+Bode-Greuelauthor=K.+J.+Nickisch&title=Value-driven+project+and+portfolio+management+in+the+pharmaceutical+industry%3A+Drug+discovery+versus+drug+development+%E2%80%93+commonalities+and+differences+in+portfolio+management+practice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1057%2Fjcb.2008.6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1057%252Fjcb.2008.6%26sid%3Dliteratum%253Aachs%26aulast%3DBode-Greuel%26aufirst%3DK.%26aulast%3DNickisch%26aufirst%3DK.%2BJ.%26atitle%3DValue-driven%2520project%2520and%2520portfolio%2520management%2520in%2520the%2520pharmaceutical%2520industry%253A%2520Drug%2520discovery%2520versus%2520drug%2520development%2520%25E2%2580%2593%2520commonalities%2520and%2520differences%2520in%2520portfolio%2520management%2520practice%26jtitle%3DJ.%2520Commer.%2520Biotechnol.%26date%3D2008%26volume%3D14%26spage%3D307%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Poland, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodge, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemen, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagnar, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dykstra, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishna, R.</span><span> </span><span class="NLM_article-title">The clinical utility index as a practical multiattribute approach to drug development decisions</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fclpt.2009.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19458614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvis1GgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2009&pages=105-108&author=B.+Polandauthor=F.+L.+Hodgeauthor=A.+Kahnauthor=R.+T.+Clemenauthor=J.+A.+Wagnarauthor=K.+Dykstraauthor=R.+Krishna&title=The+clinical+utility+index+as+a+practical+multiattribute+approach+to+drug+development+decisions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical utility index as a practical multiattribute approach to drug development decisions</span></div><div class="casAuthors">Poland B; Hodge F L; Khan A; Clemen R T; Wagner J A; Dykstra K; Krishna R</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We identify some innovative approaches to predicting overall patient benefit from investigational drugs to support development decisions.  We then illustrate calculation of a probabilistic clinical utility index (CUI), an implementation of multiattribute utility that focuses on clinical attributes.  We recommend use of the CUI for the support of early drug development decisions because of its practicality, reasonable accuracy, and transparency to decision makers, at stages in which financial factors that may dominate later-phase decisions are less critical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgPD5PSdNKJL0AGQpJZWpJfW6udTcc2ea8V6aLt6Ajp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvis1GgtQ%253D%253D&md5=31b2a128e00a6fe6ef653c27d7082ff7</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.71%26sid%3Dliteratum%253Aachs%26aulast%3DPoland%26aufirst%3DB.%26aulast%3DHodge%26aufirst%3DF.%2BL.%26aulast%3DKahn%26aufirst%3DA.%26aulast%3DClemen%26aufirst%3DR.%2BT.%26aulast%3DWagnar%26aufirst%3DJ.%2BA.%26aulast%3DDykstra%26aufirst%3DK.%26aulast%3DKrishna%26aufirst%3DR.%26atitle%3DThe%2520clinical%2520utility%2520index%2520as%2520a%2520practical%2520multiattribute%2520approach%2520to%2520drug%2520development%2520decisions%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2009%26volume%3D86%26spage%3D105%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Sartori, V.; Steinmann, M.; Evers, M.; Jantzer, P.</span> Value-driven drug development – unlocking the value of your pipeline. McKinsey Quarterly,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.mckinsey.com/Search.aspx?q=sartori&amp;l=Insights%20%26%20Publications" class="extLink">http://www.mckinsey.com/Search.aspx?q=sartori&l=Insights%20%26%20Publications</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=V.+Sartori&author=M.+Steinmann&author=M.+Evers&author=P.+Jantzer&title=McKinsey+Quarterly"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DSartori%26aufirst%3DV.%26jtitle%3DMcKinsey%2520Quarterly%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Dykstra, K.; Hodge, L.; Poland, B.; Carrothers, T. J.</span> Methods for developing differentiated drug products. Pharsight,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span><a href="http://www.pharsight.com/library/Methods%20for%20Developing%20Differentiated%20Drug%20Products.pdf" class="extLink">http://www.pharsight.com/library/Methods%20for%20Developing%20Differentiated%20Drug%20Products.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Dykstra&author=L.+Hodge&author=B.+Poland&author=T.+J.+Carrothers&title=Pharsight"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3DDykstra%26aufirst%3DK.%26jtitle%3DPharsight%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Frye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juliano, E.</span><span> </span><span class="NLM_article-title">US academic drug discovery</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">410</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=409-410&author=S.+Fryeauthor=M.+Crosbyauthor=T.+Edwardsauthor=E.+Juliano&title=US+academic+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrye%26aufirst%3DS.%26aulast%3DCrosby%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DT.%26aulast%3DJuliano%26aufirst%3DE.%26atitle%3DUS%2520academic%2520drug%2520discovery%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D409%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Huryn, D. H.</span><span> </span><span class="NLM_article-title">Drug discovery in an academic setting: Playing to the strengths</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml400012g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=313-315&author=D.+H.+Huryn&title=Drug+discovery+in+an+academic+setting%3A+Playing+to+the+strengths"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fml400012g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400012g%26sid%3Dliteratum%253Aachs%26aulast%3DHuryn%26aufirst%3DD.%2BH.%26atitle%3DDrug%2520discovery%2520in%2520an%2520academic%2520setting%253A%2520Playing%2520to%2520the%2520strengths%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D313%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Prinz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlange, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asadullah, K.</span><span> </span><span class="NLM_article-title">Believe it or not: How much can we rely on published data on potential drug targets?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=713&author=F.+Prinzauthor=T.+Schlangeauthor=K.+Asadullah&title=Believe+it+or+not%3A+How+much+can+we+rely+on+published+data+on+potential+drug+targets%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPrinz%26aufirst%3DF.%26aulast%3DSchlange%26aufirst%3DT.%26aulast%3DAsadullah%26aufirst%3DK.%26atitle%3DBelieve%2520it%2520or%2520not%253A%2520How%2520much%2520can%2520we%2520rely%2520on%2520published%2520data%2520on%2520potential%2520drug%2520targets%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Silber, B. M.</span><span> </span><span class="NLM_article-title">Driving drug discovery: The fundamental role of academic labs</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">30cm16-1</span><span class="NLM_x">–</span> <span class="NLM_lpage">30cm16-6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1126%2Fscitranslmed.3000169" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=30cm16-1-30cm16-6&author=B.+M.+Silber&title=Driving+drug+discovery%3A+The+fundamental+role+of+academic+labs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000169%26sid%3Dliteratum%253Aachs%26aulast%3DSilber%26aufirst%3DB.%2BM.%26atitle%3DDriving%2520drug%2520discovery%253A%2520The%2520fundamental%2520role%2520of%2520academic%2520labs%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D30cm16-1%26epage%3D30cm16-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Huryn, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resnick, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wipf, P.</span><span> </span><span class="NLM_article-title">Contributions of academic laboratories to the discovery and development of chemical biology tools</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7161</span><span class="NLM_x">–</span> <span class="NLM_lpage">7176</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400132d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7161-7176&author=D.+H.+Hurynauthor=L.+O.+Resnickauthor=P.+Wipf&title=Contributions+of+academic+laboratories+to+the+discovery+and+development+of+chemical+biology+tools"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm400132d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400132d%26sid%3Dliteratum%253Aachs%26aulast%3DHuryn%26aufirst%3DD.%2BH.%26aulast%3DResnick%26aufirst%3DL.%2BO.%26aulast%3DWipf%26aufirst%3DP.%26atitle%3DContributions%2520of%2520academic%2520laboratories%2520to%2520the%2520discovery%2520and%2520development%2520of%2520chemical%2520biology%2520tools%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7161%26epage%3D7176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Kotz, J.</span><span> </span><span class="NLM_article-title">Small (molecule) thinking in academia</span> <span class="citation_source-journal">SciBX</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">4</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fscibx.2011.559" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=1-4&author=J.+Kotz&title=Small+%28molecule%29+thinking+in+academia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2Fscibx.2011.559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fscibx.2011.559%26sid%3Dliteratum%253Aachs%26aulast%3DKotz%26aufirst%3DJ.%26atitle%3DSmall%2520%2528molecule%2529%2520thinking%2520in%2520academia%26jtitle%3DSciBX%26date%3D2011%26volume%3D4%26spage%3D1%26epage%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Donatella, V.</span><span> </span><span class="NLM_article-title">Predictive methods as a powerful tool in drug discovery</span> <span class="citation_source-journal">Biochemica Medica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">318</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=314-318&author=V.+Donatella&title=Predictive+methods+as+a+powerful+tool+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDonatella%26aufirst%3DV.%26atitle%3DPredictive%2520methods%2520as%2520a%2520powerful%2520tool%2520in%2520drug%2520discovery%26jtitle%3DBiochemica%2520Medica%26date%3D2010%26volume%3D20%26spage%3D314%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-715&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Prentis, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, S. R.</span><span> </span><span class="NLM_article-title">Pharmaceutical innovation by the seven UK-owned pharmaceutical companies</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1111%2Fj.1365-2125.1988.tb03318.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=3358900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADyaL1c7ptlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1988&pages=387-396&author=R.+A.+Prentisauthor=Y.+Lisauthor=S.+R.+Walker&title=Pharmaceutical+innovation+by+the+seven+UK-owned+pharmaceutical+companies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)</span></div><div class="casAuthors">Prentis R A; Lis Y; Walker S R</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-96</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">1 A total of three hundred and nineteen new chemical entities (NCEs) were investigated in man for the first time between 1964 and 1985 by seven UK-owned pharmaceutical companies.  The majority (96.2%), were self-originated by the UK company or one of its overseas subsidiaries. 2 There was an increase in the number of NCEs investigated each year in man, doubling from an average of 12 per year up to 1980, to over 20 per year between 1981 and 1985.  The majority of first drug evaluations in human volunteers were carried out in the UK (92.2%), in contrast to evaluation of new medicines in patients, where 42.9% were first tested outside the UK. 3 The majority of NCEs evaluated in man (78%), were in four therapeutic classes: anti-infectives (32%), anti-allergics (22%), drugs acting on the central nervous system (13%) and cardiovascular system agents (11%). 4 By the end of 1985, 49 (15.4%) of these NCEs had been marketed in the UK and 198 (62.0%) discontinued from further development.  The main reasons for termination were inappropriate pharmacokinetics in man (39.4%), and lack of clinical efficacy (29.3%). 5 Average development times increased from less than 2 years between 1964 and 1965, to around 8 years in the 1980s with a consequent reduction in the effective patent life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa4QASkgAlyfx2phytoz6_fW6udTcc2eYNqhNB3veT37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c7ptlShtQ%253D%253D&md5=5648b42a95dca30156b601835fcaf1bd</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1988.tb03318.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1988.tb03318.x%26sid%3Dliteratum%253Aachs%26aulast%3DPrentis%26aufirst%3DR.%2BA.%26aulast%3DLis%26aufirst%3DY.%26aulast%3DWalker%26aufirst%3DS.%2BR.%26atitle%3DPharmaceutical%2520innovation%2520by%2520the%2520seven%2520UK-owned%2520pharmaceutical%2520companies%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1988%26volume%3D25%26spage%3D387%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Lapinski, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=P.+A.+Lapinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLapinski%26aufirst%3DP.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Res.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Gleeson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hersey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J.</span><span> </span><span class="NLM_article-title">Probing the links between in vitro potency, ADMET and physicochemical parameters</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fnrd3367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=21358739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=197-208&author=M.+P.+Gleesonauthor=A.+Herseyauthor=D.+Montanariauthor=J.+Overington&title=Probing+the+links+between+in+vitro+potency%2C+ADMET+and+physicochemical+parameters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the links between in vitro potency, ADMET and physicochemical parameters</span></div><div class="casAuthors">Gleeson, M. Paul; Hersey, Anne; Montanari, Dino; Overington, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-208</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  A common underlying assumption in current drug discovery strategies is that compds. with higher in vitro potency at their target(s) have greater potential to translate into successful, low-dose therapeutics.  This has led to the development of screening cascades with in vitro potency embedded as an early filter.  However, this approach is beginning to be questioned, given the bias in physicochem. properties that it can introduce early in lead generation and optimization, which is due to the often diametrically opposed relationship between physicochem. parameters assocd. with high in vitro potency and those assocd. with desirable absorption, distribution, metab., excretion and toxicity (ADMET) characteristics.  Here, we describe analyses that probe these issues further using the ChEMBL database, which includes more than 500,000 drug discovery and marketed oral drug compds.  Key findings include: first, that oral drugs seldom possess nanomolar potency (50 nM on av.); second, that many oral drugs have considerable off-target activity; and third, that in vitro potency does not correlate strongly with the therapeutic dose.  These findings suggest that the perceived benefit of high in vitro potency may be negated by poorer ADMET properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovOslFSgIkUbVg90H21EOLACvtfcHk0lhSK1IAVU_R-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFemsr8%253D&md5=e275044516e9b0245b71c9603477ef74</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnrd3367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3367%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DMontanari%26aufirst%3DD.%26aulast%3DOverington%26aufirst%3DJ.%26atitle%3DProbing%2520the%2520links%2520between%2520in%2520vitro%2520potency%252C%2520ADMET%2520and%2520physicochemical%2520parameters%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D197%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Shultz, M. D.</span><span> </span><span class="NLM_article-title">Setting expectations in molecular optimizations: strengths and limitations of commonly used composit parameters</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5980</span><span class="NLM_x">–</span> <span class="NLM_lpage">5991</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5980-5991&author=M.+D.+Shultz&title=Setting+expectations+in+molecular+optimizations%3A+strengths+and+limitations+of+commonly+used+composit+parameters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520expectations%2520in%2520molecular%2520optimizations%253A%2520strengths%2520and%2520limitations%2520of%2520commonly%2520used%2520composit%2520parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5980%26epage%3D5991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Kenny, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montanari, C. A.</span><span> </span><span class="NLM_article-title">Inflation of correlation in the pursuit of drug-likeness</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2Fs10822-012-9631-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=23306465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1SrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1-13&author=P.+W.+Kennyauthor=C.+A.+Montanari&title=Inflation+of+correlation+in+the+pursuit+of+drug-likeness"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Inflation of correlation in the pursuit of drug-likeness</span></div><div class="casAuthors">Kenny, Peter W.; Montanari, Carlos A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Drug-likeness is a frequently invoked, although not always precisely defined, concept in drug discovery.  Opinions on drug-likeness are to a large extent shaped by the relationships that are obsd. between surrogate measures of drug-likeness (e.g. aq. soly.; permeability; pharmacol. promiscuity) and fundamental physicochem. properties (e.g. lipophilicity; mol. size).  This article draws on examples from the literature to highlight approaches to data anal. that exaggerate trends in data and the term correlation inflation is introduced in the context of drug discovery.  Averaging groups of data points prior to anal. is a common cause of correlation inflation and results from anal. of binned continuous data should always be treated with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreGcOTh1EJCrVg90H21EOLACvtfcHk0lhSK1IAVU_R-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1SrtbY%253D&md5=e8542e2402b11cfb2fd98ae8a5185f46</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1007%2Fs10822-012-9631-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-012-9631-5%26sid%3Dliteratum%253Aachs%26aulast%3DKenny%26aufirst%3DP.%2BW.%26aulast%3DMontanari%26aufirst%3DC.%2BA.%26atitle%3DInflation%2520of%2520correlation%2520in%2520the%2520pursuit%2520of%2520drug-likeness%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2013%26volume%3D27%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Refsgaard, H. H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockhoff, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padkhaer, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buldbrandt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, M. S.</span><span> </span><span class="NLM_article-title">In silico prediction of membrane permeability from calculated molecular parameters</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">805</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049661n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=805-811&author=H.+H.+F.+Refsgaardauthor=B.+F.+Jensenauthor=P.+B.+Brockhoffauthor=S.+B.+Padkhaerauthor=M.+Buldbrandtauthor=M.+S.+Christensen&title=In+silico+prediction+of+membrane+permeability+from+calculated+molecular+parameters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjm049661n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049661n%26sid%3Dliteratum%253Aachs%26aulast%3DRefsgaard%26aufirst%3DH.%2BH.%2BF.%26aulast%3DJensen%26aufirst%3DB.%2BF.%26aulast%3DBrockhoff%26aufirst%3DP.%2BB.%26aulast%3DPadkhaer%26aufirst%3DS.%2BB.%26aulast%3DBuldbrandt%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DM.%2BS.%26atitle%3DIn%2520silico%2520prediction%2520of%2520membrane%2520permeability%2520from%2520calculated%2520molecular%2520parameters%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D805%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Peach, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaknarov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pugliese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallqlvist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicklaus, M. C.</span><span> </span><span class="NLM_article-title">Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1932</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.4155%2Ffmc.12.150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=23088273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCqtrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1907-1932&author=M.+L.+Peachauthor=A.+V.+Zaknarovauthor=R.+Liuauthor=A.+Puglieseauthor=G.+Tawaauthor=A.+Wallqlvistauthor=M.+C.+Nicklaus&title=Computational+tools+and+resources+for+metabolism-related+property+predictions.+1.+Overview+of+publicly+available+%28free+and+commercial%29+databases+and+software"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software</span></div><div class="casAuthors">Peach, Megan L.; Zakharov, Alexey V.; Liu, Ruifeng; Pugliese, Angelo; Tawa, Gregory; Wallqvist, Anders; Nicklaus, Marc C.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1907-1932</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Metab. has been identified as a defining factor in drug development success or failure because of its impact on many aspects of drug pharmacol., including bioavailability, half-life and toxicity.  In this article, we provide an outline and descriptions of the resources for metab.-related property predictions that are currently either freely or com. available to the public.  These resources include databases with data on, and software for prediction of, several end points: metabolite formation, sites of metabolic transformation, binding to metabolizing enzymes and metabolic stability.  We attempt to place each tool in historical context and describe, wherever possible, the data it was based on.  For predictions of interactions with metabolizing enzymes, we show a typical set of results for a small test set of compds.  Our aim is to give a clear overview of the areas and aspects of metab. prediction in which the currently available resources are useful and accurate, and the areas in which they are inadequate or missing entirely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlJNQ-tDEqYrVg90H21EOLACvtfcHk0lheIv9kohmtGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCqtrvP&md5=73a6e90caa7df9d457dde7eae3368e4c</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.150%26sid%3Dliteratum%253Aachs%26aulast%3DPeach%26aufirst%3DM.%2BL.%26aulast%3DZaknarov%26aufirst%3DA.%2BV.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DPugliese%26aufirst%3DA.%26aulast%3DTawa%26aufirst%3DG.%26aulast%3DWallqlvist%26aufirst%3DA.%26aulast%3DNicklaus%26aufirst%3DM.%2BC.%26atitle%3DComputational%2520tools%2520and%2520resources%2520for%2520metabolism-related%2520property%2520predictions.%25201.%2520Overview%2520of%2520publicly%2520available%2520%2528free%2520and%2520commercial%2529%2520databases%2520and%2520software%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1907%26epage%3D1932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">AbdulHameed, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhury, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sing, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallqvist, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawa, G. J.</span><span> </span><span class="NLM_article-title">Exploring polypharmacology using a ROCS-based target fishing approach</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">492</span><span class="NLM_x">–</span> <span class="NLM_lpage">505</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci2003544" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Oju7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=492-505&author=M.+D.+AbdulHameedauthor=S.+Chaudhuryauthor=N.+Singauthor=S.+H.+Wallqvistauthor=G.+J.+Tawa&title=Exploring+polypharmacology+using+a+ROCS-based+target+fishing+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring Polypharmacology Using a ROCS-Based Target Fishing Approach</span></div><div class="casAuthors">AbdulHameed, Mohamed Diwan M.; Chaudhury, Sidhartha; Singh, Narender; Sun, Hongmao; Wallqvist, Anders; Tawa, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">492-505</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. has emerged as a new theme in drug discovery.  In this paper, we studied polypharmacol. using a ligand-based target fishing (LBTF) protocol.  To implement the protocol, we first generated a chemogenomic database that links individual protein targets with a specified set of drugs or target representatives.  Target profiles were then generated for a given query mol. by computing maximal shape/chem. overlap between the query mol. and the drug sets assigned to each protein target.  The overlap was computed using the program ROCS (Rapid Overlay of Chem. Structures).  We validated this approach using the Directory of Useful Decoys (DUD).  DUD contains 2950 active compds., each with 36 property-matched decoys, against 40 protein targets.  We chose a set of known drugs to represent each DUD target, and we carried out ligand-based virtual screens using data sets of DUD actives seeded into DUD decoys for each target.  We computed Receiver Operator Characteristic (ROC) curves and assocd. area under the curve (AUC) values.  For the majority of targets studied, the AUC values were significantly better than for the case of a random selection of compds.  In a second test, the method successfully identified off-targets for drugs such as remantadine, propranolol, and domperidone that were consistent with those identified by recent expts.  The results from our ROCS-based target fishing approach are promising and have potential application in drug repurposing for single and multiple targets, identifying targets for orphan compds., and adverse effect prediction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlyFxT_WLxY7Vg90H21EOLACvtfcHk0lheIv9kohmtGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Oju7zN&md5=8158d3042eee891660426077bfdbe163</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fci2003544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2003544%26sid%3Dliteratum%253Aachs%26aulast%3DAbdulHameed%26aufirst%3DM.%2BD.%26aulast%3DChaudhury%26aufirst%3DS.%26aulast%3DSing%26aufirst%3DN.%26aulast%3DWallqvist%26aufirst%3DS.%2BH.%26aulast%3DTawa%26aufirst%3DG.%2BJ.%26atitle%3DExploring%2520polypharmacology%2520using%2520a%2520ROCS-based%2520target%2520fishing%2520approach%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D492%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Valerio, L. G.</span><span> </span><span class="NLM_article-title">In silico toxicology for the pharmaceutical sciences</span> <span class="citation_source-journal">Toxicol. Appl. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">241</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.taap.2009.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19716836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyrsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=241&publication_year=2009&pages=356-370&author=L.+G.+Valerio&title=In+silico+toxicology+for+the+pharmaceutical+sciences"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">In silico toxicology for the pharmaceutical sciences</span></div><div class="casAuthors">Valerio, Luis G.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">241</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">356-370</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The applied use of in silico technologies (a.k.a. computational toxicol., in silico toxicol., computer-assisted tox, e-tox, i-drug discovery, predictive ADME, etc.) for predicting preclin. toxicol. endpoints, clin. adverse effects, and metab. of pharmaceutical substances has become of high interest to the scientific community and the public.  The increased accessibility of these technologies for scientists and recent regulations permitting their use for chem. risk assessment supports this notion.  The scientific community is interested in the appropriate use of such technologies as a tool to enhance product development and safety of pharmaceuticals and other xenobiotics, while ensuring the reliability and accuracy of in silico approaches for the toxicol. and pharmacol. sciences.  For pharmaceutical substances, this means active and impurity chems. in the drug product may be screened using specialized software and databases designed to cover these substances through a chem. structure-based screening process and algorithm specific to a given software program.  A major goal for use of these software programs is to enable industry scientists not only to enhance the discovery process but also to ensure the judicious use of in silico tools to support risk assessments of drug-induced toxicities and in safety evaluations.  However, a great amt. of applied research is still needed, and there are many limitations with these approaches which are described in this review.  Currently, there is a wide range of endpoints available from predictive quant. structure-activity relationship models driven by many different computational software programs and data sources, and this is only expected to grow.  For example, there are models based on non-proprietary and/or proprietary information specific to assessing potential rodent carcinogenicity, in silico screens for ICH genetic toxicity assays, reproductive and developmental toxicity, theor. prediction of human drug metab., mechanisms of action for pharmaceuticals, and newer models for predicting human adverse effects.  How accurate are these approaches is both a statistical issue and challenge in toxicol.  In this review, fundamental concepts and the current capabilities and limitations of this technol. will be critically addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzkrrxfkNNVrVg90H21EOLACvtfcHk0lj4B73VxvhXuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyrsbvO&md5=70e08282b489f0472b9522bc2422aefb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2009.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2009.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DValerio%26aufirst%3DL.%2BG.%26atitle%3DIn%2520silico%2520toxicology%2520for%2520the%2520pharmaceutical%2520sciences%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2009%26volume%3D241%26spage%3D356%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Hewitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enoch, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madden, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearden, J. C.</span><span> </span><span class="NLM_article-title">In silico prediction of aqueous solubility: the solubility challenge</span> <span class="citation_source-journal">J Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2572</span><span class="NLM_x">–</span> <span class="NLM_lpage">2587</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci900286s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtleqtLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=2572-2587&author=M.+Hewittauthor=M.+T.+D.+Croninauthor=S.+J.+Enochauthor=J.+C.+Maddenauthor=D.+W.+Robertsauthor=J.+C.+Dearden&title=In+silico+prediction+of+aqueous+solubility%3A+the+solubility+challenge"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Prediction of Aqueous Solubility: The Solubility Challenge</span></div><div class="casAuthors">Hewitt, M.; Cronin, M. T. D.; Enoch, S. J.; Madden, J. C.; Roberts, D. W.; Dearden, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2572-2587</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The dissoln. of a chem. into water is a process fundamental to both chem. and biol.  The persistence of a chem. within the environment and the effects of a chem. within the body are dependent primarily upon aq. soly.  With the well-documented limitations hindering the accurate exptl. detn. of aq. soly., the utilization of predictive methods have been widely investigated and employed.  The setting of a soly. challenge by this journal proved an excellent opportunity to explore several different modeling methods, utilizing a supplied dataset of high-quality aq. soly. measurements.  Four contrasting approaches (simple linear regression, artificial neural networks, category formation, and available in silico models) were utilized within our lab. and the quality of these predictions was assessed.  These were chosen to span the multitude of modeling methods now in use, while also allowing for the evaluation of existing com. soly. models.  The conclusions of this study were surprising, in that a simple linear regression approach proved to be superior over more-complex modeling methods.  Possible explanations for this observation are discussed and also recommendations are made for future soly. prediction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuHCgKjzGtE7Vg90H21EOLACvtfcHk0lj4B73VxvhXuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtleqtLvE&md5=7983f8d3133655a4d8967d5b7e9fbdbd</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fci900286s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900286s%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DM.%26aulast%3DCronin%26aufirst%3DM.%2BT.%2BD.%26aulast%3DEnoch%26aufirst%3DS.%2BJ.%26aulast%3DMadden%26aufirst%3DJ.%2BC.%26aulast%3DRoberts%26aufirst%3DD.%2BW.%26aulast%3DDearden%26aufirst%3DJ.%2BC.%26atitle%3DIn%2520silico%2520prediction%2520of%2520aqueous%2520solubility%253A%2520the%2520solubility%2520challenge%26jtitle%3DJ%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D2572%26epage%3D2587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Davis, A. M.; Bruneau, P.</span><span> </span><span class="NLM_article-title">In silico prediction of solubility</span>. In:  <span class="citation_source-book">Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability</span>, <span class="NLM_edition">2</span>nd ed.; <span class="NLM_contrib-group">van de WaterBeemd, H.; Testa, B.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">40</span> , pp  <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=53-68&author=A.+M.+Davis&author=P.+Bruneauauthor=H.+van+de+WaterBeemd&author=B.+Testa&title=Drug+Bioavailability%3A+Estimation+of+Solubility%2C+Permeability%2C+Absorption+and+Bioavailability"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DA.%2BM.%26atitle%3DIn%2520silico%2520prediction%2520of%2520solubility%26btitle%3DDrug%2520Bioavailability%253A%2520Estimation%2520of%2520Solubility%252C%2520Permeability%252C%2520Absorption%2520and%2520Bioavailability%26aulast%3Dvan%2Bde%2BWaterBeemd%26aufirst%3DH.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2009%26volume%3D40%26spage%3D53%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Abad-Zapatero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, J. T.</span><span> </span><span class="NLM_article-title">Ligand efficiency indices as guideposts for drug discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">464</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FS1359-6446%2805%2903386-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=15809192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=464-469&author=C.+Abad-Zapateroauthor=J.+T.+Metz&title=Ligand+efficiency+indices+as+guideposts+for+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices as guideposts for drug discovery</span></div><div class="casAuthors">Abad-Zapatero Cele; Metz James T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">464-9</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHqVfZXUq224qdXsLcGTEUfW6udTcc2ebQbMT60qcR_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D&md5=1720f263a306122c86a57463e5a39287</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903386-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903386-6%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DMetz%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520efficiency%2520indices%2520as%2520guideposts%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D464%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eYvF2srDzA4Nrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Abad-Zapatero, C.</span> <span class="citation_source-book">Ligand Efficiency Indices for Drug Discovery: Towards an Atlas-Guided Paradigm</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">Boston, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=C.+Abad-Zapatero&title=Ligand+Efficiency+Indices+for+Drug+Discovery%3A+Towards+an+Atlas-Guided+Paradigm"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26btitle%3DLigand%2520Efficiency%2520Indices%2520for%2520Drug%2520Discovery%253A%2520Towards%2520an%2520Atlas-Guided%2520Paradigm%26pub%3DAcademic%2520Press%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St.-Gallay, S. A.</span><span> </span><span class="NLM_article-title">The influence of the ‘organizational factor’ on compound quality in drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=749-765&author=P.+D.+Leesonauthor=S.+A.+St.-Gallay&title=The+influence+of+the+%E2%80%98organizational+factor%E2%80%99+on+compound+quality+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSt.-Gallay%26aufirst%3DS.%2BA.%26atitle%3DThe%2520influence%2520of%2520the%2520%25E2%2580%2598organizational%2520factor%25E2%2580%2599%2520on%2520compound%2520quality%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D749%26epage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Perola, E.</span><span> </span><span class="NLM_article-title">An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2986</span><span class="NLM_x">–</span> <span class="NLM_lpage">2997</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100118x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2986-2997&author=E.+Perola&title=An+analysis+of+the+binding+efficiencies+of+drugs+and+their+leads+in+successful+drug+discovery+programs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">An Analysis of the Binding Efficiencies of Drugs and their Leads in Successful Drug Discovery Programs</span></div><div class="casAuthors">Perola, Emanuele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2986-2997</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to investigate the evolution of binding efficiency in successful drug discovery programs, a data set of 60 lead/drug pairs with known binding affinities has been compiled and analyzed.  Low-end thresholds for the binding efficiencies of viable leads and drugs have been derived.  On av., the drugs in the set are significantly larger and more potent but have similar lipophilicity relative to their originating leads, suggesting that the ability to maintain low levels of lipophilicity while increasing mol. wt. is one of the keys to a successful drug discovery program.  A no. of examples demonstrate that large increases in binding efficiency from leads to more elaborate drugs sharing the same scaffold can be achieved.  The importance of dissecting a lead structure to identify the most efficient fragments and the option of sacrificing binding efficiency to optimize other properties are discussed, and relevant examples are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRqzYFBuX2Q7Vg90H21EOLACvtfcHk0lhwRv8IOZCG_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlWqu7o%253D&md5=a7eaad792f1518d093588951df64d22f</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Fjm100118x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100118x%26sid%3Dliteratum%253Aachs%26aulast%3DPerola%26aufirst%3DE.%26atitle%3DAn%2520analysis%2520of%2520the%2520binding%2520efficiencies%2520of%2520drugs%2520and%2520their%2520leads%2520in%2520successful%2520drug%2520discovery%2520programs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2986%26epage%3D2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Oprea, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span> </span><span class="NLM_article-title">Is there a difference between leads and drugs? A historical perspective</span> <span class="citation_source-journal">J. Chem. Inf. Comput. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1308</span><span class="NLM_x">–</span> <span class="NLM_lpage">1315</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci010366a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Okt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=1308-1315&author=T.+I.+Opreaauthor=A.+D.+Davisauthor=S.+J.+Teagueauthor=P.+D.+Leeson&title=Is+there+a+difference+between+leads+and+drugs%3F+A+historical+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Is There a Difference between Leads and Drugs? A Historical Perspective</span></div><div class="casAuthors">Oprea, Tudor I.; Davis, Andrew M.; Teague, Simon J.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1308-1315</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To be considered for further development, lead structures should display the following properties: (1) simple chem. features, amenable for chem. optimization; (2) membership to an established SAR series; (3) favorable patent situation; and (4) good absorption, distribution, metab., and excretion (ADME) properties.  There are two distinct categories of leads: those that lack any therapeutic use (i.e., "pure" leads), and those that are marketed drugs themselves but have been altered to yield novel drugs.  We have previously analyzed the design of leadlike combinatorial libraries starting from 18 lead and drug pairs of structures (S. J. Teague et al. Angew. Chem., Int. Ed. Engl. 1999, 38, 3743-3748).  Here, we report results based on an extended dataset of 96 lead-drug pairs, of which 62 are lead structures that are not marketed as drugs, and 75 are drugs that are not presumably used as leads.  We examd. the following properties: MW (mol. wt.), CMR (the calcd. mol. refractivity), RNG (the no. of rings), RTB (the no. of rotatable bonds), the no. of hydrogen bond donors (HDO) and acceptors (HAC), the calcd. logarithm of the n-octanol/water partition (CLogP), the calcd. logarithm of the distribution coeff. at pH 7.4 (LogD74), the Daylight-fingerprint druglike score (DFPS), and the property and pharmacophore features score (PPFS).  The following differences were obsd. between the medians of drugs and leads: ΔMW = 69; ΔCMR = 1.8; ΔRNG = ΔHAC =1; ΔRTB = 2; ΔCLogP = 0.43; ΔLogD74 = 0.97; ΔHDO = 0; ΔDFPS = 0.15; ΔPPFS = 0.12.  Lead structures exhibit, on the av., less mol. complexity (less MW, less no. of rings and rotatable bonds), are less hydrophobic (lower CLogP and LogD74), and less druglike (lower druglike scores).  These findings indicate that the process of optimizing a lead into a drug results in more complex structures.  This information should be used in the design of novel combinatorial libraries that are aimed at lead discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG4E0R8n7tLrVg90H21EOLACvtfcHk0lhwRv8IOZCG_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Okt7s%253D&md5=422b9cf937168d9c2f3d1c8429648ea0</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fci010366a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci010366a%26sid%3Dliteratum%253Aachs%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DDavis%26aufirst%3DA.%2BD.%26aulast%3DTeague%26aufirst%3DS.%2BJ.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DIs%2520there%2520a%2520difference%2520between%2520leads%2520and%2520drugs%253F%2520A%2520historical%2520perspective%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2001%26volume%3D41%26spage%3D1308%26epage%3D1315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Shahzad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLachlan, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gault, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohrs, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wangb, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, G.</span><span> </span><span class="NLM_article-title">Global translational medicine initiatives and programs</span> <span class="citation_source-journal">Transl. Biomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=1-7&author=A.+Shahzadauthor=C.+S.+McLachlanauthor=J.+Gaultauthor=R.+J.+Cohrsauthor=X.+Wangbauthor=G.+Kohler&title=Global+translational+medicine+initiatives+and+programs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShahzad%26aufirst%3DA.%26aulast%3DMcLachlan%26aufirst%3DC.%2BS.%26aulast%3DGault%26aufirst%3DJ.%26aulast%3DCohrs%26aufirst%3DR.%2BJ.%26aulast%3DWangb%26aufirst%3DX.%26aulast%3DKohler%26aufirst%3DG.%26atitle%3DGlobal%2520translational%2520medicine%2520initiatives%2520and%2520programs%26jtitle%3DTransl.%2520Biomed.%26date%3D2011%26volume%3D2%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit115"><span>NIH Bench-to-Bedside Program Home Page. <a href="http://clinicalcenter.nih.gov/ccc/btb/" class="extLink">http://clinicalcenter.nih.gov/ccc/btb/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+Bench-to-Bedside+Program+Home+Page.+http%3A%2F%2Fclinicalcenter.nih.gov%2Fccc%2Fbtb%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargreaves, R.</span><span> </span><span class="NLM_article-title">Clinical biomarkers in drug discovery and development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=566-580&author=R.+Frankauthor=R.+Hargreaves&title=Clinical+biomarkers+in+drug+discovery+and+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DHargreaves%26aufirst%3DR.%26atitle%3DClinical%2520biomarkers%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D566%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Biomarkers Definitions Working Group</span><span> </span><span class="NLM_article-title">Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1067%2Fmcp.2001.113989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=11240971" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2001&pages=89-95&author=Biomarkers+Definitions+Working+Group&title=Biomarkers+and+surrogate+endpoints%3A+Preferred+definitions+and+conceptual+framework"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2001.113989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2001.113989%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DBiomarkers%2520and%2520surrogate%2520endpoints%253A%2520Preferred%2520definitions%2520and%2520conceptual%2520framework%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D69%26spage%3D89%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Strimbu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travel, J. A.</span><span> </span><span class="NLM_article-title">What are biomarkers?</span> <span class="citation_source-journal">Curr. Opin. HIV AIDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1097%2FCOH.0b013e32833ed177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=20978388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BC3cbisFSgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=463-466&author=K.+Strimbuauthor=J.+A.+Travel&title=What+are+biomarkers%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">What are biomarkers?</span></div><div class="casAuthors">Strimbu Kyle; Tavel Jorge A</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in HIV and AIDS</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">463-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  This article provides working definitions and a conceptual framework to understand the roles of biomarkers in clinical research.  RECENT FINDINGS:  The definitions of the terms discussed in this article--medical signs, symptoms, biomarkers, surrogate endpoints, clinical endpoints, validation--are still under discussion, as are their relationships to each other, but broad consensus has developed in the past decade and a half about the necessity of distinguishing between, in particular, surrogate and clinical endpoints.  SUMMARY:  This article outlines the major definitions of the key terms in this field and considers select cases in which misunderstandings about the terms led to flawed research conclusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTK-9zJcAGcuLt9HypzAgQfW6udTcc2eaEAUTsEdbHqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbisFSgtQ%253D%253D&md5=3884ee39f4923e3a592f7ead3551f4f4</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1097%2FCOH.0b013e32833ed177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0b013e32833ed177%26sid%3Dliteratum%253Aachs%26aulast%3DStrimbu%26aufirst%3DK.%26aulast%3DTravel%26aufirst%3DJ.%2BA.%26atitle%3DWhat%2520are%2520biomarkers%253F%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2010%26volume%3D5%26spage%3D463%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Day, M.; Rutkowski, J. L.; Feuerstein, G. Z.</span><span> </span><span class="NLM_article-title">Translational medicine – a paradigm shift in modern drug discovery and development: The role of biomarkers</span>. In  <span class="citation_source-book">Pharmaceutical Biotechnology: Advances in Experimental Biology and Medicine</span>; <span class="NLM_contrib-group">Guzman, C. A.; Feuerstein, G. Z.</span>, Eds.; <span class="NLM_publisher-name">Springer Verlag</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">655</span>, pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1007%2F978-1-4419-1132-2_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=1-12&author=M.+Day&author=J.+L.+Rutkowski&author=G.+Z.+Feuersteinauthor=C.+A.+Guzman&author=G.+Z.+Feuerstein&title=Pharmaceutical+Biotechnology%3A+Advances+in+Experimental+Biology+and+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1007%2F978-1-4419-1132-2_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4419-1132-2_1%26sid%3Dliteratum%253Aachs%26aulast%3DDay%26aufirst%3DM.%26atitle%3DTranslational%2520medicine%2520%25E2%2580%2593%2520a%2520paradigm%2520shift%2520in%2520modern%2520drug%2520discovery%2520and%2520development%253A%2520The%2520role%2520of%2520biomarkers%26btitle%3DPharmaceutical%2520Biotechnology%253A%2520Advances%2520in%2520Experimental%2520Biology%2520and%2520Medicine%26aulast%3DGuzman%26aufirst%3DC.%2BA.%26pub%3DSpringer%2520Verlag%26date%3D2009%26volume%3D655%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Lee, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farde, L.</span><span> </span><span class="NLM_article-title">Using positron emission tomography tro facilitate CNS drug development</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">310</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=310-316&author=C.-M.+Leeauthor=L.+Farde&title=Using+positron+emission+tomography+tro+facilitate+CNS+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.-M.%26aulast%3DFarde%26aufirst%3DL.%26atitle%3DUsing%2520positron%2520emission%2520tomography%2520tro%2520facilitate%2520CNS%2520drug%2520development%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D310%26epage%3D316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Kapur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zipursky, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remington, G.</span><span> </span><span class="NLM_article-title">Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=9989565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADyaK1M7kt1Kksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1999&pages=286-293&author=S.+Kapurauthor=R.+B.+Zipurskyauthor=G.+Remington&title=Clinical+and+theoretical+implications+of+5-HT2+and+D2+receptor+occupancy+of+clozapine%2C+risperidone+and+olanzapine+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia</span></div><div class="casAuthors">Kapur S; Zipursky R B; Remington G</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">286-93</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Dopamine D2 receptor occupancy measurements provide a valid predictor of antipsychotic response, extrapyramidal side effects, and elevation of prolactin levels.  The new antipsychotics clozapine, risperidone, and olanzapine obtain antipsychotic response with few extrapyramidal side effects and little prolactin elevation.  The purpose of this study was to compare the D2 and serotonin 5-HT2 receptor occupancies of these drugs in patients receiving multiple-dose, steady-state regimens.  METHOD:  Forty-four patients with schizophrenia (16 taking risperidone, 2-12 mg/day; 17 taking olanzapine, 5-60 mg/day; and 11 taking clozapine, 75-900 mg/day) had their D2 and 5-HT2 occupancies determined with the use of [11C]raclopride and [18F]setoperone, respectively, and positron emission tomography imaging.  RESULTS:  Clozapine showed a much lower D2 occupancy (16%-68%) than risperidone (63%-89%) and olanzapine (43%-89%).  Risperidone and olanzapine gave equal D2 occupancies at doses of 5 and 20 mg/day, respectively.  All three drugs showed greater 5-HT2 than D2 occupancy at all doses, although the difference was greatest for clozapine.  CONCLUSIONS:  Clozapine, at doses known to be effective in routine clinical settings, showed a D2 occupancy clearly lower than that of typical antipsychotics, while risperidone and olanzapine at their usual clinical doses gave the same level of D2 occupancy as low-dose typical antipsychotics.  The results also suggest that some previous clinical comparisons of antipsychotics may have been confounded by different levels of D2 occupancy.  Clinical comparisons of these drugs, matching for D2 occupancy, may provide a better measure of their true "atypicality" and will help in understanding the contribution of non-D2 receptors to antipsychotic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8__ZcHLPhBjW1zwg2yUK5fW6udTcc2eYkH0CL51XiVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7kt1Kksw%253D%253D&md5=30cdcea9c4ae28aa2e8a978635baa894</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DZipursky%26aufirst%3DR.%2BB.%26aulast%3DRemington%26aufirst%3DG.%26atitle%3DClinical%2520and%2520theoretical%2520implications%2520of%25205-HT2%2520and%2520D2%2520receptor%2520occupancy%2520of%2520clozapine%252C%2520risperidone%2520and%2520olanzapine%2520in%2520schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1999%26volume%3D156%26spage%3D286%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Chawla, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunburg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gralla, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesketh, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rittenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmer, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carides, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horgan, K. J.</span><span> </span><span class="NLM_article-title">Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">2290</span><span class="NLM_x">–</span> <span class="NLM_lpage">2300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2003&pages=2290-2300&author=S.+P.+Chawlaauthor=S.+Grunburgauthor=R.+J.+Grallaauthor=P.+J.+Heskethauthor=C.+Rittenbergauthor=M.+E.+Elmerauthor=C.+Schmidtauthor=A.+Taylorauthor=A.+D.+Caridesauthor=J.+K.+Evansauthor=K.+J.+Horgan&title=Establishing+the+dose+of+the+oral+NK1+antagonist+aprepitant+for+the+prevention+of+chemotherapy-induced+nausea+and+vomiting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChawla%26aufirst%3DS.%2BP.%26aulast%3DGrunburg%26aufirst%3DS.%26aulast%3DGralla%26aufirst%3DR.%2BJ.%26aulast%3DHesketh%26aufirst%3DP.%2BJ.%26aulast%3DRittenberg%26aufirst%3DC.%26aulast%3DElmer%26aufirst%3DM.%2BE.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DCarides%26aufirst%3DA.%2BD.%26aulast%3DEvans%26aufirst%3DJ.%2BK.%26aulast%3DHorgan%26aufirst%3DK.%2BJ.%26atitle%3DEstablishing%2520the%2520dose%2520of%2520the%2520oral%2520NK1%2520antagonist%2520aprepitant%2520for%2520the%2520prevention%2520of%2520chemotherapy-induced%2520nausea%2520and%2520vomiting%26jtitle%3DCancer%26date%3D2003%26volume%3D97%26spage%3D2290%26epage%3D2300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Keller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snavely, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargreaves, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hietala, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lines, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reines, S.</span><span> </span><span class="NLM_article-title">Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder</span> <span class="citation_source-journal">Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">216</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2Fj.biopsych.2005.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=16248986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlaqu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=216-223&author=M.+Kellerauthor=S.+Montgomeryauthor=W.+Ballauthor=M.+Morrisonauthor=D.+Snavelyauthor=G.+Liuauthor=R.+Hargreavesauthor=J.+Hietalaauthor=C.+Linesauthor=K.+Beebeauthor=S.+Reines&title=Lack+of+efficacy+of+the+substance+P+%28neurokinin1+receptor%29+antagonist+aprepitant+in+the+treatment+of+major+depressive+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder</span></div><div class="casAuthors">Keller, Martin; Montgomery, Stuart; Ball, William; Morrison, Mary; Snavely, Duane; Liu, Guanghan; Hargreaves, Richard; Hietala, Jarmo; Lines, Christopher; Beebe, Katherine; Reines, Scott</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-223</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">An early clin. trial suggested that the substance P (neurokinin1 receptor) antagonist, aprepitant, might provide a unique mechanism of antidepressant activity.  Phase III trials were conducted to confirm these findings.  Five 8-wk, randomized, double-blind, parallel-groups, placebo-controlled, multicenter trials in outpatients with Major Depressive Disorder were performed.  Aprepitant 160 mg and placebo were included in all trials.  Aprepitant 80 mg and paroxetine 20 mg (active comparator) were included in three trials.  Approx. 150 patients were enrolled per treatment group in each trial.  The primary end point was the mean change-from-baseline of the first 17 items of the Hamilton Rating Scale for Depression (HAM-D17) score at 8 wk.  A positron emission tomog. (PET) study was also performed in normal subjects to det. the relationship between neurokinin1 receptor occupancy and aprepitant plasma concns. in dosing regimens relevant to the trials.  No statistically significant differences from placebo on the HAM-D17 were obsd. at week 8 for either dose of aprepitant in any of the trials, whereas paroxetine 20 mg was significantly (p ≤ .05) more effective than placebo at week 8 in each of the three trials in which it was included.  Results from the PET study indicated that the aprepitant dosing regimens provided continuously high levels of neurokinin1 receptor blockade over 8 wk.  Because the methodol. employed confirmed the antidepressant efficacy of paroxetine, the absence of an effect for aprepitant indicates that it was not an effective treatment for depression.  The concept of neurokinin1 receptor antagonism as an antidepressant mechanism was not supported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9V3m5cxalq7Vg90H21EOLACvtfcHk0lhDieEOWOMMuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlaqu74%253D&md5=3b757ca50e7e72151af389acf17f94e2</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DS.%26aulast%3DBall%26aufirst%3DW.%26aulast%3DMorrison%26aufirst%3DM.%26aulast%3DSnavely%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DHargreaves%26aufirst%3DR.%26aulast%3DHietala%26aufirst%3DJ.%26aulast%3DLines%26aufirst%3DC.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DReines%26aufirst%3DS.%26atitle%3DLack%2520of%2520efficacy%2520of%2520the%2520substance%2520P%2520%2528neurokinin1%2520receptor%2529%2520antagonist%2520aprepitant%2520in%2520the%2520treatment%2520of%2520major%2520depressive%2520disorder%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D216%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Schirmer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calimia, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wenger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klauser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvarani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moncayo, R.</span><span> </span><span class="NLM_article-title"><sup>18</sup>F-fluorodeoxyglucose-positron emission topography: A new explorative perspective</span> <span class="citation_source-journal">Exp. Gerentol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">470</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1016%2FS0531-5565%2802%2900267-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=12670633" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=463-470&author=M.+Schirmerauthor=K.+T.+Calimiaauthor=M.+Wengerauthor=A.+Klauserauthor=C.+Salvaraniauthor=R.+Moncayo&title=18F-fluorodeoxyglucose-positron+emission+topography%3A+A+new+explorative+perspective"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2FS0531-5565%2802%2900267-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0531-5565%252802%252900267-X%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmer%26aufirst%3DM.%26aulast%3DCalimia%26aufirst%3DK.%2BT.%26aulast%3DWenger%26aufirst%3DM.%26aulast%3DKlauser%26aufirst%3DA.%26aulast%3DSalvarani%26aufirst%3DC.%26aulast%3DMoncayo%26aufirst%3DR.%26atitle%3D18F-fluorodeoxyglucose-positron%2520emission%2520topography%253A%2520A%2520new%2520explorative%2520perspective%26jtitle%3DExp.%2520Gerentol.%26date%3D2003%26volume%3D38%26spage%3D463%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Bhatnager, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hustinx, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alavi, A.</span><span> </span><span class="NLM_article-title">Nuclear imaging methods for non-invasive drug monitoring</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=41-54&author=A.+Bhatnagerauthor=R.+Hustinxauthor=A.+Alavi&title=Nuclear+imaging+methods+for+non-invasive+drug+monitoring"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBhatnager%26aufirst%3DA.%26aulast%3DHustinx%26aufirst%3DR.%26aulast%3DAlavi%26aufirst%3DA.%26atitle%3DNuclear%2520imaging%2520methods%2520for%2520non-invasive%2520drug%2520monitoring%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2000%26volume%3D41%26spage%3D41%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Aboagye, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, T.</span><span> </span><span class="NLM_article-title">In vivo pharmacokinetics and pharmacodynamics in drug development using positron emission topography</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=293-302&author=E.+O.+Aboagyeauthor=P.+M.+Priceauthor=T.+Jones&title=In+vivo+pharmacokinetics+and+pharmacodynamics+in+drug+development+using+positron+emission+topography"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DPrice%26aufirst%3DP.%2BM.%26aulast%3DJones%26aufirst%3DT.%26atitle%3DIn%2520vivo%2520pharmacokinetics%2520and%2520pharmacodynamics%2520in%2520drug%2520development%2520using%2520positron%2520emission%2520topography%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2001%26volume%3D6%26spage%3D293%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Taneja, S. S.</span><span> </span><span class="NLM_article-title">ProstaScint® scan: Contemporary use in clinical practice</span> <span class="citation_source-journal">Rev. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">S19</span><span class="NLM_x">–</span> <span class="NLM_lpage">S28</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=16985928" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=S19-S28&author=S.+S.+Taneja&title=ProstaScint%C2%AE+scan%3A+Contemporary+use+in+clinical+practice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaneja%26aufirst%3DS.%2BS.%26atitle%3DProstaScint%25C2%25AE%2520scan%253A%2520Contemporary%2520use%2520in%2520clinical%2520practice%26jtitle%3DRev.%2520Urol.%26date%3D2004%26volume%3D6%26spage%3DS19%26epage%3DS28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Schettino, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taneja, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabhan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepor, H.</span><span> </span><span class="NLM_article-title">Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer</span> <span class="citation_source-journal">Am. J. Roentgenol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.2214%2Fajr.183.2.1830519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD2czmsVagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2004&pages=519-524&author=C.+J.+Schettinoauthor=E.+L.+Kramerauthor=M.+E.+Noxauthor=S.+Tanejaauthor=P.+Padmanabhanauthor=H.+Lepor&title=Impact+of+fusion+of+indium-111+capromab+pendetide+volume+data+sets+with+those+from+MRI+or+CT+in+patients+with+recurrent+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer</span></div><div class="casAuthors">Schettino Chris J; Kramer Elissa L; Noz Marilyn E; Taneja Samir; Padmanabhan Priya; Lepor Herbert</div><div class="citationInfo"><span class="NLM_cas:title">AJR. American journal of roentgenology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">519-24</span>
        ISSN:<span class="NLM_cas:issn">0361-803X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Our goal was to evaluate the impact of image fusion on the interpretation of indium-111 Prosta-Scint SPECT scans.  MATERIALS AND METHODS:  Sixty-seven consecutive patients referred for rising prostate-specific antigen (PSA) levels after initial therapy for primary prostate cancer underwent SPECT 96 hr after infusion of (111)In Prosta-Scint, with simultaneous technetium-99m blood pool imaging.  Volume data sets from the SPECT scans were then fused with those from CT and MR images of the pelvis using a 3D landmark-based warping program.  The SPECT scans were initially interpreted without benefit of MRI or CT fusion.  The fused Prosta-Scint MRI-CT volumes were reevaluated by a nuclear radiologist and an MRI radiologist.  Independent reviews before and after fusion were available in these patients.  Validation of results after fusion was performed through correlation with PSA changes after radiation therapy.  RESULTS:  Six patients with sites that could not be evaluated and three without their original Prosta-Scint scanning reports were excluded; thus, 58 patients were studied clinically.  Seventy-four of 161 prefusion-positive sites were found to be negative after fusion.  These 74 sites subsequently were identified primarily as showing bowel, vessel, or marrow uptake after fusion.  In two patients, nodal disease was identified although the review before perfusion indicated none.  Twenty-five patients previously thought to have nodal disease appeared to have only local disease after fusion.  After local radiation therapy, PSA levels decreased in 12 of 25 patients, increased in five, and were unavailable in eight.  CONCLUSION:  Although Prosta-Scint SPECT alone can help in the proper management of recurrent prostate cancer, fusion with MRI-CT of the pelvis can improve the specificity of the examination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlMjqKVyHdC8jl5L8hwNX0fW6udTcc2eZv3WY_Cm3HWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czmsVagtA%253D%253D&md5=a4dced9a7901e17e009ef48fc51a66d3</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.2214%2Fajr.183.2.1830519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2214%252Fajr.183.2.1830519%26sid%3Dliteratum%253Aachs%26aulast%3DSchettino%26aufirst%3DC.%2BJ.%26aulast%3DKramer%26aufirst%3DE.%2BL.%26aulast%3DNox%26aufirst%3DM.%2BE.%26aulast%3DTaneja%26aufirst%3DS.%26aulast%3DPadmanabhan%26aufirst%3DP.%26aulast%3DLepor%26aufirst%3DH.%26atitle%3DImpact%2520of%2520fusion%2520of%2520indium-111%2520capromab%2520pendetide%2520volume%2520data%2520sets%2520with%2520those%2520from%2520MRI%2520or%2520CT%2520in%2520patients%2520with%2520recurrent%2520prostate%2520cancer%26jtitle%3DAm.%2520J.%2520Roentgenol.%26date%3D2004%26volume%3D183%26spage%3D519%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Krishna, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nerman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J. A.</span><span> </span><span class="NLM_article-title">Accellerating drug development using biomarkers: A case study with sitagliptin, a novel DPP4 inhibior for type 2 diabetes</span> <span class="citation_source-journal">AAPS J</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=401-409&author=R.+Krishnaauthor=G.+Nermanauthor=J.+A.+Wagner&title=Accellerating+drug+development+using+biomarkers%3A+A+case+study+with+sitagliptin%2C+a+novel+DPP4+inhibior+for+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrishna%26aufirst%3DR.%26aulast%3DNerman%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DJ.%2BA.%26atitle%3DAccellerating%2520drug%2520development%2520using%2520biomarkers%253A%2520A%2520case%2520study%2520with%2520sitagliptin%252C%2520a%2520novel%2520DPP4%2520inhibior%2520for%2520type%25202%2520diabetes%26jtitle%3DAAPS%2520J%26date%3D2008%26volume%3D10%26spage%3D401%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Velonas, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dos Remedios, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assinder, S. J.</span><span> </span><span class="NLM_article-title">Current status of biomarkers for prostate cancer</span> <span class="citation_source-journal">Int. J. Mol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">11034</span><span class="NLM_x">–</span> <span class="NLM_lpage">11060</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.3390%2Fijms140611034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=23708103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2jsbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=11034-11060&author=V.+M.+Velonasauthor=H.+H.+Wooauthor=C.+G.+dos+Remediosauthor=S.+J.+Assinder&title=Current+status+of+biomarkers+for+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of biomarkers for prostate cancer</span></div><div class="casAuthors">Velonas, Vicki M.; Woo, Henry H.; dos Remedios, Cristobal G.; Assinder, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">11034-11060, 27 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Prostate cancer (PCa) is a leading cause of cancer-related death of men globally.  Since its introduction, there has been intense debate as to the effectiveness of the prostate specific antigen (PSA) test as a screening tool for PCa.  It is now evident that the PSA test produces unacceptably high rates of false pos. results and is not prognostic.  Here we review the current status of mol. biomarkers that promise to be prognostic and that might inform individual patient management.  It highlights current efforts to identify biomarkers obtained by minimally invasive methods and discusses current knowledge with regard to gene fusions, mRNA and microRNAs, immunol., and cancer-assocd. microparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsPVUX_K_4rVg90H21EOLACvtfcHk0ljcEEekdXPVsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2jsbbI&md5=bae975612dcef03909f95d5313a56ab6</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.3390%2Fijms140611034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms140611034%26sid%3Dliteratum%253Aachs%26aulast%3DVelonas%26aufirst%3DV.%2BM.%26aulast%3DWoo%26aufirst%3DH.%2BH.%26aulast%3Ddos%2BRemedios%26aufirst%3DC.%2BG.%26aulast%3DAssinder%26aufirst%3DS.%2BJ.%26atitle%3DCurrent%2520status%2520of%2520biomarkers%2520for%2520prostate%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D11034%26epage%3D11060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit131"><span>Guidance for Industry: S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. U.S. Food and Drug Administration, Oct<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span><a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074963.pdf" class="extLink">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074963.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Guidance+for+Industry%3A+S7B+nonclinical+evaluation+of+the+potential+for+delayed+ventricular+repolarization+%28QT+interval+prolongation%29+by+human+pharmaceuticals.+U.S.+Food+and+Drug+Administration%2C+Oct+2005%3B+http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fucm074963.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Hampel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broich, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teipel, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herholz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokde, A. L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoessler, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanhai, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterberg, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodcock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blennow, K.</span><span> </span><span class="NLM_article-title">Biomarkers for Alzheimer’s disease: academic industry and regulatory perspectives</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">574</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=560-574&author=H.+Hampelauthor=R.+Frankauthor=K.+Broichauthor=S.+J.+Teipelauthor=R.+G.+Katzauthor=J.+Hardyauthor=K.+Herholzauthor=A.+L.+W.+Bokdeauthor=F.+Jessenauthor=Y.+C.+Hoesslerauthor=W.+R.+Sanhaiauthor=H.+Zetterbergauthor=J.+Woodcockauthor=K.+Blennow&title=Biomarkers+for+Alzheimer%E2%80%99s+disease%3A+academic+industry+and+regulatory+perspectives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHampel%26aufirst%3DH.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DBroich%26aufirst%3DK.%26aulast%3DTeipel%26aufirst%3DS.%2BJ.%26aulast%3DKatz%26aufirst%3DR.%2BG.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DHerholz%26aufirst%3DK.%26aulast%3DBokde%26aufirst%3DA.%2BL.%2BW.%26aulast%3DJessen%26aufirst%3DF.%26aulast%3DHoessler%26aufirst%3DY.%2BC.%26aulast%3DSanhai%26aufirst%3DW.%2BR.%26aulast%3DZetterberg%26aufirst%3DH.%26aulast%3DWoodcock%26aufirst%3DJ.%26aulast%3DBlennow%26aufirst%3DK.%26atitle%3DBiomarkers%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520academic%2520industry%2520and%2520regulatory%2520perspectives%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D560%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Rosen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blennow, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zetterberg, H.</span><span> </span><span class="NLM_article-title">Fluid biomarkers in Alzheimer’s disease – current concepts</span> <span class="citation_source-journal">Mol. Neurodegener.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">20-1</span><span class="NLM_x">–</span> <span class="NLM_lpage">20-11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1186%2F1750-1326-8-20" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=20-1-20-11&author=C.+Rosenauthor=O.+Hanssonauthor=K.+Blennowauthor=H.+Zetterberg&title=Fluid+biomarkers+in+Alzheimer%E2%80%99s+disease+%E2%80%93+current+concepts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1186%2F1750-1326-8-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1750-1326-8-20%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DC.%26aulast%3DHansson%26aufirst%3DO.%26aulast%3DBlennow%26aufirst%3DK.%26aulast%3DZetterberg%26aufirst%3DH.%26atitle%3DFluid%2520biomarkers%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520%25E2%2580%2593%2520current%2520concepts%26jtitle%3DMol.%2520Neurodegener.%26date%3D2013%26volume%3D8%26spage%3D20-1%26epage%3D20-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Ravine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurlan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascherio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galpem, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoulson, I.</span><span> </span><span class="NLM_article-title">Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease</span> <span class="citation_source-journal">Mov. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1392</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=1392-1397&author=B.+Ravineauthor=K.+Marekauthor=S.+Eberlyauthor=D.+Oakesauthor=R.+Kurlanauthor=A.+Ascherioauthor=F.+Bealauthor=J.+Beckauthor=E.+Flaggauthor=W.+R.+Galpemauthor=J.+Harmanauthor=A.+E.+Langauthor=M.+Schwarzschildauthor=C.+Tannerauthor=I.+Shoulson&title=Dopamine+transporter+imaging+is+associated+with+long-term+outcomes+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRavine%26aufirst%3DB.%26aulast%3DMarek%26aufirst%3DK.%26aulast%3DEberly%26aufirst%3DS.%26aulast%3DOakes%26aufirst%3DD.%26aulast%3DKurlan%26aufirst%3DR.%26aulast%3DAscherio%26aufirst%3DA.%26aulast%3DBeal%26aufirst%3DF.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DFlagg%26aufirst%3DE.%26aulast%3DGalpem%26aufirst%3DW.%2BR.%26aulast%3DHarman%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DSchwarzschild%26aufirst%3DM.%26aulast%3DTanner%26aufirst%3DC.%26aulast%3DShoulson%26aufirst%3DI.%26atitle%3DDopamine%2520transporter%2520imaging%2520is%2520associated%2520with%2520long-term%2520outcomes%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2012%26volume%3D27%26spage%3D1392%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Hong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesking, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jankovic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabetian, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverenz, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, U. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span> </span><span class="NLM_article-title">DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease</span> <span class="citation_source-journal">Brain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">713</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2010&pages=713-726&author=Z.+Hongauthor=M.+Shiauthor=K.+A.+Chungauthor=J.+F.+Quinnauthor=E.+R.+Peskingauthor=D.+Galaskoauthor=J.+Jankovicauthor=C.+P.+Zabetianauthor=J.+B.+Leverenzauthor=G.+Bairdauthor=T.+J.+Montineauthor=A.+M.+Hancockauthor=J.+Hwangauthor=C.+Panauthor=J.+Bradnerauthor=U.+J.+Kangauthor=P.+H.+Jensenauthor=J.+Zhang&title=DJ-1+and+%CE%B1-synuclein+in+human+cerebrospinal+fluid+as+biomarkers+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DK.%2BA.%26aulast%3DQuinn%26aufirst%3DJ.%2BF.%26aulast%3DPesking%26aufirst%3DE.%2BR.%26aulast%3DGalasko%26aufirst%3DD.%26aulast%3DJankovic%26aufirst%3DJ.%26aulast%3DZabetian%26aufirst%3DC.%2BP.%26aulast%3DLeverenz%26aufirst%3DJ.%2BB.%26aulast%3DBaird%26aufirst%3DG.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DHancock%26aufirst%3DA.%2BM.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DC.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DU.%2BJ.%26aulast%3DJensen%26aufirst%3DP.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DDJ-1%2520and%2520%25CE%25B1-synuclein%2520in%2520human%2520cerebrospinal%2520fluid%2520as%2520biomarkers%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DBrain%26date%3D2010%26volume%3D133%26spage%3D713%26epage%3D726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albanell, J.</span><span> </span><span class="NLM_article-title">Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2825</span><span class="NLM_x">–</span> <span class="NLM_lpage">2831</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=2825-2831&author=J.+Baselgaauthor=L.+Nortonauthor=J.+Albanell&title=Recombinant+humanized+anti-HER-2+antibody+%28Herceptin%29+enhances+the+antitumor+activity+of+paclitaxel+and+doxorubicin+against+HER2%2Fneu+overexpressing+human+breast+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DAlbanell%26aufirst%3DJ.%26atitle%3DRecombinant%2520humanized%2520anti-HER-2%2520antibody%2520%2528Herceptin%2529%2520enhances%2520the%2520antitumor%2520activity%2520of%2520paclitaxel%2520and%2520doxorubicin%2520against%2520HER2%252Fneu%2520overexpressing%2520human%2520breast%2520cancer%2520xenografts%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D2825%26epage%3D2831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Schilsky, R. L.</span><span> </span><span class="NLM_article-title">Personalized medicine in oncology: The future is now</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">363</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=363-366&author=R.+L.+Schilsky&title=Personalized+medicine+in+oncology%3A+The+future+is+now"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchilsky%26aufirst%3DR.%2BL.%26atitle%3DPersonalized%2520medicine%2520in%2520oncology%253A%2520The%2520future%2520is%2520now%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D363%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Chiang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Million, R. P.</span><span> </span><span class="NLM_article-title">Personalized medicine in oncology: Next generation</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">895</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=895-896&author=A.+Chiangauthor=R.+P.+Million&title=Personalized+medicine+in+oncology%3A+Next+generation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChiang%26aufirst%3DA.%26aulast%3DMillion%26aufirst%3DR.%2BP.%26atitle%3DPersonalized%2520medicine%2520in%2520oncology%253A%2520Next%2520generation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D895%26epage%3D896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Sadigh-Eteghad, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talebi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farhoudi, M.</span><span> </span><span class="NLM_article-title">Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer’s disease. A meta-analysis</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=321-326&author=S.+Sadigh-Eteghadauthor=M.+Talebiauthor=M.+Farhoudi&title=Association+of+apolipoprotein+E+epsilon+4+allele+with+sporadic+late+onset+Alzheimer%E2%80%99s+disease.+A+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSadigh-Eteghad%26aufirst%3DS.%26aulast%3DTalebi%26aufirst%3DM.%26aulast%3DFarhoudi%26aufirst%3DM.%26atitle%3DAssociation%2520of%2520apolipoprotein%2520E%2520epsilon%25204%2520allele%2520with%2520sporadic%2520late%2520onset%2520Alzheimer%25E2%2580%2599s%2520disease.%2520A%2520meta-analysis%26jtitle%3DNeuroscience%26date%3D2012%26volume%3D17%26spage%3D321%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Harrison, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberger, D.</span><span> </span><span class="NLM_article-title">Schizophrenia genes, gene expression and neuropathology: on the matter of their convergence</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1038%2Fsj.mp.4001558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=15263907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=40-68&author=P.+Harrisonauthor=D.+Weinberger&title=Schizophrenia+genes%2C+gene+expression+and+neuropathology%3A+on+the+matter+of+their+convergence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence</span></div><div class="casAuthors">Harrison, P. J.; Weinberger, D. R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-68</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This review critically summarizes the neuropathol. and genetics of schizophrenia, the relationship between them, and speculates on their functional convergence.  The morphol. correlates of schizophrenia are subtle, and range from a slight redn. in brain size to localized alterations in the morphol. and mol. compn. of specific neuronal, synaptic, and glial populations in the hippocampus, dorsolateral prefrontal cortex, and dorsal thalamus.  These findings have fostered the view of schizophrenia as a disorder of connectivity and of the synapse.  Although attractive, such concepts are vague, and differentiating primary events from epiphenomena has been difficult.  A way forward is provided by the recent identification of several putative susceptibility genes (including neuregulin, dysbindin, COMT, DISC1, RGS4, GRM3, and G72).  We discuss the evidence for these and other genes, along with what is known of their expression profiles and biol. roles in brain and how these may be altered in schizophrenia.  The evidence for several of the genes is now strong.  However, for none, with the likely exception of COMT, has a causative allele or the mechanism by which it predisposes to schizophrenia been identified.  Nevertheless, we speculate that the genes may all converge functionally upon schizophrenia risk via an influence upon synaptic plasticity and the development and stabilization of cortical microcircuitry.  NMDA receptor-mediated glutamate transmission may be esp. implicated, though there are also direct and indirect links to dopamine and GABA signaling.  Hence, there is a correspondence between the putative roles of the genes at the mol. and synaptic levels and the existing understanding of the disorder at the neural systems level.  Characterization of a core mol. pathway and a genetic cytoarchitecture' would be a profound advance in understanding schizophrenia, and may have equally significant therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEeG0dw3pqdbVg90H21EOLACvtfcHk0lgQN3q15Kf93A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFeisL3N&md5=6e69aab6f45644278ca29a89ea03724a</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4001558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4001558%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DP.%26aulast%3DWeinberger%26aufirst%3DD.%26atitle%3DSchizophrenia%2520genes%252C%2520gene%2520expression%2520and%2520neuropathology%253A%2520on%2520the%2520matter%2520of%2520their%2520convergence%26jtitle%3DMol.%2520Psychiatry%26date%3D2005%26volume%3D10%26spage%3D40%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Abou-Gharbia, M. A.; Childers, W. E.</span><span> </span><span class="NLM_article-title">The discovery of Effexor® and Pristiq®</span>. In  <span class="citation_source-book">Analogue-Based Drug Discovery II</span>; <span class="NLM_contrib-group">Fischer, J.; Ganellin, C. R.</span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1002%2F9783527630035.ch21" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=507-524&author=M.+A.+Abou-Gharbia&author=W.+E.+Childersauthor=J.+Fischer&author=C.+R.+Ganellin&title=Analogue-Based+Drug+Discovery+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2F9783527630035.ch21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527630035.ch21%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%2BA.%26atitle%3DThe%2520discovery%2520of%2520Effexor%25C2%25AE%2520and%2520Pristiq%25C2%25AE%26btitle%3DAnalogue-Based%2520Drug%2520Discovery%2520II%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%26date%3D2010%26spage%3D507%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Nelson, J. C.</span><span> </span><span class="NLM_article-title">Managing treatment-resistant major depression</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.4088%2FJCP.v64n0301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=12625799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1Wqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=5-12&author=J.+C.+Nelson&title=Managing+treatment-resistant+major+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Managing treatment-resistant major depression</span></div><div class="casAuthors">Nelson, J. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Psychiatry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">5-12</span>CODEN:
                <span class="NLM_cas:coden">JCLPDE</span>;
        ISSN:<span class="NLM_cas:issn">0160-6689</span>.
    
            (<span class="NLM_cas:orgname">Physicians Postgraduate Press, Inc.</span>)
        </div><div class="casAbstract">A review.  A sizable proportion of patients suffering from nonpsychotic unipolar depression experience only partial or no clin. response to antidepressant treatment.  Switching, augmenting, and combining various pharmaceutical agents can be effective strategies for patients with treatment-resistant depression.  The empirical evidence supporting these approaches is inconsistent, however, and there is a paucity of controlled studies to support their efficacy.  Addnl., it has been difficult to demonstrate the advantages of these strategies over increasing the dose or duration of the initial drug treatment.  This article will review available evidence and clin. considerations regarding switching, augmenting, and combining various agents in the treatment of patients suffering from nonpsychotic unipolar depression who have failed adequate courses of antidepressant treatment.  More research is needed that controls for continued time on the initial agent, that compares different strategies, and that dets. which patients are the best candidates for which treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN5ZLGjxOZQLVg90H21EOLACvtfcHk0lipdLNKpgSvbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1Wqtrk%253D&md5=4184177f5193d20a0134cc7387786033</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.4088%2FJCP.v64n0301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.v64n0301%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DJ.%2BC.%26atitle%3DManaging%2520treatment-resistant%2520major%2520depression%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2003%26volume%3D64%26spage%3D5%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Deecher, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andree, T. H.</span><span> </span><span class="NLM_article-title">Desvenlavaxine succinate: a new serotonin and norepinephrine reuptake inhibitor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1124%2Fjpet.106.103382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=16675639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslOlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2006&pages=657-665&author=D.+C.+Deecherauthor=C.+E.+Beyerauthor=G.+Johnstonauthor=J.+Brayauthor=S.+Shahauthor=M.+Abou-Gharbiaauthor=T.+H.+Andree&title=Desvenlavaxine+succinate%3A+a+new+serotonin+and+norepinephrine+reuptake+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor</span></div><div class="casAuthors">Deecher, Darlene C.; Beyer, Chad E.; Johnston, Grace; Bray, Jenifer; Shah, S.; Abou-Gharbia, M.; Andree, Terrance H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">657-665</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The purpose of this study was to characterize a new chem. entity, desvenlafaxine succinate (DVS).  DVS is a novel salt form of the isolated major active metabolite of venlafaxine.  Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with Ki values for DVS of 40.2±1.6 and 558.4±121.6 nM, resp.  DVS showed weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter.  Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3±19.4 and 531.3±113.0 nM, resp.  DVS (10 μM), examd. at a large no. of nontransporter targets, showed no significant activity.  DVS (30 mg/kg orally) rapidly penetrated the male rat brain and hypothalamus.  DVS (30 mg/kg orally) significantly increased extracellular NE levels compared with baseline in the male rat hypothalamus but had no effect on DA levels using microdialysis.  To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory 5-HT1A autoreceptors, a 5-HT1A antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.), was administered with DVS (30 mg/kg orally).  5-HT increased 78% compared with baseline with no addnl. increase in NE or DA levels.  In conclusion, DVS is a new 5-HT and NE reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios, suggesting utility in a variety of central nervous system-related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkQZEaoTYCvrVg90H21EOLACvtfcHk0lipdLNKpgSvbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslOlsbw%253D&md5=3aee610641ebcc865d849d7e400f1ea5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.103382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.103382%26sid%3Dliteratum%253Aachs%26aulast%3DDeecher%26aufirst%3DD.%2BC.%26aulast%3DBeyer%26aufirst%3DC.%2BE.%26aulast%3DJohnston%26aufirst%3DG.%26aulast%3DBray%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26atitle%3DDesvenlavaxine%2520succinate%253A%2520a%2520new%2520serotonin%2520and%2520norepinephrine%2520reuptake%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D318%26spage%3D657%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Yardley, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husbands, G. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bicksler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muth, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andree, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, H. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleleck, A. R.</span><span> </span><span class="NLM_article-title">2-Phenyl-2-(1-hydroxycycloalkyl)ethyl)amine derivatives: Synthesis and antidepressant activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2899</span><span class="NLM_x">–</span> <span class="NLM_lpage">2905</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00172a035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=2899-2905&author=J.+P.+Yardleyauthor=G.+E.+M.+Husbandsauthor=G.+Stackauthor=J.+Butchauthor=J.+Bickslerauthor=J.+A.+Moyerauthor=E.+A.+Muthauthor=T.+Andreeauthor=H.+F.+Fletcherauthor=M.+N.+G.+Jamesauthor=A.+R.+Sleleck&title=2-Phenyl-2-%281-hydroxycycloalkyl%29ethyl%29amine+derivatives%3A+Synthesis+and+antidepressant+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fjm00172a035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00172a035%26sid%3Dliteratum%253Aachs%26aulast%3DYardley%26aufirst%3DJ.%2BP.%26aulast%3DHusbands%26aufirst%3DG.%2BE.%2BM.%26aulast%3DStack%26aufirst%3DG.%26aulast%3DButch%26aufirst%3DJ.%26aulast%3DBicksler%26aufirst%3DJ.%26aulast%3DMoyer%26aufirst%3DJ.%2BA.%26aulast%3DMuth%26aufirst%3DE.%2BA.%26aulast%3DAndree%26aufirst%3DT.%26aulast%3DFletcher%26aufirst%3DH.%2BF.%26aulast%3DJames%26aufirst%3DM.%2BN.%2BG.%26aulast%3DSleleck%26aufirst%3DA.%2BR.%26atitle%3D2-Phenyl-2-%25281-hydroxycycloalkyl%2529ethyl%2529amine%2520derivatives%253A%2520Synthesis%2520and%2520antidepressant%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D2899%26epage%3D2905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Preskorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patroneva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isler, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burczynski, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, A. I.</span><span> </span><span class="NLM_article-title">Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers</span> <span class="citation_source-journal">J. Clin. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1097%2FJCP.0b013e318192e4c1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19142106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FmvFOmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=39-43&author=S.+Preskornauthor=A.+Patronevaauthor=H.+Silmanauthor=Q.+Jiangauthor=J.+A.+Islerauthor=M.+E.+Burczynskiauthor=S.+Ahmedauthor=J.+Paulauthor=A.+I.+Nichols&title=Comparison+of+the+pharmacokinetics+of+venlafaxine+extended+release+and+desvenlafaxine+in+extensive+and+poor+cytochrome+P450+2D6+metabolizers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers</span></div><div class="casAuthors">Preskorn Sheldon; Patroneva Albena; Silman Heather; Jiang Qin; Isler Jennifer A; Burczynski Michael E; Ahmed Saeeduddin; Paul Jeffrey; Nichols Alice I</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical psychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The goal of this study was to evaluate the impact of cytochrome P450 2D6 extensive metabolizer (EM) or poor metabolizer (PM) status on the pharmacokinetics of single doses of venlafaxine extended release (ER) and desvenlafaxine (administered as desvenlafaxine succinate) in healthy adults.  METHODS:  In an open-label, crossover study, 14 healthy volunteers (aged 18-55 years; 7 EMs and 7 PMs) received, in randomized sequence, single doses of venlafaxine ER 75 mg/d or desvenlafaxine 100 mg/d.  Cytochrome P450 2D6 genotyping was performed, and plasma drug levels were measured.  The arithmetic means and standard deviation (SD) for area under the plasma concentration-versus-time curve (AUC) and peak plasma concentration (Cmax) were calculated.  Comparisons of AUC and Cmax between cytochrome P450 2D6 EMs and PMs were calculated using a Wilcoxon exact test.  RESULTS:  After administration of venlafaxine ER, mean Cmax and AUC of venlafaxine were significantly greater in PMs compared with EMs, whereas mean Cmax and AUC of its metabolite, desvenlafaxine, were significantly lower for PMs than for EMs (P = 0.001, all comparisons).  In contrast, mean Cmax and AUC of desvenlafaxine after administration of desvenlafaxine were comparable between EMs and PMs.  CONCLUSIONS:  Cytochrome P450 2D6 genetic polymorphisms had no discernible impact on exposure to desvenlafaxine after desvenlafaxine administration; in contrast, compared with an EM phenotype, a PM phenotype had a significant effect on venlafaxine and desvenlafaxine plasma concentrations after venlafaxine ER administration.  This reduced pharmacokinetic variability of desvenlafaxine may translate into better uniformity of response for patients receiving desvenlafaxine versus venlafaxine, but additional studies are required to test this hypothesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYAEo4W4qorty3lHz94U-GfW6udTcc2ea55cc9Njrn7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FmvFOmsw%253D%253D&md5=abea14db55147faaa9e2a0f2fc57cb63</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1097%2FJCP.0b013e318192e4c1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJCP.0b013e318192e4c1%26sid%3Dliteratum%253Aachs%26aulast%3DPreskorn%26aufirst%3DS.%26aulast%3DPatroneva%26aufirst%3DA.%26aulast%3DSilman%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DIsler%26aufirst%3DJ.%2BA.%26aulast%3DBurczynski%26aufirst%3DM.%2BE.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DA.%2BI.%26atitle%3DComparison%2520of%2520the%2520pharmacokinetics%2520of%2520venlafaxine%2520extended%2520release%2520and%2520desvenlafaxine%2520in%2520extensive%2520and%2520poor%2520cytochrome%2520P450%25202D6%2520metabolizers%26jtitle%3DJ.%2520Clin.%2520Psychopharmacol.%26date%3D2009%26volume%3D29%26spage%3D39%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span> </span><span class="NLM_article-title">Discovery of innovative small molecule therapeutics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8012823" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2-9&author=M.+Abou-Gharbia&title=Discovery+of+innovative+small+molecule+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm8012823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012823%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520innovative%2520small%2520molecule%2520therapeutics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Childers, W.</span><span> </span><span class="NLM_article-title">Targeting neurodegenerative diseases: Drug discovery in a challenging arena</span> <span class="citation_source-journal">Pure Appl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1543</span><span class="NLM_x">–</span> <span class="NLM_lpage">1556</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=1543-1556&author=M.+Abou-Gharbiaauthor=W.+Childers&title=Targeting+neurodegenerative+diseases%3A+Drug+discovery+in+a+challenging+arena"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DChilders%26aufirst%3DW.%26atitle%3DTargeting%2520neurodegenerative%2520diseases%253A%2520Drug%2520discovery%2520in%2520a%2520challenging%2520arena%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D2012%26volume%3D84%26spage%3D1543%26epage%3D1556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Graziani, E. I.</span><span> </span><span class="NLM_article-title">Uncoupling neuroprotection from immunosuppression: The discovery of ILS-920</span>. In  <span class="citation_source-book">Accounts in Drug Discovery</span>; <span class="NLM_contrib-group">Barrish, J. C.; Carter, P. H.; Cheng, P. T. W.; Zahler, R.</span>, Eds.; <span class="NLM_publisher-name">RSC Publishing</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">331</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=316-331&author=E.+I.+Grazianiauthor=J.+C.+Barrish&author=P.+H.+Carter&author=P.+T.+W.+Cheng&author=R.+Zahler&title=Accounts+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3DUncoupling%2520neuroprotection%2520from%2520immunosuppression%253A%2520The%2520discovery%2520of%2520ILS-920%26btitle%3DAccounts%2520in%2520Drug%2520Discovery%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26pub%3DRSC%2520Publishing%26date%3D2011%26spage%3D316%26epage%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Saunders, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, M. L.</span><span> </span><span class="NLM_article-title">Rapamycin in transplantation: A review of the evidence</span> <span class="citation_source-journal">Kidney Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1046%2Fj.1523-1755.2001.00460.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=11135052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot1yguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2001&pages=3-16&author=R.+N.+Saundersauthor=M.+S.+Metcalfeauthor=M.+L.+Nicholson&title=Rapamycin+in+transplantation%3A+A+review+of+the+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin in transplantation: A review of the evidence</span></div><div class="casAuthors">Saunders, Richard N.; Metcalfe, Mathew S.; Nicholson, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">A review with 125 refs.  The calcineurin inhibitors have been the mainstays of immunosuppression for solid organ transplantation over the last two decades, but nephrotoxicity limits their therapeutic benefit.  Rapamycin is a new drug with both immunosuppressant and antiproliferative properties that has a unique mechanism of action distinct from that of the calcineurin inhibitors.  It has a role as a maintenance immunosuppressant either alone or in combination with a calcineurin inhibitor and can also be used to treat refractory acute rejection.  Theor. evidence suggests that it may limit the development and progression of chronic rejection in transplant recipients, but this has yet to be confirmed.  This review examines the current in vitro animal and human work underlying the use of rapamycin and, in addn., comments on the pharmacokinetics and side-effect profile of this promising new agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXwUZLv9en7Vg90H21EOLACvtfcHk0ljDOxpwk2CGVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot1yguw%253D%253D&md5=d94b7d45cd50461178347a8868dbe6ff</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1755.2001.00460.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1755.2001.00460.x%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DR.%2BN.%26aulast%3DMetcalfe%26aufirst%3DM.%2BS.%26aulast%3DNicholson%26aufirst%3DM.%2BL.%26atitle%3DRapamycin%2520in%2520transplantation%253A%2520A%2520review%2520of%2520the%2520evidence%26jtitle%3DKidney%2520Int.%26date%3D2001%26volume%3D59%26spage%3D3%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Faiver, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Current development of mTOR inhibitors as anticancer agents</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">688</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=671-688&author=S.+Faiverauthor=G.+Kroemerauthor=E.+Raymond&title=Current+development+of+mTOR+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaiver%26aufirst%3DS.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DCurrent%2520development%2520of%2520mTOR%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D671%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Skotnicki, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou-Gharbia, M. A.</span><span> </span><span class="NLM_article-title"> Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: The identification of CCI-779</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3749S</span><span class="NLM_x">–</span> <span class="NLM_lpage">3750S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=3749S-3750S&author=J.+S.+Skotnickiauthor=C.+L.+Leoneauthor=A.+L.+Smithauthor=Y.+L.+Palmerauthor=K.+Yuauthor=C.+M.+Discafaniauthor=J.+J.+Gibbonsauthor=P.+Frostauthor=M.+A.+Abou-Gharbia&title=+Design%2C+synthesis+and+biological+evaluation+of+C-42+hydroxyesters+of+rapamycin%3A+The+identification+of+CCI-779"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSkotnicki%26aufirst%3DJ.%2BS.%26aulast%3DLeone%26aufirst%3DC.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DPalmer%26aufirst%3DY.%2BL.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%2BA.%26atitle%3D%2520Design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520C-42%2520hydroxyesters%2520of%2520rapamycin%253A%2520The%2520identification%2520of%2520CCI-779%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D3749S%26epage%3D3750S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Rini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Temsirolimus</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=599-600&author=B.+Riniauthor=S.+Karauthor=P.+Kirkpatrick&title=Temsirolimus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRini%26aufirst%3DB.%26aulast%3DKar%26aufirst%3DS.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DTemsirolimus%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D599%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clardy, J.</span><span> </span><span class="NLM_article-title">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP12-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0liAx9e6Ht9hhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP12-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26spage%3D239%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Summers, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, E. I.</span><span> </span><span class="NLM_article-title">3-Normeridamycin: A potent non-immunosuppresive immunophilin ligand is neuroprotective in dopaminergic neurons</span> <span class="citation_source-journal">J. Antibiot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=184-189&author=M.+Y.+Summersauthor=M.+Leightonauthor=D.+Liuauthor=K.+Pongauthor=E.+I.+Graziani&title=3-Normeridamycin%3A+A+potent+non-immunosuppresive+immunophilin+ligand+is+neuroprotective+in+dopaminergic+neurons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSummers%26aufirst%3DM.%2BY.%26aulast%3DLeighton%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPong%26aufirst%3DK.%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3D3-Normeridamycin%253A%2520A%2520potent%2520non-immunosuppresive%2520immunophilin%2520ligand%2520is%2520neuroprotective%2520in%2520dopaminergic%2520neurons%26jtitle%3DJ.%2520Antibiot.%26date%3D2006%26volume%3D59%26spage%3D184%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Ruan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jow, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowlby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crozier, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercado, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schack, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaleska, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magolda, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skotnicki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pangalos, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehn, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abou-Gharbia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graziani, E. I.</span><span> </span><span class="NLM_article-title">Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=33-38&author=B.+Ruanauthor=K.+Pongauthor=F.+Jowauthor=M.+Bowlbyauthor=R.+A.+Crozierauthor=D.+Liuauthor=S.+Liangauthor=Y.+Chenauthor=M.+L.+Mercadoauthor=X.+Fengauthor=F.+Bennettauthor=D.+van+Schackauthor=L.+McDonaldauthor=M.+M.+Zaleskaauthor=A.+Woodauthor=P.+H.+Reinhardtauthor=R.+L.+Magoldaauthor=J.+Skotnickiauthor=M.+N.+Pangalosauthor=F.+E.+Koehnauthor=G.+T.+Carterauthor=M.+Abou-Gharbiaauthor=E.+I.+Graziani&title=Binding+of+rapamycin+analogs+to+calcium+channels+and+FKBP52+contributes+to+their+neuroprotective+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuan%26aufirst%3DB.%26aulast%3DPong%26aufirst%3DK.%26aulast%3DJow%26aufirst%3DF.%26aulast%3DBowlby%26aufirst%3DM.%26aulast%3DCrozier%26aufirst%3DR.%2BA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMercado%26aufirst%3DM.%2BL.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3Dvan%2BSchack%26aufirst%3DD.%26aulast%3DMcDonald%26aufirst%3DL.%26aulast%3DZaleska%26aufirst%3DM.%2BM.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DReinhardt%26aufirst%3DP.%2BH.%26aulast%3DMagolda%26aufirst%3DR.%2BL.%26aulast%3DSkotnicki%26aufirst%3DJ.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26aulast%3DKoehn%26aufirst%3DF.%2BE.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26aulast%3DAbou-Gharbia%26aufirst%3DM.%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3DBinding%2520of%2520rapamycin%2520analogs%2520to%2520calcium%2520channels%2520and%2520FKBP52%2520contributes%2520to%2520their%2520neuroprotective%2520activities%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D33%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Dinleyici, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yargic, Z. A.</span><span> </span><span class="NLM_article-title">Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine</span> <span class="citation_source-journal">Expert Rev. Vaccines</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">986</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm401564r&amp;key=10.1586%2Ferv.09.68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm401564r&amp;key=19627181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm401564r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFOls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=977-986&author=E.+C.+Dinleyiciauthor=Z.+A.+Yargic&title=Current+knowledge+regarding+the+investigational+13-valent+pneumococcal+conjugate+vaccine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine</span></div><div class="casAuthors">Dinleyici, Ener Cagri; Yargic, Zeynel Abidin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Vaccines</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">977-986</span>CODEN:
                <span class="NLM_cas:coden">ERVXAX</span>;
        ISSN:<span class="NLM_cas:issn">1476-0584</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The introduction of a 7-valent pneumococcal conjugate vaccine (PCV-7) into the routine childhood vaccination schedule has been shown to be effective in preventing invasive pneumococcal disease (IPD), pneumonia, otitis media and meningitis in infants and young children as detd. by epidemiol. surveillance studies.  There has been a rise in IPD due to nonvaccine serotypes; however, this rise is small compared with the overall redn. in IPD.  Non-PCV-7 serotypes and vaccine-related serotypes, such as serotypes 1, 5, 7F, 6A and 19A, have also been reported to cause IPD in some parts of the world where morbidity and mortality from pneumococcal disease are higher.  An investigational 13-valent pneumococcal conjugate vaccine (PCV-13) uses CRM197 as a carrier, similar to the current PCV-7, and covers serotypes 1, 3, 5, 6A, 7F and 19A, in addn. to the serotypes of PCV-7 (serotype 4, 6B, 9V, 14, 18C, 19F and 23F).  PCV-13 is safe and well tolerated with other pediatric vaccines in infants according to clin. trials.  IgG anticapsular polysaccharide-binding concns. and opsonophagocytic assay responses are similar and noninferior between PCV-13 and PCV-7 and, according to immunogenicity studies, PCV-13 has more potential to protect against pneumococcal diseases with the addnl. six serotypes.  With the addn. of these new serotypes, it could be possible to cover potential pneumococcal serotypes causing IPD throughout the world.  The cost of the vaccine, its length of duration, optimal scheduling, combination and boosting with PCV-7 are still unresolved issues.  Assessment of the vaccine's effectiveness and efficacy following potential licensure will require carefully designed cohort and case-control studies that can assess the indirect effects of PCV-13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpppav-RL6wv7Vg90H21EOLACvtfcHk0liAx9e6Ht9hhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFOls7o%253D&md5=24483a3712b533806afc15a508accc9c</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1586%2Ferv.09.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Ferv.09.68%26sid%3Dliteratum%253Aachs%26aulast%3DDinleyici%26aufirst%3DE.%2BC.%26aulast%3DYargic%26aufirst%3DZ.%2BA.%26atitle%3DCurrent%2520knowledge%2520regarding%2520the%2520investigational%252013-valent%2520pneumococcal%2520conjugate%2520vaccine%26jtitle%3DExpert%2520Rev.%2520Vaccines%26date%3D2009%26volume%3D8%26spage%3D977%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Sucher, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chahine, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sucher, B. J.</span><span> </span><span class="NLM_article-title">Prevnar13, the new 13-valent pneumococcal conjugate vaccine</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1516</span><span class="NLM_x">–</span> <span class="NLM_lpage">1524</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2011&pages=1516-1524&author=A.+J.+Sucherauthor=E.+B.+Chahineauthor=M.+Nelsonauthor=B.+J.+Sucher&title=Prevnar13%2C+the+new+13-valent+pneumococcal+conjugate+vaccine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSucher%26aufirst%3DA.%2BJ.%26aulast%3DChahine%26aufirst%3DE.%2BB.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DSucher%26aufirst%3DB.%2BJ.%26atitle%3DPrevnar13%252C%2520the%2520new%252013-valent%2520pneumococcal%2520conjugate%2520vaccine%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2011%26volume%3D45%26spage%3D1516%26epage%3D1524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Gruber, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emini, E. A.</span><span> </span><span class="NLM_article-title">Development and clinical evaluation of of Prevnar 13, a 13-valent pneumococcal CRM<sub>197</sub> conjugate vaccine</span> <span class="citation_source-journal">Ann. N.Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1263</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1263&publication_year=2012&pages=15-26&author=W.+C.+Gruberauthor=D.+A.+Scottauthor=E.+A.+Emini&title=Development+and+clinical+evaluation+of+of+Prevnar+13%2C+a+13-valent+pneumococcal+CRM197+conjugate+vaccine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGruber%26aufirst%3DW.%2BC.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DEmini%26aufirst%3DE.%2BA.%26atitle%3DDevelopment%2520and%2520clinical%2520evaluation%2520of%2520of%2520Prevnar%252013%252C%2520a%252013-valent%2520pneumococcal%2520CRM197%2520conjugate%2520vaccine%26jtitle%3DAnn.%2520N.Y.%2520Acad.%2520Sci.%26date%3D2012%26volume%3D1263%26spage%3D15%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Brant, A.</span> 20 top selling vaccines – H1, 2012. <i>FierceVaccines</i>, Sept 25,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.fiercevaccines.com/special-report/20-top-selling-vaccines/2012-09-25" class="extLink">http://www.fiercevaccines.com/special-report/20-top-selling-vaccines/2012-09-25</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Brant%2C+A.+20+top+selling+vaccines+%E2%80%93+H1%2C+2012.+FierceVaccines%2C+Sept+25%2C+2012%3B+http%3A%2F%2Fwww.fiercevaccines.com%2Fspecial-report%2F20-top-selling-vaccines%2F2012-09-25."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DBrant%26aufirst%3DA.%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Mullin, R.</span><span> </span><span class="NLM_article-title">The future is now</span> <span class="citation_source-journal">Chem. Eng. News</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2013&pages=12-17&author=R.+Mullin&title=The+future+is+now"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMullin%26aufirst%3DR.%26atitle%3DThe%2520future%2520is%2520now%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2013%26volume%3D91%26spage%3D12%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401564r&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-13%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm401564r%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401564r" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799dabee81cd932","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
